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Abstract 
Background: This thesis presents work from a clinical pharmacist practicing as an 
Embedded Researcher. The majority of the research presented was conducted 
within the Mental Health Service of the Northern Territory (NT). The NT is unique in 
terms of its demographics; it has a small, culturally diverse population which is 
dispersed over a large geographic area. Over one third of the NT population live in 
remote areas and 71% of those living remotely identify as Aboriginal or Torres Strait 
Islanders. This poses unique challenges in regards to the delivery of health-services 
to individuals and communities, particularly those living in remote areas.  
Prior to the employment of a pharmacist within the Mental Health Service, there were 
high risk medication practices occurring. Following an initial observation period 
completed by the pharmacist, significant evidence-practice gaps in care for patients 
with mental illness were identified. Due to the large number of these evidence-
practice gaps, the pharmacist undertook a multitude of change management and 
quality improvement activities by adopting the Embedded Researcher technique.  
The studies within this thesis include all aspects of the medication management 
cycle. The studies include assessments of prescribing practices, medication 
management, electronic medication management systems, risk minimisation, 
medication safety and quality, medicines information and hospital discharge. 
Aim: The aim of this thesis is to investigate the effectiveness of an Embedded 
Pharmacist Researcher (EPhR) and their impact on the Quality Use of Medicines. 
This thesis is designed to demonstrate how a clinical pharmacist, embedded within a 
team, can identify problems, develop innovative interventions, and implement 
sustainable solutions. 
Method: All research was conducted using the Embedded Researcher technique 
and targeted areas which were identified during clinical work as a translation gap 
between literature and practice. 
The National Medicines Policy, coupled with the Quality Use of Medicine principles, 
provided a foundation that supported the development, implementation and 
evaluation of the interventions within each healthcare setting. The applications of 
well-known theoretical models were used to develop a conceptual framework for 
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each intervention and are detailed in the introduction to each section or study.  Each 
framework uses an extensive selection of behaviour change theories developed in 
areas such as education, social marketing, public health and health promotion. 
Models such as Social Cognitive Theory, The Transtheoretical Model, PRECEDE-
PROCEED were used to develop the key building blocks and processes needed to 
facilitate behaviour change and to achieve high quality medicines use which has 
been sustained. 
Using the Embedded Researcher technique lends itself to incorporating both 
Qualitative and Quantitative Evaluation for each intervention. This enables each 
study to achieve a depth of understanding due to the ability to add descriptive data. 
For many of the studies presented, examples of mixed methodology are applied to 
demonstrate a robust analysis of each intervention.  
Results: Outcomes for all interventions within this thesis were successful. Results 
for each intervention were evaluated using the Clinical Value Compass targeting a 
multifaceted assessment of clinical outcomes, functionality of the service, patient 
satisfaction and costs due to direct medical or indirect social expenditure. There are 
over twenty studies presented within this thesis, all of which demonstrate the variety 
and depth of research that can be conducted using the Embedded Researcher 
Technique. 
The quality improvement and practice changes reported include;  
Clinical Outcomes; review of the impact of prescribing a new medicine promoted by 
the pharmaceutical industry on patient outcomes. This was evaluated by assessing 
tolerability of medicine, treatment failure and total number of patients who remained 
on the new therapy. 
Functionality of the Service; Multiple studies demonstrated quality improvement 
activities required to meet National Accreditation Standards. Examples include 
reviewing prescribing practices and targeted education to improve adherence to best 
practice, design and implementation of a Mental Health Community Medication Chart 
to meet legal requirements and to improve continuity, and safety initiatives such as 
an evaluation of a rapid implementation quality improvement program for medicine 
security.  
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Patient Satisfaction; Implementation of an independent non-biased medication 
information website for Mental Health patients, targeted patient surveys to provide 
feedback on medication management within Mental Health, and demonstrating that a 
ward based clinical pharmacist can help to meet patient’s needs in regards to 
medicines information. 
Costs due to Direct or Indirect Social Expenditure; Changing medication 
management systems in both the inpatient and community based Mental Health 
facilities resulted in an ongoing annual cost savings of greater than $35 000 to the 
NT government, and seeking funding for a technician to help with medication co-
ordination for a high-risk population group to potentially reduce the financial 
expenditure associated with re-admission which accounted for $601 772 to the 
Mental Health service.  
Utilising the Embedded Researcher Technique gives each intervention a greater 
likelihood of success due to the Embedded Researcher’s understanding of the 
importance of the culture, the potential resistance and lines of communication 
available for each stage of change. 
Conclusion: This thesis indicates the abundance of opportunities available for 
Embedded Pharmacist Researchers within a practice based setting. Providing these 
studies demonstrates how an Embedded Pharmacist Researcher can develop 
research questions from clinical practice, conduct appropriate evaluations using 
scientific methodology, and put forward a translation of the results to practice 
development. The outcomes of these change management projects gave the 
Embedded Pharmacist Researcher the opportunity to expand the pharmacy 
workforce, extend current roles of pharmacists, improve patient outcomes and 
determine ways to reduce expenditure for the Northern Territory Government. 
This work of an Embedded Researcher has demonstrated what can be offered by a 
pharmacist to a healthcare system, and this work can be seen as an example of a 
response that can be replicated by any pharmacist, in any position, as long as key 
methodology and insights are utilised, and the specialist skills of a pharmacist are 
executed.  
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Chapter 1 Pharmacy Practice and Research – the Need and Methodology for Better 
Integration 
1.1 Overview 
Expert pharmaceutical care is essential for safe and effective medication management:  
Effective medication management is a prerequisite for successful healthcare outcomes. 
Within Australia the knowledge, skills and training of a clinical pharmacist is guided by the 
Quality Use of Medicines (QUM) principles.1 Pharmacists have traditionally been involved 
within the healthcare team as the expert in the safe and timely provision of medications 
and in complementing the physician, nurse and allied health professionals in achieving 
optimal health outcomes.  Since then, some pharmacist practitioners have forged an 
additional role as an advisor in pharmacotherapy for both healthcare team members and 
for the patient. Pharmacists following non-traditional career paths rely on initiative, 
experience and mentorship to clearly make a difference within their workplace and 
contribute effectively to the healthcare team. This work explores and develops the further 
extension of the pharmacist’s role, through their effective use of activities, such as 
practicing as an embedded pharmacist researcher (EPhR), to provide high level 
pharmacotherapy knowledge and subsequent improvement of patient outcomes. 
Within this thesis, examples of how an Embedded Pharmacist Researcher (EPhR) has 
applied theoretical models of behaviour change, in particular, those from health promotion 
and health psychology, demonstrate the central place of an EPhR within interventions, to 
improve medication use.2 There are three stages in the development of interventions; 
Planning, Delivery and Evaluation.3 Each stage relies on information from Drug Utilisation 
Research and includes stakeholder engagement.4 The outcomes of these change 
management projects gave the EPhR the opportunity to expand the pharmacy workforce, 
extend current roles of pharmacists, improve patient outcomes and determine savings 
from expenditure for the Northern Territory Government.  
The studies in this thesis describe the integration of an EPhR within various areas of 
healthcare. The approach that the EPhR took in the introduction to each role was as 
follows: observation, engagement with all stakeholders, identification of allies, and working 
at a high clinical level to discover how to deliver the best possible health-service.2,5  
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1.2 Current Roles of Pharmacists 
Pharmacists are in a prime position within the healthcare system to work collaboratively 
with patients.6-8 Both patients’ accessibility to pharmacists and pharmacists’ 
communication skills and knowledge, enable pharmacists to be the ambassadors for 
patient-centred care.9 Sharing their knowledge, listening to patients and providing care 
plans are essential parts of a pharmacist’s role.  
The qualities and characteristics of a ‘good’ pharmacist have been explored via a survey 
of health professionals:10 “Caring, compassionate, knowledgeable, and responsive” were 
words used frequently to describe what is considered a good pharmacist.10 Patients agree 
with this, noting that “Fast, productive and accurate” were not at the top of anyone’s list.10 
These descriptions do not align with how pharmacists and our government are currently 
prioritising services to meet society’s needs. For too long, pharmacists have provided 
access to medicine and have missed opportunities to provide a patient-centred approach 
to medicines management.9,11  
In recent times there has been much research, discussion and debate over the changing 
roles of pharmacists, particularly those based in the community.12-15 Throughout the world 
we have seen a trend for pharmacists to move away from medicine supply towards a more 
inclusive focus on patient care.9,16,17 Progressive pharmacists continue to try to leave 
behind roles related to supply of pharmaceutical products and shift towards that of a 
provider of services and information, and ultimately, a provider of patient care.9,18-24 
Moving away from dispensing and a supply service is essential for the evolution of 
pharmacists. Dispensing activities have already begun to be done by trained technicians 
and appropriate technology.25-30 “The fact that pharmacists have an academic training and 
act as healthcare professionals puts a burden upon them to better serve the community 
than they currently do.”31,32  
Increasingly, the pharmacist’s task is to ensure that clinicians partnering with patients are 
achieving QUM.1,7 In fact, the QUM principles cannot be applied if pharmacists are offering 
the service of supply alone without the engagement with patients.33  By taking direct 
responsibility for an individual’s medicine-related needs, pharmacists can make a unique 
contribution to the outcome of patients health and to their quality of life.9 The imperative for 
pharmacists to become more patient-centred and to better utilise their distinctive 
competency as a medicine expert is abundantly clear.9  
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1.3 What is an Embedded Researcher? 
Within this thesis the terms Embedded Researcher, Clinician-Scientist and Practitioner 
Fellow will be used interchangeably. Although these terms are often associated with the 
medical profession, this thesis has been assembled to uniquely expose how a pharmacist 
can also work successfully within this role.  
Definition: “Clinician-scientists possess a distinctive set of skills, being trained as a 
clinician to apply scientific knowledge to patient care, and trained as a scientist with an 
enquiring mind designed to test hypotheses. Understanding the clinical relevance of 
observations in science and the ability to translate this back into clinical practice is truly 
the domain of the clinician-scientist, and uniquely so.”34 
1.4 A Brief History of Embedded Researchers and Lessons from Other Professions 
The term Embedded Researcher appears to have been borrowed from ‘embedded 
journalism.’ This approach was used during war journalism in which reporters from the 
United States were attached to military units. This style of journalism arguably allowed the 
journalists unparalleled access to stories unfolding on the front line.35,36  
The first health field to truly adapt and evolve the Embedded Research design was 
psychology.2 Many health psychology studies have detailed the method of being an 
Embedded Researcher, in particular the influential position of the researcher who can 
facilitate change and benefits to the service by directly evaluating and delivering 
outcomes.2 
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Table 1.1: Characteristics of the articles included in the review and definition of embedded research/researcher: Reproduced from Vindrola-Padros 
C et al.37 
Article Country Year Sector Definition of Embedded 
Research/ Researchers 
Characteristics of the 
embedded 
researcher/researchers 





Australia 2002 Education “Researcher in Residence is 
a phrase used to connote a 
role analogous to a ‘writer in 
residence’ or ‘artist in 
residence’. However, it is a 
positioning which is 
distinctive from being a 
resident in the fullest sense 
of the term, in that the 
researcher maintains her 
affiliation with her university 
and broader educational 
research and professional 
development consultancy”. 
Researcher has relative 
autonomy in the host 
organisation. 
 
If the embedded 
position is funded by 
the host organisation, 
it allows the 
researcher to develop 
long-term 
relationships with 
staff and guarantee 
the sustainability of 
the research. 
The researcher might 
face difficulties 
understanding and 
navigating the terrain 
of the host 
organisation, and thus 




Reiter-Theil39 Switzerland  2004 Health “Researchers carrying out 
research in the relevant 
context without performing 
the same practices as those 
studied.” 
Carried out observations and 
documented clinical practice. 
Acted as ‘some kind of team 
member.’ 
 
Provided valid and 
meaningful results to 
practice. 
Allowed researchers 
to ask the ‘right’ 
questions. 
Effort required to 
maintain trust, 
reliability and stamina 






2006 Health “Method of the embedded 
researcher […] allows for a 
combination of methods of 
systematic observation and 
case documentation in a 
naturalistic setting”. 
Carried out observations and 
documented clinical practice. 
Used the embedded research 
method outlined in 
Not specified Not specified 
Pyett et al41 Australia 2008 Health Three researchers-in-
residence employed by an 
aboriginal community-
controlled health 
organisation. Two of the 
researchers are also 
affiliated to a university. 
- - - 
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Nutley et al42 UK 2008 Education “Interactive  relationship  
between researchers, 
managers, and practitioners 
in the development of 
research-based guidance, 
protocols, and tools” 
Based on the translation of 
research into practice by 
individuals in local policy or 
management roles. 
Research becomes embedded 
in systems, processes and 
standards. 
Model may be suited 
to staff in certain 
circumstances and 
where practice tools 
can be tailored to the 
local context. 
Embedded research 
model needs to adapt 
to the particular 
research questions 
that need to be 
addressed 
Jenness43 USA 2008 Judicial 
System 
“I use the term embedded 
researcher to talk about 
something […] that provides 
multiple vantage points from 
which to view the scene: 
occupying multiple locations 
within and under the control 
of a single field of play while 
also moving from one site to 
another, one level of 
analysis to another, and one 
constituency to another-
ultimately having a presence 
as a didactic participant 
throughout a field of play”.  
Worked as ‘a public servant.’ 
Carried out in-depth fieldwork 
with inmates and wardens in the 
California prison system. 
A good way to get a 
unique perspective, 
insight and data. 
The researcher has 
relations of 
dependence with the 
host organisation, 
which might shape the 
type of research that 
is conducted and the 
dissemination of 
findings. 
Nutley et al44 UK 2009 Social 
Care 
“Research enters practice 
indirectly; it becomes 
embedded in systems, 
processes and standards. 
[…] Research knowledge is 
translated into frontline 
practice activities by 
intermediaries”.  
Translation of research-insights 
into practice activities. 
 
 
Model may be suited 
to staff in certain 
circumstances and 
where practice tools 
can be tailored to the 
local context 
Embedded research 
model needs to adapt 
to the particular 
research questions that 
need to be addressed 
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Wong45 Australia 2009 Education Researcher employed full-
time to conduct research 
within an organisation. 
   
Worked alongside, shared office 
space and socialised with 
practitioners. 
Embedded researchers participated 
in six studies focused on 
programme evaluations (outcomes 
and processes) and research 
projects addressing questions that 
arose from practice and/or the 
literature. 
One of the goals was also to 
increase staff engagement with 
research. 
 
Increased local staff 
members’ capacity to 
conduct research. 




Provided local staff 
the opportunity to 
reflect on their work, 
increase their skills 
and knowledge, and 




to inform policy and 
practice. 
 
Not all researchers 




dispositions play an 
important role. 
There needs to be a 
‘good fit’ between the 
researcher and the 
organisation. 
Sharing of findings 
might be restricted if 
the organisation owns 
the intellectual property. 
Hackett and 
Rhoten46 
USA 2011 Science 
Policy 
Two researchers worked as 
transient government 
officials at the National 
Science Foundation (NSF) 
“with responsibility to 
manage a research 
program, direct a division, 
develop new research 
solicitations, serve on NSF 
policy committees, and 
conduct our research”.  
 
 
Managed a research programme 
and carried out research. 
Developed new research 
solicitations. 








events and processes. 
Allows the 
researchers to 
engage in discussion 
and reflection with 
members of the 
organisation. 
Allows researchers to 
engage with real 
problems in a real 
context. 
Researchers might face 
restrictions in the 
dissemination of 
findings. 
Researchers occupy an 
intermediate status with 


















UK 2011 Health “A situationally appropriate 
way of ‘doing ethnography’ 
that is founded on the 
principles and practice of 
immersion fieldwork while 
being responsive to working 
with reflexive collaborators, 
adaptive to the requirements 
of ethics and other forms of 
research regulation, and 
accommodating to 
audiences eager for new 
forms of ethnographic 
output”.  
Researcher acts as ‘some kind of 
team member.’ 
Researcher maintains a 
collaborative relationship with co-
workers. 
Researcher uses traditional 
principles of ethnographic 
fieldwork. 
 




Requires a certain 
critical distance. 
Researchers must deal 
with working in a state 
of ’in-between-ness.’ 
 
Rowley48 UK 2014 Education “Individuals or teams who 
are either university-based 
or employed undertaking 
explicit research roles within 
host schools or other  
educational  organizations, 
legitimated by staff status or 
membership with the 
purpose of identifying and 
implementing a collaborative 
research agenda” 
 
Carried out quantitative and 
qualitative research to inform future 
practice. 
Performed informal tasks to 
develop trusting relationships. 
Attended and participated in 
steering board meetings. 




The researcher has 
access to a wide 
range of people and 
informal practices, 
increasing the depth 
and diversity of 
collected data. 
The research can 
respond in an ad hoc 




researcher to tailor 
the research to meet 




always be adapted to 
the realities and 
timeframes of embedded 




within the organisation 
which can sometimes 
come into conflict. 
The researcher 









UK 2014 Health Researcher is a core 
member of the delivery 
team, with a sense of shared 
responsibility for the success 
or failure of an improvement 
initiative 
The researchers are in close 
connection to routine practice and 




addresses the barriers 
between researchers 
and practitioners, 




chances it will be used 
in practice 
Embedded researchers 
are subjected to 
different requirements 
for career development 
in the academic and 
health organisations, 
which are not always 
compatible. Research 




and evaluation of the 
approach are required. 
Marshall50 UK 2014 Health “Researchers-in-Residence 
blur the traditional boundary 
between their expertise and 
that of the health service 
team by becoming an 
integral part of the team 
rather than central 
commentators”. 
Negotiate their knowledge and 
integrate it with the expertise of 
practitioners. 
Researcher interprets research 
evidence in relation to the local 
context. 
Evaluates improvement efforts 
looking at the intended and 





expertise to the team 






might not be 
considered valuable 
under the reward 
systems used in most 
academic institutions. 
Embedded approaches 
might put scientific 
objectivity at risk. 
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Marshall51 UK 2014 Health “An integrated member of a 
service-based improvement 
team” 
Carried out qualitative research to 
collect evidence for a new 
initiative. Devised an evaluation 
framework. Contributed to funding 
applications for internal projects. 
 
Encourages 
researchers to be 
more useful to 
practitioners. 
Encourages 
practitioners to be 
responsive to scientific 
evidence. Can help 
deliver better care 
with limited resources. 
There are no set 
guidelines on the 
required personal skills 
and level of experience 
of the researcher. 
Embedded researchers 
must negotiate between 
their sense of 
ownership over the 
work and their 
independent 
evaluation. 




explicit research roles within 
host schools or other 
educational organizations, 
legitimated by staff status or 
membership with the 
purpose of identifying and 
implementing a collaborative 
research agenda” 
Researchers ‘get under the skin’ 
of organisations in order to 
document multiple perspectives 
and processes. 
A ‘mutually beneficial relationship’ 
is created between the host 
organisation and university. 
 
Allowed the researcher 
to gain insight into 




can be disrupted by 




UK 2014 Education “Individuals or teams who 
are either university-based 
or employed undertaking 
explicit research roles within 
host schools or other 
educational organizations, 
legitimated by staff status or 
membership with the 
purpose of identifying and 
implementing a collaborative 
research agenda” 
Researcher is embedded in a 
programme team (employed by 
university but maintains an 
affiliation with the health 
organisations). 
Based on collaboration, reflection 
and collective inquiry. 
The researcher focuses on initiating 
change through shared learning 
and knowledge of the local context. 
The researcher obtains 
greater access to the 
organisation, which 
facilitates data 
collection and can help 
with funding. The host 
organisation gains 
academic knowledge 
and critical approaches 
to inform its policies 
and practices. 
Embedded research is 




and changes. Funding 
arrangements create 
particular power 
relations and shape the 
role of the embedded 
researcher. Flexibility, 
adaptation and 
reflexivity are required. 





China 2014  “agents of knowledge 
transfer that eventually 
translates into policy 
comprise not only think 
tanks for policy formulation 
in central-state institutions 
but also researchers in 
universities supporting 
policy implementation at 
local levels” 
”Those that access data via 
local administration but not in 
a role of academics testing 
their ideas, but as consultants” 
Strengthen local 
relationships between 





research contracts and 
intervention studies. 
problems arose in the 
wake of data collection 
about how to interpret 
and contextualize the 
survey and interview 
results 
Eyre et al54 UK 2015 Health “An emerging model of 
participative research […] 
that embraces the concept 
of ‘co-creating’ knowledge 
between researchers and 
practitioners.” 




needs to respond to the 
complex processes and 
structures of the 
organisations where the 
researcher works. 
Platt et al55 USA 2016 Health  “Health systems and 
providers become incidental 
research subjects, 
trials can involve hundreds 
of thousands of people 
who do not give explicit 
consent.” 
 Encourages the growth 





identification is higher, 
and the consequences 
may be more severe.  
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The literature referencing clinician-scientists and Embedded Researchers is worldwide and 
spans many professions (see Table 1.1).37,56 
Within Australia, the role of clinician-scientists, as with the majority of the international 
literature, has been well established within the medical discipline.34,39-41,47,50,54,55 The 
challenges that face non-physician clinician-scientists is that health professionals are able 
to secure roles as either a clinician or an academic, but seldom are there roles which 
accommodate both.57 
To be an Embedded Pharmacist Researcher (EPhR) enables ‘real time’ and ‘real-life’ 
observations in the work environment. Engagement with all stakeholders can lead to 
positive implication for the uptake and sustainability of change.  
The work of the EPhR provides information on current medication usage, examines 
underlying processes, the culture of practice and explores aspects of care and patient 
outcomes.  
For the studies which have been collated to construct this thesis, the author, Alice V 
Gilbert, is the clinician-scientist. The link which joins all studies is the Embedded 
Researcher approach which has been practiced by Alice V Gilbert. 
1.5 The Relationship between Practice-Based Research and Embedded Research 
(Exploring their Similarities and Differences) 
Practice-based research and Embedded Research work on the same premise of 
improving the translation between bench top to bedside. Both methods of research are 
designed so that the data is collected ‘on the ground’ through daily practice.58 Commonly 
both methods of research are a joint collaboration between academic and clinical 
environments, with the results of the research produced, often being co-owned by 
partnering institutions.34,44  
The immediate difference between Practice-Based Research and Embedded Research 
can be attributed to the unique knowledge, characteristics and skills of the researcher.37 
Embedded Research relies on the researcher being integrated within an organisation and 
therefore able to provide better insight into the issues and to ensure that the research is 
relevant to the local context.59 Furthermore, the established relationships of the Embedded 
Researcher with practitioners, managers and patients, enables change to be more easily 
translated into practice. This highlights the important of the integration of the researcher 
within an organisation.37 
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Although practice-based research occurs where patients receive care,60 it can be done by 
researchers who are not a part of the practice organisation and therefore they can lack the 
knowledge and relationships required to find effective solutions and implement those into 
practice. 
1.6 Why Use the Embedded Researcher Approach? 
A gap exists between health research and clinical practice. While researchers constantly 
produce new knowledge relevant to clinical care, much of their work is not incorporated 
into practice. Similarly, clinical problems are rarely translated into research projects.61 In 
the continual change within healthcare there is not just a need for collaboration between 
researchers and clinicians, but a need for individuals who are confident in both research 
and practice.34  
The translational time-lag between research and practice has been improving. In 2007, it 
was suggested that it takes an average of 17 years for 14% of new scientific discoveries to 
enter day-to-day clinical practice.58 Later, in a study conducted in 2011, found that there 
was an average of seven years for research evidence to find its place in practice.62 
Although the time-lag has shortened, there is still further need to improve the translation 
from literature to bedside.  
A core responsibility for a practicing clinical pharmacist is to be involved in quality 
improvement activities related to improving patient safety, QUM and medicines 
management.  
The primary benefits of being an EPhR, is that the position allows the researcher to be part 
of the team that will facilitate change. Whilst working in the research environment, areas of 
risk, or evidence gaps noticed between best practice (evidence-based) and current 
practice can be identified by the EPhR.  
1.7 The Benefits of the Embedded Researcher Technique 
The Embedded Researcher Technique makes all stages of research a collaborative 
process. In an interactive perspective this technique equalises the power between the 
practitioners and researchers and allows the practitioners to provide research questions 
and play a vital role in providing and supporting solutions.59,63  
There are advantages of adapting the research to a particular healthcare environment. A 
successful Embedded Researcher is able to compromise because of their background and 
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training which enables them to understand the path of clinical decision making. The 
complexities of clinical decision making are often overlooked in other research methods 
and findings.64 
Researchers who are aware of the complexities of the environment, in which they are 
conducting research, may translate experiences more sensitively.65 Not only are the 
research questions usually more acceptable to clinicians, but the methods used are 
familiar and well established grounded theory techniques, such as change management.66 
Embedded Researchers have a framework, and the motivation, to critically review, utilise 
self-reflection and examine biases. The research is more relevant for practitioners, and 
potentially, be made more relevant for boards or funding agencies.59  
1.8 Limitations of the Embedded Researcher Technique 
As the Embedded Researcher is conducting research in a specific environment, 
sometimes the outcomes from the research can only be applied as a local solution and 
may be difficult to replicate in other organisations.67 The ability to source data from 
clinicians that the EPhR works alongside, may make communication uncomfortable, and 
although most methods of research can be isolating, it can be particularly so for the EPhR, 
if the research is not supported by work colleagues.39 Utilising this technique often relies 
on researchers being interested in forming partnerships, and relies on an organisation that 
is supportive of collaboration.45,46,52  
Articles which critique this method of research are often concerned with bias which is 
introduced by the researcher themselves.68 The researcher’s bias, as with other forms of 
qualitative studies, cannot be removed from the research methods. “Indeed, some 
qualitative proponents argue that the researchers themselves, with their biases, insights, 
and deep understanding of the context, are the best research tool.”69 
As the Embedded Researcher is aware of the workplace culture and communication, I 
argue that this inside knowledge adds as much as it detracts from the research validity. 
Good research demands "scepticism, commitment and detachment."10,69 The Embedded 
Researcher approach also requires comradeship, enthusiasm, and a willingness to 
actively support the intervention. “Thus, a certain wisdom is needed to walk this narrow 
line between objectivity and bias. The personal skill to hold all of these attitudes 
simultaneously is a challenge and a defining feature of a quality Embedded Researcher.”69 
Table 1.2 provides a summary of quotes from the literature to demonstrate the benefits 
and limitations when critiquing the Embedded Researcher Method.  
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Table 1.2: Benefits and Limitations of the Embedded Researcher 
 
Benefits of the Embedded Researcher Method Limitations of the Embedded Researcher 
Method 
“This technique builds relationships between 
concepts, academics and practitioners, the 
researchers and the researched.”59 
“The nature of this research requires significant 
abstraction for generalizability.”67 
 
“Practitioners will translate, adapt and renegotiate 
new knowledge in order to make sense of it 
within the contexts of their day-to-day work.”42 
“Sometimes interactions can feel awkward or 
forced.”70 
 
“Constantly engage in reflexivity by journaling 
and paying attention to reactions, experiences, 
emotions, and in the end, to be able to articulate 
the pathways that led to interpretations.” 70,71  
“Practitioners have a large workload to achieve 
their frontline duties and are usually too busy and 
often ill trained to conduct rigorous research.”69  
“Conventional linear models of evidence transfer 
do not seem to adequately reflect real differences 
in the ways in which people from academia and 
the health service think about evidence, the 
nature of their training, and the complex process 
of management decision making.”49 
"if a researcher is intimately involved in the 
conceptualization, design, development, 
implementation, and researching of a 
pedagogical approach, then ensuring that 
researchers can make credible and trustworthy 
assertions is a challenge."68  
“Clinicians know all of the problems, but none of 
the solutions; scientists know all of the solutions, 
but none of the problems.”34  
 
“While collaborative methods can bridge the lack 
of research knowledge of practitioners and the 
lack of tacit knowledge of researchers, such 
collaboration is costly, and time-intensive.”59 
“My participation in my researched activities 
helped me understand their subjective 
experiences; on the other hand, it allowed me to 
enrich the data by adding personal and emotional 
depth to my work.”72 
“Challenges abound regarding the “soft” nature of 
any qualitative research in its credibility and bias, 
but especially one in which the researcher lacks 
“scientific” distance from the researched.”59 
“It includes the study of influences on healthcare 
professionals' behaviour and methods to enable 
them to use research findings more effectively.”66 
“Effort required to maintain trust, reliability and 
stamina among clinicians and research team.”39  
“There is great “value of ''belonging'' to the 
research team, being involved in projects from 
conception through to publication, and developing 
in-depth relationships.”63 
“The researcher has relations of dependence with 
the host organisation, which might shape the type 
of research that is conducted and the 
dissemination of findings.”43  
“Enable local people to seek their own solutions 
according to their priorities.”59 
 
“Not all researchers are suitable for embedded 
roles; personal characteristics and dispositions 
play an important role.”45  
“This technique incorporates the practitioner’s 
tacit knowledge into the research, both 
methodologically and as an actionable response 
to the analysis.”73  
“Researchers might face restrictions in the 
dissemination of findings. Researchers occupy an 
intermediate status with commitments to often 
conflicting values.”46  
“The research narrows the gap between the 
actual and the empirical, and the events and the 
studied, recalled experiences.”74 
“Ethical regulation procedures cannot always be 
adapted to the realities and timeframes of 
embedded research.”48  
“Being situated in a real educational context 
provides a sense of validity to the research and 
ensures that the results can be effectively used to 
assess, inform, and improve practice in at least 
this one (and likely other) context.”69  
“Embedded research can be disrupted by policy, 
personnel or organisational change.”52  
1.9 Change Management Principles and Their Application 
For the success of a change management project, every organisation undergoing change 
should consider factors in its own story about why it must change.75 These factors are 
referred to as the drivers of change.76 It is important to identify the drivers of change, as 
many of the study examples presented in this thesis utilise these drivers to their 
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advantage. For example, understanding the importance of a health service meeting 
national accreditation standards, allows those external pressures to influence internal 
organisation design.77 In transformational change, the scope of organisational change is 
often so significant that it may also require cultural change in order that the new 
organisational design might operate smoothly and thus produce required outcomes.75  
Culture change demands change in both leaders’ and employees’ behaviour requiring 
leaders and employees to shift their mindsets.75 This involves reviewing their professional 
model: considering how work is done, and how they work with each other to meet the 
needs of patients. Each of the drivers of change is a critical factor required for 
organisational change to succeed.  If mindsets do not change, then behaviour cannot 
change; if behaviour does not change, culture will not, and therefore changes in the 
organisation will not succeed, and the project will fail.75,76,78,79 
The integration of the EPhR into the Northern Territory Health Services is described in 
detail to show the application of the PRECEED-PROCEED model.5  
The PRECEDE-PROCEED model incorporates individual behaviour change, 
organisational change and public health principles.5  
PRECEDE is an acronym that stands for predisposing, reinforcing and enabling constructs 
in educational diagnosis and evaluation. This aspect of the model highlights the need to 
identify factors which predispose individuals towards given health-related behaviours, 
alongside those that enable and reinforce health-related behaviours.  
The PROCEED component of the model recognises the influence of the wider 
environment on health.  PROCEED is an acronym which stands for policy, regulatory, and 
organisational constructs in educational and environmental development.  
The model draws attention to the need for organisational support for change and the need 
for interventions which develop a supportive environment within educational strategies. 
Within this aspect of the model, interventions also need to address the regulatory, political 
and organisational factors that may impact on the success of any education program 
targeted towards individuals.4   
The driving factors for change were different in each project conducted by the EPhR. 
However, the goal was always the same, to achieve Quality Use of Medicines.1,80  
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Implementation projects conducted by the EPhR were continually evaluated. As with all 
quality improvement activities, assessment should occur more often than once post 
implementation. Repeat assessment is necessary to determine sustainability, beyond an 
initial trial, and also to redefine the health services against a needs assessment. Quality 
improvement should be fluid and transitional, as demonstrated within the theoretical 
framework, and change should continue to occur. Evaluation of implementation projects 
have been presented to executives within the Northern Territory Department of Health to 
demonstrate the need for an EPhR and the impact that one can have. Interventions can be 
assessed in many ways. This thesis applies the Clinical Value Compass, targeting a 
multifaceted assessment of clinical outcomes, functionality of the service, patient 
satisfaction, and costs due to direct medical or indirect social expenditure.81,82  
1.10 The Australian Framework Which Currently Drives Australian Practice 
1.10.1 Conceptual Framework: From Actions to Outcomes.  
A conceptual framework is “an analytical tool with several variations and contexts. It is 
used to make conceptual distinctions and organise ideas. Strong conceptual frameworks 
capture something real and do this in a way that is easy to remember and apply.”83 
The conceptual framework for this thesis draws on principles from Australia’s National 
Medicines Policy (NMP)84 and the evidence supporting the National Strategy for Quality 
Use of Medicines.1  The National Strategy for Quality Use of Medicines provides a guide to 
the essential components required for interventions to improve medicine use, and ensure 
sustainable change as a result.1 The NMP outlines the need for evaluation of QUM 
activities within a quality improvement framework. 
Australia’s National Strategy for Quality Use of Medicines has a strong conceptual 
framework.  
1.11 The Development of Australia’s National Medicine Policy (A Brief History) 
1.11.1 Health for All Australians 
In 1987, the then Minister for Health, Neal Blewett, outlined a plan to ensure Health for all 
Australians. It recognised the need to ensure appropriate use of medicines and reduction 
of misuse.85 
Consumer concerns about use of medicines in Australia, in particular overuse of 
medicines such as benzodiazepines and antibiotics, led to the formation of the Consumers 
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Health Forum (CHF), with help for funding by the Health Minister.86 The CHF is the peak 
organisation providing leadership in representing the interests of Australian healthcare 
consumers. “It works to achieve safe, good quality, timely healthcare for all Australians, 
supported by the best health information and systems the country can afford.”86 This was 
one of the starting points for the development of the Pharmaceutical Health and Rational 
Use of Medicines (PHARM) Committee. 
1.11.2 The Pharmaceutical Health and Rational Use of Medicines (PHARM) 
Committee 
The Australian Government took a major step forward in the area of a National Medicines 
Policy, when, in 1988, the then Minister of Health and Ageing, Peter Staples, called for an 
expert advisory committee to develop, implement and monitor Australia’s National Strategy 
for Rational Use of Medicines (PHARM).87 The PHARM Committee first met in 1990 with a 
view to meeting the Minister and discussing his requirements in establishing Australia’s 
NMP. The committee’s first Chair, Mary Murray, and her committee of 12 members, did 
not represent any organisations, but were appointed to bring their expertise and 
commitment to advice on Rational Use of Medicines. Members were variously health 
professionals, consumers, pharmaceutical industry and government workers, people from 
health promotion and health communication sectors. Working parties addressed particular 
issues and initiatives such as defining Rational Use of Medicines, designing guiding 
principles, and using them in practice and evaluating outcomes.87 
The PHARM Committee examined the existing appropriate theoretical models in areas 
such as public health, health promotion, community development, social advocacy, 
education and behaviour change, as well as examining how to open the bridge between 
designing models of care and using them in practice.88   
The Committee recommended, oversaw and evaluated research pertinent to achieving 
QUM.87  In 1992, the government endorsed a Policy on the QUM developed by the 
PHARM committee. One recommendation from the PHARM committee was to form an 
advisory council to draw together all Australian organisations currently dealing with 
pharmaceuticals.  
1.11.3 Australian Pharmaceutical Advisory Council. 
In 1996 Michael Wooldridge, then Minister, Department of Health and Aged Care, as an 
initiative recommended by the PHARM committee, established the Australian 
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Pharmaceutical Advisory Council (APAC), to inform him on medicines policy.1 APAC, 
chaired by Professor Lloyd Sansom, was a consultative forum that brought together 
stakeholders from the medical, nursing and pharmacist professions, as well as industry, 
consumers, and members of Government.1  
Australia already had many of the components of a NMP when compared to that of the 
World Health Organisation1,86,87; however, the Australian model required material that 
joined the standard components of:  
1) Equity of access, so that all people in Australia can acquire needed medicines 
2) Quality, safety and efficacy, so selected medicines are of good standards, safe to take 
and able to deliver the required response, and 
3) Industry and trade policies which produce and/or deliver needed medicines for the 
Australian population.1 
Australia’s NMP aims to improve health outcomes for all Australians, through a focus on 
the availability of safe and effective medicines, universal access to those medicines, a 
responsible and viable pharmaceutical industry and a strategy to ensure quality use of 
medicines, at a cost that both individuals and the country can afford.84 The policy 
emphasises the need for collaboration between all partners (consumers, healthcare 
providers, educators, industry, government and the media) in order to achieve this goal. 
The QUM principles were the binding that would tie all objectives together within the NMP. 
With the inclusion of QUM, all components are interdependent, meaning that failure to 
meet one component would/could affect other objectives.89  
The standing policy elements of Quality, Safety and efficacy, Equity and access, and a 
viable pharmaceutical industry, were joined by QUM.84 See Figure 1.1. The NMP also 
recognises the need for collaboration between all stakeholders to achieve the goal of 
healthy Australians. 
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Figure 1.1: Interdependence of the four components of Australia’s National Medicine Policy. 
(Reproduced from The National Strategy for Quality Use of Medicines1) 
The Australian Pharmaceutical Advisory Council moved appropriate recommendations 
from studies into policy. For example, Consumers’ Medicines Information (CMI).90  In 1991 
a report from Professor Baume, “A Question of Balance: The future of drug evaluation in 
Australia,” was commissioned by the Minister for aged, family and health services.85 All 
new prescription products were required to have a CMI document by 1993, as required in 
the Therapeutic Goods Registration. By 2003 all prescriptions and Schedule Three 
products were required to have a CMI. A CMI document was written by the pharmaceutical 
company responsible for the medicine.  In perhaps the first achievement of the new 
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partnerships under the QUM policy was that consumers worked with government and the 
pharmaceutical industry to produce CMI leaflets. A decade later, CMIs can be accessed by 
community and hospital pharmacists to be printed out at the time of dispensing.91  
The APAC report set a target to develop an NMP by 1990, in line with recommendations 
made by the World Health Organisation (WHO).84,85,92  
In 1999 the Government endorsed “Australia’s National Medicines Policy”,84 and in 2002 
the government re-named the Policy on the Quality Use of Medicines as the “National 
Strategy for Quality Use of Medicines.”1 
The central objectives of the NMP are outlined below. 
1.11.4 Equity of Access 
The NMP recognises that individuals require timely access to medicines, at a cost which is 
affordable to both the individual and the community. In Australia, affordable access to 
medicines is enabled by the Pharmaceutical Benefits Scheme (PBS), which has been in 
operation since 1948.93  
The medicine subsidy process in Australia is clearly stated as follows: once a medicine 
has been approved for supply in Australia, the manufacturer will usually apply to have the 
medicine listed on the Schedule of Pharmaceutical Benefits.93 The Pharmaceutical 
Benefits Advisory Committee (PBAC), which was established in 1954, is an independent 
statutory body that advises the Federal Minister for Health on which medicines should be 
subsidised under the PBS.93 In considering whether a medicine should be available 
through the PBS, the committee considers the evidence which supports the medicine’s 
effectiveness, the risk versus benefits, and the cost-effectiveness of the medicine 
compared to therapies already available in Australia.93 If the PBAC recommends that a 
medicine should be listed on the PBS, the Pharmaceutical Benefits Pricing Authority is 
engaged to negotiate an appropriate price for the medicine with the manufacturer.93 The 
Federal Minister for Health is responsible for making the final decision as to whether to list 
the medicine on the Schedule of Pharmaceutical Benefits, based on the advice of the 
PBAC and the Pharmaceutical Benefits Pricing Authority.93 Medicines which are not listed 
are available as private prescriptions, where the consumer pays the full cost of the 
medicine.93,94 In 2013 – 2014, the Australian Government paid 83% ($9 148.5 million) of 
the total cost of the medicines supplied under the PBS, with the remainder paid through a 
patient co-payment system.95 
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1.11.5 Quality, Safety and Efficacy 
The Therapeutic Goods Administration (TGA), which is part of the Australian Government 
Department of Health, is responsible for regulating therapeutic goods including 
prescription medicines, vaccines, sunscreens, vitamins and minerals, medical devices, 
blood and blood products.96 Almost any product for which therapeutic claims are made 
must be entered in the Australian Register of Therapeutic Goods (ARTG) before it can be 
supplied in Australia.  
The TGA administers the Therapeutic Goods Act 1989, applying a risk management 
approach designed to ensure that therapeutic goods supplied in Australia meet acceptable 
standards of quality, safety and efficacy, when necessary. The TGA relies on the public, 
healthcare professionals and industry to report problems with medicines or medical 
devices. The TGA investigates reports received to determine any necessary regulatory 
actions.96 
1.11.6 Industry and Trade Policies which Produce and/or Deliver Needed Medicines 
for the Australian Population. 
Maintaining a sustainable medicines industry in Australia is important to achieving the 
other objectives of the NMP, and other government policies. In the past, various schemes 
have been used to provide financial support for manufacturers of medicines and to 
encourage pharmaceutical research and development in Australia.97-99 Industry 
representatives, such as Medicines Australia, work closely with the Australian Government 
and regulatory bodies to address concerns regarding manufacturing and supply of 
pharmaceuticals in Australia.100 
1.11.7 Quality Use of Medicines 
To ensure that patients and healthcare providers used medicines safely and effectively, 
the QUM principles were outlined as follows: 
1. Selecting management of a patient’s health wisely 
a. Considering the place of medicines in treating illness and maintaining health  
b. Recognising that there may be better ways than medicines to manage some 
disorders 
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2. Choosing suitable medicines if medicines are required, and ensuring that the 
best possible available option is selected by taking into account: 
a. The individual 
b. The clinical condition 
c. Risks and benefits 
d. Dosage and length of treatment 
e. Any coexisting conditions 
f. Other therapies 
g. Monitoring considerations 
h. Costs for the individual, the community and the health system as a whole 
3. Using medicines safely and effectively to have best possible results by: 
a. Ensuring that patients and carers understand how to use the medicines and 
how to stop using medicines 
b. Ensuring health carers also understand the patient’s treatment 
c. Knowing what medicines are stopped and what are needed when patients 
are visiting hospitals, aged-care residences, and other environments 
d. Monitoring outcomes and changes 
These became the QUM principles that enabled a practical application of the NMP.1,84 
1.11.8 The Loss of PHARM and APAC  
Between the PHARM committee and APAC, a long range of activities were established. 
Examples include such aspects as: establishment of the APAC Continuity of Care 
Guidelines101; the setting up of The National Prescribing Service (NPS)102;the QUM 
consumer education initiative, which is contracted to NPS102, QUM scholarship program, 
and APAC guidelines on medication management.103 QUM was recognised as the missing 
link in Australia’s Medicines Policy.  
In 2005, the Department of Health and Ageing engaged a consultant to undertake a review 
of APAC's operational arrangements, and in 2006 both the APAC and PHARM were 
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discontinued. The activities and understandings of the NMP and QUM are, however, still 
used in government agencies as a way of ensuring best possible health outcomes. 
1.11.9 The Role of Pharmacists in Supporting the National Medicines Policy (NMP) 
Pharmacists have been instrumental in the development of the NMP by raising awareness 
for the need of a national policy to the Australian Government. Pharmacist contributed to 
the development of the policy contents which ensured the incorporation of associated 
QUM principles. Pharmacists were an integral part of evaluating and translating the NMP 
into practice. Pharmacists have been the link between all stakeholders that utilise 
medicines within healthcare and the community.  
The principles which underpin the practice of pharmacists all link to the NMP and QUM. 
Pharmacists are able to derive the required medication management systems, which 
include policy, from the NMP and apply it to their practice based settings. 
1.12 The Resulting Reasons for the Focus of this Thesis 
The NMP, coupled with the QUM principles, provide a foundation that supports the 
development, implementation and evaluation of interventions within healthcare. 
The application of well-known theoretical models to develop conceptual framework for 
each intervention is detailed in the introduction to each section or study.  
Using the Embedded Researcher Technique lends itself to incorporating both Qualitative 
and Quantitative Evaluation for each intervention. This enables each study to achieve a 
depth of understanding due to the ability to add descriptive data. For many of the studies 
presented, examples of mixed methodology are applied to demonstrate a robust analysis 
of each intervention. Utilising the Embedded Researcher Technique gives each 
intervention a greater likelihood of success due to the Embedded Researcher’s 
understanding of the importance of the culture, the potential resistance and the open lines 
of communication available for each stage of change. 
1.13 Setting 
The EPhR of this study is located in the Northern Territory of Australia. An important 
consideration in the Northern Territory (NT) is its unique demographics. The NT has a 
small, culturally diverse population which is dispersed over a large geographic area. The 
NT covers approximately 18% of Australia’s landmass. Despite being the third largest of all 
states and territories, the NT has the smallest population.31 In June 2015, the resident 
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population was estimated to be 244 600 persons (1%) of the national population.33 The NT 
has the lowest population density of all jurisdictions, with no areas in the NT classified as a 
‘major metropolitan area’ or an ‘inner regional area.’104 Even the NT capital, Darwin, is 
classified as outer regional area by the Accessibility/Remoteness Index of Australia.104 
Over one third of the NT population live in remote areas and 71% of those living remotely 
identify as Aboriginal or Torres Strait Islanders.105 This poses unique challenges in 
delivering health-services to individuals and communities, particularly those living in 
remote areas.106,107 Throughout this thesis, when the term ‘Indigenous’ is used, the 
authors are referring to the Aboriginal and Torres Strait Islander0F* peoples of Australia.  
In the NT health literacy is low, limiting people’s abilities to access health services, 
navigate through the complex health system or use medicines safely and effectively.108 
There are significant barriers to people accessing both GP’s and community pharmacy 
services.106 The majority of health services, including medications, are provided through 
health-centres based in remote communities which are predominantly staffed by nurses.109 
Even the “nearest” remote health care centres can be located hundreds of kilometres from 
people’s homes.110 
The setting for the majority of this research is based in the Royal Darwin Hospital (RDH). 
The RDH is a 400-bed general teaching hospital which provides a broad range of services, 
in all specialty areas, to the urban population, as well as serving as a referral centre to 
remote populations and for national trauma response.31 This hospital has a special focus 
on the care of people living in regional and remote areas, on Indigenous Australians and 
on infectious diseases.31 The pharmacy department provides a broad range of services for 
both inpatients and outpatients, and is an active contributor to the hospital’s quality 
improvement activities and patient safety research projects.  
1.14 Situating this Research 
In this thesis, the pharmacist used an Embedded Researcher technique. This thesis is not 
only designed to contribute to this area of research, but to offer practical advice for other 
pharmacists and health professionals wishing to utilise this model.  
Pharmacists rarely see research as part of their core role. The organisational structure, as 
well as the degree itself, constructs a barrier to influence future researchers.  For example, 
                                                          
* Torres Strait Islanders are the Indigenous people of the Torres Strait Islands, which are a part of Australia. 
They are culturally and genetically linked to Melanesian and Papua New Guinea peoples, and are regarded 
as being distinct from other Aboriginal peoples from the rest of Australia. 
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a recent study conducted in the United Kingdom explored pharmacists’ perceptions and 
experiences of pharmacist-led research in the workplace.111 The study had approximately 
equal number of pharmacists working in the hospital and community sector.111 Common 
responses from these pharmacists were as follows: 
“Our career progression is towards management and administration. It is not towards 
practice and research.” “The [pharmacy] career framework we've got is either clinical or 
managerial: Research is not seen as a career objective.”111  
Importantly, this thesis examines the benefits as well as the difficulties in combining 
research and practice. 
One of the most effective methods of learning for any health professional is through role 
modelling and professional socialisation. Role modelling, is “teaching by example and 
learning by imitation,”112 and occurs when an individual learns by observing another, and is 
influenced by the following: 
• The relationship between role model and student 
• The usefulness of what is modelled 
• The student’s ability to undertake the role and 
• The student’s motivation.113,114 
Professional socialisation is the process of individuals learning their profession as they 
become emerging members of the professional culture.115 Unlike role modelling, 
professional socialisation is not purely a reactive process. It is not only the interaction 
between a professional and their environment, but also relies on past experiences and the 
ability to reflect.56,116  
The best way of learning is by experience, and working in the professional environment 
provides one of the most effective methods of education: learning on the job by way of 
mentorship and professional socialisation.116  
Pharmacist rarely work with other pharmacists and are often sole practitioners within their 
area of work, therefore limited professional socialisation happens within the discipline. Due 
to the limited interaction with other pharmacists “on the job” what pharmacists learn at 
university, and during their internship, becomes the way pharmacists practice.  
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Additional reasoning for pharmacists working in silos includes: 
1. They are not actively engaged in their profession, in a range of workplaces, from 
day one in their undergraduate courses, and 
2. They train in isolation of the other health professions students so that trust, 
openness and recognition of roles are not properly developed at a time when this 
is easiest to be achieved. 
Unfortunately, due to the limited number of pharmacists prioritising research, the next 
generation of pharmacists learning by mentorship do not see the use of integration of 
research into their professional practice. 
This thesis highlights how abundant the research opportunities are within the pharmacist’s 
profession. Targeted research can help to improve the healthcare environment. Improving 
the quality of the environment in which a pharmacist works can not only lead to greater 
satisfaction within their work place, it can also help demonstrate the application of a 
pharmacists knowledge and skills which will ensure the best possible patient outcomes.  
“Well, I think if we are going to survive as a profession we have to have [research]. We 
have to develop as a profession.”111 
Not only will pharmacists benefit from incorporating research into their practice but so will 
the health-system as a whole. Their employers will also benefit from this bridge between 
academic knowledge, networks and critical approaches to policy and practice 
implementations.56  
Chapter 2 General Methodology 
2.1 Application of the Conceptual Framework 
The National Strategy for Quality Use of Medicines provides a conceptual framework 
which describes the approach necessary to design, implement and evaluate QUM 
initiatives.1 This framework was developed using an extensive selection of behaviour 
change theories developed in areas such as education, social marketing, public health and 
health promotion. Models such as Social Cognitive Theory,117 The Transtheoretical 
Model,118 PRECEDE-PROCEED5 and others2,119-123 were used to develop the key building 
blocks and processes needed to facilitate behaviour change and to achieve high quality 
medicines use which can be sustained. 
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Australia’s National Strategy for QUM has a strong conceptual framework and utilises a 
pyramid shaped model, developed by PHARM, to indicate a strong, long lasting effect.1 
(See figure 2.1) 
 
Figure 2.1: Levels of the Quality Use of Medicines pyramid (reproduced from1) 
The pyramid has three shelves and four sides through which people and their actions are 
developed. The sides represent stakeholder groups such as:  
1. Health practitioners and health educators 
2. Public face: Consumers and media  
3. Government/regulatory: Commonwealth, state, territory and local governments  
4. Industry: medicines industry, health funders and purchasers 
The shelves represent the level at which people, or groups, are in a stage of 
preparedness, and in their ability to achieve QUM. Note: The groups all meet at the top of 
the pyramid when QUM is reached.1 At Level 1, strategies are mainly awareness raising, 
exploring, informing and the provision of information. Level 2 involves provision of 
opportunities to develop knowledge and skills, to make appropriate decisions, and to offer 
opportunities to trial and adopt behaviours. At Level 3 people and organisations are at the 
evaluation level, where they are routinely monitoring effects, practicing quality assurance, 
and problem solving. Strategies required at each level vary depending on levels of 
agreement, the nature of issues, activities, skills, costs and commitment.1  
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By targeting all stakeholders at all stages of the pyramid simultaneously, the policy 
provides a framework for sustained change and improvement in health outcomes. 
Importantly, all stakeholder groups from the pyramid must be included in the development, 
implementation and evaluation of any initiatives. 
Underpinning the pyramid are six resources and initiatives;  
1. Objective information and ethical promotion 
2. Facilitation and coordination 
3. Education and training 
4. Policy development and implementation 
5. Services and interventions  
6. Strategic research, evaluation and routine data collection1,84 
This thesis focuses on the QUM management at varying stages of the pyramid. The 
Embedded Researcher Technique has been adopted by a clinical pharmacist to examine 
activities of people on all sides of the QUM pyramid, and to consider the six resources and 
initiatives underpinning the pyramid to plan and evaluate interventions.  
2.2 An Overview of Health Program Planning and Behavioural Theories to Support 
Change Management and Improve Health Outcomes: Bridging the Gap between 
Research and Practice. 
This thesis draws on aspects from behavioural theories that have been well established in 
healthcare research. The studies presented in this thesis have identified sub-optimal care 
or evidence gaps in practice. 
Failing to include theoretical behaviour frameworks in health program interventions may 
lead to varying success.66 The greater the use of behaviour theoretical frameworks has 
been shown to improve the uptake of research findings and, therefore, to bridge the gap 
between research and practice.88  
Instead of viewing a behaviour change as either having occurred or not occurred, staged 
theories emphasise that change happens over a series of stages, and furthermore that 
change happens by transitioning between those stages.66 While different stage theories 
describe different numbers and categories of individual stages, they all follow a similar 
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pattern that starts with a pre-contemplation stage, moves through a motivation stage, and  
reaches conclusion with the initiation and maintenance of a recommended behaviour.78 An 
integrative approach to health promotion planning recommends that each theoretical 
framework should be applied to the identified issue to form a robust intervention.120 This is 
based on the understanding that each framework offers a different perspective and 
thereby increases the strength of the intervention developed and, consequently, the 
likelihood of the intervention being successful.2 
2.2.1 Theoretical Models Supporting Successful Implementation Programs. 
Stage 1: Planning 
 
Figure 2.2: Stage 1: Planning an intervention2,4,5  
From a medicines’ utilisation research perspective, the epidemiological analysis involves 
medication-related problems identification.  This is further explored in the model, the 
analysis examining how stakeholder consultation assists in framing the intervention and its 
delivery, and how both stakeholder consultation and epidemiological analysis contributes 
to planning an evaluation that is based on measurable and agreed outcomes. Using the 
Embedded Researcher technique allows access for both the researcher and the 
stakeholders to examine and explore activities, new and old, and allows consultation and 
compromise throughout an intervention. 
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Stage 2: Delivery 
 
Figure 2.3: Stage 2: Program Delivery 2,4,5 
Individual behaviours are often the target of medicines utilisation research interventions, 
and this work will examine how behavioural theories118 support the place of QUM 
interventions in changing behaviour through raising awareness, improving knowledge, and 
promoting skill development for clinicians and patients, as well as providing motivation for 
action. Audit and feedback are examples of interventions that are guided by these 
theoretical models.117,118   
The Transtheoretical Model is an important model within the implementation or delivery of 
an intervention.124 It works on the theory that change is transitional through stages. Social 
Cognitive Theory as with the Transtheoretical Model provides an opportunity for reflection 
on learning and for self-evaluation. This is particularly important in that it allows the 
individual or organisation being examined to understand that if the implemented change 
will benefit them, it can help them to continue on to further stages, and they may finally 
reach maintenance stage where the intervention is able to be sustained.88,117 
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Stage 3: Evaluation 
 
Figure 2.4: Stage 3: Evaluation 2,4,5 
For the evaluation stage, the project will highlight how the evaluation must connect with 
the medication-related problem analysis that was undertaken at the beginning of the 
intervention. It is also important in any evaluation that the stakeholders have the 
opportunity to interpret outcome data from their own perspective. Again, the Embedded 
Researcher technique supports and encourages reflective behaviour that can add valuable 
insights to data. 
2.2.2 The Quality Improvement Framework 
The National Strategy for Quality Use of Medicines1 advises that, in order to provide 
sustained change, leading to appropriate medicines use and improved health outcomes, 
the development, implementation and evaluation of QUM initiatives (including the national 
strategy) should occur within a quality improvement cycle.125 The four phases of the quality 
improvement cycle are depicted in figure 2.5.  
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Figure 2.5: The Quality Improvement Cycle (Reproduced from 125) 
The four phases of the quality improvement cycle are described in Table 2.1. In practice, 
interventions are designed, tested and implemented using a series of cycles.125 This 
enables an intervention to be tested on a small scale, with adjustment and refinement 
before progressing to widespread implementation.77,126  
Table 2.1: Phases of the quality improvement cycle 
Phase Description 
Plan Stakeholders may review the literature and examine current performance to 
identify gaps in existing processes and prioritise areas for improvement. 
Stakeholders define the objective(s) of the activity, identify the target groups and 
potential barriers, and plan the intervention.125 Methods used to collect and 
analyse data are also determined.127,128 
Do The intervention is carried out, usually on a small scale. 
Study Data are collected and analysed according to predefined measures to identify if a 
change in performance has occurred.125,128 
Act Results can be used to refine an intervention, plan for ongoing monitoring and 
identify future directions.125,127 Findings may also be used to provide feedback to 
individuals, organisations or policy makers on performance, and for benchmarking 
purposes.127 
2.3 Summary and Future Directions 
Clinician-scientists are often associated with the term translational research. Translational 
research suggests a two-way process of translating research findings into clinical 
application (literature to bedside), and providing clinical data to be researched (bedside to 
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The importance of being an Embedded Researcher, and the approach of this thesis, is the 
recognition of the necessity of working within a team and the understanding that the team, 
rather than individuals make decisions. This work of an Embedded Researcher is thus: to 
help define what can be offered by a pharmacist to a healthcare system, and to ensure 
that this work is seen as an example of a response that can be replicated by any 
pharmacist, in any position, as long as key methodology and insights are utilised, and the 
specialist skills of a pharmacist are executed.  
The aim of this thesis is to investigate the effectiveness of an Embedded Pharmacist 
Researcher impact on Quality Use of Medicines. This thesis is designed to demonstrate 
how a clinical pharmacist, embedded within a team, can identify problems, develop 
innovative interventions, and implement sustainable solutions. 
This thesis is divided into four sections, each of which contains a series of studies. Each 
section has a dedicated introduction which includes how the research questions for that 
section developed, a thorough literature review, and outlines the role of the Embedded 
Pharmacist Researcher. The studies detail the methodology which have been used, the 
intervention made and the evaluation techniques. Throughout the sections, obstacles, 
challenges and rewards are detailed in an attempt to capture the story of an Embedded 
Pharmacist Researcher.  
Chapter 3 provides detailed review of an Embedded Pharmacist Researcher integrating 
within a Mental Health setting with a particular focus on Indigenous Mental Health. 
Chapter 4 demonstrates how an Embedded Pharmacist Researcher can capitalise on 
revenue and cost savings provided by their quality improvement studies to help build a 
sustainable work force. 
Chapter 5 utilises the ideal position of being an Embedded Pharmacist Researcher to 
change practice for a high risk area in healthcare; communication between the hospital 
and community sector.  
Chapter 6 the Embedded Pharmacist Researcher identifies gaps between research and 
practice in evaluating risk, and risk management within healthcare. 
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Chapter 3 Opportunities for an Embedded Researcher in Indigenous Health in the 
Northern Territory 
3.1 An Introduction to Mental Health and Mental Illness in the Northern Territory 
Mental illness is epidemic in the Northern Territory (NT).130 Unfortunately, we as 
healthcare practitioners, are still far from knowing the extent of Mental Illness, nor do we 
know culturally appropriate methods of treatment.  
Looking purely at statistics, it is not surprising that the NT is one of the highest rating 
states or territories for Mental Illness within Australia. The NT has the youngest population, 
which is predominately male, the highest birth rate, the highest rate of homelessness, and 
with a large proportion of the population being Indigenous. All of these are known risk 
factors for Mental Illness.105,131-133 (See table 3.1). 
Table 3.1 Australian and Northern Territory Demographics in 2016 
Mental Illness Risk Factors Australian Data NT data 
Total Population 24 127 200 244 900 
Median Age 37.4 years 32.2 years 
Gender proportion (male) 99 males per 100 females 112.3 males per 100 females 




Rate of homelessness 105 237 
(49 people per 10,000 people 
are homeless) 
15 479  
(730.7 people per 10,000) 
Indigenous population 
(Aboriginal and Torres 
Straight Islanders) 
698 583 
(3% of total population) 
71 054 
(29% of NT population) 






Regardless of where a health practitioner is employed, Indigenous patients will be a part of 
their interactions. For this reason, it is important to understand the spread of Indigenous 
populations with Australia. See Figure 3.1. 
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Figure 3.1: Estimated Indigenous population by jurisdiction, Australia, 2014 
Notes:  
1. Australian population includes Jervis Bay Territory, the Cocos (Keeling) Islands, and Christmas Island  
2. Proportions of jurisdiction population have used total population figures estimated from demographic information for 
June 2014 
Source:  
Australian Indigenous HealthInfoNet (2015). Overview of Australian Indigenous health status, 2014. Retrieved 20/2/2016 
from http://www.healthinfonet.ecu.edu.au/health-facts/overviews.   
 
The largest population of people who identify as Indigenous live in New South Wales 
(NSW) and Queensland (QLD); however, with regard to the proportion of a population, 
Indigenous people make up 30% of the NT.33 It is well known that Indigenous people are 
over-represented in the health-system and so, even in states like Tasmania and the 
Australian Capital Territory, which have small numbers of Indigenous people, Indigenous 
people are still likely to frequent health-services. The five hospitals within the NT have 70-
80% Indigenous patients at any one time.134  
3.1.1 Mental Health and Wellbeing of Aboriginal and Torres Strait Islander People 
Indigenous Australians view health in a holistic context as reflected in the definition of 
health contained within the National Aboriginal Health Strategy (1989): “‘Aboriginal health’ 
means not just the physical wellbeing of an individual but refers to the social, emotional 
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their full potential as a human being, thereby bringing about the total wellbeing of their 
community. It is a whole-of-life view and includes the cyclical concept of life-death-life.”135 
Individual health in the Indigenous culture is not thought to be as important as the 
wellbeing of the community. This explains why people will leave hospital if humanly 
possible for example, for another person’s funeral. An example of this is a patient self-
discharging from the High Dependency Unit of the Royal Darwin Hospital. Not attending a 
funeral has consequences not only for the individual, but also for their community and for 
the natural order. Therefore, the consequences of not attending are greater than attending 
and risking death. From a health professional’s point of view this can be hard to accept 
due to concern about the individual’s health and/or the anticipated outcomes if continual 
care is not provided. However, it is best that a safe discharge is facilitated given that, if this 
does not occur, the patient will take their own leave regardless. 
Until recently Mental Health statistics which were available for Indigenous Australians 
included suicide rate, hospitalisation rate for diagnosed mental disorders, emergency 
department attendances for Mental Health, substance misuse related conditions and 
contacts with public community health services.136 
Mental Health in Indigenous populations needs to be explored in the same way that 
“closing the gap” for physical health has been examined. With physical health, much of the 
gap has been found to be attributable to tobacco use, high body mass, physical inactivity, 
high blood cholesterol levels and alcohol misuse, but the role of mental illness in health-
related behaviours has not been explored.136  
Statistics regarding suicide within Australia’s Indigenous people have been summarised in 
Appendix 1 from the “Creative Spirits Website.”130 
The most recent statistics from the Australian Bureau indicates that suicide is the leading 
cause of death for Indigenous people aged 15 to 35 years.137 For this age bracket 
Indigenous Australians are three times more likely to take their own life than other 
Australians.138 Deaths from ‘mental and behavioural disorders’ do not include deaths from 
‘intentional self-harm’ (suicide).139 Indigenous children are nearly nine times more likely to 
commit suicide than non-Indigenous children.138 The Northern Territory has the highest 
rate of youth suicide in Australia.137  
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3.1.2 Indigenous Culture 
Indigenous cultures are not all the same across Australia, however there are some 
aspects that are universal. The EPhR experiences with Indigenous cultures come from a 
Top End perspective and certain practices are different in Central Australia, showing a 
variance even within the NT.  
Health professionals within the Northern Territory Department of Health are required to 
undergo Cultural Awareness Training and are taught that Indigenous culture is an 
incredibly polite culture.140 Indigenous people will generally stay back and wait to be 
invited to join someone or to talk within a group. Relationships are very important as is 
saving face, not arguing or disagreeing. This needs to be taken into account when 
communicating with someone from an Indigenous background.140 
Knowledge is not freely shared in Indigenous cultures. It is impolite to ask questions in 
general and there is a belief that information will be shared with a person when it is 
believed that they are ready.140 For this reason, an Indigenous health worker will often, if 
they have a correct relationship with the patient, obtain much more information, not only on 
their life circumstances but also on their beliefs surrounding their illness. 
From clinical experience, it has been noted that often the commencement of a new 
medication will be handed over to a patient’s community clinic as the staff there will have 
developed a trust relationship with the patient. The community clinic staff are in a better 
position to have an extended conversation about the treatment and to allow adequate time 
for questions and family discussion.  
3.1.3 Diagnosing Mental Illness with Aboriginal and Torres Strait Islander People 
Diagnostic tests, such as the Diagnostic and Statistical Manual of Mental Disorders-5 
(DSM-5),141 used by the majority of psychiatrists,  do not allow for the required cultural 
differences. The American Psychiatry Society is attempting to implementing a “Cultural 
Formulation Interview and the Evolution of Cultural Assessment in Psychiatry”.141 The 
DSM-5 has acknowledged and incorporated more cultural sensitivity throughout this 
manual than was included in previous versions. “Different cultures and communities exhibit 
or explain symptoms in various ways. Because of this, it is important for clinicians to be 
aware of relevant contextual information stemming from a patient’s culture, race, ethnicity, 
religion or geographical origin. For example, uncontrollable crying and headaches are 
symptoms of panic attacks in some cultures, while difficulty breathing may be the primary 
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symptom in other cultures. Understanding such distinctions will help clinicians to more 
accurately diagnose problems as well as more effectively treat them.”141 This 
understanding however still relies heavily on clinicians receiving culturally appropriate 
training as well as access to health workers who can clarify if particular behaviours and 
symptoms are culturally appropriate.  
From observation, asking an Indigenous person if they have seen or heard spirits or 
something that no one else can see or hear, most would say yes. In fact, if it is culturally 
appropriate to be seeing and hearing spirits it is a blessing, and an important part of being 
well and staying well. However, using the western diagnostic model from the DSM-5 it 
would take a physician down the lines of suggesting that the patient has a potential 
psychosis.142 It is essential to include Australian Aboriginal Health Workers in interviews 
with patients to determine if what the patient is describing is appropriate culturally.140  
Another example of requiring a culturally appropriate diagnosis for an Indigenous person is 
the approach to discussing and exploring self-harm. Mental Status Examinations, which 
are commonly used, can include questions regarding self-harm. For Indigenous people, 
asking if they “have ever engaged in deliberate acts of self-harm” the majority of patients 
would say “yes”, particularly those of Central Australian origin, where this is common 
practice. If a person dies, part of the grieving process of the surviving family is to cut 
themselves, called “sorry cuts”. Answering “yes” to this question alone can result in a 
patient being sent inappropriately to a psychiatric inpatient unit.142,143 
There are many more examples which demonstrate that the non-Aboriginal models of 
diagnosing and treating Mental Illness in the Australian Indigenous populations are not 
working; a cultural approach is needed and can only be done within the individual 
communitie’s.143-145 
The first culturally and scientifically validated psychological test has been developed 
specifically for use with/by Aboriginal Australians, and is now been utilised worldwide143, 
however it is not used in routine practice within the Northern Territory.  
3.1.4 The Impact of Health Literacy in the Area of Mental Health 
Language and health literacy are challenges that must be recognised at the start of any 
interaction between clinician and patient.  
The Indigenous language map of Australia, Appendix 2, demonstrates that there are 
around 80 distinct languages, not dialects, in the NT alone.146 There are some languages 
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which many groups will speak, such as Kriol. Most Indigenous people are fluent in five or 
more languages; however, English may not be a dominant language for them. This can 
still be the case with young people.  
Language takes into account different world views of Indigenous people and thus it is not 
easy to translate medical theory into Indigenous languages. Translators are exceptionally 
useful; however, they are usually not medically trained and medical words may not exist in 
a particular language. For example, there is no word in the Yolngu language that describes 
‘suicide.’130 
Table 3.2 notes the key colloquial terms that are of particular importance within the Mental 
Health settings. These terms are common across languages within the NT, however there 
are differences between the Top End and Central Australia, for example, the use of the 
colloquial terms Gunja (Top End) or Wiame (Central Australia) for Marijuana.  
Table 3.2 Key Colloquial Terms and their Application within the Mental Health Setting 
Colloquial Terms Meaning Application within the Mental Health Setting 
Sorry business Funeral and 
mourning 
practices147 
Due to the “life-death-life” cycle, it is vital for Indigenous 
patients to attend sorry business within their community. As 
there are high rates of premature death within the Indigenous 
population, sorry business is a common occurrence. 
Treatment, including hospitalisation, needs to be flexible to 
accommodate the need to attend.144,148  
Humbugging Make a 
nuisance of 
oneself149 
Humbugging is particularly descriptive if patients are unwell 
out in their communities. Often the family and other 
community members will start complaining of a person 
humbugging everyone and that the humbugging is getting 
worse. Quite often, especially in the locked ward, 
humbugging is usually part of a behavioural management 
plan to help the patient and the staff to monitor compulsive 
behaviour and concentration. 










Homelessness is a risk factor for mental illness.  
This is also essential information in regards to medication 
choice. For example, medicines which require refrigeration 
will not be appropriate for patients who are sleeping rough.151 
Galka Sorcerer or 
spirits152 
A common persecutory delusion for Indigenous patients with 
thought disorders involves curses or sorcery.152 This is in 
contrast to non-Indigenous Australian who commonly 
experience persecutory delusions involving spies, bikies or 
the government.153 
Black magic Being cursed or 
have had spells 
being cast152 
Waime/ gunja Marijuana154 There is substantial evidence of the association between 
Marijuana use and the development of schizophrenia or other 
psychoses, with the highest risk among the most frequent 
users.155 Marijuana use can also increase the chance of 
relapse and an increase in positive symptoms.155  
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It is important to note that health literacy works from both sides; Western Clinicians are 
restricted due to the limitation of their accessibility to cultural words and the Indigenous 
patients’ understanding is often limited when medical terminology is used.142  
3.1.5 Causality of Illness 
There is a view within the Indigenous culture that all death and illness before old age is 
due to social and spiritual causes. Supernatural intervention is regarded as the main cause 
of serious illness.156 For example, if somebody died in a car crash, the fault would not be 
due to poor driving conditions or lack of seat belts, but could be blamed on a curse or an 
action of the person.156 Death of an infant, the very old or chronically ill is considered a 
normal course of events, whereas death outside of these situations may have a 
supernatural cause, especially if the death is unexpected and premature.156  See 
Appendix 3. 
Within Mental Health, causality of illness can be related to cultural phenomena and can be 
difficult to differentiate from what is culturally appropriate and what can be detrimental to a 
patient’s Mental Health. This highlights the importance of engaging with Aboriginal Health 
Workers and gathering information from members of family and community. 
3.1.6 Staying in Balance 
Indigenous emotional and social wellbeing can be understood as being a good balance 
between the strengths and stressors experienced at any given time. Although stressors 
can be out of an individual’s control they can always build on strengths to restabilise their 
wellbeing.  
Within the NT setting, Stay Strong Plans (See Appendix 4) are used, with the help of 
Indigenous health workers. These are key in communication and in working out what 
stressors maybe affecting each patient during a period of illness, and who and what a 
patient relies on to restabilise their balance.157  
3.1.7 Traditional Healers 
Ngangkari are the traditional healers (or spirit doctors) of Australia.139,158 They work to treat 
the spiritual side of illness, and in the clinics of Mutitjulu and The Akeyulerre Healing 
Centre, both Ngangkari and “Western” doctors work out of the same clinic, treating 
traditional and western causes of illness side by side.159,160 When in hospital, most Top 
End Indigenous patients (63%), involve a traditional healer in their care.148 Another 
organisation, The Ngaanyatjarra Pitjantjatjara Yankunytjatjara Women's Council, currently 
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employ Ngangkari to deliver treatments to patients across a three-state region of about 
350 000 square km, in more than 25 communities in SA, WA and NT.158 At the Royal 
Darwin Hospital as well as other Top End Hospitals, the Indigenous Traditional Healers 
are signed in and out, by hospital staff, as visitors. An exception is that visiting hours are 
not restricted for Ngangkari to see their patients.  
The EPhR would suggest that an important step towards engaging with Indigenous 
patients would be to acknowledge Traditional Healers as health professionals and have 
them welcomed to work collaboratively within the healthcare team. Many Ngangkari, who 
are employed by the Ngaanyatjarra Pitjantjatjara Yankunytjatjara Women's Council in Alice 
Springs, work hand in hand with western health professionals.158 Central Australia in 
particular in the Alice Springs Hospital, has worked towards collaboration with Traditional 
Healers providing traditional care for Indigenous patients in hospitals, nursing homes, jails, 
hostels and wherever Indigenous people need healthcare.161  However, even within the 
much advanced collaborative framework such as that of Alice Springs, there is still an 
obvious knowledge gap of the western practitioners in understanding the practices of 
Traditional Healers.159  
The Department of Health and Families in Alice Springs provided funding for the 
Akeyulerre Healing Centre for three years with a requirement that the outcomes of this 
service be evaluated.159 The Akeyulerre Healing Centre provides traditional care to 
Indigenous patients within a wide variety of settings, including hospitals. A report was 
conducted by Charles Darwin University to examine the outcomes of this service.159 One 
recommendation that came from the report was to strengthen Indigenous Support 
Services at Alice Springs Hospital to enable workers to better advocate for the traditional 
healing needs of patients.159  
This recommendation relates to a concern that medical staff do not necessarily understand 
or respect traditional healing and its place for Indigenous people. In its attempts to find 
respondents who could give informed comment about the Hospital’s relationship to 
Akeyulerre and what it does, “the evaluators could not be directed to any person—even 
among the Aboriginal Liaison or Support staff—who felt able to comment.” This is perhaps 
indicative of the low level of awareness among professionals within the hospital system.159 
There are multiple reasons for Ngangkari’s not being recognised within Australia’s 
healthcare system. This includes having no official pay scale, and what they earn for their 
work, varies wildly. The logistics and cost of getting people from remote areas to a city, the 
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difficulty of a government department engaging Ngangkari in a system where employees 
need Australian Business Numbers and bank accounts, and the lack of any system of 
formal accreditation contributes to the funding issues.162 Further, cultural issues arise, with 
many people only comfortable when they are seeing Ngangkari to whom they are 
related.162 
Australia is still far behind other countries with Indigenous populations in regards to the 
acknowledgment of traditional healers. “In New Zealand you can walk into a clinic and you 
can choose between seeing a western doctor or a traditional healer. It’s a two-way system. 
Canada has the same.”162 
3.2 Medication Management in Indigenous Populations 
General health statistics and life expectancy of Indigenous people are markedly lower than 
the non-Indigenous population in Australia.163 There is also much literature detailing the 
inequity of chronic disease in the Indigenous population, with a contributing factor being 
the low rate of adherence to medication.163 According to the World Health Organisation, 
there are five dimensions that can impair a patient’s adherence with medication.164 These 
are the healthcare team or system, socioeconomic factors, the nature of the therapy, the 
patient and the medical condition. These dimensions ring true for the Indigenous 
population of Australia.164,165 
What is not widely appreciated is how poorly Australia compares with other developed 
nations.166 While Indigenous people have seen no improvement in all-cause standardised 
mortality over the last generation, rates for Maori people of New Zealand fell by 41% in the 
20 years since 1994, and  28% for Native Americans in the USA.167 In these countries, 
expectation of life at birth now approaches that of the general populations. Key policy 
differences in Australia include confused responsibility for funding, and service delivery 
between different levels of government.168 
Despite numerous health-related studies, very little has been documented about 
medication management for Indigenous people. While some studies have evaluated 
medication access schemes and funding, very little research has been conducted into 
Indigenous people’s perceptions, experiences and understanding of medicines, or 
applying Quality Use of Medicine principles within the remote setting.169,170  
In the remote setting, pharmaceutical care is managed by other primary health care staff. 
Many of these staff have no formal training in the management of medicines or 
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pharmacotherapeutics which is required for basic dispensing and counselling services.109  
In non-remote Australia, pharmacists are the most accessible health professionals in the 
community, seeing around two per cent of Australian adults at least once a fortnight and 
providing an estimated 42 million primary care consultations each year.171 Yet this service 
is generally not available to the residents of remote Indigenous communities.109  The 
involvement of a pharmacist, as a part of the primary health care team, is essential to the 
quality use of medicines in urban and rural areas, but has yet to be established in remote 
Australia.106  
3.3 Integration of an EPhR into the Mental Health Team 
The EPhR was employed as the first clinical pharmacist within the Northern Territory 
Mental Health Service. This inaugural position was to provide care for patients with Mental 
Illness that were being treated within a government hospital or healthcare facility. The 
EPhR’s position covered five hospitals in the Northern Territory; Royal Darwin Hospital, 
Alice Springs Hospital, Gove District Hospital, Katherine District Hospital, and Tennant 
Creek Hospital. The community-based Mental Health teams that the EPhR was 
responsible for included: forensics, perinatal, child and adolescent, adult teams, clozapine 
clinics, consultant liaison teams, crisis assessment and telephone triage, and rural and 
remote teams. 
The scope of this NTMHS pharmacist position provided an exciting opportunity to develop 
career paths for both clinical pharmacists and technicians. It was a chance to break the 
mould of traditional ‘hospital pharmacists’ and to become a ‘trail blazer.’ This position was 
unique as it provided a service to both hospital and community. This allowed for help with 
continuity of care, and recognised that healthcare is fluid. The original hospital network in 
the Northern Territory has now transitioned to a health-service with the understanding that 
previously there was a silo effect1F†.172 Primary and community healthcare has now been 
brought under the same governance to make the transition of care between different 
health-services smoother.173 The Mental Health position was the first pharmacist position 
not allocated to a ‘ward’ or ‘team’. Rather the position allows the pharmacist to cross the 
boundary of both community and hospital practice. 
                                                          
† The Silo Effect in business refers to the lack of communication and cross-departmental support often found 
in large companies. Teams work only on their own goals, often ignoring the needs of others, and information 
(and patients) get lost in the middle 
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3.4 Building a Sustainable Service 
Mental Health has been a high-profile government area. The Commonwealth Government 
invested $2.2 billion dollars in Mental Health over a five year period from 2011, in new and 
expanded initiatives, to drive fundamental reform in the Australian Mental Healthcare 
system.174  
The reforms span initiatives across a number of portfolios, reflecting the cross-sectoral 
nature of mental healthcare. The Commonwealth government had the intention of 
improving access to better integrated and targeted mental healthcare in the community.174 
The Northern Territory, although having a prolific number of patients with mental illness, 
has often experienced a two to three-year gap before national initiatives have reached the 
local level (see Appendix 5).175  Parts of the national health reforms included a 
strengthening of primary Mental Health services and ensuring quality, accountability and 
innovation in Mental Health services.174 
The chief pharmacist of the Northern Territory had been lobbying for a pharmacist position 
with the Mental Health executives for over nine years. The Northern Territory Mental 
Health Service (NTMHS) pharmacist’s position was funded in 2012. There were many 
driving factors for the timeliness of this position being approved by the NT government, 
including but not limited to: 
• National Accreditation 
• The development of QUM indicators specific for Mental Health 
• The shift of Mental Health to come under the Northern Territory health-service 
network 
The EPhR was employed as a sole pharmacist within a large service. The ideal would be 
to capitalise on opportunities to expand the pharmacist workforce within Mental Health. 
Looking at bed numbers and patient ratios alone, the NT was still well below 
recommended pharmacist staffing levels within Mental Health.176 The quality improvement 
cycle and the PRECEDE-PROCEED model were employed to help the EPhR focus on the 
most-needed areas for change.5,125,177 The quality improvement cycle helped the EPhR to 
utilise an outcomes-based approach to demonstrate the need for an expansion of 
pharmacist services within Mental Health.  
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This section of the thesis is set out to demonstrate the benefits of having a pharmacist 
within the service and to describe how to utilise the outcomes of Embedded Research to 
lobby for an increased number of pharmacists and technicians that will enable the service 
to continue to drive improvements and quality outcomes.  
3.5 Standard Study Plan  
The study plan outlined in this section was applied to achieving medication safety and 
quality in mental health. The studies associated are presented in Chapter 4. Although this 
study plan has been used as an example for the integration of an EPhR into the mental 
health setting and the quality improvement activities associated, it can be used as a 
template and applied to other healthcare settings.   
The Embedded Pharmacist Researchers Integration into a Mental Health Service 
Problem identified: Concerns regarding unsafe and ungoverned medication management 
across the Mental Health service.  
Intervention: Employment of a clinical pharmacist 
Methods: The clinical pharmacist undertook the new position by practicing as an 
Embedded Pharmacist Researcher (EPhR). The EPhR identified the need to build a 
sustainable and distributed pharmacist service to achieve Quality Use of Medicines within 
Mental Health. 
The technique utilised by the EPhR was that of knowledge translation. Knowledge 
translation is defined as ‘ensuring that stakeholders are aware of and use research 
evidence to inform their health and healthcare decision-making.’88  
As a strategically targeted approach to improving Quality Use of Medicine within the 
service, the EPhR went in to the service with the knowledge and understanding of current 
medication safety evidence. Fortunately, there is increasing knowledge on how to improve 
medication practices and it is important for health-services to be aware of these measures 
so they can avoid medication errors.178 Often interventions are based on beliefs or on the 
instincts of health professionals, which can still result in clinically important change; 
however, the results are unpredictable and vary between a 14% to 34% success rate.179 
The EPhR’s Strategic approach was to “complement evidence-based medicine with 
evidence based implementation” techniques.179,180  
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As a senior pharmacist the EPhR provided advanced clinical knowledge and could draw 
on past experience to develop what works in other areas, and the correct ways to have 
successful implementation (such as the quality improvement cycle, PRECEDE-PROCEED 
model, engagement with stakeholders, pharmacoepidemiology and drug utilisation 
research methods).1,5,82,181  
The program delivery was about examining the drivers of change: for example, looking at 
what regulatory and organisational issues needed to be targeted.76  
The EPhR had observed the current processes, procedures and targeted areas where 
change was possible and where change would have a positive influence on a multitude of 
factors such as patient safety, reducing expenditure, QUM, passing accreditation, just to 
name a few. The EPhR completed the interventions by building a team. Additions to the 
team consisted of both pharmacists and technicians to work with the EPhR. The idea was 
that a team would help to provide support for the interventions and provide sustainability 
and continuity of care.  
Identification of Potential Barriers 
The EPhR employed diverse methods for identifying potential barriers including qualitative 
approaches (individual interviews, focus groups), surveys and direct observation. 
Barriers for changing the medication management processes within the Mental Health 
setting occurred at different levels of the healthcare system, many of which operate at 
levels beyond the control of the EPhR. For example, barriers may operate at other levels 
of the healthcare system including: structural barriers (e.g. financial disincentives), 
organisational barriers (e.g. inappropriate skill mix, lack of facilities or equipment), peer 
group barriers (e.g. local standards of care not in line with desired practice), professional 
(e.g. knowledge, attitudes and skills) and professional-patient interaction barriers 
(e.g. communication and information processing issues).3,88 
Choosing the Methods for Each Intervention 
For each intervention the EPhR identified fixed and flexible barriers relating to behaviour; 
identified potential allies and practice environments; and prioritised which quality 
improvement activities to target based upon consideration of high risk or patient safety 
areas.  
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The EPhR had to consider drivers of change, time management and available resources 
for each knowledge translation activity.88 Each activity was conducted using evidence-
based implementation methods. For example, activities to support effective professional 
behaviour change include; printed education materials, educational meetings, audit and 
feedback and academic detailing. Whilst activities to support effective knowledge 
translation for patients included decision aids, interventions to enhance adherence, written 
information and alternative methods of communication. 
How the EPhR Worked within the Intervention 
The EPhR worked as the primary investigator at all stages of each intervention, from 
observation to evaluation. The EPhR developed relationships with staff via professional 
socialisation and utilised staff interactions to build credibility as a senior clinician and as a 
researcher. There is evidence to suggest that when knowledge translation is applied by 
clinicians who have credibility with the target audience, the uptake of evidence is more 
likely to occur.88 
Program Delivery:  
Evaluation Stage: Evaluation of each project was to produce a two factor outcome; 
Factor 1: The benefits of the pharmacist profession: 
• Demonstrating the transition of pharmacists as a profession working in different 
areas 
• Demonstrating the ability of pharmacists to not be confined to hospitals or 
community sectors (the importance of working along the transition of care) 
• Scoping different roles from traditional pharmacist’s duties. Indicating where a 
pharmacist can be a benefit to a health-service. These include governance, quality 
improvement activities, revenue, capping of expenditure and patient safety 
• Increasing time for clinical work 
• Removing tasks that are high-effort/low-reward for pharmacists, and providing 
opportunities for technicians 
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Factor 2: Benefits for the Mental Health Service: 
• Evaluating whether the intervention has had a positive impact on specific clinical 
targets 
• Benefits to Mental Health patients, either directly for an individual or by improving 
the quality of healthcare each patient receives from the service 
• Benefits to other health professionals, for example freeing their time to perform their 
core duties 
• Improving patient and staff safety in relation to medications 
• Benefits to the Mental Health service reputation by improving the standard of care 
delivered to the community 
• Financial savings to federal and local budgets, individuals, and the community  
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Chapter 4 Medication Safety and Quality in Mental Health  
Chapter 4 is dedicated to examining medication safety within the Mental Health setting and 
implementing evidence-based practices to improve the quality of the service delivered. 
This chapter examines a number of areas of medication safety and quality targeted by the 
EPhR. The EPhR strategically capitalised on the results of the interventions to develop 
and grow a Mental Health Pharmacy Team. The studies included in this section are all 
core criteria from the Australian National Safety and Quality Healthcare Standards and 
include; medication governance, storage, distribution systems, provision of medicines 
information to consumers and carers, medication histories and reconciliations, medication 
charts, high risk medicines and academic detailing.182 These examples demonstrate how 
the EPhR has not only chosen areas to target, but how the EPhR has translated her 
findings into practice.   
4.1 Australian National Safety and Quality Health Service Standards 
4.1.1 Background 
Accreditation has been commonly used as an approach to monitor and improve quality of 
care in hospitals.183 Accreditation within healthcare was originally introduced in the United 
States of America, in 1917, as an approach by the medical profession to demonstrate 
higher quality and to provide them with a marketing advantage, and it has been adopted 
and adapted in many countries.184-187 The key characteristic of accreditation is the ‘public 
recognition of the achievement of a ‘standard’, through ‘independent external peer 
assessment.’188  
Quality of care in hospitals has been identified as a key focus in high income countries, 
such as Australia, because of evidence of high rates of inappropriate care, variations in the 
incidence of procedures unrelated to differences in patterns of disease, and high 
expenditure on treatment of adverse events and medical errors.186,189,190 While some have 
defined quality as ‘the degree of excellence, the extent to which an organisation meets 
clients’ needs and exceeds their expectations,’188 others have suggested a simpler and 
more direct statement: ‘Doing the right thing, to the right person, at the right time, at the 
lowest cost.’191  
Quality and safety go hand-in-hand, and the way to improve safety and quality is to 
recognise potential risk and minimise the chance of incidents occurring. By striving to 
provide a work environment that is free from unacceptable risks and hazards, these 
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measures ensure the safety of our patients, staff and the quality of our work. Healthcare 
accreditation supports and facilitates the minimisation of risk.186  
Prior to 1 January 2013, when accreditation was a voluntary process in Australia, all public 
hospitals were accredited under contractual agreements with a single accrediting agency, 
that being the Australian Council on Healthcare Standards (ACHS).182 
In 2006 an important Government project was initiated to develop what is now the National 
Accreditation Scheme for hospitals and healthcare facilities.178 There were a number of 
factors that caused the Health Ministers to seek the development of a National 
Accreditation Scheme. These included the following: 
• The safety and quality accreditation of health-services in Australia was seen as 
fragmented 
• Safety and quality accreditation was perceived by health-service organisations as 
too complex and resource intensive 
• Accreditation outcomes lacked the transparency expected by governments and 
consumers 
• There were no standards in use that applied across all settings of care.178 
The Australian Commission on Safety and Quality in Health Care worked towards 
accreditation reforms to improve safety and quality outcomes for patients. This activity has 
resulted in the development of a set of safety and quality health service standards for use 
in an Australian Health Service Safety and Quality Accreditation (AHSSQA) Scheme. 
These National Safety and Quality Health Service (NSQHS) Standards were submitted to 
the Australian Health Ministers’ Council (AHMC), and were approved in September 
2011.178 
With the introduction of the mandatory accreditation to the NSQHS Standards, ACHS 
changed the accreditation product available to health services. One of the primary 
differences between the National Accreditation Scheme and the Accreditation process 
prior to its implementation was the criteria on which hospitals were assessed. There are 
209 core actions and 47 developmental actions, with three categories of compliance: 
• Not Met – the actions required have not been achieved.  
• Satisfactorily Met – the actions required have been achieved. 
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• Met with Merit – in addition to achieving the actions required, measures of good 
quality and a higher level of achievement are evident. This would mean that a 
culture of safety, evaluation and improvement is evident throughout the organisation 
in relation to the action or standard under review.181 
The previous accreditation system was much more focused on being a developmental 
assessment, and accreditation was lenient in acknowledging actions that were in progress 
or evidence that a health-service was implementing a required action to encourage quality 
improvement. The National Accreditation Scheme is assessing whether a healthcare 
system is doing a required action or if they are not. The National Safety and Quality Health 
Service (NSQHS) Standards were developed by the Commission to drive the 
implementation of safety and quality systems and improve the quality of healthcare in 
Australia. The 10 NSQHS Standards provide a nationally consistent statement about the 
level of care consumers can expect from health-service organisations. (See 
Appendix 6).181 
“Although couched in the language of continuous quality improvement, the accreditation 
process is, at its core, a risk reduction activity. It begins with the setting of contemporary 
standards that address important organisational functions—for example, patient 
assessment, medication usage—and then encourages organisations, through the 
awarding of accreditation, to comply with these standards.”187  
In 2014, the Northern Territory Hospitals were due to undergo National Accreditation. The 
Mental Health Service, which had recently moved under the governance of the Top End 
Health Service (TEHS), placed TEHS at great risk of not achieving accreditation. Due to 
the Mental Health Service being a governance unto its own, policies and procedures had 
developed that were not in line with the hospital, and not in line with best practice, on 
which the NSQHS Standards are based. In 2012, the EPhR was employed as the Mental 
Health Pharmacist for the Northern Territory; this led to a daunting responsibility of raising 
the standards of medication management within the Mental Health Service to ensure the 
required actions were met in order to be granted accreditation. 
Of the 10 NSQHS Standards, Standard four was dedicated to medication safety. Standard 
4 is one of the largest standards with 31 core actions and six developmental actions.181 
This is an example of an external factor which could be used as a driver of change.76 As a 
Health Service, the image of failing accreditation is detrimental. Pressure and fear of failing 
are motivators, particularly for Hospital Executives who understand the consequences, 
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such as society losing trust in their service and facing, potentially, a lack of funding 
opportunities.184-187 
Utilising accreditation to move the Mental Health Service in a positive direction was 
supported by strategies implemented by the EPhR. One essential strategy was the 
development of a Mental Health Medication Safety and Quality Working Group. This was 
done early in the employment of the EPhR. The reason that this strategy was needed was 
to provide recognition that the governance of medicines and their management needed to 
be agreed upon by all stake-holders, reinforcing the need for sustainable systems, rather 
than relying on an individual. This multidisciplinary workgroup, which had representatives 
from all Mental Health teams and disciplines, shared responsibility for the uptake and 
sustainability of interventions (See Appendix 7). The other important factor in the formation 
of this working group was that it became protected time for the managers and executives 
of the Mental Health service to focus on medication safety and quality. The Mental Health 
Medication Safety and Quality Working Group gave a platform for the EPhR to 
demonstrate the gains from a pharmacist’s point of view but also the gaps within our 
service that would prevent Mental Health from passing Accreditation.76,192 Finally, it also 
provided an opportunity for the EPhR to utilise the expertise of other disciplines and to 
provide immediate feedback on ideas and strategies.  
As the scope of the EPhR position was so broad, the importance of having collaboration 
within the service, to focus on medication quality and safety, was essential in order to 
make changes. Initially the Mental Health Safety and Quality Working Group included 
Central Australian representatives; however, as accreditation dates were set, the Top End 
and Central Australia Mental Health Services were due to be evaluated independently. A 
second Mental Health Safety and Quality Working group was established and also chaired 
by the EPhR in Central Australia.  
4.1.2 Gap Analysis and Medication Action Plan 
A recommendation by the Australian Commission on Safety and Quality in Healthcare was 
that hospitals complete The Medication Safety Self-Assessment® survey (MSSA) for 
Australian Hospitals.193 The MSSA is a risk assessment tool specifically designed to help 
hospitals take an active and system-based approach to medication safety.194 The tool was 
designed to assist hospitals in verifying their services against the National Safety and 
Quality Healthcare standards.182 The MSSA was essential for the EPhR to complete a gap 
analysis. The purpose of completing a gap analysis was to place another external driver 
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for change by engaging the executives of the hospitals. Mental Health was to be 
accredited as part of the hospital and health service accreditation; however Mental Health 
had only recently fallen under the Governance of the Hospital Network. Mental Health was 
a high risk area that could limit the success of the hospitals. This was well known by the 
executives of the hospital network, and therefore it was essential to acknowledge the gaps 
and improvements needed for the Mental Health Service to reach the required standard. 
As a start, it provided an incentive to have another Pharmacist for Central Australia. The 
example below is from the Top End, and a similar story was presented to the Central 
Australian Hospital Executives. 
4.1.3 Methods   
A MSSA Survey was completed by nursing staff, the inpatient manager, the General 
Manager, the community-based case manager, prescribers, EPhR (pharmacist), and team 
leaders from The Top End Mental Health Service. The MSSA Survey results were entered 
into the national online database by the EPhR. The online database automatically 
calculates weighted aggregate scores for each key element and core characteristics. This 
allows for comparison against other hospitals (in a de-identified way) according to 
demographic variables selected.195 
The self-assessment is divided into ten key elements that significantly influence safe 
medication use. Each element is defined by one or more core characteristics that further 
define a safe medication system. Each core characteristic contains individual self-
assessment items to help the hospital evaluate its success in achieving each core 
characteristic.  
The key elements within the MSSA are;  
1. Patient Information  
2. Medicines Information 
3. Communication of Medication Orders and Other Medication Information 
4. Medication Labelling, Packaging and Nomenclature 
5. Medication Standardisation, Storage and Distribution 
6. Medication Device Acquisition, Use and Monitoring 
7. Environmental Factors, Workflow and Staffing Patterns 
8. Staff Competency and Education 
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9. Patient Education  
10. Quality Processes and Risk Management 
Comparing the current Mental Health Service against the core actions required to meet 
Accreditation Standards, provided a gap analysis, which could be used to prepare a 
Medication Action Plan.193 
The MSSA was conducted by the EPhR independently for the Mental Health service, and 
then compared back to the associated referral hospital, e.g. the MSSA for the Top End 
Mental Health Service (TEMHS), was compared to the Royal Darwin Hospital (RDH), 
whereas the Central Australian Mental Health Service (CAMHS) MSSA was compared to 
results from the Alice Springs Hospital (ASH). 
The results helped drive change by identifying, and measuring, areas for improvement.  
4.1.4 Results from Medication Safety Assessment Survey TEMHS Presented to the 
Hospital Executives. 
Overall TEMHS scores were lower than the aggregate data (national results) and were 
also below the Royal Darwin Hospital results. See Figure 4.1: Summary graphs of results 
below




Figure 4.1: Summary graphs of results from MSSA.194 
Key elements presented on the X axis above are; 1. Patient Information, 2.  Medicines Information 3. Communication of Medication Orders and Other 
Medication Information, 4. Medication Labelling, Packaging and Nomenclature, 5. Medication Standardisation, Storage and Distribution, 6. Medication 
Device Acquisition, Use and Monitoring, 7. Environmental Factors, Workflow and Staffing Patterns, 8. Staff Competency and Education, 9. Patient 
Education and 10. Quality Processes and Risk Management.
RDH-MSSA 2013 TEMHS-MSSA 2013 
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4.1.5 Discussion 
The suggested reasons for the difference between TEMHS and RDH include; 
• TEMHS did not come under the hospital network and therefore did not have the 
same governance of medication policies and procedures. 
• TEMHS did not have pharmacy services (no clinical pharmacist or technician) 
therefore the role of medication management was primarily completed by nursing 
staff. 
Below are the key elements that the TEMHS Safety and Quality working group decided to 
focus on as a result of this baseline information. The key elements which were targeted 
were key element one, two, six, eight, nine and ten. As displayed in the graphs above, 
TEMHS was meeting the national average aggregated data for key elements three, four, 
five and seven therefore they were not a focus area for improvement. 
Key Element One: Is Essential Patient Information Obtained, Readily Available in a 
Useful Form and Considered When Prescribing, Managing and Administering 
Medication? 
TEMHS currently has many systems in place (at least 8) that rely heavily on transcription 
to allow the information to be available to all practitioners (including after hours). 
The primary limiting factor for TEMHS improving this key element is the use of a multitude 
of computer systems that do not interface with each other and therefore rely heavily on 
human input to transcribe between multiple software systems (duplication, a tendency to 
be error prone and having limited accessibility were noted). The systems in place included 
paper-based documentation on wards and for prescribing in outpatient clinics, Community 
Care Information System (CCIS) in outpatient clinics, Primary Care Information System 
(PCIS) in forensics and remote, Communicare in remote, Electronic Medication 
Management Application (eMMa) in RDH, Westerns pathology vs RDH, and General 
Practitioner (GP) systems.  
Key Element Two: Essential Medicines Information Being Available at Time of 
Prescribing, Dispensing and Administering. 
As with RDH, a formal reconciliation process needed to be implemented. A source of 
validating accuracy between all systems also needed to be established. 
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Key Element Six: Devices Used to Deliver Medication. 
This key element is based on infusion pumps etc. (N/A for mental health setting).  
Key Element Eight and Nine: Education for Both Staff and Patients around 
Medications.  
Anecdotally, these two elements have improved since the addition of a pharmacist to 
TEMHS. Formal and routine education (especially for new staff in orientation) has been 
initiated. 
Prior to the employment of a pharmacist both staff and patient education was provided by 
drug company representatives and advertising. Patient information throughout Mental 
Health has been moving away from relying on drug company activity to now having 
independent and non-biased resources. This includes subscription to a Mental Health 
webpage which is specifically designed to provide patients with current, non-biased 
medicines information.196 
Key Element Ten: Quality Processes and Risk Management 
This is an area which was also highlighted during the last accreditation as needing 
improvement. The quality cycle and evaluation of new initiatives has been lacking. 
To reduce medication risk within TEMHS, small working groups have been established 
including management and clinical staff to focus on three main areas:  
• PRN prescribing and administration 
• Monitoring and high risk medications 
• Benzodiazepine storage and distribution 
Baseline and audit schedules have been created and TEMHS will work to be in line with 
the RDH audit schedule. 
4.1.6 Translation to Practice 
As a result of the gap analysis and completion of the MSSA, a Medication Action Plan was 
developed, with a supporting audit schedule, by the EPhR. (See Appendix 8: TEMHS 
Medication Safety and Quality Action Plan and Audit Schedule). The Medication Action 
Plan included the quality initiatives which were identified by completing the MSSA, as well 
as additional items identified by a gap analysis against the National Standards. Within the 
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Medication Action Plan it has been noted where the quality initiative was identified. The 
Medication Action Plan was vital to inform the whole of the service what was needed to be 
achieved to meet accreditation standards. The EPhR identified the core criteria that was 
required, the action that needed to occur, who was responsible for the action, how it would 
be measured (i.e. if we have achieved this as a service), and any additional actions linked 
to the core criteria, and the preparation of a timeline. 
After completion of a Gap Analysis by the EPhR to determine how the Central Australian 
Mental Health Service (CAMHS) was performing, compared with the Accreditation 
standards, it was clear that the CAMHS would require intensive support to ensure that 
their medication management was sustained and supported by a full time pharmacist. This 
created an opportunity for the EPhR to lobby for a CAMHS Pharmacist position, essentially 
dividing the original pharmacist position into two jurisdictions. 
Below are examples of studies essential to improve the quality and safety of the medicine 
management within the Northern Territory Mental Health Service (NTMHS). These studies 
also provided evidence for the NTMHS accreditation and to help the EPhR demonstrate 
the positive impact a pharmacist can have within a health-service.  
4.2 Medication Management within the Mental Health Inpatient Units 
The first study within this section was directed at the acute sector (Mental Health patients 
who are being treated in the hospital environment). It was designed to show reallocation of 
work to improve patient safety and cost savings for the service. The first study 
implemented by the EPhR, used the understanding and knowledge of the evidence to 
achieve efficient and safe medicine management within the hospital setting.197 The EPhR 
was also aware of the potential cost savings that could be gained and then used to petition 
for a technician through these improvement outcomes. 
4.2.1 Background 
Prior to the employment of a specific pharmacist, the Northern Territory Mental Health 
Service (NTMHS) had not had any pharmacist’s input since its establishment. Many 
medication management systems were developed by nurses and doctors, out of necessity, 
and many did not follow evidence-based practices;190,198,199 this was clearly demonstrated 
by The Inpatient Medication Management Review presented in Paper 1. 
The clinical pharmacist (EPhR) who was recruited to this new position faced significant 
expectations from both the pharmacy department, due to the long awaited funding, and 
Alice Victoria Gilbert | 2016    P a g e  | 59 
 
from the NTMHS, due to the preconceived ideas of what a pharmacist would bring to their 
service. The appointed Mental Health pharmacist recognised the need to first work as an 
EPhR.  
The studies in this section describe the integration of an EPhR within NTMHS. The 
approach that the EPhR took in the introduction to the role in Mental Health was as 
follows: observation, engagement with stakeholders, identification of allies, and working at 
a high clinical level to discover how to deliver the best possible Mental Health service. This 
included finding ways to enlarge the team of one, and ways to enable growth of this role to 
best deliver the ideal model of care. 
4.2.2 Method - Change Management Principles and Their Application 
4.2.2.1 Stage 1: Planning 
The EPhR dedicated a one-month observation period to assess how the service was 
currently functioning prior to any pharmacist input. This was vital as an opportunity to 
identify areas which were running smoothly and areas which required improvement.2  
During the observation period the EPhR engaged with stakeholders to identify their roles in 
the current medication management systems.5 The EPhR also grasped opportunities to 
attend ward rounds to identify key clinicians, to watch medication rounds, and to observe 
the methods of storage and supply.88 The EPhR attended both staff and managerial 
meetings to hear which issues regarding medicines were voiced within a formal setting. 
During the engagement with stakeholders, there was also an opportunity to determine 
what roles the different stakeholders believed belonged to a pharmacist. This inevitably 
opened up conversations of current frustrations regarding medication management within 
the service and apprehensions regarding change.2,115  
During this stage of planning, drivers of change needed to be identified.5,75 The timely 
employment of a pharmacist, the EPhR, was noticed. The pending external pressures on 
the NTMHS included two key drivers of change: 
1) The NTMHS, which was governance unto its own, would be merging with the Top 
End Health Service in 2013.173 This meant that the NTMHS would now need to be 
in line with the same policies and procedures as those at the Royal Darwin Hospital 
2) The next external driver was a move to a National Accreditation Scheme which 
would evaluate the NTMHS against Safety and Quality Healthcare Standards182  
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To meet these milestones, as stated above, the Governing Body of the NTMHS employed 
a pharmacist (EPhR).  
Within this section examples of applying change management principles and their 
outcomes are detailed.76,192 The EPhR used prioritisation strategies to target areas of 
improvement. After observation, change that was needed was separated into three broad 
categories: 
 IMMEDIATE ACTION REQUIRED  
 Prioritised mainly due to safety concerns 
 QUICK WINS  
 How to get Mental Health staff on side 
 LONG TERM AIMS 
 Improving the service and embedding pharmacists to improve practice 
During this period of observation, the identified problems included safety concerns such as 
high potential for selection errors, no routine evaluation of medicines stocked or how they 
were utilised, high wastage, which equates to cost and lack of patient specific 
initiatives.190,197,200 See Paper 1. As Mental Health was under its own jurisdiction, at the 
initiation of the EPhR’s employment, medication management had been assigned to 
nursing staff. There were makeshift policies that were procedure-based and were 
noticeably without responsibilities, regulatory standards and/or the ability to evaluate the 
service against the policy, thus an ensuing outcome was a lack of accountability. There 
was a preconceived notion, due to practices of other pharmacists, that the EPhR was 
employed to take over these nursing duties and to manage supply of medicine.115,201 The 
observation and consultative process left the common feeling of resistance to change, and 
the evidence of why change was necessary.5,117,118,124 
4.2.2.2 Stage 2: Delivery 
During the intervention stage it was vital to educate the NTMHS on what a pharmacist’s 
true clinical model would look like. The role was presented in the way of the Quality Use of 
Medicines principles.1 Introduction to the role of a pharmacist was presented in many 
formats, from staff education sessions, professional socialisation, and patient and carer 
engagement.88 It was essential during this knowledge building stage that preconceived 
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notions of a pharmacist’s role be addressed. The EPhR made it clear, from initiation, that 
roles of a pharmacist were more than the supply of medicines.180,202 While facilitating the 
supply and ensuring the continuity of care is a responsibility of the EPhR, walking between 
the dispensary and wards to deliver medicines was not one of them. The time expended 
for supplying medicine detracted from alternative clinical priorities.202 As the Mental Health 
service had ‘set-up’ supply arrangements prior to having a pharmacist, the EPhR 
suggested that this method should continue.  
The first priorities were to reduce risk. This included risk to the patients, risk to the 
organisation (due to legality issues) and risk to the staff (who were not meeting 
professional standards and were placing their registrations at risk). The program delivery 
stage included a plan presented to the executive level, as well as grass route staff, to 
describe how the EPhR would endeavour to move Mental Health in line with best practice 
and evidence-based medication management.5,203 This was relatively easy information to 
deliver to the hospital’s management level. However, ward staff were resistant to change 
as they used many shortcuts, such as having drawers full of high use medicines for nurses 
to access easily, and sample packs from pharmaceutical companies which were 
dispensed by doctors. All of the above situations were contributing to unsafe 
practices.176,197 (See figure 4.2 a, b, c)  
 
Figure 4.2 a, b & c: Examples of Medication Practices in the Mental Health Inpatient Units Prior to the 
EPhR’s interventions 
The essential adoption and support of improved practices by the leaders of Mental Health, 
who understood the drivers of change and the risks associated with the service, 
particularly in regard to meeting National Accreditation Standards, was gained.181 The 
Mental Health Executives supported the EPhR and the proposed plan featuring strategic 
staged areas to target. The Executives helped provide opportunities for the EPhR to not 
only engage with staff, but also to educate staff of the need for change. 
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The Royal Darwin Hospital (RDH) Mental Health inpatient units were a logical place to 
start for a number of reasons:  
1. The inpatient units were based on the RDH campus and therefore the idea of 
being in line with hospital policies and procedures was easier for staff to 
envisage as they could be seen as ‘part of the hospital’ 
2. As Mental Health patients often have multiple co-morbidities, staff on the 
inpatient unit would frequent other wards within the RDH and would be aware of 
their layout and processes 
3. Many staff had previously worked in other areas of RDH and therefore could 
reinforce systems they had used in those settings 
4. The junior medical staff rotated between RDH and Mental Health throughout 
their learning stages and would transition between sites more efficiently if there 
was consistency with medication management standards 
5. Many opinion leaders were based in the acute Mental Health setting, meaning 
that change within the inpatient units would filter to other Mental Health settings  
6. According to figure 2.3: Program Delivery, this would allow for awareness raising 
of staff in other settings prior to a change occurring 
The initial project, to demonstrate the need for change, was to address the storage and 
management of medicine on the inpatient wards (see Paper 1). There was much 
resistance to change, however, often while working within an established system, the 
ability to engage in self-reflection can be challenging. Part of the education and 
implementation was providing photographs to staff of how the medicines were currently 
being managed. This highlighted “near miss” and “high-risk” practices thus showing 
evidence of the need to change. Presenting an alternative was eye-opening to all.  
4.2.3 Results 
Evaluation of implementation projects were presented to executives both within the Mental 
Health setting and the Northern Territory Department of Health to demonstrate the need 
for an EPhR and the impact that one can have. The key findings from this initial change 
management project that were presented to the Mental Health Executives included; 
Alice Victoria Gilbert | 2016    P a g e  | 63 
 
• Imprest stock and Imprest lists had not been reviewed since the Mental Health 
inpatient units had opened 17 years ago. Therefore, medications which were 
commonly requested had not been available or added and medications which were 
no longer “first-line” had not been removed. Usage and stock levels were reviewed 
and updated to reflect TEMHS needs and first-line therapies 
• Training for new and junior staff about medications and medication management 
was not formalised, therefore the unit did not have consistent practices  
• There was a high potential for medication error due to the existence of a 
disorganised and non-uniform imprest system used for administration of medication 
to a patient. This has now been changed to a patient specific medication 
administration system 
• Large cost to the service, and patients, due to medications not being returned when 
appropriate: 
o 171 different medications (4713 units) were suitable for return to the 
pharmacy department. The service re-credited the Mental Health unit 
$6 060.87  
o Large volume of wastage due to medications not being returned before 
expiry dates (46 different medications (855 units) were expired – total cost 
$1 347.70. All of these expired medications would have been suitable for 
return and re-use 
o Total cost potentially saved if medications were returned prior to expiry was 
$7 408.57  
A process for “returns” has now been implemented, with a requirement that it is done on a 
weekly basis. 
• Previously the Mental Health inpatient units were unable to track medicines 
utilisation, diversion or medication usage patterns. This included patient’s own and 
non-imprest supplies were being used between patients. (110 different patient’s 
own medications (1 555 units) were still on the ward for patients who had been 
discharged – total potential cost to patient and service $2 649.06). As imprest stock, 
returns and patient’s own medicines have now been returned and the imprest 
cupboard stock updated, medicines utilisation can now be assessed 
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• Total cost of medicines suitable for return, expired stock and patients’ own 
medicines $10 057.63 
• Consideration of a pharmacy technician position to co-ordinate the supply, storage 
and return of medication 
4.2.4 Discussion and Translation to Practice 
Due to the financial savings demonstrated by this implementation project, the EPhR 
utilised this opportunity to prepare a business case for the employment of a pharmacy 
technician (See Appendix 9). As the implemented model of medication management was 
time-intensive for nursing staff to maintain, this was another factor that could be used to 
influence the proposal. The then General Managers of Mental Health, as well as the 
Inpatient Unit Manager, were both nurses. They personally identified with the frustrations 
of nursing staff being moved from their core business in order to do duties that a 
technician could provide. It was also made clear that time is money, and nurses are much 
more expensive to provide a medicine delivery service than a technician, who is trained to 
perform this role. The business case was successful due to the patient safety and 
economic benefits presented by the EPhR and a pharmacy technician was employed.  
The primary role of hospital technicians is to undertake basic technical procedural duties 
such as the labelling and dispensing, bulk distribution, recording and prepacking of drugs 
with all dispensing, pre-packing and labelling work checked by a pharmacist or a medical 
officer, in accordance with relevant legislation, prior to its release. 
In 2012 there was a shift in the work-load of hospital technicians to assist pharmacists with 
duties on the wards to help clinical work flow. The Society of Hospital Pharmacists of 
Australia (SHPA) published guidelines to detail what was an acceptable or non-acceptable 
duty for pharmacy technicians whilst assisting in clinical roles.176  
Although assisting clinical roles for technicians are still not seen as ‘core duties’, positions 
have been created around Australia which enable pharmacist to spend more time utilising 
their clinical knowledge, rather than focusing on dispensing and supply activities. 
The key responsibilities when advertising positions now include “assistance with 
coordination of information” as well as “supply.” The advertising of positions has also 
moved to include formalised training with entry level having a certificate as ‘desirable’ and 
technician 2 positions listing qualifications as “essential” but recognising that support to 
achieve these criteria may be required. “Completion of Certificate III (or equivalent) in 
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Hospital / Health Services Pharmacy Support, or the ability and willingness to complete 
Certificate III in Hospital / Health Services Pharmacy Support204 within 18 months of 
commencement.”  
To help with the implementation of clinical technicians within the NT health service network 
a check list was developed to detail the appropriate duties (see Appendix 10). This 
position was implemented on our medical wards with varying success and dependant on 
three key factors: 
Key limitations: 
Supervising pharmacist: 
• Time and pressure required to train technician 
• Ability to hand over duties and not to supervise when not needed 
• Fear of staff turnover when time has been invested in training and supervision 
Technician: 
• Individual traits and attributes 
• Willingness to learn 
• Additional duties for no additional pay 
• Understanding of the responsibility 
Department staff: 
• In times of staff shortages or staff turnover this position was often the first to be 
pulled back to cover work within the dispensary 
• This led to additional pressure and frustration for the pharmacist who had to either 
train new technicians or pick up duties that were now usually done by a technician 
• Lack of value placed on this role by the department – not seen as a ‘core’ role, 
rather a pleasant addition 
The biggest barrier to this position being a success was consistent with what the EPhR 
had observed during the training of intern pharmacists. It was a lack of autonomy and 
trust. Pharmacists are not willing to trust the training provided, and found to be ‘hand-
holding’ or feel that it is easier to do a task themselves. The true benefit of having a well-
Alice Victoria Gilbert | 2016    P a g e  | 66 
 
trained and skilled technician is that it frees time to allow pharmacists to do clinical tasks 
and to have a greater impact on patient safety and outcomes.25,26,205 
The preparation for the Top End Mental Health clinical technician first came through the 
Mental Health service recognising that this technician position is a core role, and needs to 
be a protected position. 
The EPhR was unsatisfied with the current model of training provided to the clinical 
technicians in Australia. It was understood that the United Kingdom (UK) had a well-
developed technician program which produced highly skilled technicians working 
independently.25,26,28,205 
Examples of UK training guides, modified for Australia by the EPhR, allowed a technician 
to have the practical skills required for day to day support (see Appendix 11). An addition 
to this was to mentor the technician through a Certificate III in hospital/health service 
pharmacy support.204 
For training to be successful, time was allocated to establish a good working relationship 
between technician and pharmacist, to allow the technician to openly ask questions and 
recognise when to refer to a pharmacist.114,201 
Once a technician has passed the initial assessment, routine auditing continued to ensure 
that the technician maintains a high standard of work and to ensure that ongoing education 
and support is provided and used. The EPhR wanted the TEMHS technician to develop 
their skills and ensure they were aware of their valuable contribution to the Mental Health 
team. To build on this, the EPhR wanted the technician to be closely involved with the next 
change management project conducted within the community based mental health 
service. The EPhR tasked the technician with collecting data, such as concession card 
details from patients, and invoices, as well as helping to embed the new system by 
education for nursing staff. This project was prepared by the EPhR with the data analysed, 
and then presented the results with the technician at a national conference to ensure the 
TEMHS technician felt valued and to encourage her research and learning. The primary 
concept adopted by the EPhR with growing and retaining her team was based on a 
famous quote from Richard Branson, “train people well enough so they can leave, treat 
them well enough, so they don’t want to.”  
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4.3 Medication Management in Community Based Mental Health Services 
After improving medication management practices within the inpatient sector of the Top 
End Mental Health Service, it was deemed necessary to address the safety concerns of 
how the medicines were managed, administered, and distributed within the community 
based setting. 
This next study was a review of the depot medication within the largest Top End Mental 
Health Service outpatient facility. Depot medications are medications which are given by 
injection into the muscle, which releases the drug slowly over some weeks.206 Within the 
Mental Health setting, the most common class of medicines to be given via a depot 
injection are antipsychotics.206 The EPhR strategically chose the largest clinic in the NT to 
conduct the review. The EPhR had knowledge of the number of patients receiving depot 
medications at this clinic, an understanding of the high cost of depot medicines if they 
were not being managed correctly, and appreciation of the risk to the patients if they 
received an incorrect depot. The EPhR predicted that a safer method of managing depot 
medicines within the community setting and a large financial reduction to the service could 
be demonstrated. 
How a Pharmacy Technician Can Provide a Cost Savings to a Community-Based 
Mental Health Department 
4.3.1 Background 
The storage, distribution and supply of stock had not been managed or reviewed by a 
pharmacist within a Mental Health outpatient setting. Medication management was done 
by nursing staff which removed nurses from their core duties and contributed to high 
medicines cost. There was a high potential for medication error due to the disorganised 
and non-uniform imprest system used for distribution and administration of medication to a 
patient.197,207 This has now been changed to a patient specific administration system to 
improve patient safety and for cost saving benefits.197,207-211 (See Figure 4.2 a, b & c). 
4.3.2 Aim 
To demonstrate the impact of a pharmacy technician on costs associated with medicines 
use within a Mental Health (MH) outpatient unit. 
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Figure 4.3 a, b & c: Examples of Original Medication Management in Outpatient Mental Health Setting 
4.3.3 Methods 
A retrospective audit of costs associated with medications over a three-year period 
between 2012 and 2014 (January to April) was conducted. This study period examines 
costs prior to employment, during initial employment and training, and 12 months after the 
employment, of a pharmacy technician within the MH team. The pharmacy technician was 
responsible for acquiring patient healthcare and concession card information, ordering and 
maintaining appropriate stock levels, and ensuring that PBS requirements were met for 
common MH medications. The pharmacy technician provided education to MH staff on 
ordering procedures and built relationships with the community pharmacy responsible for 
supply. Cost analysis was done using the invoices provided by the community pharmacy 
supplying to the MH clinic. 
   
Figure 4.4 a, b & c: Medication management Post Technician Joining the MH service 
4.3.4 Results 
Prior to employment of the technician, activities associated with medicine use were 
undertaken by nursing staff and medicines were provided through a community pharmacy. 
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The technician employed within the MH team was hospital-trained and had worked across 
both the inpatient and outpatient areas. Costs associated with medicine use in 2012 were 
$17 529.65 over the four-month study period. The technician joined the service in March 
2013 and the cost of medications within the 2013 study period was $9 102.25. After a 
year, with the MH service providing all aspects of medication ordering, supply and 
maintenance, the total cost of patient specific medications supplied to the outpatient MH 
unit was $8 685.31. This represents a potential annual saving of around $26 533 (See 
Figure 4.5). 
 
Figure 4.5: Cost for Medication to an Outpatient MH Service 
4.3.5 Conclusion 
A pharmacy technician can provide cost savings and improve ways to manage 
medications within an outpatient setting. Improvement in safety and quality of medication 
$17,529.65  












Pre-Technician Implementing Technician With Technician
2012 2013 2014
Total spending on medication in outpatient 
setting 
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ordering, storage and dispensing was achieved by the employment of a pharmacy 
technician. 
4.3.6 Discussion and Translation to Practice 
After demonstrating the success of the above studies to the mental health executives, the 
same projects were then replicated in Central Australia. The EPhR implemented the 
change and provided the financial evidence that validated and supported a pharmacist’s 
and technician’s input. During this time the EPhR was providing a service to Central 
Australia predominantly over the phone and the internet, and made a face-to-face visit on 
four days each month. 
The change in how medicines were stored and managed in Central Australia was now 
consistent with the Top End. However, the ongoing support for supply was still allocated to 
nursing staff, as there was no full time pharmacist or technician available to assist with 
these tasks. 
This was one of the driving factors for change: that the implementation of an evidence-
based medicine management system should be supported by staff who are trained and 
skilled at maintaining it.212 The EPhR utilised the cost savings in conjunction with the gap 
analysis presented in 4.1 to campaign for a pharmacist to provide a service to the Central 
Australian Mental Health team. The benefits of a pharmacist were evident for a number of 
reasons. Firstly, a technician must work under the supervision of a pharmacist; therefore 
having a technician with a visiting pharmacist would not have met legislative 
requirements.213 Secondly, national accreditation was looming and the tasks required to 
meet national standards in the area of medicine safety would be dependent on a 
pharmacist’s input (See section 4.1.4).182 
A business case was prepared by the EPhR for a Central Australian Mental Health 
Pharmacist position and submitted to the Central Australian executives. This business 
case was approved and a new pharmacist was appointed to the Central Australian Mental 
Health Pharmacist position. 
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4.4 Prescribing Practices within the Inpatient Mental Health Units 
4.4.1 Background 
The Northern Territory Mental Health Service (NTMHS) is divided into the Top End Mental 
Health Service (TEMHS) and the Central Australian Mental Health Service (CAMHS). 
Both jurisdictions are currently using the National Inpatient Medication Chart (NIMC) as 
their medication management documentation system within the acute setting. This audit 
was designed to provide a baseline for NIMC use and future quality improvement 
initiatives within the mental health setting. 
This audit was developed to improve the safety of prescribing medicines, evaluate the 
effect of NIMC safety features (such as slow release tick box), evaluate the safety and 
quality of prescribing and related medication documentation, and to identify areas for 
medication management improvement. 
This audit was also be used as evidence for the national accreditation standards (Standard 
4).182,207,214 
4.4.2 Aim 
To evaluate current prescribing practices within Mental Health (MH) Inpatient units, to 
improve safety and to guide future quality improvement initiatives. 
4.4.3 Methods 
An adapted version of the National Inpatient Medication Chart (NIMC) audit tool215 was 
used to assess prescribing practices in two hospitals (four MH inpatient wards) over a one-
day period. Indicators relating to warfarin and venous thromboembolism in the original tool 
were replaced with MH related indicators such as “multiple antipsychotics prescribed”, 
“antipsychotic depots” and “when required, Pro Re Nata (PRN) antipsychotics.” 216-218 
Training was provided by the NTMHS pharmacist to two of the auditors.  
4.4.4 Results 
Thirty-One patients (38 charts) and 257 individual medication orders were evaluated. 
Where computer-generated patient ID labels were used, patient identification was only 
considered complete if the patient’s name was also printed by the first prescriber. Fifteen 
percent (6) of the 38 charts had complete patient identification, 94% (36 of 38) charts had 
adverse drug reaction status recorded, 98% (253 of 257) of orders had prescriber 
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signatures and 84% (216 of 257) had a legible prescriber’s name. (See table 4.1 for 
prescribing examples). 
Antipsychotic depot orders, which were prescribed on different sections of the NIMC at 
each hospital, were examined. One hospital prescribed using the “once only” section, with 
medication frequency specified on 16% (1 of 6) of orders. The second hospital prescribed 
using the “regular medication” section, in line with best practice, with frequency specified 
on 100% of orders. One order (6%; 1 of 16) had site of administration of depot recorded 
post injection by nursing staff. Seventy-Seven percent (24 of 31) of patients had multiple 
antipsychotics prescribed with 45% (29 of 64) of these as PRN.  
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Table 4.1: Prescribing examples from audits 
  Unclear orders and error prone 
abbreviations 





            






     
 
 
Best practice Avoid fractions - 1/7 could be interpreted as ‘for one day’, ‘once daily’, 
‘for one week’ or ‘once weekly’. Best practice to write in full e.g. every 
two weeks. Prescriber must write dose and hourly frequency. PRN alone 
is not sufficient as there is a risk of overdose and a medicine being 





    
Best Practice The dose maybe different for different routes, as maybe the rate of how 
a medicines is absorbed and it potency. Separate orders should be 







Best practice  PRINT all information and avoid cursive or illegible writing. Prescribers 
should be asking ‘will someone else be able to interpret my order?’219 
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4.4.5 Conclusion 
This audit highlighted the limited adherence by MH staff to the best practice 
recommendations for prescribing using the NIMC. The audit identified target areas for 
improving practice and medication safety within MH inpatient units. The audit data was 
used to provide feedback to staff as part of the quality improvement cycle. 
4.4.6 Discussion and Translation to Practice  
The Medication Safety module for Accreditation includes key duties which are usually 
performed by direct contact with patients by clinical pharmacists.193 Core criteria for 
medication management are the reviews performed by pharmacists, including medication 
histories, reconciliation activities and information at discharge.190,220-223 Mental Health in 
The Northern Territory has been well understaffed for pharmacists when looking at the 
recommendations by the Society of Hospital Pharmacists of Australia (SHPA). The SHPA 
recommends that there is one pharmacist for every 20 mental health patients.176 
The Northern Territory was in desperate need of a facility that could safely assess both 
Children and Adolescents. Funding for a Child and Adolescent Unit to be opened at the 
Royal Darwin Hospital continued to change due to government priorities and election 
politics. A cabinet submission went to Parliament to support and fund a new ward and is 
now to be called Youth In-Patients (YIP).  
There were “6 737 mental health-related occasions of service provided in Territory 
emergency departments in 2012-13, up from 3 170 in 2009-10.”224,225 “The opening of the 
facility coincided with the release of a report by the Australian Institute of Health and 
Welfare showing that mental health-related occasions of care in NT public hospital 
emergency departments more than doubled in the three years.”224,225 This appeared to be 
the perfect opportunity to add a business case to the cabinet submission for an inpatient 
pharmacist.  
A business case, written by the EPhR, was specifically aimed at the YIP ward. However, 
when discussed with the Mental Health General Manager and the Inpatient Manager, it 
was clarified that this position was to cover all three inpatient wards for the Top End 
Mental Health Service.  
The funding for the YIP ward was approved and a clinical pharmacist to provide a service 
to the inpatient Mental Health wards was successfully included in the Cabinet submission. 
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This position, however, was only granted funding for 6 months, therefore ensuring that 
data collection and targeting key performance indicators were an essential task.  
The next study was a repeat of the above audit to easily demonstrate the impact of a 
pharmacist working full time on the wards. A large evidence-practice gap, which was 
identified from audits and the MSSA, demonstrated that the Mental Health Service was not 
meeting the standards in regards to pharmacist review, medication histories and 
reconciliation as well as appropriate and available patient information. With a pharmacist 
working on the wards, the gap would be expected to close. Both education for patients, as 
well as evidence of a pharmacist being involved in histories and reconciliations221,222,226,227, 
are part of the Accreditation Standards.182,190  
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4.5 Impact of a Ward-Based Clinical Pharmacist for Mental Health Inpatient Units 
against Key Performance Indicators 
4.5.1 Background  
The Top End Mental Health Service (TEMHS) is currently using the National Inpatient 
Medication Chart (NIMC) as their medication management documentation system. This 
audit is part of the routine audit schedule to monitor and implement quality improvement 
activities along the medication management cycle.89  
A baseline audit was performed in 2014 and repeated annually. The third audit was 
conducted earlier to evaluate the impact of a ward based clinical pharmacist (new 
position). 
4.5.2 Aims 
This audit was designed to:   
• Assess current use of the NIMC   
• Evaluate the effect of NIMC safety features in hospitals  
• Evaluate the safety and quality of prescribing, and related medication 
documentation   
• Compare results and uptake of recommendations made in previous audits  
• Identify areas for medication management improvement  
• Guide future quality improvement initiatives  
This audit was also be used as evidence for the national accreditation standards (Standard 
4).182,207,214 
4.5.3 Methods 
The audit tool used is an adaption of the NIMC audit tool.215 To make it applicable for the 
Mental Health setting the tool has excluded warfarin and venous thromboembolism and 
included Mental Health Quality Use of Medicines indicators such as multiple antipsychotics 
prescribed, lithium monitoring, and PRN prescriptions.216  
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This audit was completed by the TEMHS Clinical Nurse Consultant and the TEMHS 
clinical pharmacist examining the charts of all admitted patients to the TEMHS inpatient 
unit over a one-day period.   
4.5.4 Results 
Cowdy (general adult mental health ward – capacity of 18 patients): 8 patients admitted 
and included in audit  
Joan Ridley Unit (high dependency adult Mental Health ward – capacity of 8 patients): 4 
patients admitted and included in audit 
CAU/YIP: (Youth Assessment Unit – capacity of 5 patients). Zero patient admitted, 
therefore ward not included in audit (closed)  
100% of admitted patients were included in audit. The number of patients admitted during 
this audit period indicated that the Mental Health wards were at 40% of their potential 
capacity.  
Total = 12 patients 
Number of charts audited: Total chart number was 13 because one patient had multiple 
charts.  
Patient Sample Size and Charts (Previous Audits)   
22 patients included for comparison in March 2014 (total of 26 charts)  
17 patients included for comparison in March 2015 (total of 18 charts)  
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Figure 4.6: Caparisons of Key Indicators Pre and Post-Ward based pharmacist 
Table 4.2: Indicators met during audit periods 
Indicator  
2014 March (%)  
  
2015 March (%)  
  
2015 Nov (%)  
Complete Identification   37.5  17  46  
Adverse drug reactions  87.5  76  100  
Lithium monitoring  100  100  100  
Depot prescribed with frequency  16  0  66.7  
Depot administered with site documented  100  100  66.7  
Depot administered with date given 
recorded  100  50  66.7  
Sustained release medication with SR box 
checked  0  0  75  
Prescriptions signed  97  99  100  
Prescribers name legible  91  84  93.7  
Prescriptions ceased correctly  14  4  20  
Prescriptions with unapproved 
abbreviations  5  15  2  
Patients prescribed multiple antipsychotics  
75  41  67  
Pharmacist review occurred  









Comparison of Key Indicators 2014 and 2015 
2014 Mar (Percentage)
2015 Mar (Percentage)
2015 Nov  (Percentage)
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Key performance indicators:  
1. Identification  
46% (6 patients) had complete identification.   
Incomplete patient identifiers or patient identification that is not visible on all sections of the 
chart may result in an adverse drug event where the medication is administered to the 
incorrect patient, or a patient being prescribed or administered medication intended for 
another patient.218   
Printing of the patient’s name under an identification label was introduced as a compulsory 
safety mechanism for the prescriber to ensure that the correct patient identification was 
placed on the medication chart and associated prescriptions218; adherence remains poor 
within the Mental Health service.  
Within the main building of the Royal Darwin Hospital, medication is managed via an 
electronic system, this includes prescribing. It is likely that the Registered Medical Officers 
rotating from the hospital who are used to electronic prescribing may not be immediately 
compliant of this requirement for paper-based prescribing. This will be addressed for 
further training. TEMHS is preparing to implement the electronic system in 2017.   
2. Adverse Drug Reactions (ADR’s)  
100% (12 patients) had ADR status documented.   
Omission of ADR information risks re-prescribing and administering a medicine that has 
previously caused an adverse reaction or a similar agent.218 Recording the clinician’s 
signature assigns accountability for the information obtained.   
Eight percent (1 out of the 12 documented) had a previous ADR. The patient with a 
previous ADR had ADR stickers in place. This patient did not have the same class of 
medication prescribed.  
Documentation of ADR details and the use of ADR alerts should prevent patients being re-
prescribed, dispensed or administered a medication to which they have previously had a 
reaction. Within the mental health setting, a rechallenge of antipsychotics may need to be 
done as the classes are limited.202,228 The risk to benefit ratio should be documented in the 
case notes and the decision to rechallenge should involve the patient’s consent.228,229 It is 
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likely that the commencement of a ward-based clinical pharmacist has helped to improve 
documentation of this indicator.    
3. Medication Histories  
Medication histories were evaluated for all 12 patients; 58% (7 out of 12 patients) had a 
medication history documented on their medication chart. 41% (5 out of 12 patients) had a 
medication history documented in the notes by a nurse, prescriber or pharmacist for this 
admission. 42% (5 out of the 12 completed histories) had more than one source for the 
medication history documented.   
Accurate information on the medicines that patients are taking prior to admission is an 
important component of the medication reconciliation process and forms a basis for future 
decisions about therapy.230,231 To ensure that a complete and accurate list of medicines is 
taken prior to presentation to hospital, confirmation with a second source is 
recommended.230,232 When this was discussed with those responsible, it was found that 
this procedure had been followed (confirmation with two sources), but not documented.233 
This puts documentation as an area to target.   
Sixty-seven percent (8 out of 12) of the medication histories matched the charted 
medication. Medication reconciliation ensures that the patient receives all intended 
medicines and reduces common errors of transcription, omission, duplication, medicine-
medicine and medicine-disease interactions.80,230,232,234  Medication reconciliation is a 
process that needs to be documented within our service and is done by the pharmacist 
when a patient is reviewed. There is currently a clinical pharmacist based on the ward who 
is able to perform reconciliation. However, funding is not secured for this position and this 
is not formally carried out when a pharmacist is not based on the ward.  
For the four patients who had a medication history completed which did not match the 
prescribed medications, there was a documented reason for the change in three of these 
patients.  
It is important that the intent to change therapy is documented in the notes. A pharmacist 
reconciling the medications will formally endorse that the documented treatment plan is 
reflected correctly on the NIMC. To complete the medication reconciliation process 
accurately, the care plan for each of the patients’ prior-to-admission medicines has to be 
known.230,234-236   
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4. Depot medications  
Sixty-seven percent (8 out 12) admitted patients were prescribed a depot antipsychotic. All 
eight patients had their depot charted on the regular section of the NIMC, with (100%) 
stating the frequency. Intermittent orders, such as depots, should be charted within the 
regular medication order section to ensure that subsequent doses are not forgotten.218  
This was an area originally targeted by the EPhR. As this study indicates, RDH previously 
prescribed all depots on the “once only” section. This section does not have room or 
prompting mechanisms for the prescriber to include a frequency in the prescription or for 
nursing staff to record date or site of administration. It also posed a high risk for our 
patients if the depot prescription was overlooked, or not transcribed to the next chart. This 
focus area by the EPhR has shown an improvement from zero prescriptions including a 
frequency to 100%.   
Two out of eight had been administered. Of these one (50%) documented the site given on 
medication chart, one (50%) had an entry into CCIS (the electronic notes system for 
Mental Health) and two (100%) included date of administration.  
Nursing staff need to continue to annotate on the chart and document in CCIS the date 
and site of depot administration. This annotating has implications for the patient both in the 
inpatient and outpatient settings by reducing the risk of patients being administered 
medications in error. This can have a significant long-term impact in the event of a depot 
antipsychotic being duplicated or given too early.228,237   
5. Lithium Monitoring 
One patient was prescribed lithium and had lithium levels taken during this admission 
(100%). This indicator appears to have been done well in previous audits, however it has 
been based on consistently low numbers. 
6. Sustained Release (SR) Preparation  
Four SR preparations were ordered and three of these (75%) had the SR box checked.  
Some medicines come in multiple presentations so it is important to distinguish what is 
actually intended as this can have implications for the time to effect, side effects, 
absorption profile and dosing frequency to name a few.218 It is expected that the presence 
of a clinical pharmacist on the ward can aid with compliance with this indicator.  
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7. Overall Prescribing  
All orders were evaluated (excluding nurse initiated): The total number of orders was 111. 
111 (100%) of prescriptions had a prescriber’s signature, 104 (93.7%) of prescriptions had 
a printed and legible prescriber name, 2% of prescriptions included error-prone 
abbreviations for example:  iu (being used for international units), abbreviated medicine 
names such as Na Valproate (sodium valproate), roman numerals (ii) (instead of correctly 
writing 2) and 10 (hourly).214 Twenty of the evaluated orders were ceased with 20% (4 out 
of 20) ceased correctly including a date and prescriber signature.  
8. Pro Re Nata (PRN) Prescribing  
All evaluated patients had more than one Pro Re Nata (PRN) medication prescribed 
(range of three to six PRN orders) comprising a total of 48 PRN prescriptions.  
The Number of PRN medications with a dose range prescribed: no usable result for this as 
the indicator was misconstrued as being the presence of a dosage not a dose range e.g. 
5 mg to 10 mg or 10 mg to 20 mg.  
Forty (83%) included a frequency within the order, 45 (94%) had a maximum in 24 hours 
included with the PRN order, 4 (8%) had two routes included in the order (e.g. PO/IM), The 
dose may be different for different routes, as the rate of how a medicines is absorbed and 
it potency may vary. Separate orders should be written for each route.219 
Thirty-nine (81%) of the PRN orders included an indication with 18 (37.5%) orders having 
the same indication (i.e. olanzapine and diazepam prescribed for agitation). In the instance 
of PRN orders with identical indication, the order of administration should be documented 
to clarify to the nurses which medicine should be trialled first, or if they should be given 
together. One (2%) of the PRN medicines was also prescribed as a regular medication.   
Of the evaluated PRN orders, a total of 43 administrations occurred. 43 (100%) of the 
administrations-documented-dose were administered and 42 (98%) documented the route 
of administration. On one order the route of administration was not documented.  
9. Multiple Antipsychotics  
Eight patients (67%) had multiple antipsychotics prescribed (range 2-3). Twenty-five 
antipsychotics were prescribed for the 12 study patients with 10 (40%) prescribed as a 
PRN.  
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This is common practice in mental health despite the lack of evidence. In the majority of 
cases the second antipsychotic was prescribed as a PRN. 228 This part of the audit can 
also be used to evaluate the continuation of multiple antipsychotics post-discharge into the 
outpatient setting.  
10. Pharmacist Review  
Pharmacist review occurred for 10 out of the 12 patients (83%). Having a continuous ward-
based pharmacist has enabled significantly higher adherence to this indicator. As this audit 
was conducted prior to the pharmacist commencing reviews for the day, it was expected 
that there would not be 100% compliance due to new admissions.   
4.5.5 Discussion and Translation to Practice 
This audit was conducted slightly earlier than the annual review (usually conducted in 
February/March), to assess the impact of a continuous ward-based pharmacist on the 
TEMHS inpatient wards. It was pleasing to note that there were improvements in most 
evaluated indicators.  
There was a great improvement in delivery of pharmacist services on the inpatient ward 
including obtaining medication histories, chart reconciliation and chart review which were 
previously unable to be adhered to with a single pharmacist allocated to the entire NT 
Mental Health Service.  
Previously, correction of prescribing practice was done retrospectively via auditing or 
education sessions rather than incidentally as part of daily routine work. The combination 
of ongoing education, auditing and continual review by a ward-based pharmacist is optimal 
for embedding safe prescribing and administration practices as well as addressing 
medication mismanagement proactively rather than reactively. As this position has not yet 
secured extra funding, it can be surmised that compliance with many of the indicators will 
once again fall to previous audit figures if this role is not reinstated.     
Four key indicators were identified as requiring improvement:  
• Patient Identification remains a priority (medical staff)  
• Correct documentation of depot administration (NIMC and CCIS) (nursing staff) is 
important  
• Prescriptions need to be ceased correctly (medical staff)  
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• Prescription of multiple antipsychotics (medical staff) needs to evaluated further 
Although the results indicate an improvement on previous audits, the compliance to patient 
identification still requires some work. It was noted that patient ID labels were being used; 
however, a hand-written name was not included on all pages of the chart. Education will 
be provided to staff rotating from a ward that uses electronic prescribing as this is not 
routine practice for them.  
Prescription of depot medication in the regular section of the NIMC shows that this practice 
has been embedded. The March 2015 audit showed that invariably depots were being 
charted as once-off doses. However, depot administration was not well documented and 
may require increased training, particularly to new or rotating staff.  
Cessation of orders or prescriptions should be documented on the NIMC as clearly as 
possible and accompanied by the prescriber’s signature and a date. A reason for the 
change must be documented in the notes to indicate the prescriber’s intentions. 
Annotating this on the chart is also good practice.  
It was also noted that there was an increase in the number of people prescribed multiple 
antipsychotics as compared to the March 2015 audit; this may be reflective of consultant 
preference or the acuity and complexity of the patients within the Inpatient Unit. However, 
prescription of multiple antipsychotics should not be routine practice due to the increased 
risk of adverse effects and the lack of evidence supporting its effectiveness. Prescription of 
multiple antipsychotics should be employed for as short a period as possible and avoided 
on discharge.   
One area that will require reassessment is the number of PRN medications with a dose 
range prescribed. The data collected for this indicator was not in line with the intent of the 
audit and therefore data on PRN’s were evaluated but not for quality. 
Another limiting factor for this audit was the reduced number of charts available for review. 
The ACSQHC recommends that at least 20 charts are included in the audit. To enable a 
larger number of charts to be reviewed, it may be advisable that data collection take place 
over a longer period of time (depending on staffing and resources). This may also remove 
the bias of conducting the audit in the morning before charts had been reviewed for the 
day. It was expected that some indicators would be lower to account for overnight patients 
not yet seen (e.g. for pharmacist review, medication histories and chart reconciliation).    
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It is recommended that this audit be conducted post electronic prescribing implementation 
if this occurs prior to the next annual chart audit (next due early 2017).  
4.6 Prescribing Practices within the Community Mental Health Setting 
4.6.1 Introduction 
The Northern Territory is a relatively isolated work environment away from other 
pharmacists; the EPhR used networking to enable learning opportunities. Established 
pharmacist services both nationally and internationally could also be used as a resource to 
support the EPhR in sharing information and refining ideas. 
Whilst building networks the EPhR was invited to provide consultation for the Scoping 
review of medication safety in Mental Health commissioned by the Australian Commission 
on Safety and Quality in Healthcare (ACSQHC).238  The initial project was designed to 
explore the current level of uptake of the National Safety and Quality Health Service 
Standard 4 (Medication safety);193 identify the enablers, barriers and challenges in 
implementing this standard; and identify strategies for improving medication safety in 
Mental Health in Australia.229 It included structured interviews and a round table discussion 
for which the EPhR provided input from a NT, and Indigenous health prospective. After this 
initial report was compiled, the ACSQHC created a working party to target Reducing 
Adverse Medication Events in Mental Health. The first task of this group was to design and 
distribute a national survey to capture data on current medication practices within Mental 
Health. The resulting report includes results of the survey that was undertaken across 
Australia in 2016 investigating the extent to which medication safety practices were 
implemented in Mental Health units.238   
The Reducing Adverse Medication Events in Mental Health Working Party (RAMEMHWG) 
was then tasked with suggesting projects which can help bridge the gap between evidence 
and practice in Mental Health. These projects are to be prepared and presented at the 
Australian Health Ministers Advisory Council in December 2016.  
The next study in this thesis details a quality improvement implementation project that was 
designed and conducted by the EPhR. Although this was done prior to the EPhR joining 
the RAMEMHWG, it has tied in with the strategic goals that the working group are trying to 
address. This project has now been shared with the RAMEMHWG, and the Community 
Mental Health Chart (Appendix 12) designed by the EPhR will be presented to the 
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Australian Health Ministers Advisory Council with the premise that this chart become a 
national chart which can be used in all Mental Health community clinics.  
4.6.2 Community Mental Health Medication Chart Project Plan 
One of the first large gaps identified by the EPhR within the Mental Health service, was in 
the continuum of medication management. An immediate issue that needed to be 
addressed from a safety, quality and legal perspective, was how medicines were 
documented, prescribed and administered in the community-based Mental Health 
clinics.239,240 
The EPhR made contact with Mental Health pharmacists within Australia to see what 
current practices were being used in each state. It was clear, from this initial background 
search, that other jurisdictions had faced this same problem and had created a ‘Depot 
Medication Chart’, or a ‘Community Mental Health Medication Chart’ (CMHMC), to 
overcome these issues. 
Prior to employing a pharmacist in Mental Health in the Northern Territory Mental Health 
Service (NTMHS), medication prescriptions in the community-based setting were entered 
as a progress note onto the patient’s record in the electronic system: The “Community 
Care Information System” (CCIS). This process resulted in inconsistencies and failed to 
meet legal and policy requirements.239,240 In an attempt to standardise practise and 
address these failings a policy entitled “Adult Teams Medication Record”, was developed 
by the NTMHS.  When the newly appointed Mental Health pharmacist (EPhR) arrived, she 
identified multiple health-related issues within the policy. 
These risks/issues included the following aspects: 
• Recognition that CCIS is not a valid prescription or legal administration order239  
• That a nurse cannot administer, and a pharmacist cannot dispense, a medicine to a 
patient unless all details are correct and complete on a signed prescription. CCIS is 
not a valid electronic signature within the NT240 
• The chance that medication misadventure, due to an order being overlooked in 
CCIS progress notes, was high. Little consistency was demonstrated with recording 
of administration, doses and changes241,242  
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• There was no consistent place to access an up-to-date list of medicines that a 
patient is currently taking227,234 
• Recognition that medication errors were not being routinely reported. There  were 
cases known to the pharmacist, such as a change in depot dose being overlooked, 
and a patient receiving less than the prescribed dose for two months, leading to a 
re-admission to the acute setting212,243  
Since 2011, a priority for the management of medications in the NTMHS has been the 
consolidation of modalities of medication prescribing and administration. Medications are 
recorded in a variety of ways in different healthcare settings that include but are not limited 
to: the Primary Care Information System (PCIS) - electronic, Community Care Information 
System (CCIS) - electronic, and multiple paper-based systems.   
The Northern Territory Government was an early adopter of an Electronic Medication 
Management Application (eMMa), to be implemented in the acute and community-based 
government healthcare facilities.244  For the Mental Health service, the implementation of 
an eMMa was intended to help provide a continuous electronic medication chart that would 
be available to a wide variety of clinicians in settings throughout the NT. A financial 
commitment, along with the investment in project officers, and the necessary hardware to 
drive this quality improvement activity, was made by the Mental Health executives in 2011. 
In 2016 however, the community-based component of this software is still in the 
development stage.  
This delay in development has had a significant impact on Mental Health services, 
including finances, time dedicated for staff to attend training and scoping days, and now an 
obvious lack of trust in a program that has been promising to deliver for many years 
without any outcomes to prove its efficacy. The Mental Health executives made the 
decision to ‘pressure’ the vendor to deliver on the community-based module by refusing to 
implement eMMa in acute Mental Health facilities. This resistance is seen as a safety plea:  
by not introducing another system to a complex workflow of medication management, if 
again that system does not aid in handover and continuity of care. This decision was made 
possible due to Mental Health being governance unto its own until mid-2014. 
Whilst the Mental Health services are awaiting the unfulfilled promises of an electronic 
medication management system, the Community Mental Health Medication Chart provides 
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a workable solution which is both safe for our patients but also ensures that we, as a 
service, and as individual health professionals, are meeting legal obligations.  
Objectives 
Implement a Community Mental Health Medication Chart (CMHMC) to ensure that the 
Northern Territory Mental Health Service (NTMHS) has a valid prescription and a record of 
administration that is signed.  
Intervention design 
1. Development of chart and review: An email was sent to the Mental Health 
Committee of Specialty Practice by the EPhR, (via the Society of Hospital 
Pharmacists), to source charts that were being used interstate at other facilities. 
Feedback demonstrated that a mixture of self-designed charts, nursing home 
charts, and the long-stay National Inpatient Medication Chart245, were being used 
across Australia in community settings 
2. The decision was made by the EPhR to design a chart that was adapted from the 
Queensland depot chart, which appeared to be the most comprehensive, and the R. 
Elliott interim medication chart.246,247 The reason for this decision was that the chart 
required for the NTMHS needed to be all inclusive of not only depot medicines, but 
oral medications, which were often distributed from our Community Mental Health 
facility. Having an accurate up-to-date record of medicines is essential to ensure 
safe prescribing and administration232 
3. The decision to prepare a new chart also acknowledged the gaps identified in the 
current process of handover, the hospital discharge summary.248,249 The benefit of 
collaborating a depot chart with the interim medication chart recognises the need for 
medicines information to be transferred from acute care back to a community care 
facility234,250-252 
4. Workflow process to ensure continuity of care: On discussing how to implement 
the CMHMC, multiple process and workflow issues were identified as also needing 
to be addressed. These included: 
a. Discharge summaries being late and unreliable with medicines information 
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b. A limited number of doctors available in community Mental Health settings to 
prescribe medication 
c. The current contracted community pharmacy, that provides all medicines to 
Mental Health facilities in the community setting, required a “packing sheet”, 
in addition to PBS prescriptions, to fill dose administration aids for 
discharge/community Mental Health patients.  
d. The Crisis Assessment Telephone Triage team was not meeting policy,240 
with a telephone order being signed by prescriber within 24 hours, due to a 
lack of suitable chart on which to record telephone orders. 
Identification of target groups 
The core user group of the CMHMC was clinical staff, prescribers, nurses and 
pharmacists.  Prescribers needed to understand the need for change in order to meet 
legislative requirements. To undergo this change, they needed to incorporate the CMHMC 
into their current discharge process. Discharge prescriptions varied in entirety, ranging 
from medicines being prescribed that are needed to be supplied, to a complete list of 
medicines the patient was currently taking. This habit needed to be changed to ensure that 
an accurate and up-to-date list was transferred to the next point of care.232 It would also be 
the responsibility of the community Mental Health prescribers to keep the chart valid and 
up-to-date. 
Nursing staff had been documenting administration of depot medications within CCIS. This 
was an onerous task to find information, and CCIS does not have any safety requirements 
in place, which many medication charts include.245 The new medication chart would allow 
easy review of any dose changes, when medicines were administered, and would prompt 
features such as recording site of administration and batch numbers.   
Pharmacists within the community sector were involved in discussions and agreed on the 
design and layout of the medication chart, agreeing also to use this chart as their ‘packing 
chart’ for dose administration aids. 
Other stakeholders that needed to be engaged 
• Administration staff: To help with workflow by sending charts to various 
locations from the wards, filing and collecting the CMHMC prior to 
appointments for prescribers or nursing staff 
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• Management: A project plan was presented to the TEMHS General 
Manager, Adult team manager and Community Clinical Nurse Consultant 
and agreed upon prior to implementation. This ensured that there was 
support and approval of this initiative, which would help in enforcing policy 
• Consumers: As a clinician’s workflow was to change, consumers needed to 
be aware of the different process. The new process included a more 
vigorous, and routine, identification check that was matched to the CMHMC. 
The engagement occurred post-implementation, at their first appointment, to 
explain this alternate method of documenting their medicines and what 
checks would occur at each appointment 
Potential barriers 
1. Compliance with writing charts at the point of discharge 
2. Improvement needed with discharge summaries 
3. Inclusion of all medicines (not just psychotropics) 
4. Different treating teams require different management/paper work for discharges, 
therefore training requirements increase (in particular remote and forensics) 
5. Reconciliation at the community centres and ceasing previous charts, therefore it 
would be increasing the risk with multiple charts 
6. No second checks were occurring for administration of depots, this is a 
requirement with the new chart and will take a change in practice for nursing staff 
7. No documentation of distribution, therefore there would be no accountability for 
‘lost’ charts 
8. An increase workload training new staff to the Mental Health area 
Multiple process changes occurred in order to try to overcome these barriers and to 
implement a safe and effective medication management system. These process changes 
have ranged from filing systems, when charts are commenced (i.e. at the point of 
discharge), and how the charts are designed. 
Due to the risk associated with the current practice, the decision was made to implement 
the CMHMC as a rapid roll-out rather than a staged implementation. This meant that 
Alice Victoria Gilbert | 2016    P a g e  | 91 
 
patients who presented to the community facilities were prescribed a CMHMC during their 
appointment with the doctor, and all patients discharged from the inpatient wards had a 
CMHMC written at the point of discharge. This would indicate that all patients would be 
changed to a CMHMC within a six-week period. 
Data collection and analysis 
The evaluation plan was to do an audit, at one-month post-implementation, then three 
month’s post implementation to check compliance with policy, procedural work flow, and 
the quality of the documentation on the CMHMC. The audits would then become part of 
the rolling audit schedule and the chart would be reviewed annually. Each team or section 
of the service was audited individually to help tailor feedback. An audit tool was prepared 
by the EPhR and agreed to by the TEMHS medication safety and quality working group 
that were to be involved in the data collection. This study, presented in this thesis, is an 
example of an audit report for one team from the NTMHS. This report was presented back 
to the team by the EPhR with identified areas to target. 
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4.6.3 Community Mental Health Medication Chart Evaluation  
4.6.4 Background 
The Katherine Mental Health Service (KMHS), is a team under the Top End Mental Health 
Service, and is located 315 km South of Darwin. This audit was conducted three months 
after the implementation of the Community Mental Health Medication Chart (CMHMC). 
The KMHS is currently using the CMHMC, designed by the EPhR, which includes long-
acting antipsychotic injections (depot) and oral medication chart. This CMHMC is being 
used as their medication management documentation system for community patients 
visiting their clinic. 
The audit tool used is an adaption of the NIMC audit tool.215 To make it applicable for our 
setting, the tool has excluded warfarin and venous thromboembolism, and included Quality 
Use of Medicines indicators for Mental Health such as multiple antipsychotics prescribed, 
depot prescribing and administration, and PRN prescriptions.217 
4.6.5 Aim 
This audit is designed:  
• to provide a baseline of use and future quality improvement initiatives  
• to improve the safety of medication charting in community setting 
• to evaluate the effect of the community mental health chart safety features in the 
community setting  
• to evaluate the safety and quality of prescribing and related medication 
documentation, and  
• to identify areas for medication management improvement 
4.6.6 Method 
This audit was completed by the TEMHS pharmacy technician and a registered nurse. 
Training was provided to the auditors by the EPhR and results compiled by the EPhR. 
4.6.7 Results 
Total patient number for managed by the KMHS at the time of the audit was 116. A 
random sample of 20 (17% of patients) was used for the audit. The total number of charts 
evaluated was 23 (3 patients had multiple charts). 
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Key Performance Indicators 
1. Identification 
10% (2 charts) had complete identification. 
The auditors noted that patient ID labels were being used on 100% of patients, however a 
hand written name was then not completed. 
If a patient ID label is used, the first prescriber must print the patient’s name ensuring that 
the identification label is correct. It is not required to print the patient’s name if the patient 
details are handwritten.218  
Incomplete patient identifiers or patient identification that is not visible on all sections of the 
chart may result in an adverse drug event where the medication is administered to the 
incorrect patient or a patient being prescribed or administered medication intended for 
another patient. 
Printing of the patient name under an identification label was introduced as a compulsory 
safety mechanism for the prescriber to ensure that the correct patient identification was 
placed on the medication chart and associated prescriptions; this is currently not being 
adhered to within our service.218 Feedback will be provided. 
2. Adverse drug reactions (ADR’s) 
Nighty percent (18 charts) had ADR status documented. Omission of ADR information 
risks re-prescribing and administering a medicine that has previously caused an adverse 
reaction or, prescribing a similar agent. Recording the clinician’s signature assigns 
accountability for the information obtained.218  
Documentation of ADR details, and the use of ADR alerts, should prevent patients being 
re-prescribed, dispensed or administered a medication to which they have previously had 
a reaction.80 Within a mental health setting, a re-challenge of antipsychotics may need to 
be done as the classes are limited. The risk-benefit should be documented in the case 
notes and the decision to rechallenge should involve the patient’s consent.228  
The ADR section on the community mental health medication chart was originally on the 
back page due to spacing, which could lead to not only omission of documentation, but 
potentially failing to check prior to administration. See recommendations. 
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3. Depot medications 
All patients within the audit sample were prescribed a depot antipsychotic. Seventeen out 
of the 20 (85%) patients did have documentation on their medication chart that all required 
doses were administered. 
The reason for the identified omissions will be investigated by the KMHS and feedback 
provided to the medication safety and quality working group. This follow-up by the KMHS 
will be prepared in a timely fashion. Information will also be used to confirm TEMHS 
compliance with our missed dose policy when reviewing notes and documentation.  
Zero percent (0 of 97) of depot administrations had a documented second check. 
Independent double checks are undervalued and misused.  Independent double checks of 
medication have been widely demonstrated to significantly reduce medication errors. Up to 
95% of errors can be detected through double checks.253 
4. Sustained Release (SR) Preparation 
Five Sustained Release (SR) preparations were ordered and 60% (3 out of 5) had the SR 
box checked. This low number is potentially due to the limited number of oral medications 
documented within the community setting. However, this indicates an area to target to 
ensure that the correct dose form is being administered. 
5. Overall Prescribing  
All orders were individually evaluated  
The total number of prescription orders was 87; 84 (96%) of prescriptions had a 
prescriber’s signature, 81 (93%) of prescriptions had a printed and legible prescriber 
name, 64 (27%) of prescriptions included one or more unclear parts on the prescription 
(drug name, route, dose or frequency), 48 (55%) of prescriptions included an error-prone 
abbreviation which were 96% (IMI, standing for intramuscular injection), 4% (frequency 
represented as a fraction e.g. 2/52), 27 of the evaluated orders were ceased, 11% (3 out 
of 27) were ceased correctly including a date and prescriber signature. 
6. Oral Prescribing and Distribution in an Outpatient Setting 
Fifty-one patients were prescribed oral medications (80%); however only 4% (2 out of 51) 
had documentation of administration or distribution on the medication chart. This could be 
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due to the limitation of the way in which the administration section was designed. See 
recommendations. 
7. PRN Prescribing 
Eight of the orders evaluated were PRN prescriptions. Three included a maximum dose 
within 24 hours (26%).218,228,237 
8. Multiple Antipsychotics 
Twenty-four patients (38%) had multiple antipsychotics prescribed. Eleven out of the 24 
patients (46%) had the second antipsychotic charted as PRN.  
This is common practice in mental health despite the lack of evidence. As with the 
evidence, in the majority of cases the second antipsychotic was prescribed PRN.228 This 
part of the audit will also be evaluated when comparing the use of multiple antipsychotics 
post-discharge in the outpatient setting.217 
Five out of the 24 patients (21%) had 3 or more antipsychotics charted. One systematic 
study, that followed 99 patients with schizophrenia over a 25-year period, found that those 
who were prescribed three antipsychotics simultaneously were twice as likely to die as 
those who were prescribed only one.254 Another systematic study which followed a cohort 
of patients with schizophrenia prospectively over 10 years, found that receiving more than 
one antipsychotic concurrently was associated with substantially increased mortality. 
There was no association between mortality and any measure of illness severity.255  
9. Additional areas to examine to provide baseline information 
Medication histories – there is currently no standard place to document a medication 
history in the outpatient setting and it should be asked who is responsible for this important 
part of practice. 
Distribution of medication – Is this being documented and is there a standard format for 
this documentation? 
Recommendations 
An additional audit and evaluation to be done by KMHS to investigate patients identified to 
have missed depots. 
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To take to the TEMHS medication safety and quality working group: 
• Identification, ensuring prescribers are aware that if they are starting a 
medication chart, they need to handwrite the patients name under a printed 
sticker 
• Medication histories training for staff on how to perform the best possible 
medication history, and plan to have a standard place of documentation 
• Error-prone abbreviations, education and reduction within our service 
• Multiple antipsychotics – long term and practice change. Needs to be addressed 
across the whole service. This includes a treatment plan, intended treatment 
outcomes, monitoring of potential adverse events, and patient follow-up studies 
• Updated community medication chart to be implemented, which would include a 
new location of allergy status on every page 
• Investigate ways to implement a second check, prior to administration of depots 
in community 
• Routine documentation of depots administered at different facilities (e.g. remote 
clinics) – e.g. how to document for transient patients that may be seen at 
multiple health centres. 
4.6.8 Discussion and Translation to Practice 
Three key areas that are intentionally being addressed currently with the Community 
Mental Health Medication Chart are: 
o Providing a depot administration record (both prescription and 
administration) 
o Current, complete and up-to-date list of medicines 
o Distribution record 
From this post-implementation audit, there are evidently areas that still need improvement. 
The prescribing of depots within this setting was done correctly and is now meeting 
legislation. The benefit of the CMHMC also became apparent by easily identifying patients 
who had missed a required dose of their depot antipsychotic. This would not easily or 
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routinely be looked at prior to the implementation of the CMHMC. This is a safety initiative 
which will also help the service provide medication at the correct time, to the correct 
patient, in the correct manner. Missing depots can have a great impact on the patient and 
the community. It can also be a large cost to our service if patients deteriorate and require 
admission to hospital. Therefore, ensuring our follow-up for these patients is done in an 
appropriate manner based on risk is essential.  
Medication histories, being a complete up-to-date list of medicines, as well as the 
recording of distribution of medications, are two key focus areas for education and support 
over the next six months by the EPhR. 
This initial audit allowed for feedback to individuals, in particular prescribers, as well as the 
Mental Health executives, on the service’s current performance against quality standards 
and areas to target.89,217  
As electronic medication management is still not available for TEMHS community based 
setting, the CMHMC has made important safety and quality improvements for the 
community sector of mental health. The audit findings and feedback has helped to refine 
the chart to its current version.  
4.6.9 Current Status of Community Mental Health Medication Chart  
The Community Mental Health Medication Chart (CMHMC) has been refined and updated 
over the time the EphR has been employed in Mental Health. Its format is now such that 
further modifications are unlikely to be required for some time. The working policy and 
protocols have also been changed to reflect practice, and evaluation has occurred against 
policy, to ensure that we are meeting targets and can identify areas that need 
improvement. Due to the extensive background work, and refinement of this chart 
prepared by the EPhR, it has now been shared with the Australian Commission, with the 
idea of implementing a National Version of this chart. (See Appendix 12: Northern Territory 
Community Mental Health Medication Chart). The likelihood for this chart to be adopted 
and used as a national community Mental Health chart endorses the necessity for 
development of this tool and acknowledges its applicability for use in multiple healthcare 
settings.  
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4.7 Medicine Information for Patients with Mental Illness 
4.7.1 Background 
From the initiation of the EPhR’s position within the Mental Health service, medicines 
information was deemed an essential quality improvement activity that needed to occur. 
Ensuring that patients had access to unbiased information, in a way that is easy to 
understand was originally not accessible for Mental Health patients in the Northern 
Territory. 
A major barrier for improving health outcomes of Territorians is the low level of health 
literacy. This presents a risk and limitation for patients to use medicines safely and 
effectively.256 Health literacy is essential to ensure that patients can obtain, process and 
understand health information and services, so they can make health decisions.257 
Health literacy is dependent on many variables such as: 
• Individual Factors: socioeconomic status, education, religion 
• Knowledge a consumer has of the health system, their illness and how their body 
works  
• Skills consumers have in literacy, numeracy, and in the cognitive area 
• Cultural beliefs and values 
• Past experiences with the health system/service provider258 
Medication health literacy is crucial to the success of treatment. The effectiveness and 
safety of medicines cannot be maximised unless consumers understand their role in the 
medicine taking process. Patients with Mental illness can pose an even greater challenge 
as insight into their condition may be lacking and hence they may not understand why they 
need to be taking medication at all.259 
The literature indicates that many consumers have difficulty reading and understanding 
medication labels and medication literature. Consumer education and improved healthcare 
are cited as two major strategies to improve medication adherence. Medicine information 
should be provided both verbally and in a written form.108 
Within Australia, Consumer Medicines Information (CMI) leaflets (typically provided by the 
manufacturer) are the mainstay of written information provided by a pharmacist.90 
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However, CMI’s are often very wordy and poorly understood.90,260 Studies looking at 
consumer education interventions, to improve medication safety, are varied in their scope 
but many show a positive impact on quality of life, mortality and/or hospital re-
admissions.88  
The engagement with key stakeholders as well as advantageously grasping networking 
opportunities, led to the EPhR learning of the Choice and Medicines website developed by 
Professor Bazire, an international leader in the area of Mental Health.196 This website has 
medicines information in varying formats from pictorial descriptions to more detailed 
information, including practical advice, such has how to overcome side effects if they do 
occur.196  Due to the level of health literacy within the Northern Territory, as well as the 
requirements needed to meet National Accreditation, the EPhR proposed a subscription to 
this website. This was an extremely positive initiative that is now used across our service, 
from inpatient units to remote communities.196   The ward-based pharmacist position was 
intended to deliver essential information on medicines to each patient, a role which was 
previously lacking in the mental health service. A “before and after” evaluation was 
performed on the impact of a pharmacist and patient satisfaction with both verbal and 
written information that was now part of the mental health service. 
Consumer satisfaction with medication management within the Inpatient Units of 
the Top End Mental Health Service (TEMHS)  
4.7.2 Aim 
To quantify consumer satisfaction in relation to the availability and quality of medicines 
information provided on the Inpatient Units of TEMHS.  
To identify how information is provided (written or verbal)  
To review when information is provided by staff  
To determine if consumers would like more medicines information and how to provide it  
4.7.3 Method 
A user survey was conducted over 14 days (02/11/15-13/11/15) using the tool developed 
by the EPhR. There was slight modification to the language used in the questions to 
enable better client comprehension but the audit tool was largely similar to that used in 
November 2014. The survey was filled in by the patient or verbally dictated to the clinical 
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pharmacist and intern pharmacist to admitted patients on Cowdy ward and Joan Ridley 
Unit.   
Exclusions: Multiple patients were discharged prior to completing the survey due to time 
constraints on discharge/leaving the ward before receiving the survey.   
4.7.4 Results  
Over the two-week audit period, 12 patients agreed to participate and completed the 
survey.  
Total audit number: 12  
Eighty-three percent of respondents were satisfied or very satisfied with the overall 
medication management within TEMHS. (Compared with 73% for 2014 survey).   
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Figure 4.8: Question 2: How would you rate the information given to you about medicines in the Top 
End Mental Health Service? 
Seventy-Five percent of respondents rated the information provided about medicines as 
useful or extremely useful. This is an improvement compared to 2014 where only 46% 
rated the information provided about medicines as useful or extremely useful.  
 
Figure 4.9: Question 3: How have you been given medicines information? (tick as many as apply)  
Fifty percent of respondents said they had been provided with written information about 
their medications as an inpatient. This is in contrast to 2014 where 0% of respondents 
have been provided written information about their medicines as an inpatient.  
  
Figure 4.10: Question 4: When have you been asked or given information about your medicines from 
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Medicines information was provided by many disciplines of health professionals with many 
of the respondent’s surveyed saying that they had received medicines information by 
multiple health professionals over their stay. When last surveyed in 2014 no patients had 
spoken to a pharmacist, therefore the introduction of a continuous clinical pharmacist on 
the wards to the TEMHS has improved the amount of medicines information provided.   
 
Figure 4.11: Question 5: Was the medicines information given to you in a way that was easy to 
understand?  
Eighty-nine percent of patients who responded to this question felt that the medicines 
information given to them was easy to understand.   
 
Figure 4.12: Question 6: Would you like more information about your medicines? 
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Figure 4.13: Question 7: How would you like the information to be provided to you? 
Many of our patients would appreciate written information about their medications.   
Question 8 What is the most important thing that you would like to know about your medicines?  
The response to this was varied. Some of our respondents wanted more information about 
side effects, and what to expect about their medications, others wanted to know about 
expected duration of treatment, how the medication works and medication interactions.   
 
Figure 4.14: Question 9: Have the medicines information been given to you in a way that is respectful 
to you, your family and your culture? 
Ninety-two percent of respondents felt that the information provided about their medicines 
had been done in a culturally appropriate way. One client responded “sometimes” and 












Written Verbal Both Not Applicable (I do
not want any more
information)
Yes No
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4.7.5 Discussion and Translation to Practice  
Consumer satisfaction surveys are influenced greatly by a number of factors – including 
speed of recovery of the patient, prior experience, length of stay, cognitive function and 
their mood at the time of completing the survey. To capture as accurate a snapshot as 
possible, this audit was conducted over a two-week period and disseminated to clients 
who were still inpatients but had sufficiently recovered to enable comprehension of the 
questions in the survey.   
A noted positive improvement compared to the 2014 survey was the perception that 
information provided to clients about their medications was useful. In this survey, we 
added in a question regarding how easy it was to understand the information provided and 
most respondents also found that the information provided was easy to understand. It is 
important to gauge qualitative data and avoid a “ticking the box” approach regarding 
information dissemination.  It was also noted that information was being provided by a 
range of health professionals - doctors, nursing staff and pharmacists and at multiple times 
during a client’s stay (e.g. on admission and before administration). These are all excellent 
opportunities to re-inforce important points and to improve a patient’s medication literacy.    
Since the introduction of a ward-based clinical pharmacist the percentage of respondents 
who reported that they had received counselling from a pharmacist had increased from 0% 
to 83% and provision of written information had increased from 0% to 50%. In response to 
consumer desire to have greater provision of medicines information provided, the 
pharmacy team has implemented a weekly group education session to patients (in all 
inpatient wards) about medications, which are broad in nature and also help to identify 
patients who have concerns or wish to receive more medication information.    
The respondents also placed importance on varied aspects of medicines information 
indicating that provision of information should be specifically tailored to the individual 
needs of the patient, something that clinical pharmacists based on the wards are in a good 
position to provide. During the survey period, we felt that this audit also had merit as a 
working tool in identifying patients on the ward who required more information, and these 
clients were duly provided with such.  
On discharge, all patients are provided with written medicines information and direction to 
the Choice and Medicines Website, by the ward pharmacist. However, this survey shows 
that medicines information is desired by patients while they are inpatients, prior to 
discharge.   
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Information is also routinely provided to staff by a pharmacist on how to access the 
‘Medicines and Choice’ website and other medicines information which can aid in the 
health literacy of all clients.  
4.7.6 Recommendations 
Currently the role of the Inpatient Unit Clinical Pharmacist is scheduled to be short term 
(less than 6 months) unless renewal of the contract takes place. We would highly 
recommend retaining this role to help us meet our safety and quality use of medication 
(QUM) and health literacy targets, and also to maintain a proactive approach to medicine 
information dissemination. As pharmacological treatment is an integral component of a 
patient’s therapy, it stands to reason that counselling and medicines information 
dissemination forms a core part of our service.    
4.8 Medication Information for Prescribers 
4.8.1 Background 
As with patient information, the information provided to our clinicians is vital to ensure up-
to-date and evidence-based practices are being followed. It can be overwhelming for 
clinicians to keep up with changing guidelines, new policies, and medications that are 
introduced to the market. Professor Avorn, from Harvard Medical School, Boston, USA, 
developed ‘academic detailing.’19 It is based on the effective way that pharmaceutical 
company representatives market their product to doctors, nurses, pharmacist, and 
patients. The pharmaceutical industry has managed to influence prescribing usually by 
one-to-one information sessions to clinicians within their practice. In academic detailing, 
trained doctors, pharmacists and others advise clinician of best treatment for their patients. 
This is an ideal role for pharmacists to provide education to prescribers on a needs-based 
approach. 
The role of an EPhR can include academic detailing. Education is an essential part of a 
pharmacists skill set, this includes evidence review for particular topics, developing key 
messages and tools, and providing an educational framework for other pharmacists to 
deliver the same key messages.21,261  
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4.8.2 Embedded Pharmacist Researcher Helping Prescribers and Patients in Making 
Informed Decisions 
4.8.3 Introduction 
The next study in this section is an example of the EPhR’s clinical knowledge and 
application of that knowledge. At the start of the EPhR’s employment, Mental Health was 
under its own governance and did not need to abide by Hospital policies. One of the key 
differences between Mental Health and other disciplines that worked within the Hospital 
was the influence of Pharmaceutical Companies. Unfortunately, this was exacerbated by 
the lack of pharmacist input. The Mental Health staff relied on pharmaceutical 
representatives to provide education, access to stock via samples, and first insight into 
new products for the Australian market. This was a primary concern to the EPhR as often 
new products to the market have limited evidence, particularly long-term safety data, and 
come at a large cost, See Paper 2. 
The example used within this case series is Aripiprazole Long-Acting Injection. 
Aripiprazole is a second generation antipsychotic which has been available in the oral form 
within Australia since 2003.262 The Long-Acting Injection had been approved and used in 
practice both in the United States and Europe prior to its approval by the Therapeutics 
Goods Administration of Australia.263 Strong marketing by pharmaceutical companies 
usually accompany new products to the market. Aripiprazole Long-Acting Injection was no 
exception.  
Long-acting injections (or depots) are a mechanism of medication delivery which releases 
the active ingredient over an extended period of time, usually weeks or months.206 Within 
the Mental Health Setting the most common medicines delivered by a depot are 
antipsychotics. Due to the length of time a depot medicine remains in a patient’s body, 
they are considered a high risk medicine within the Mental Health setting. The outcome to 
the patient can be devastating if the choice of medicine is wrong, or the patient 
experiences adverse effects, as there are no reversible solutions for removing a depot 
antipsychotic.  
The NT drugs and Therapeutics Committee (NTDTC) is the governing body for medicines 
across the public hospitals. This includes managing the Northern Territory Formulary. The 
majority of Australian Hospitals work from a formulary. A formulary is a list of core 
medicines which are approved for use within a state’s public hospitals and health services. 
Through a Territory-wide approach to the availability of medicines, the Northern Territory 
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Drugs and Therapeutic Committee aim to optimise the Quality Use of Medicines, improve 
and promote equity of access to medicines for patients and increase the cost-effectiveness 
of medicine use across the NT. The EPhR has previously been the secretary for the 
NTDTC. The secretary is responsible for completing the literature reviews and to provide a 
summary document for the committee to make their decision on the addition and/or 
removal of medicine for the NT formulary. The chief psychiatrist wished to add aripiprazole 
oral and a long-acting injection to the formulary, therefore an application was put to the 
NTDTC, and a discussion paper was prepared by the NTDTC.  
Due to the uptake of Aripiprazole within the NTMHS after the initial review (Paper 2), a 
12-month follow-up study on the patients treated with Aripiprazole was conducted by the 
EPhR to gain information on patient outcomes. This was particularly important to 
demonstrate to the service the need for evidence-based practices to ensure best possible 
care for our patients. Activities such as ‘academic detailing’ provide an opportunity to work 
alongside the prescribers in their decision making regarding their patients.19 
4.9 Aripiprazole Long-acting Injection: Testing outcomes Using a One Year Follow-
Up Case Series 
4.9.1 Introduction 
Schizophrenia is a chronic and severe mental illness that requires lifetime management 
with medication to prevent decompensation and worsening of symptoms.264 Adherence to 
antipsychotic therapy is one of the biggest challenges to successful treatment. Non-
adherence with antipsychotic medication is associated with an overall poorer prognosis. In 
addition to increased likelihood of recurrence of psychosis and rehospitalisation, patients 
can experience worsened medical outcomes and premature death.265 Long-acting 
injectable (LAI) antipsychotics are frequently seen as an intervention to improve 
adherence.266 In April 2015, Aripiprazole Long Acting Injection (A-LAI) was approved by 
The Therapeutics Goods Administration in Australia.96 A-LAI provides an alternative to 
other modified release injections used to treat schizophrenia, potentially allowing the 
physician an increased chance of finding an effective treatment and offering an alternative 
side-effect profile.267 Within our hospital, the use of A-LAI was met with enthusiasm by 
prescribers. However, clarification of its place in therapy was blurred by the influence of 
the pharmaceutical company’s representative’s presentation at our hospital, see Paper 2.  
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4.9.2 Background 
What is A-LAI’s place in therapy? 
Oral aripiprazole has been available on the Australian Pharmaceutical Benefit Scheme, for 
the treatment of schizophrenia in Australia, since 2003.263 The mechanism of action is 
distinct from that of other atypical agents, and the side effect profile is also unique, which 
is a selling point for the pharmaceutical company.267,268 A-LAI’s are now also on the 
Australian Pharmaceutical Benefit Scheme for maintenance treatment of schizophrenia in 
adults in whom tolerability to oral aripiprazole has been established.265,266 Prior to its 
addition to the Australian market, A-LAI had been approved for the treatment of 
schizophrenia in several European countries as well as the United States of America.267,269  
Antipsychotic medicines are the mainstay of pharmacological treatment for patients with 
schizophrenia.263 Australian guidelines recommend oral second-generation (atypical) 
antipsychotic agents for first-line treatment in most patients, due to the lower risk of 
extrapyramidal symptoms (EPS) (i.e. akathisia, tardive dyskinesia) compared with typical 
agents.263,270,271  
In which patients is there a lack of evidence for the use of A-LAI?  
The obvious answer is patients who do not have a diagnosis of schizophrenia. However, in 
the treatment of mental illness antipsychotics can be used for other indications, such as 
bipolar disorder. Some antipsychotics are approved for use in other indications. Currently 
in Australia, A-LAI is not.272 
The second indication which seems predictable is that a response should be seen from 
oral aripiprazole prior to switching to the long acting injection. If a patient is unwell the risk 
of withdrawing all antipsychotics to see the effect of a single antipsychotic may not be 
appropriate. Having a washout period for patients who are unwell can cause unnecessary 
stress and further worsening of their symptoms. So, what happens? A common 
occurrence in practice is to add aripiprazole to current therapy in what is called a cross-
titration.237  The current antipsychotic is tapered down whilst the new antipsychotic is 
added in and tapered up to a therapeutic dose.237 The issue that arises is that the 
combination is not giving a true reflection of the individual agents. This can also become a 
clinical concern as the risk of side effects increases. There is the chance that a patient will 
remain on multiple antipsychotics as the treating team may fear to stop one.237 
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Additionally, within the product information for A-LAI, it states that an additional 
antipsychotic needs to be continued for two weeks after the first A-LAI. It does not state 
which antipsychotics to continue.267 Again the evidences of combinations is limited, and 
thus suggests the need to implement additional follow-up care to ensure that this does not 
continue long term.228 The evidence supporting combinations is based on small open-
labelled studies which have not shown benefits, but evidence of harm from combinations is 
more compelling.228 Other countries, where A-LAI has been approved, recommend 
treatment with oral aripiprazole for two weeks after initial injection. Due to this lack of 
clarity within the Australian product information it can lead to patients being treated with 
multiple antipsychotics during this initiation phase.267 
Finally, treatment-resistant schizophrenia is a term given to patients that have tried and 
failed on at least two antipsychotics, with at least one of these being a second generation 
antipsychotic. For these patients, the best-practice guidelines all recommend that the 
patient should be offered clozapine.228,237,270  
What are the concerns if the treatment choice is wrong? 
• Extended admission 
• Relapse 
• Worsening of symptoms 
• Re-admission due to having a masking effect of a combination within the patient’s 
system 
• Further degeneration of disease 
• Increased costs to the individual or the community 
4.9.3 Aim 
To follow-up the clinical outcomes of prescribing A-LAI within a case-series to better 
understand A-LAI place in therapy.  
4.9.4 Method 
This study used a one-year case series follow-up on the introduction of A-LAI to patients 
admitted to the hospitals psychiatric unit, post-presentation from the pharmaceutical 
company’s representative’s presentation to medical staff in April 2015. Ten of the 26 
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patients admitted to the psychiatric inpatient unit were prescribed A-LAI. This occurred 
within one week from the presentation, from the pharmaceutical representative, to the 
medical staff.273  
4.9.5 Outcomes 
Initial evidence-based assessment of the chosen patients prescribed A-LAI did not leave 
myself, as a clinical pharmacist, with the confidence that this was an appropriate treatment 
for the majority of the patients.  
One year (March 2016) past the initiation A-LAI for ten patients, a further clinical 
assessment was undertaken. 
Key Clinical Questions  
1. Was A-LAI an appropriate choice, given the current evidence, patient’s diagnosis, 
past treatment history and current therapy? 
2. How many of the 10 patients have remained on A-LAI therapy? Was the treatment 
with A-LAI successful? This was indicated by the patient remaining on this therapy 
over the year. 
3. Although a small case series, is there any difference in response between our 
Indigenous and Non-Indigenous patients? 
4.9.6 Results 
Was Aripiprazole Long-Acting Injection an Appropriate Choice Given the Current 
Evidence and the Patient’s Diagnosis, Past Treatment History and Current Therapy? 
Understanding the challenging choices that face our psychiatrists within the acute Mental 
Health facilities should not be overlooked. All ten patients who commenced aripiprazole 
were unwell at the time and admitted to the acute Mental Health wards in a Tertiary 
Teaching Hospital.  
A-LAI was marketed to our prescribers as an antipsychotic with the promise of a different 
side-effect profile. Due to the majority of our patients having metabolic side effects, to 
varying degrees, the idea of a ‘weight neutral’ second generation antipsychotic had 
everyone interested. 
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As with all clinical decisions, weighing up the risks and benefits must be discussed. In this 
example, efficacy and side effects take the forefront.  
Of the patients selected by our physicians to be trialled on aripiprazole, four had previously 
been treated with clozapine. Clozapine is reserved for treatment resistant patients. All four 
patients had responded to clozapine; however, non-compliance with oral medicine had led 
to treatment failure and the risks associated with doses missed with clozapine meant that 
they were no longer suitable for this therapy. For these four patients, it is not surprising 
that they did not respond or remain on aripiprazole. 
Patient 2 was diagnosed with Bipolar disorder, for which A-LAI is currently not listed on the 
Pharmaceutical Benefits Scheme as a subsidised indication. The patient did not respond 
to A-LAI and, due to its side effect profile of akathisia (restlessness) and insomnia, this 
contributed to his manic symptoms. 
The driving factor for trialling aripiprazole in three patients (patients 1, 6 and 8) was their 
history of, or current, prolonged QTc intervals. Antipsychotics may increase the QTc 
interval, and thus increasing the risk of arrhythmia and sudden death.228,237 Aripiprazole 
has little or no effect on QTc intervals.237 All three patients were on multiple antipsychotics 
prior to trailing aripiprazole which may have contributed to having a high QTc interval. The 
antipsychotics, that were part of the combination, were well known for extending the QT 
interval, such as olanzapine and chlorpromazine.228 It should be noted that patients 
remaining on combinations of antipsychotics are at greater risk of adverse events and 
there is no evidence for improved outcomes to support this practice, the exception being 
combinations with clozapine.228,237 After not responding to aripiprazole, all three patients 
have been rationalised onto one antipsychotic to which they have previously responded. 
Finally, the two patients that have successfully remained on aripiprazole are both female 
with diagnoses of psychosis. One has remained on oral aripiprazole while the other has 
been managed on A-LAI. Both patients were currently being treated with a single 
antipsychotic prior to switching to aripiprazole. (See Table 4.3).    
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Table 4.3: One-year follow-up of ten patients commenced on aripiprazole. 














Additional Clinical Comments 
1 36 F Y Schizophrenia*  Previously had prolonged 
QTc intervals on 
antipsychotics 
N No improvement in 
mental state 
 
2 29 M N Bipolar disorder Was currently being 
treated with 
zuclopenthixol decanoate 
and sodium valproate. 
Weight gain as a concern. 
N Residual mania and 
difficulties with sleep 
With the introduction of A-LAI patient 
was on three antipsychotics. This patient 
was receiving two depots, 
zuclopenthixol decanoate and A-LAI (the 
plan was to taper down the 
zuclopenthixol decanoate) and oral 
olanzapine (plan to cease oral 
olanzapine). This plan was not adhered 
to and the zuclopenthixol decanoate 
dose increased during the time treated 
with aripiprazole. 
3 45 M Y Schizophrenia 
and acquired 
brain injury*^ 
Previously on clozapine 
but was non-compliant 
with oral medicines. 
N No improvement in 
mental state 
With the introduction of A-LAI patient 
was treated with two antipsychotic 
depots (A-LAI and paliperidone 
palmitate.) 
4 36 M N Schizophrenia*^ Previously on clozapine 
but was non-compliant 
with oral medicines. 
N No improvement in 
mental state 
With the introduction of A-LAI patient 
was treated with two antipsychotic 
depots (A-LAI and flupenthixol 
decanoate.) 
5 36 F Y Psychosis* Currently on Risperidone 
long-acting injection, 
concerned about weight 
gain with Risperidone 
depot, and think that 
change of medication is 
necessary. Relapse 




Y Successful switch 
from risperidone to 
aripiprazole  
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swapping back to 
paliperidone 
 
7 45 F N Psychosis Previous weight gain with 
other antipsychotics. 
Weight gain contributes to 
paranoia in this patient. 
Y Aripiprazole has 
continued in oral 
form, patient did not 
require depot and 
has been compliant.  
 
8 32 F Y Schizoaffective* Metabolic complications 
(weight gain and 
diabetes) including 
prolonged QTc with other 
antipsychotics  
N Aripiprazole was 
ineffective – no 
change in mental 
state 
 
9 36 M N Schizophrenia^ Metabolic syndrome 
(obese, hypertension and 
diabetes). Also displaying 
negative symptoms. 
N Did not start 
aripiprazole depot 









10 29 M N Schizophrenia^ High dose clozapine 
whilst still displaying 
breakthrough psychotic 
symptoms. Aripiprazole to 
augment the clozapine. 
N Poor compliance 
with oral medicines. 
Did not initiate 
aripiprazole depot, 




*Positive for illicit drugs on admission or history of substance abuse disorder 
^Previously managed on clozapine
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How many patients remained on Aripiprazole Long-Acting Injection 12 months after 
initiation? 
Of the ten patients who were commenced on aripiprazole in April 2015, two patients 
remain on this therapy as of March 2016. One patient has remained on oral aripiprazole 
without transitioning to A-LAI as originally planned, and one is receiving the A-LAI. 
Is There a Difference in Response with our Indigenous and Non-Indigenous 
Patients? 
Due to the small numbers in this case series, there are no differences in response 
between our Indigenous and non-Indigenous patients. Of the two remaining on this 
therapy, one patient identifies as Indigenous and one as non-Indigenous. 
4.9.7 Key Summary Points 
This small case series has confirmed the existing evidence, and place in therapy, for A-
LAI.  
• From this paper, health practitioners can determine that, A-LAI is not for complex 
treatment resistant patients 
• A-LAI use in bipolar disorder in Australia is yet to be established 
• Combination therapy does not add benefits to our patients and can put them at 
greater risk for adverse events 
• There are other antipsychotic options for patients who are at risk of prolonged QTc 
intervals, although aripiprazole does not seem to affect QTc; if their mental illness is 
not effectively treated, then the risks and benefits need to be explored 
• New medicines and new dose forms can be costly, again emphasising the need to 
apply evidence-based practices 
• The influence of pharmaceutical representatives on prescribing are well known, 
however they are still a source of education for the medical profession 
• The role of clinical pharmacists providing evidence-based education to prescribers 
can be of great value to both health services and patients 
Alice Victoria Gilbert | 2016    P a g e  | 115 
 
4.9.8 Discussion and Translation to Practice 
After the application to the NTDTC, Aripiprazole oral and long-acting injections were added 
to the NT formulary. Despite now having easier access to prescribe this medicine for 
Mental Health patients within the NT, the numbers have fallen, due part to the EPhR 
sharing the 12-month results with the NTMHS as well as sharing the cost to the service. 
Discussion with physicians, particularly after patients were taken off aripiprazole, 
suggested that aripiprazole did not provide the new solution they were after. 
The 12-month study period, examined ten patients who were treated with A-LAI. Further to 
this ten, six additional patients were trialled on A-LAI during the 12-month study period. 
This was at a cost of $6 636 to the Mental Health service for medication alone. After the 12 
month time period, due to the decrease in patient numbers, the cost to the service for 
aripiprazole long-acting injection has fallen by 56% to $2 899. This is an example of Drug 
Utilisation Research conducted by an EPhR which can influence patient outcomes and 
financial savings. 
4.10 High Risk Medication 
Within the hospital setting there is a recognised list of medicines which are considered 
high risk. High risk medicines include: 
• medicines with a low therapeutic index 
• medicines that present a high risk when administered by the wrong route or when 
other system errors occur.274 
High risk medicines may vary between hospitals and healthcare settings depending on the 
types of medicines used and patients treated. The TEMHS Medication Safety and Quality 
working group determined their list of high risk medicines for the Mental Health setting. 
The group decided on the following list: 
• Depot antipsychotics 
• Benzodiazepines 
• Clozapine 
• Propofol and neuromuscular blocking agents used in Electroconvulsive Therapy. 
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The National Safety and Quality Health Service Standard 4 requires health services to 
identify high-risk medicines used within the organisation and take appropriate action to 
ensure that they are stored, prescribed, dispensed and administered safely.193,274 
The EPhR recognised the additional burdens of clozapine for patients living in the 
Northern Territory, which can create higher risk due to potential breaks in therapy. From 
experience, using remote area practitioners to provide ongoing prescriptions for clozapine, 
due to specialists not being available, is a huge burden on both the pharmacist involved 
and the specialist who is overseeing the patients care.  
There are many challenges in instituting clozapine for patients in the outback. These range 
from geographical barriers, needing to send the regular blood work via charter to a capital 
city, the faxing of scripts, cultural and language issues with respect to explaining the 
process and monitoring of clozapine administration, physical state and bloods and 
ensuring that the whole family is ‘on board’ for this treatment. In addition, given that all of 
our communities are not within the vicinity of a hospital means that, after the initiation of 
clozapine, the patient is required to stay in hospital or in a step-down facility for at least the 
first 10 or so weeks due to the difficulties of monitoring blood tests. This creates an undue 
burden on our patients and their families due to separation, homesickness, and sometimes 
employment commitments. 
It is important to recognise that clozapine is considered as the treatment of choice for 
patients with treatment resistant schizophrenia. 228,237 Due to its side-effect profile, 
Clozapine is considered a high risk medicine within Mental Health, however using 
clozapine prevents another option such as multiple antipsychotics being used when there 
is no evidence for efficacy but much evidence of harm.  
One of the benefits of having the mandated blood tests is that it also ensures patients 
have regular review and input from their mental healthcare practitioners. In some respects, 
clozapine patients receive better care, as their regular contact with the health-clinic for 
supply and monitoring helps them to form a vital therapeutic relationship. 
Remote patients pose a unique set of clozapine issues, mainly around supply and 
monitoring. It is impossible in some instances to have the bloods, prescriptions and supply 
all being done within 24 hours, as outlined in policy,275 due to the location of the patient. 
Exemptions should be stated within the drug company’s policies for registering patients, 
however it is not.275 More patients are suitable for clozapine in remote areas than the 
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number that is treated. The main reason for this is the difficulties when supply is delayed. 
Supply is often delayed if it needs to go to a community pharmacist for packing with other 
medicines (as community pharmacists provide the S1002F‡ service to these clinics). 
Occasionally clozapine is packed separately by the pharmacist due to not being a part of 
the blister packing cycle for the rest of the patient’s medicines. This action could lead to a 
high chance of serious health outcomes if it is assumed the clozapine has already been 
collected. The urban-based clozapine co-ordinators do not have the capacity or knowledge 
of the remote systems, pharmacist processes nor time to provide an oversight for these 
patients.  
4.10.1 Benchmarking the Top End Mental Health Clinical Technician Position 
After the initial employment of the TEMHS clinical technician position the EPhR was began 
the process of benchmarking. Benchmarking a position means that it is measured against 
competency standards to determine an appropriate pay scale and position. This was 
important for a number of reasons, it is important for retainment of staff, acknowledgement 
of acquired skills and career progression for technicians.  
Unfortunately, as with many non-professional careers, pay scale and job satisfaction can 
often lead to high staff turnover and retention of trained staff is challenging. The 
government system of pay scales within the Northern Territory, which is consistent with 
other states, has pharmacy technicians with a three-tier approach: 
Technical 1: Entry level (no previous experience) 
Technical 2: On the job experience and willing to undergo formalised certificate. 
Technical 3: Manager or supervising technicians, usually organising rosters, meetings and 
trained administration skills. 
Experience of training and allowing technicians to utilise their skills, continues to be 
dampened by financial constraints. With no room to continue to ‘move-up’ within a career 
this situation tempts technicians to move on. With this in mind, the EPhR began the 
process of re-evaluating this position to move the technician to a technical 3. The re-
evaluation process for the TEMHS clinical technician was successful and this position 
became the first in the Northern Territory to be a Technical 3 position based on clinical 
                                                          
‡ Special arrangements exist under the provisions of Section 100 (S100) of the National Health Act 1953 to 
address identified barriers in accessing the Pharmaceutical Benefits Scheme (PBS) in remote regions of 
Australia. Under the S100 arrangements, Primary Health Care Remote clients in most communities are 
eligible to receive essential medicines which are currently listed in the PBS, at no cost.  
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skills and specialisation. Promotion to the next tier provided acknowledgment of additional 
training and knowledge. 
4.10.2 Addressing the Need for a Clozapine Technician 
The additional complexities of treating remote patients with clozapine prompted the EPhR 
to apply for a technician to help with coordination and logistics for our remote clozapine 
patients. The technician would provide support, follow-up, information and organisation of 
supply for our remote clozapine patients. The benefit for our patients will mean: 
• If a patient is suitable for clozapine, living in a remote location won’t be a limitation 
• Less time, stress and frustration of ‘missing’ clozapine due to not making deliveries 
• Reduced chance of re-admissions if there has been a break in therapy (this is a 
huge cost to our service and very stressful for our remote patients and family) 
• Higher levels of care are needed by the remote communities if a patient returns to a 
remote community after re-admission to hospital due to the frequency of blood tests 
and observations required to ensure the safety of this patient; remote area staff do 
not have this capacity  
Clozapine patients often have the most input and often have the best physical healthcare 
out of all mental health patients – but this is not currently true for our remote patients. The 
clinical staff time is spent on organisation of supply of bloods and medicines rather than 
patient care. The proposal was to improve our current service for remote area clozapine 
patients. 
As the success of benchmarking the original TEMHS clinical technician was complete. 
This would also develop management skills for this technician as they would become the 
line manager to the clozapine technician, and it would start to build a sustainable 
technician team for Mental Health. The idea would be to also have the TEMHS technician 
train the clozapine technician on roles within the service to provide a cover arrangement 
during periods of leave. 
Of course, not all remote clozapine admissions to hospital occurred due to logistical 
nightmares, however, the majority do. This became known as the EPhR was often the first 
point of call when clozapine had not arrived at a remote community, or to provide 
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information on missing doses, or to detail to prescribers how to re-titrate a patient to their 
previous dose.  
The EPhR presented a proposal to the Mental Health Executives to initiate a trial of a 
Remote Clozapine technician to help with co-ordination between all parties. The roles of 
the remote clozapine technician would include: being proactive in requesting blood 
appointments, ensuring the bloods are processed urgently via pathology, driving 
medicines to the airport to ensure that interruption of supply, would not be the reason for a 
patient to deteriorate and be readmitted to hospital.  
Managing potential frustrations in the co-ordination of services may also help to encourage 
and support remote clinics to be more accepting of patients who require clozapine. 
4.10.3 Aim 
For TEMHS to fund a pharmacy technician position to act as a remote clozapine co-
ordinator. This position would help facilitate supply between hospital, community 
pharmacies and remote area healthcare workers. They would also be responsible for 
requesting blood tests and prescriptions on designated days to ensure it is in line with the 
remote healthcare clinic. 
4.10.4 Timing 
Initial three month trial, with plan for clozapine pharmacy expansion if benefit is 
demonstrated 
4.10.5 Potential Financial Impact 
This service would have a positive financial impact by preventing CareFlight3F§ costs, 
readmissions and staff time/frustrations. The trial position will be required to collect data to 
support this positive financial impact. 
Within the three-month trial of this position the technician will be collecting statistics to 
demonstrate the financial burden of clozapine patients who live remote, and the cost 
saving measures of employing such a position. Non-financial statistics such as number of 
phone calls, queries and frustrations should also be documented to represent ‘time is 
money’ and the resources required to provide this service. 
                                                          
§ CareFlight is an aero-medical charity established in May 1986 by a group of Australian doctors. CareFlight 
uses a variety of aircraft including aero-medical helicopters, jets and aeroplanes to bring injured and ill 
patients within Australia and overseas to emergency hospital care. 
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Table 4.4: Potential Cost Saving Analysis 
Factors to consider for remote patient 
admission 
Cost to service 
Average cost per CareFlight® to hospital (one 
patient)  
$12 500 
ACUTE CARE (RDH / ASH) (Overnight)  $1 461 per day 
Number of remote patients treated with 
Clozapine in 2015 
11 (one of the 11 patients was interstate for all 
of 2015) 
Number of patients admitted from remote areas 
on Clozapine in 2015 
4 patient admitted 
1 of the 4 patients had two admissions 
1 of the 4 patients had three admissions 
Average length of stay for remote clozapine 
patients if admitted to hospital (based on 2015 
figures)  
25 nights (range 7 nights -76 nights) 
Total nights spent in hospital were 176 
Total cost of clozapine admission in 2015 (7 
admission) including cost per day and 
Careflight. 
Total of 176 days plus 7 care flights =  
$514 272 + $87 500 = $601 772 
** It is important to note that occasionally patients need to be CareFlighted multiple times, for example from 
their home in remote location, to nearest district hospital, if admission is required then CareFlighted again to 
Major Referral Hospital (Alice Springs or Royal Darwin) 
`additional costs may be incurred if the patient elects to have a boarder attend with them (flight, food and 
accommodation) 
#additional costs may be incurred if the patient remains in Darwin in a step-down facility. 
 
The salary of a Technical 2 Position is $55 000 per annum. 
The proposal is to have a Technical 2 position for a 3-month trial, which will cost 
approximately $10 000 to demonstrate cost savings, co-ordination of services and 
potential prevention of admissions. 
4.10.6 Implications if the Proposal is not Approved 
Patients will be provided with suboptimal treatment due to lack of organisation and 
planning for remote locations to manage patients treated with clozapine. High burden on 
staff time (TEMHS pharmacist, RDH pharmacist, TEMHS clozapine co-ordinators and 
technical staff) chasing bloods, scripts, and delivery services. 
4.10.7 Consultation 
This has been discussed at the remote planning day and with the pharmacy manager to 
help improve our clozapine processes. 
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4.10.8 Results and Translation to Practice 
This project was approved and the position was filled mid-2015 with the results of the 
success of this intervention pending. 
Knowing the adverse outcomes to our patients if they deteriorate on clozapine, the 
clinician time co-ordinating supply to remote areas and the potential high cost to the 
NTMHS, the EPhR presented a proposal to the Mental Health Executives to initiate a trial 
of Remote Clozapine technician to help with co-ordination between all parties. Being 
proactive to request blood appointments, ensuring the bloods are processed urgently via 
pathology, driving medicine to the airport to ensure that interruption of supply would not be 
the reason for a patient to deteriorate and being readmitted to hospital, were all 
documented as vital steps to be named.  
Managing potential frustrations in co-ordination in services may also help to encourage 
and support remote clinics to be more accepting of patients who require clozapine.  
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4.11 Conclusion of Chapter 4 
Using the evidence-based methods of implementing evidence-based practices has been 
successful in building a pharmacy team for the Mental Health Service in the Northern 
Territory. Beginning with a sole pharmacist, the EPhR, to a current team of five, over a 
three-year period, speaks volumes for its success in a period of a government freeze on 
new positions. 
The ability to demonstrate positive outcomes from projects, and therefore to demonstrate 
cost-benefit analysis for the health-system by savings, Quality Use of Medicines and 
activity-based funding, has led to the support and approval of proposed positions. The 
Central Australian pharmacist position was originally given a six-month trial period to 
demonstrate the position’s impact. With close support and mentorship from the EPhR it is 
now a permanent position within the Central Australian Mental Health Service. Although 
two of the positions, the ward-based clinical pharmacist and the clozapine position, have 
been funded as short term trials, the success of converting the Central Australian 
pharmacist to a permanent position gives great hope for the future. 
For the pharmacy profession itself, this section within the thesis details the unlimited scope 
in which a pharmacist can provide input. A pharmacist’s skill-set is unique, but often not 
exposed, due to tasks such as dispensing which remove them from the clinical team. 
The above studies demonstrate that pharmacists can contribute meaningfully to healthcare 
services by: 
• Governance (for example initiating a multidisciplinary Medication Safety 
Committee) 
• Research (see above) 
• Training and mentoring (for both technicians, pharmacists and other disciplines) 
• Leading services through accreditation (project management and 
implementation of best practice standards)  
• Reducing risk to individuals and the organisation 
• Financial savings to both patients and the government 
• Producing a greater quality of healthcare that can be delivered to our community 
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Chapter 5 Continuity of Care 
5.1 An Introduction to Medication Management and the Continuum of Care: 
Medicine Information Transfer Fax (MITF). 
Chapter 5 of this thesis is dedicated to medicine information transferred across the 
continuum of care. In particular, this chapter examines how medicines information is 
transferred between health professionals at the point of discharge from the acute sector 
(hospital) to the primary health sector (community).  
To achieve continuity in medication management (the Medication Management Cycle), 
pharmacists, the medication experts, must provide input. The Australian Pharmaceutical 
Advisory Council (APAC) guiding principles, the Society of Hospital Pharmacists of 
Australia (SHPA) guidelines and practice standards, all delegate the role of handing over 
medicines information to the pharmacist profession.101,176,230  Whilst practicing, a 
pharmacist is autonomous and their work is rarely evaluated or bench-marked against 
peers, although it is something that the profession is trying to implement.276 This leads to 
the development of ad hoc practice and individual methods. The highest quality 
interventions for safety all point to the standardisation and systemisation of practice.212 
The evidence is vast when looking at the positive impacts pharmacists can have on 
medication histories and reconciliation (guiding principle 4), and post-discharge or 
management of medicines in the community setting (guiding-principle 2) especially in the 
area of Home Medication Reviews (HMR’s).12,277-279 Pharmacists continue to demonstrate 
a beneficial input by contributing their pharmaceutical knowledge to a multidisciplinary 
team to improve patient outcomes, to reduce harm and provide financial cost savings.251 
For the purposes of this research, discharge has been broadly defined as ‘the processes, 
tools and techniques by which an episode of treatment and/or care to a patient is formally 
concluded by a health professional, health provider organisation or individual.’251 At the 
point of discharging a patient, handing over the information to the next healthcare provider 
is a critical factor for the ongoing health of the patient and prevention of readmission. 
Handover is defined as ‘transfer of professional responsibility and accountability for some 
or all aspects of care for a patient, or group of patients, to another person or professional 
group on a temporary or permanent basis.’280 The EPhR would suggest that the definition 
of discharge should be updated to include clinical handover, a key component of ending 
an episode of care. 
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Improving communication and quality of medicines information provided between 
healthcare professionals is essential for preventing adverse events to our patients and to 
improve outcomes. Adverse medicine events are commonly caused by lack of effective 
communication about medicines, especially in the transition between the community and 
hospital settings.198  
Currently, both nationally and internationally, the acute sector relies on a hospital 
discharge summary (HDS) to provide communication to the next point of care. A discharge 
summary is a “collection of information about events during care by a provider or 
organisation.”280 The transfer of a patient to a different care setting should be 
accompanied by prompt, relevant and accurate communication about the episode, 
including details of active clinical problems and plans for ongoing management.251 
Unfortunately, this is often not the case. The evidence suggests that an HDS reaches the 
primary care provider by the time of the first follow-up visit in only 12 to 34 percent of such 
visits, and even then often lacks key information.281 Also, the discharge summary itself, 
and the expectation of what it should contain, can differ in opinion between the hospital 
physicians, who send the summary and the General Medical Practitioners (GP’s), who 
receive it. The evidence suggests that GP’s would prefer shorter and faster delivery of 
discharge summaries than those they are currently receiving.251,282,283  
There are gaps in the literature regarding any other means of communication. Although 
discharge summaries are being revised and methods reformed, such as prescription 
integration and electronic summaries, they are the mainstay of our communication 
strategies.251,252 
The current discharge procedure at the study hospital requires an intern or registered 
medical officer to complete an electronic Hospital Discharge Summary (HDS), which is 
common practice internationally, reinforcing current concerns about this important 
handover tool being completed by junior staff.284 The HDS contains a section documenting 
changes to medications and provides a list of discharge and continuing medicines. The 
hospital provides the HDS to the patient’s general medical practitioner (GP), aged-care 
facilities, remote area clinics, or the patient, once the HDS has been completed.  
The continuum of medication management and clinical handover has been identified as a 
major risk in the Australian health system.101 How medicines information is communicated, 
particularly at the dangerous interface of transition of care from hospital to the community, 
and how can this be improved, is the question being asked. 
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The EPhR identified the need for an innovative way to improve the provision of medicines 
information at the point of discharge to primary healthcare professionals. The reasons 
behind this were the well-known failures in the current system for clinicians to have time to 
complete accurate and timely hospital discharge summaries. This is confirmed by phone 
calls from GP’s, patients and remote clinics asking pharmacists to clarify medicines on 
discharge and by viewing the hospital discharge summaries, for example if a patient is or 
has been re-admitted. This observation is confirmed by literature both nationally and 
internationally.190,234,250,251,285-287 
The driving factor for change in this series of studies is an understanding of the importance 
of delivering correct medicines information, predominantly at different stages of handover 
to maintain continuum of care.190,235 
To facilitate this, the EPhR recognised that a concise, informative, timely, accurate and 
trusted handover tool for medicines information needed to be developed. This should be 
the responsibility of a pharmacist, as the medication expert. 
The introduction of a standardised method of medicines’ handover for pharmacists came 
from this series of research questions and objectives: 
5.1.1 Questions and Objectives 
• How can medicine information transfer be improved?  
• What are the enablers and barriers for implementing a new tool? 
• How can we translate the first two aims into practice? 
5.1.2 Methodology 
Intervention: Medicines Information Transfer Fax (MITF) provided by hospital 
pharmacists (HP) at discharge, to community health practitioners. 
Methods: Mixed methods using explanatory sequential design conducted over a 7-year 
period in four Tertiary Teaching Hospitals. (See table 5.1 and figure 5.1). Quantitative data 
(4 audits; accuracy and timeliness of Hospital Discharge Summary (HDS), comparing 
severity of errors in medicines handover in HDS and MITF, selection of high risk patients 
by HP, and 2 surveys) were analysed using Chi-square (CS) method. Qualitative data 
(workshop of 19 pharmacists, and survey of 47 Medical Practitioners and 31 Community 
Pharmacists) analysed thematically and interpretively. (See table 5.1) 
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A detailed methods section is included in each section of this thesis. The sections for 
which the studies can be located are table 5.1. 
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Study Type Study Name Methods Sample 
Size (n) 
Aims Results Location 
in 
Thesis 









This study was a 
retrospective audit of 
a randomised 
convenience sample 
of patients who had 
a Medicines 
Information Transfer 
Fax completed by a 
pharmacist* 
80 This study compares the number 
and clinical significance of 
medication errors and omissions in, 
and the timeliness of delivery of, 
discharge medicines information 
provided to community-based health 
professionals in the existing Hospital 
Discharge Summary (HDS) and the 
Medicines Information Transfer Fax 
(MITF). 
The MITF was superior in timeliness 
and accuracy when compared to the 
Hospital Discharge Summary with 
less clinically significant medication 
errors. 
Paper 3  












Focus groups and 
structured interview* 
 
19 Part 1: To conduct a literature review 
to determine what should be in a 
MITF for it to be cost effective and 
timely. 
Part 2: To establish what are the 
enablers and barriers for providing a 
MITF service? 
Part 3: How to translate findings 
from part 1 and part 2 into practice? 
Key learnings from the literature 
review regarding high-quality 
discharge summaries include: Short 
(less than 2 pages), contain pertinent 
information (e.g. discharge medicines 
and follow up) and are delivered 
quickly (best within the week). The 
MITF was designed to meet these 
criteria. 
Common themes arising from 
workshop groups were: The 
enablers; having accurate medicines 
information for high risk patients 
delivered within 48 hours to the next 
point of care. The current barriers 
are; a need for improvements in 
electronic systems, mechanisms for 













Two online surveys 
with two sets of 
survey questions: 
one tailored for 
GP’s/RMP’s, and 








The aim of this study is to continue 
the development of the MITF by 
formalising feedback from primary 
healthcare providers. This will help 
ensure that the information provided 
is meeting the primary healthcare 
provider’s needs.  
This study demonstrated that the 
community-based healthcare 
providers, for whom the MITF is 
targeted, are enthusiastic and 
supportive of the initiative. Useful 
quantitative and qualitative 
information has been gathered to 
Section 
5.3 




An End User 
Survey 
The questions 
included a mixture of 
open-ended and 
closed questions 
which allowed for 
both quantitative and 
qualitative 
information to be 
gathered. 
Ethics: Approved by 
the NT Ethics 
Committee (see 
appendix 14) 
This includes finding out if primary 
healthcare providers find the MITF; 
• Useful? 
• It contains all desired 
information? 
• Is used in a way that is 
intended? 
• Improves continuum of care 
by communication? 
enable us to continue to refine and 
develop this key tool to assist with 
the continuum of medication 
management. 
 









This study was a 
retrospective audit of 
a randomised 
convenience sample 
of patients who had 
a Medicines 
Information  Transfer 
Fax completed by a 
pharmacist*  
83 The objectives of this study were to 
examine the following: 
1. If the MITF has been 
successfully implemented and 
sustained as a routine practice 
for hospital pharmacists at a 
tertiary teaching hospital in 
Australia  
2. If the quality of the MITF has 
been maintained by reviewing 
the accuracy and timeliness of 
the medicines information 
provided by pharmacists 
compared with Hospital 
Discharge Summaries 
3. If medicines, ‘auto populated’ 
into medical discharge 
summaries via an EMMS, 
improved the Hospital Discharge 
Summaries accuracy and 
timeliness 
The accuracy and timeliness of the 
MITF remained superior to the 
Hospital Discharge Summaries. The 
MITF maintained high standard from 
study period 1 (2009) to study period 
2 (2014). 
The accuracy and timeliness of the 
Hospital Discharge Summaries 
significantly improved post 
implementation of an Electronic 
Medication Management System, 
however they did not match the high 












This study was a 
retrospective audit of 
a random sample of 
hospital patients* 
 
76 To evaluate the accuracy and 
timeliness of Hospital Discharge 
Summaries provided to patients and 
their primary care providers at 
discharge. 
 
The lack of information on the 
primary care provider recorded in the 
patient’s clinical system and 
discharge summaries limited the 
timely transfer of essential 
information on post-discharge 
medicine management to the 
Paper 4  










patient’s primary care provider.  
 




From Trial to 
Policy 
This study was a 
retrospective audit of 
a randomised 
sample* 
99 To examine patient prioritisation by 
pharmacists when providing MITF to 
inform policy development and direct 
clinical services. 
All patients met at least one of the 
high risk criteria as defined in the 
high risk medication misadventure 
tool. This study has demonstrated 
that pharmacists are allocating 
patients appropriately by selecting 
those who are at the greatest risk of 
medication misadventure post-
discharge.  
Policy development will commence, 
based on these results, to ensure 
that MITF is a mandated activity 
undertaken by clinical pharmacists. 
Paper 5  
*Ethics: This research was exempt from ethics approval as it is deemed a low risk quality assurance audit as assessed against the national statement on ethical 
conduct in human research. These studies were all approved by the Hospital Executive. 
There were three main aims for the overall project as stated in 5.1.1. The individual projects stated in table 5.1 were used to answer the 
three main aims. Studies MITF-A and MITF-E were used to establish current practices and determine how medicines information can be 
improved. Studies MITF-B, MITF-D and MITF-F were used to design new practices and determine what the enablers and barriers were 
for doing so, and studies MITF-B, MITF-C, MITF-D and MITF-F demonstrate how the new practices were implemented and evaluated 




Alice Victoria Gilbert | 2016    P a g e  | 130 
 
March 2008
Implementation to all 
clinical pharmacists at RDH
January 2007








April 2014 - September 2014
MITF-D STUDY
MITF-F STUDY
March 2014 - March 2014
MITF-E STUDY
October 2014 - October 2014
MITF-B STUDY
December 2015 - January 2016
MITF-C
September 2016
MIXED METHODOLOGY PUBLICATION 
(ALL STUDIES)  
Figure 5.1: Timeline of Medicines Information Transfer Fax (MITF Studies) 
Key: 
MITF-A Providing Community-Based Health Practitioners with Timely and Accurate Discharge Medicines Information 
MITF-B Examining Enablers and Barriers for Hospital Pharmacists Providing Medicines Information to Community-Based Health Practitioners 
 
MITF-C Review of the Uptake and Benefits of Hospital Discharge Medicines Information Provided by Pharmacists: An End User Survey 
MITF-D Providing Timely, Accurate and Sustainable Discharge Medicines Information: What is Required? 
MITF-E An audit of medicines information quality in electronically generated discharge summaries – evidence to meet the Australian national safety and quality health service 
standards 
MITF-F Hospital Discharge Medicines Information: From Trial to Policy 









Figure 5.3: Outline of sequential studies 
Quantitative: 
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5.1.3 Discussion and Translation to Practice 
This original version of the Medicines Information Transfer Fax (MITF) was trialled for 
patients under the EPhR’s care. Informal but positive feedback from GP’s and community 
pharmacists was received as well as interest from other pharmacists to utilise the same 
tool. This led to introducing the MITF to our clinical pharmacy department at the RDH. 
Education sessions to pharmacists by the EPhR were provided on how to identify 
appropriate high risk patients who require this tool, how to fill in the MITF, which primary 
carers it should go to, where to save and file the information and how to document, in the 
notes, that this service was provided. Baseline audits, a thorough literature review and on 
the ground clinical experience was used to establish current practice for providing hospital 
discharge summaries.  
The literature review presented at the start of chapter 5.1 as well as 5.2 helped develop 
the requirements of the MITF template. The MITF template has continued to be evaluated 
and improved, to meet the needs of both the clinical pharmacists completing the tool, and 
the primary health care providers who receive it, see Appendix 13. 
The implementation methods used, began from the conception of the idea for a pharmacist 
specific medication handover tool at discharge. Due to the EPhR’s relationships and 
reputation within her practice setting, the uptake and utilisation of the MITF has been 
successful. 
The EPhR ensured that all stakeholders were not only engaged throughout the 
implementation and evaluation processes, but that they also had the ability to reflect on 
their own practices and contribute valuable insight into the refinement of both the MITF 
and the process and policies to support it. 
An essential part of ensuring the success of implementation is to also to provide ongoing 
feedback.  As the EPhR works within the organisation, the hospital provided the avenues 
to allow feedback to both the users of the MITF as well as the hospital executives and 
decision makers.  
The evaluation processes were strategically included for specific drivers of change, such 
as hospital accreditation, evidence for new pharmacist positions and performance 
indicators against QUM and medication safety milestones. 
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The EPhR was a representative on multiple medication management committees including 
the NT Drugs and Therapeutics Committee and the TEHS Medication Safety Committee. 
This helped to present the results and implement change in a timely manner. 
5.1.4 Results 
See table 5.1. Medicines information (92%) contained in the MITFs matched that of the 
Discharge Prescription (DP). Comparison of the Hospital discharge summary (HDS) 
against the MITF revealed that no HDS was prepared for 16 (21%) patients. Of the 
remaining 61 patients, 33 (54%), had required medications omitted and 38 (62%) had 
medication errors in their HDS. 28 (35%) patients had their HDS dispatched to their 
community-based practitioners within 48 hours post discharge compared to 80 (100%) of 
MITFs.248(Paper 3) 
After 18 months of all pharmacists within the study hospital, utilising the MITF, the EPhR 
undertook a formalised audit to check and ensure that the MITF was providing what it was 
created to do: to provide accurate and timely medicines information, see Paper 3. 
Paper 3 and Paper 4 provided valuable information on the quality of the hospital discharge 
summaries which were prepared by the medical staff to use as a baseline. The poor 
quality and timeliness of the HDS identified within these studies supported the initial 
clinical observations. 
Paper 4 acknowledges that running alongside the MITF innovation was the changing 
hospital environment in which the EPhR works. Two key quality improvement initiatives for 
medication safety were put in place during this seven-year study period. The first was the 
introduction of an Electronic Medication Management System (EMMS) and the second 
was the National Accreditation Scheme for Australian Hospitals.182,288 
EMMS provided a unique opportunity for medicines management. A functionality of the 
software was to allow electronic discharge prescriptions to ‘auto-populate’ within the 
Hospital Discharge Summary. This feature is a great safety initiative and prevents 
transcription errors. The majority of discharge prescriptions are checked by a pharmacist, 
meaning that the medicines transferred into the discharge summary are reconciled and 
accurate, and it saves the doctor’s time.  
Due to the MITF being a responsibility assigned to the pharmacist profession, the EPhR 
thought it essential to review how the clinical pharmacists were prioritising patients who 
received a MITF. The pharmacist-to-patient ratio within the Northern Territory Department 
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of Health is well below the best practice recommendations.176 Therefore, at this current 
staffing level, it is impossible to provide a MITF for every patient who is discharged. 
Hence, identifying patients at high-risk of medication misadventure and prioritising these 
patients to receive this service are essential. Paper 5 was conducted to identify if the level 
of support and training provided had helped make these decisions or if additional training 
was required. Additionally, this information can help to develop policy and practice 
guidelines to ensure that this service is directed to those who need it and that pharmacists 
can have accountability for provision of this service. At the time of writing this thesis, the 
development of a MITF policy for the Northern Territory Department of Health is currently 
in progress. 
The next two studies in the MITF series were conducted to gather feedback, and to 
provide continuing education for the clinical pharmacists preparing MITF’s. To this, focus 
groups were conducted by the EPhR. This qualitative section of this series of studies 
provided a valuable exploration into the motivations and limitations of the clinical 
pharmacists preparing the MITF. 
The feedback gathered from these focus groups, also provided valuable information on 
how to update the MITF, and future directions in its development and application; in 
particular, the ability to have the MITF available on the hospital software. 
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5.2 Examining Enablers and Barriers for Hospital Pharmacists Providing Medicines 
Information to Community-Based Health Practitioners 
5.2.1 Background 
Clinical pharmacists from the study hospital had reported frequent contacts from 
community-based practitioners seeking clarification of the medicines information provided 
in the HDS. They also identified that the length of time for the provision of the HDS to the 
patient’s community-based practitioners was outside of hospital guidelines (of 48 hours).289 
In 2002 approximately 2% to 3% of hospital admissions in Australia were medication-
related.198 At that time a study of 203 cases indicated that 79% of GPs were not notified by 
the hospital of their patient’s admission, with medicine changes being made to 87% of 
patients. The mean time for GP’s to receive a discharge summary was three days (range 
one to 21 days).290 A systematic review by Kripalani et al281 published in 2007, showed 
that there were modest improvements in the availability of a discharge summary, from the 
literature available in 2002. Kripalani’s study demonstrated that the discharge summary 
available at the first post-discharge visit was low (12% to 34%) and remained less than 
ideal at 4 weeks (51% to 77%). Indicating that four weeks post discharge 23% to 49% of 
GP’s did have direct notification from the hospital of their patient’s hospital admission.281 A 
literature review conducted in 2013 noted that medication-related hospital admissions 
remains at 2% to 3% of all Australian hospital admissions, with rising estimates of 
prevalence when sub-populations are studied. For example, 12% of all medical 
admissions and 20% to 30% of all admissions in the population aged 65 years and over 
are estimated to be medication-related.190 Although the rising estimates of subpopulations 
is predicted to continue to rise due to the ageing population which are usually on multiple 
and complex medicines regimes, the discharge summaries appear to be improving. 
However, discharge summaries are still not meeting the GP’s expectations. The literature 
demonstrates that discharge summaries can often lack key information (such as 2% to 
40% missing discharge medicines) and this can affect the quality of care in approximately 
25% of follow-up visits and contribute to dissatisfaction amongst primary care 
physicians.234,281,291 
As accurate and timely information about medication management along the continuum of 
care is essential to achieving best outcomes for patients and for avoiding harm234,250,292,293 
the pharmacists at the study hospitals developed a Medicines Information Transfer Fax 
(MITF). Handover is deemed an essential role for all clinicians within healthcare, and 
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pharmacists are no exception. Government policy, guidelines and practice standards all 
recommend pharmacists to provide handover.84,101,176 The MITF enables this to be 
embedded into daily practice and assigns accountability to clinical pharmacists. The 
unknowns at this stage are to define what should be in the MITF, and how best to translate 
this into practice by identifying the enablers and barriers from the clinical pharmacists who 
are using it. 
Due to the time that the NT hospitals have had the MITF in operation, the primary 
researcher, with support from senior staff, wished to gather an understanding of the 
motivations and limitations for pharmacists in preparing the MITF. By using a focus group 
technique, both the research group and the pharmacy department wished to move the 
MITF into a supported policy, and share the tool nationally, to open the possibility of 
standardising handover provided to community-based clinicians by hospital pharmacists. 
Creating a policy would also allow future opportunities for auditing against the policy and 
Key Performance Indicators to see how pharmacists are prioritising handover within their 
core responsibilities.  
5.2.2 Aims 
Part 1: To conduct a literature review to determine what should be in a MITF for it to be 
cost effective and timely. 
Part 2: To establish what are the enablers and barriers for providing a MITF service 
Part 3: To translate findings from part 1 and part 2 into practice 
5.2.3 Methods 
Part 1: A literature review was undertaken by the EPhR using Medline, Google Scholar 
and CINAHL to identify publications on discharge summaries. Search terms included; 
hospital discharge, discharge summaries, discharge summary, medication summary, 
electronic discharge, patient separation, hospital transfer, hospital communication, acute 
care discharge, discharge medications, medication information, communication on 
medicines, readmission. 
After the initial search using the key terms, papers were briefly evaluated to identify those 
outside of the scope (e.g. human discharge). The papers were then identified that had 
relevance to the question; what determines a high quality cost effective discharge 
summary.  
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Part 2: A focus group was conducted by the EPhR based on the general principles of 
presentation and analysis. The focus group design followed the definition by Krueger and 
Casey, "A carefully planned series of discussions designed to obtain perceptions on a 
defined area of interest in a permissive, nonthreatening environment.”294    
This study was a stepped approach using grounded theory. Grounded theory is a research 
method that involves forming a theory based on the gathered data as opposed to 
gathering data after forming a theory. It is called ‘grounded’ as the theory is grounded in 
the data.295 
Participants were invited via email one week prior to the focus group session. The email 
included a brief overview of the research that is being conducted, and included ‘what to 
expect at the focus group’. The focus group questions were also emailed to all participants 
one week prior to the meeting to help them have time to think about the questions in 
relation to their experiences with the MITF. The background to the research was provided 
in a brief preamble and presentation by the facilitator (the EPhR) at the start of the 
session. As a warm up, the group was invited to have an open conversation about the 
MITF. This was to start conversations about how the MITF can be utilised in practice. The 
EPhR then arranged pharmacists into focus groups. The EPhR prepared a set of five 
questions based on her examinations of pharmacist’s activities related to use or non-use 
of MITFs. Data was then gathered from the participants. A series of questions was 
proposed by the facilitator and discussed with the research team as well as the senior 
pharmacists’ group. Five questions were chosen which were thought to give the required 
insights and opinions to answer study objectives.  
Participants provided informed consent. Information was sent via email prior to the focus 
group and consent was acknowledged by signing an attendance record which included 
agreeing to participate in a group 2 continuing education activity.  
Research team, reflexivity and relationships to participants:  
The facilitator (AVG) is currently employed as a senior clinical pharmacist for the Top End 
Health Service (TEHS), Department of Health, Northern Territory Government. The 
facilitator had been given the opportunity to work as an Embedded Researcher which 
allowed her to observe practices on a daily basis and to develop ideas for remedying 
problems.   
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The TEHS occupies the Top End of the Northern Territory including; Arnhem Land, 
Darwin, and down to Katherine.  Pharmacists employed in the TEHS (n = 27) were all 
invited by email to participate in the MITF workshop. The facilitator was well known to all 
participants as a colleague and peer.   
This workshop was exempt from Ethics approval as it was deemed ‘low risk research’ by 
the National Statement on Ethical Conduct in Human Research.296 Approval and review of 
this research was granted by the director of pharmacy for all participating hospitals.  
Participant demographics and selection 
Three hospitals were included from the Top End Health Service; the Royal Darwin 
Hospital, Katherine District Hospital and Gove District Hospital.  Where possible, the 
pharmacists were arranged into focus groups. 
Setting  
The MITF focus groups were conducted in a weekly timeslot allocated to the continuing 
pharmacists’ education program. This timeslot was chosen to ensure that the majority of 
staff were available and able to participate as this is considered protected time from their 
clinical duties. The continuing education sessions are provided in the Royal Darwin 
Hospital library and via an internet meeting (MS Link). Only the facilitator and the 
participants were present. 
Data Collection  
In opening statements the facilitator checked that the questions were understood and 
described how the focus groups would work.  Each group had the same set of five 
questions developed by the facilitator. (See Table 5.2). Members of each group discussed 
the questions and used the facilitator to clarify points if required. Group discussions were 
documented by a scribe in their group to record their answers. At the end of the group 
discussions all pharmacists came back together. Each group presented their discussion 
which helped identify themes to the primary researcher. Often responses were common. 
Data saturation was achieved by utilising a chain model where each group was allowed 
one at a time to give their answers/ideas. Each group had a time as first or second to 
avoid any bias arising. By the time the fifth group answered first there were no new issues.  
Each group then selected the four focus areas that they felt were the most important. 
These four issues were written on posters and placed around the room. Each individual 
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pharmacist then went to each poster and ticked their top response from each group’s 
work.  
Data analysis  
A qualitative analysis of both the written and verbal discussions that were held throughout 
the workshop was conducted. Responses within the workshop were thematically and 
interpretively analysed. Both major and minor themes were explored and categorised by 
two members of the research team who individually identified trends using a spreadsheet 
in Microsoft Excel®. Common themes were identified in all groups.  
5.2.4 Results 
Part 1: Literature Review 
Within Australia, when patients are transferred between hospitals to the primary sector, 
healthcare professionals must ensure that the healthcare professional taking over the 
patient’s care is supplied with an accurate and complete list of the patient’s 
medicines.198,232 Studies have shown that unintended discrepancies in the medication 
information provided on discharge are common.248,250,281 
A recently published audit of discharge communication from inpatient care is entitled, An 
audit of written medical discharge summary procedure against the new National Health 
Service Standard for clinical handover.287 This audit demonstrated that incomplete, 
inaccurate and unavailable discharge summaries are common and expose patients to 
greater health risks. Junior staff members find completing discharge summaries difficult, 
and often fail to receive appropriate education or support.287 There is little published 
evidence regarding the discharge summary practices of inpatient health services, such as 
training and time allotted. 
Across Australia, and around the world, there is no standard template which has been 
chosen as the gold standard to provide discharge information. A number of authors have 
identified a range of items deemed as necessary for inclusion in a discharge summary. It is 
notable that not all items are identified by all authors as critical. Some of the most common 
items identified as necessary include: Diagnosis, diagnostic investigations, medications on 
discharge, ceased medications, clinical interventions, allergies and adverse reactions and 
arranged services.280 
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The above items are all included in the National E-Health Transition Authority’s (NEHTA’s) 
discharge summary (version 1.5.1).297 
The Australian Commission on Safety and Quality in Healthcare e-Discharge Literature 
Scan251 was completed in July 2010 and suggested that the information within a discharge 
summary be provided in the broad categories of: event, medications, health profile, and 
plan, with the facility for reports and additional documents to be included as necessary.  
In some jurisdictions, there are standards in place which specify the required content items 
for inclusion in the discharge summary. Generally, these tend to represent only a subset of 
the items identified above. For example, in United States of America, the Joint 
Commission on Accreditation of Healthcare Organizations (JCAHO), standards require the 
following elements to be included: Reason for hospitalisation, procedures performed, care, 
treatment and services provided, patient’s condition at discharge and information provided 
to the patient and family.298   
JCAHO also specify that the discharge summary must be completed within 30 days of 
discharge. Interestingly, medicines information is considered an area of risk when 
transferring information, however it is not included as a mandated field in JCAHO.299 
The main themes within the literature of the risks involved in hospital discharge summaries 
include: medication information, communication on medicines, problems with 
communication (i.e. timeliness), readmission and patient characteristics.251 These terms 
were used in my literature reviews. 
Key learnings regarding high-quality discharge summaries include: Short (less than 2 
pages), contain pertinent information (e.g. discharge medicines and follow up) and are 
delivered quickly (best within the week).283 
This is how the EPhR determined the most pertinent information to include within the 
MITF, see Appendix 13). 
Part 2: Focus Group 
All 27 pharmacists employed in the TEHS were invited to participate in the focus groups 
which were to run during a weekly Continuing Education (CE) Session. No characteristics 
(e.g. bias) which may risk the value of results were reported about the facilitator. However, 
there is the possibility that the bias may not be clear, and if present, may not be reported.  
Alice Victoria Gilbert | 2016    P a g e  | 141 
 
Of the 27 employed pharmacists, seven pharmacists did not attend the workshop. One 
pharmacist was rostered to cover the dispensary during the CE session, 2 were at a 
conflicting meeting, 3 were on leave and 1 is a part-time worker who was not rostered at 
that time. The facilitator was the other employed pharmacist.  As a result, 19 Pharmacists, 
working across the NT, participated. The participating pharmacists ranged in experience 
and time in the NT (from 3 months to 12 years’ employment). Their experience ranged 
from the Director of Pharmacy to an Intern Pharmacist. Three hospitals were included from 
the Top End Health Service; the Royal Darwin Hospital, Katherine District Hospital and 
Gove District Hospital.  The pharmacists were arranged in three groups of four, one group 
of five and one group of two. The group of two were the sole pharmacists from the remote 
hospitals (Gove and Katherine). The remote area pharmacists met via a “MS Link web 
meeting” 4F** and communicated via a “chat feature” in our Web Meeting Software.  
Data analysis 
A qualitative analysis was conducted of both the written and verbal discussions that were 
held throughout the workshop. Responses within the workshop were thematically and 
interpretively analysed. Both major and minor themes were explored and categorised, by 
two members of the team individually, identifying trends using a spread sheet in Microsoft 
Excel. Common themes were identified in all groups. (See table 5.2) 
After primary analysis of themes by two authors, key questions were proposed and taken 
to a meeting of the senior clinical pharmacists at the Royal Darwin Hospital. The senior 
pharmacists clarified whether the interpretations of the themes were consistent or not and 
how they also interpreted the themes whilst participating in the focus groups. These 
primary themes by the researchers helped to develop a list of actions. 
                                                          
** Lync Server is now Skype for Business Server 2015 with the enterprise-grade security, compliance, and control of 
Lync. Skype for Business Server offers features including presence, IM, voice and video calls, and online meetings.  
300 Courtney J. Skype on Office 365, Outlook. Com and Lync.  Experience Skype to the Max: Springer; 2015. p. 
205-15.  
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Table 5.2: Thematic and Interpretive analysis of group responses 
  
 Group questions for discussion Major Theme(s) Minor Themes Questions arising from themes 
1 What are the main limitations 
associated with the MITF? 
The predominant theme 
that rang true with all five 
groups was limited staff 
resources to provide a 
core clinical service and 
time to provide a MITF. 
Documentation around changes to medicines, such 
as why a medicine was ceased, is often lacking or 
misplaced in the patients’ notes and it is time-
consuming to find them. 
Difficulties in updating details of primary healthcare 
providers for patients in multiple hospital systems.  
Frustration over the nonexistence of electronic 
auto-population of patient information onto the 
MITF, or that the hospital electronic systems do not 
talk to each other. 
Of interest, a limitation which was both raised in the 
open group discussion as well as in the small group 
work, was the lack of uptake from their community 
pharmacist peers. It was understood and stated that 
“Community pharmacist can’t do much with it until 
the GP reviews” and “In the community they are not 
used (referring to the MITF) until their doctor has 
seen them and made changes” 
Can clinical pharmacists re-prioritise 
their work to make time to complete 
this key task? 
What are the pharmacists doing in 
regard to the documentation of 
medicine changes throughout the 
admission, and are the medicines in 
an ‘easy to find’ location? 
How can the work that hospital 
pharmacists are delivering to 
community pharmacists provide 
patient-centred care opportunities 
for community pharmacists? 
 
2 What feedback have you received 
from GP/Pharmacists/patients etc. 
regarding the MITF? 
The majority of the 
answers detailed positive 
feedback that they had 
received, particularly from 
healthcare professionals. 
A common theme 
identified was that the 
MITF is a comprehensive 
summary in one page and 
that it is particularly 
helpful for community 
pharmacists who pack 
dose administration aids. 
Minor themes suggested that detailing the reasons 
for changes is a must for the information to be 
trusted and interpreted correctly by GP’s. This is 
also now recognised as essential, and examined 
during the clinical handover standard in The 
National Accreditation182 process.  
One group also commented on ‘frequent flyers’ 
which is an affectionate term given to patients who 
bounce in and out of hospital: “sometimes these 
patients don’t get changes made to their medicines 
due to the lack of a MITF.” This applies in particular 
to patients moving to and from remote areas. 
Incorporate a mandated area on the 
MITF to document the reason for 
changes to medicine to encourage 
all pharmacists to provide this 
information. 
Provide a workshop with community 
pharmacists to discuss how this 
information could be best utilised. 
Seek formalised feedback 
Continue to provide staff with the 
opportunity to share feedback that 
they have received.  
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3 What can each one of us do to make 
either the MITF template, or the way 
we use it, better?  
All five groups wanted a 
standard template. 
The other two major themes 
which were discussed in all 
five groups were: creating an 
electronic version which can 
also be sent; wanting the 
fields to be pre-entered to 
auto-populate telephone 
numbers, and the provision 
of a fax for remote clinics, 
pharmacists and GP’s, to 
save time.  
Ensuring that the MITF is available to other clinicians on 
the electronic system as well as pharmacists if a patient 
re-presents. This was also raised.  
A consistent method of documentation within the case 
notes, so it is easy to identify when a MITF has been 
provided during a subsequent admission, was also 
suggested. 
Other minor themes involved patients “Patients should 
receive a copy” and “Identify patients who must have a 
discharge fax” 
How to move forward the integration of 
the MITF into the hospitals’ electronic 
systems? 
How can we, as a short term measure, 
improve the ease of completing the 
MITF, such as pre-formatting MITF’s for 
specific clinics? 
How can we have a protected template 
to prevent individuals changing it and to 
standardise our service? 
Why are individuals making changes to 
the template? A review of what changes 
should be made to see if the template 
should be updated.  
Encourage and support provision of the 
MITF to patients at the point of 
discharge, but recognise that they do 
not replace other patient tools such as 
medication profiles. 
Prepare a standardised note template 
for documenting a provision of a MITF. 
4 Think back to your past, have you 
worked in a different organisation or 
within RDH where medication 
handover has been done differently? 
What worked well? 
A common theme that was 
raised in this section was 
about electronic systems 
that talk to each other and 
auto-population of 
information. 
Each group had different responses: this was due to the 
wide variety of previous employment throughout the 
group. 
The descriptions varied: medication action plans being 
faxed if required; pharmacists signing medicines in the 
doctors discharge summary; having a similar system to 
the MITF but no template; medication lists handed to 
patients, and discharge prescriptions faxed to GP’s. 
Would there be any benefit in surveying 
hospital pharmacists around Australia to 
determine current practice and to 
understand what other work is being 
done in this area? 
5 Do you have any reaction from other 
hospital staff (good or bad) regarding 
the MITF? 
All groups mentioned that 
there is a lack of awareness 
of this initiative from other 
staff. The majority of the 
groups mentioned that they 
have not received any 
reaction from other staff.  
“Consultants’ lack of knowledge regarding the pharmacist 
MITF.”  
“Positive feedback from junior medical staff as it saves 
the doctor’s time.” 
 
How to inform other disciplines of this 
service, such as orientation at the start 
of each intake of new doctors? 
How can we make this available for 
doctors to utilise when preparing their 
discharge summaries? 
How can staff refer a patient to receive 
this service? Would this help the 
pharmacist prioritise? 
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1. To gain an understanding of the motivating factors for clinical pharmacists to 
provide a MITF 
The main themes and motivations for pharmacists to provide this service centred on;  
a) The positive feedback which had been received from community-based 
practitioners 
b) Examples of the risks to our patients that the pharmacists identified if the medicines 
handover was incorrect 
c) That as a pharmacist they could reduce potential risks  
d) That it can reduce a pharmacist’s work load if the handover is done correctly. For 
example, when patients are re-admitted, time required for medication histories and 
reconciliation can be saved   
2. To provide insights into the perceived and actual barriers for pharmacists to 
provide a MITF 
The main themes identified involved;  
a) The frustrations of our current available electronic systems and poor accessibility to 
an electronic system   
b) Community pharmacies not having secure email accounts to receive patient 
information, with the majority of the pharmacists indicating that the information 
should be emailed and not faxed, if possible 
c) Responsibility for updating pharmacy information such as fax details and GP details 
on hospital software  
d) Having enough time with other clinical responsibilities to prioritise completing a 
MITF  
Further, mechanisms for follow up and acknowledgement were seen across groups, and 
time saving measures, including, but not limited to, electronic solutions. In the early 
development of the MITF, and in consultation with hospital executives, it was discussed 
and agreed that the MITF template could be uploaded on to the Clinical Work Stations 
(CWS) software. This is the software program where pathology and discharge summaries 
are received and sent. As a result of the focus groups, the Director of Pharmacy has 
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organised to meet with the executives and the CWS team to implement this action. It is 
expected that this will happen within the next six months; recognising however, that this 
was requested four years earlier.   
All at the focus group sessions agreed that the MITF should be available at the time 
doctors are preparing their medical discharge summaries. Again this relies on the upload 
to CWS to allow the MITF to be viewed electronically, and/or the permission to place it in 
the patients’ notes. The intention is for the MITF to be available for doctors to copy and 
paste this information into their discharge summaries, or for them to be attached as an 
appendix. All participants agreed that the MITF needed to be sent independently by the 
pharmacists because the doctors discharge summaries, at this stage, are not yet sent 
within an appropriate time frame.  
3. To uncover prevalent trends in thought and opinion within the clinical 
pharmacists group who provide this service  
The prevalent trends in thought and opinion within the group are;  
a. Although not asked directly to comment on the implementation of a policy, themes 
were gathered which supported its development. For example, maintaining a 
consistent template, discussion of a process for acknowledgement of receipt from 
the community-based practitioners, and providing consistent documentation after 
completion of a MITF 
b. From previous experience at other hospitals, the group members stated that they 
usually provided a service which was ‘ad hoc’, with multiple methods that were not 
consistent even within the same workplace  
After the focus group sessions were completed, and themes grouped, a meeting of the 
senior clinical pharmacists examined responses. Utilising the PRECEDE-PROCEED 
model,5 the study team was able to evaluate what could be learned and what could be 
adjusted. The meeting with the senior team also provided a platform for discussions 
around policy, and if a policy should be developed. The benefits for creating a policy would 
support how the MITF is utilised, guide choices to help pharmacists allocate their time and 
provide an opportunity for further quantitative research.  
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The meeting also enabled the senior pharmacists to develop a list of actions to help 
improve the MITF service. These actions included organising a meeting with the CWS 
team to have the MITF template available electronically, meeting with the forms committee 
to have the MITF approved for filing in the patient’s hard copy notes and setting up a MITF 
template with auto-populated fields in Microsoft Word®.   
A focus group method was selected because it is an effective method for exploring and 
understanding people’s beliefs and attitudes towards particular issues.294 Focus groups 
are facilitated group discussions where topics are introduced and participants are asked to 
comment. These are interactive group settings and participants can talk with other group 
members.301 It is usual practice to continue to start new group discussions until the point of 
saturation in the data where no new issues are being identified.294 The outcome of a focus 
group is the identification of common themes through a thematic analysis. The analysis 
can be conducted manually by researchers or by using computer techniques. 
The MITF was first piloted at the Royal Darwin Hospital (RDH) in 2009.302 After a 
successful trial, the MITF was implemented in 2010 for use by pharmacists at the RDH. 
Over the next two years the value of the MITF was seen by pharmacists working across 
the Northern Territory (NT) and the MITF template was adopted by four of the five 
hospitals. The remaining hospital does not have a pharmacist. Our previous research 
demonstrated that clinical pharmacists working within the acute healthcare setting are 
successful in providing this essential information on a patient’s medications.248 Our 
previous quantitative research has demonstrated that the MITF offers accurate and timely 
medicines information to community-based health practitioners that are not offered in the 
current model of medical discharge summaries. Our previous study was used to determine 
the quality of the MITF and how it was being utilised by the pharmacists.248 The accuracy 
and timeliness of this information was superior to that of the medical discharge summary 
prepared and dispatched by hospital physicians.248  
Our research group has also completed a retrospective audit to determine if pharmacists 
were appropriately selecting the high risk patients for medication misadventure that would 
benefit most from this service.303 Within this study, all 79 patients met at least one of the 
eight high risk criteria for medication misadventure.303  
Clinical handover, in particular at the transition of care, is a well examined area for 
medicine misadventure.207,250,291,304 Pharmacists continue to demonstrate beneficial input 
by contributing to a multidisciplinary team to improve patient outcomes, financial cost 
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savings and reducing harm.251,279  Interventions have been evaluated, such as pharmacist 
reconciliation at discharge, counselling and follow-up telephone calls. However, little 
evidence can be sourced in pharmacists taking responsibility and accountability for 
handing over medicines information between healthcare professionals.251   
This study provides a novel method of medicines handover which has been standardised 
by clinical pharmacists and where the responsibility lies with the pharmacist’s profession. It 
is not designed to replace the medical discharge summary, but to complement it.  
Within Australia, when patients are transferred between hospitals and the primary sector, 
healthcare professionals must ensure that the healthcare professional taking over the 
patient’s care is supplied with an accurate and complete list of the patient’s medicines.207 
However, studies have shown that unintended discrepancies in the medication information 
provided on discharge are common.248,250,281   
Repeating an audit to determine if the accuracy and timeliness of the MITF is maintained, 
and a survey of primary healthcare providers is currently in progress to determine if the 
MITF is being utilised as intended. If outcomes of the survey are positive, they will help to 
motivate the clinical pharmacists. 
5.2.5 Limitations  
The MITF is utilised in all NT hospitals which have pharmacists employed including 
Central Australia (in particular Alice Springs Hospital). Due to the time and date set for the 
focus groups no pharmacists from Alice Springs attended the session and did not provide 
input.  
The primary author and research team consider that the MITF is a worthwhile method of 
handover for clinical pharmacists to complete. The positives of being part of a solution with 
medication issues and continuum of care may have been highlighted more than the 
potential limitations; in particular, using the start of the workshop to present positive results 
from our original study may have demonstrated the positives of the MITF.  Attempts were 
made to minimise limitations and bias by the facilitator by having the focus group 
questions prepared prior to the session. This was to ensure that they were non-influential 
in the tone and wording of each question. Also, during analysis and grouping of themes, 
two researchers grouped the themes independently. This was to reduce selection bias 
towards positive results only and ensured that the common themes identified were the 
ones reported.  
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5.2.6 Conclusions  
The format of the MITF is designed to reflect what is required in a high quality discharge 
summary, including the timeliness of delivery. The prevalent trends in thought and opinion 
within the group was that the MITF is a valuable service and that a standardised tool is 
beneficial for providing this service and maintaining its sustainability. The focus group 
sessions enabled both the researchers and the pharmacists to gain an understanding of 
the underlying enablers and motivators for clinical pharmacists to provide a MITF. It 
allowed an opportunity to discuss barriers (both perceived and actual) of pharmacists to 
provide this service and a forum within the focus group, and after the focus group, to 
generate ideas to overcome such issues. Policy development will begin to support the 
pharmacists to provide the MITF, help in prioritising patients, and time allocation. Both 
local fixes and generic changes will help enable the possibility of a standardised handover 
form to become a national tool for hospital pharmacists.  
5.2.7 Discussion and Translation to Practice 
The major themes identified involved the suggestion that the system should be made 
electronic and accessible in an electronic form. Mechanisms for follow-up and 
acknowledgement were also discussed across groups, and time-saving measures, 
including but not limited to, electronic solutions were raised. 
After the focus group sessions were finished, and themes grouped, the senior clinical 
pharmacists met to examine the responses. The meeting of the senior team also provided 
a platform for discussions around policy, particularly considering if a policy should be 
developed. The benefits of creating a policy would support ways in which the MITF is 
utilised, guide choices to help pharmacists allocate their time, and provide an opportunity 
for further quantitative research in the future. 
In the early development of the MITF, and in consultation with hospital executives, it was 
discussed, and agreed, that the MITF template could be uploaded onto the Clinical Work 
Stations (CWS). This is the software program where pathology, and discharge summaries, 
are received and sent. This agreement however, is yet to be realised. The previous 
limitations with CWS were: 
• Community pharmacies not having secure email accounts to receive patient 
information, and 
• Who will be responsible for updating pharmacy information such as fax details 
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• Investigating whether pharmacists would have permission to update the GP details 
on the software 
These limitations still exist. It is, however, seen as essential to move this action forward. 
The Director of Pharmacy has organised to meet with the executives and the CWS team to 
implement this action. It is expected that this will happen within the next six months, 
recognising, however, that this had been requested 4 years earlier and it had not been 
ratified.  
All agreed that the MITF should be available at the time doctors are preparing their 
medical discharge summaries, however all pharmacists agreed that the MITF needed to 
be sent independently by the pharmacists because the doctors discharge summaries are 
not sent within an appropriate time frame. 
The senior group also recognised the quick changes that could be implemented after the 
focus group. For example, a standardised note on discharge would be appropriate as this 
would be quick to generate and easy to find. Originally we had prepared discharge stickers 
which could be placed in the notes with tick boxes to see which activities were performed, 
such as counselling and a MITF organised and provided. It became apparent during the 
focus groups that these stickers were not utilized, mainly due to the lack of awareness by 
new staff and the lack of formal training in the completion of the MITF. As accreditation 
was looming, this was used as an opportunity to refine the sticker and transfer the 
information to a pre-printed case note that prompted the pharmacists to complete the 
required information of activities performed. This has been actioned. 
The MITF template was also updated to ensure that reasons for changes to medicine were 
included, see Appendix 13. 
Stamps were purchased which stated “Patient copy – Please take to next doctor’s 
appointment” which could be used for MITF’s as well as medication profiles. 
Finally, the idea of repeating an audit to see if the accuracy and timeliness of the MITF is 
maintained, was also discussed. A survey of primary healthcare providers’ feedback to 
ensure that the MITF is being utilised as intended, was also proposed and is currently was 
undertaken, the results of this are presented in section 5.3 of this thesis. Until this stage 
the benefits of the MITF and feedback had only been anecdotal. It was important to 
formalise feedback from community-based practitioners to ensure that we are meeting 
their requirements and that it is useful to their practice. Formalised feedback is not only 
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important to encourage staff to continue a service if it is worthwhile, but also to refine 
practice to suit the needs of the community-based practitioners. 
Two important hypotheses were confirmed within this workshop. The first was that our 
pharmacy department did not have the resources to provide the MITF service for every 
patient and therefore a clinical decision needed to be made to identify those patients at 
high risk for medicine misadventure. The second was that information regarding reasons 
for medication changes was essential for the MITF to be trusted and utilised by primary 
healthcare providers. 
This led to a review of the MITF template to include the addition of changes to medicines 
during admission and a field to document the reasons for the changes. 
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5.3 Review of the Uptake and Benefits of Hospital Discharge Medicines Information 
Provided by Pharmacists: An End User Survey. 
Ethics: Full ethics approval granted by the Human Research Ethics Committee of the 
Northern Territory Department of Health and Menzies School of Health Research. 
Approval number: HREC 2015-2503. (See Appendix 14) 
5.3.1 Background 
The need for high quality clinical handover is exaggerated in the Northern Territory (NT) of 
Australia. The NT has a unique demographic, it is a small, culturally diverse population 
which is dispersed over a large geographic area. The NT covers approximately 18% of 
Australia’s landmass. Despite being the third largest of all states and territories, the NT 
has the smallest population.134 In June 2015 the resident population was estimated to be 
244 600 persons (1%) of the national population.33 NT also has the lowest population 
density of all jurisdictions, with no area in the NT classified as a major metropolitan area or 
inner regional. Even the capital, Darwin, is classified as outer regional area by the 
Accessibility/Remoteness Index of Australia.104 Over one third of the NT population live in 
remote areas and 71% are Aboriginal or Torres Strait Islanders.105 The life expectancy for 
a male Aboriginal and Torres Strait Islander is 61.5 years, 17 years less than non-
Indigenous males, and for a female Aboriginal and Torres Strait Islander 69.2 years, 13 
years less than non-Indigenous females. The median age at death of Aboriginal and 
Torres Strait Islander males is 50 years.139 Many issues, including low health literacy, 
differing cultural beliefs about health and illness, access to health services and availability 
of health professionals limit people’s ability to access and navigate their way through the 
complex health system.108 The profile of discharges by Indigenous status across Northern 
Territory hospitals shows that, with the exception of Royal Darwin Hospital, all had 70% or 
more Aboriginal separations. The Royal Darwin Hospital profile suggests between 50% to 
60% of separations are for Indigenous and Torres Strait Islanders and this has remained 
consistent over the past 15 years.31 
The current discharge procedure at the study hospital requires an intern or registered 
medical officer to complete an electronic Hospital Discharge Summary (HDS). Evidence 
indicates that a patient in an urban area will visit their pharmacy within 10 days and their 
doctor 30 days after discharge.305 While most GPs are provided with a discharge 
summary, community pharmacists are rarely provided with this information and patients 
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are not encouraged to notify their community-based practitioners of recent hospitalisations 
and changes to their medicines.305 
The MITF is now cemented into practice in all five NT hospitals. The MITF has been 
reviewed and updated over the past 10 years and evaluated by assessing its efficacy, 
efficiency and pharmacist prioritisation to ensure that the correct patients are receiving this 
vital service.  
5.3.2 Aim 
The aim of this study is to continue the development of the MITF by formalising feedback 
from primary healthcare providers. This will help ensure that the information provided is 
meeting the primary healthcare provider’s needs.  
A further aim of this study was to ask primary healthcare workers to provide feedback on 
the discharge medicines information provided by hospital pharmacists to community 
healthcare professionals. In particular, we were hoping to gather information from GP’s, 
RMP’s and community pharmacists to determine if the MITF: 
• Is useful? 
• Contains all desired information? 
• Is used in a way that is intended? 
• Improves continuum of care by communication? 
Additionally, I used this opportunity to plan for a multidisciplinary discharge summary in the 
future. 
5.3.3 Method 
There were two sets of survey questions: one tailored for GP’s/RMP’s, and one for 
Community pharmacists. The questions included a mixture of open-ended and closed 
questions which allowed for both quantitative and qualitative information to be gathered. 
All General Practitioners, Remote Medical Practitioners and Community Pharmacists, who 
are primarily located in the Northern Territory, were invited to participate in this survey. 
There are currently 233 General Practitioners on the Australian Health Practitioner 
Regulation Agency (AHPRA) working in the Northern Territory, including 97 in remote area 
health clinics, and 49 community pharmacies staffing approximately 101 pharmacists; this 
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list is a comprehensive coverage of primary healthcare providers in the Northern Territory 
that could take over care for a patient once discharged from hospital. The link to the 
survey was also distributed in the Northern Territory Primary Health Networks 
Newsletter.306 The Embedded Researcher hoped to gain agreement to participate from 
20% of each subgroup to ensure that the collected data would include both breadth and 
depth of the topic of interest and saturation of data. This is appropriate for the scope of the 
research methods being employed.  
The survey, including a participant information sheet and an invitation to participate email, 
was distributed to GPs, RMPs and Community Pharmacists via their clinics/practices (see 
Appendix 15).  To maximise the response rate the study design included a personalised 
explanatory letter including the endorsement of this research by the Human Research 
Ethics Committee of the Northern Territory Department of Health and Menzies School of 
Health Research. The questionnaire was kept short; and used mainly quick ‘tick-box’ 
responses. The participants were provided with the option to complete the survey online, 
print and then fax or mail the response. After 3 weeks the study group sent a reminder 
email informing survey participants of the last day to respond. Incomplete surveys and 
non-respondents were excluded from the project. 
The survey was designed using the SurveyMonkey® program which allows for protection 
of identity and online responses. 
5.3.4 Results 
Of the 233 General Medical Practitioners and Remote Medical Practitioners, there were 47 
(20%) responders. Of the 101 pharmacists who were invited to participate 31 (31%) 
responded. This met our agreed 20% of each subgroup to ensure the collected data will 
include both breadth and depth of the topic of interest and saturation of data. 
To first gauge which health practitioners were aware of this initiative, they were asked if 
they had previously received a MITF. A greater proportion of community pharmacist 
respondents had received a MITF in comparison to GP’s/RMP’s; 23 (74%) and 23 (49%) 
respectively. 
To continue with the MITF service it was essential to determine if the end users found the 
MITF useful for their practice. The large majority, 25 (81%) and 42 (91%), of both 
subgroups indicated that they found the MITF useful or very useful for their practice. 
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Figure 5.4: The usefulness of a MITF for your practice 
Timeliness of the receipt of this information, within 48 hours of discharge, was also 
deemed useful or extremely useful for 45 (98%) of GP/RMPs and 27 (87%) of the 
community pharmacists. 
Next, the Embedded Researcher asked how the information in the MITF was used: 
whether the health professional would store the information and then have it available 
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Figure 5.5: Community pharmacists: Have you stored the information from the MITF? 
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Not only is it important to gather feedback to see if the information is useful, needed in a 
timely manner, and stored, but also if the recommendations by the clinical pharmacist on 
handover are actioned. The following charts, below, indicate that the majority of 
respondents would action the recommended changes. 
 




Yes (if still clinically relevant and
patient has confirmed this change)
No (not until it is confirmed with the
medical discharge summary)
Unsure
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Figure 5.8: Community pharmacists: Would you action any changes due to the information provided 
in the MITF? 
Both the Community pharmacists 60% (18), and GP/RMP’s 64% (27), would prefer to 
receive this information by email or electronically, with their second preferences being fax, 
followed by mail. 
When asking the community pharmacists who they think should write/provide medicines 
handover information at discharge, (and we offered one or more preferences), the hospital 
pharmacists providing handover was the clear preference with 68% (25) believing it should 
be a hospital pharmacist and 19% (7) stating it should be an intern or registrar. One 
respondent chose a consultant and 11% (4) had no preference.  
The GP/RMP’s were asked if the MITF should be sent at the same time as the medical 
hospital discharge summary. The clear preference was “no” 64% (30). A further open-
ended question enabled explanation for their decision on when the MITF should be sent. 
Of the 47 responders to this question, 44 elaborated what led to their preference (see 
Appendix 16). The most common theme was the delays in receiving the medical discharge 





0% Yes, when the patient arrived for
their next supply, I have/would
contact the GP/RMP and discussed
the changes
Yes, I have/would confirmed with the
patient and acted on changes I could
make without a doctors input (such
as not supplying a medication that
had been ceased during admission)
No, I only work from doctors
directions or instructions
No, I would only work from the
prescriptions I have even if there has
been changes that have been noted
by the hospital pharmacist
Unsure
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percent (28) mentioned in their answer that the timeliness of the medical discharge 
summaries was a common problem, for example: 
 “Sometimes the only information we get is the pharmacy 
discharge. If you wait until the medical discharge is done, we may 
never receive any information at all!” 
“Medical discharge summary is often delayed unacceptably. 
Patients need their medications and follow ups quite soon after 
discharge.” 
“There are always going to be delays in the discharge summary 
coming out. Having this very important information ASAP is really 
helpful.” 
“Sometimes you never get a discharge summary so we at least 
need the medicines” 
Other minor themes included concerns regarding the accuracy of the medical discharge 
summaries, for example; 
“[the MITF contains] Clear explanations of medication changes and 
potentially more accurate info about medications than the 
discharge summary itself.” 
“Because there are sometimes discrepancies and safer to check 
where mistake lies earlier and when the doctor is updating patient’s 
medication summary and prescription etc.” 
The major themes for those indicating that they would prefer the MITF and the discharge 
summary to be sent at the same time, focused on the concern of an increase in workload 
and the frustrations of double handling. 
 “Easier to check for inconsistency and also saves double 
handling” 
“Less confusion. Single point of communication” 
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“To avoid double up of work and review medical summary at same 
time” 
“Reduce data processing” 
However, within this common theme, many commented that, due to the time delay of the 
medical discharge summary (waiting for that to be completed); to send the MITF and the 
HDS together may cause unacceptable delays. 
 “But only if the medical discharge summary is in a timely manner. 
When we get two separate documents we have to open the file 
twice and go through the history twice to sort everything out, which 
would be easier to do it once (but often the medical discharge 
summary is delayed and I would prefer to get a pharmacy discharge 
on time rather than delaying it)” 
“Obviously both are potentially valuable, but one should never be 
delayed for the other” 
Finally, to determine if we are meeting the requirements of the end-users, it was important 
to ask directly what the community-based health care providers would like included in the 
MITF template. (See table 5.3). Table 5.3 includes what information the end-users needs 
versus what is currently being provided. 
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Table 5.3: If a MITF is useful to your practice, what information would like included? 
What information 
would like included 








0 skipped question 
Combined 
(n=76) 




Date of admission 77% (35) 67% (21) 87%(66) N 
Date of discharge 88% (40) 96% (30) 92%(70) Y 
Accurate diagnosis 77% (35) 58% (18) 70%(53) N 
Discharge 
medicines 
97% (44) 93% (29) 96%(73) Y 
Medication 
changes 
95% (43) 100% (31) 97%(74) Y 
Reasons for 
changes to medicines 
88% (40) 93% (29) 91%(69) Y 
Any specific follow-







































N/A I do not find 
this service useful 
0% 0% 0% N/A 
*Currently there is no specific section on the template to detail follow-up or plans for short 
term medications; however, this is commonly specified in the “changes” section of the 
template. 
 
Additional items that community-based health care providers would like on the MITF 
template include; 
“Official HMR referral that can start the process”  
“Where the person is going after discharge e.g. RACF, home” 
“Hospital to support patient making the next appointment” 
When asked in conclusion for any other comments or feedback, the over-riding themes 
were positive and thankful for this initiative, see Appendix 17. 
“I commend pharmacists in this. I see mistakes with discharge 
medication frequently causing harm as patients stop when the 
[blister] pack runs out. This is a high cause of harm that discharge 
info would make a large difference. Please make it happens soon.” 
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“Anything that improves communication is good - medicines are 
particularly important” 
“Essential to have as soon as the patient is discharged” 
“We need pharmacists and their input - and recommendations 
when it comes to polypharmacy...” 
Themes in the comments which offer constructive criticism include the need to understand 
the challenges facing the remote health work force. In particular, the decision to only 
supply patients with seven to fourteen days of medicines can cause problems with 
continuity. There were also common themes regarding the importance of having this 
information electronically on the remote health information systems, rather than emailed or 
faxed. 
“[the MITF] Must be sent electronically to patients record i.e. 
Communicare®, PCIS® and all others. If sent via fax, it can be lost in 
the clinic or never received if error our end (or yours), if sent by 
email say to clinic manager, it depends on clinic manager being 
present (not on leave), the job of printing off these emails passed 
on to an acting health centre manager etc, on occasions where I 
work, no one has even been assigned the acting health centre 
manager role. You really must make it electronic like discharge 
summaries from Jadecare® for patient safety and risk minimisation” 
“I would like this summary to be sent via PCIS® system” 
“Where possible ensure that discharge medications are available in 
a remote community - hospital doctors may not be aware of what 
medications are unavailable in remote clinics (or at least ensure 
that several weeks’ supply is provided to provide time for supply 
from pharmacy to clinic)” 
“Sending us a discharge letter for a patient on a Friday when they 
only have 7 days’ worth of meds is not that helpful as it often takes 
14 days to get new meds out at remote clinics” 
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“The instigation of discharge medication has been very helpful in 
allowing us to continue quality patient care. The difficulty I see is 
when a client is discharged and doesn't immediately return home 
either due to follow up treatment or from personal choice. It is then 
when the supply of ongoing medication becomes problematic. 
Whether this means that a greater amount of discharge medication 
is supplied at discharge or if a doctor writes scripts to cover the 
client’s medication needs on discharge I am not sure.” 
5.3.5 Conclusion 
This study demonstrated that the community-based healthcare providers, for whom the 
MITF is targeted, are enthusiastic and supportive of the initiative. Useful quantitative and 
qualitative information has been gathered to enable us to continue to refine and develop 
this key tool to assist with the continuum of medication management. 
5.3.6 Discussion and Translation to Practice 
This end-user survey has enabled us to explore what our colleagues working in the 
primary health sector require and to consider suggestions of how we can improve our 
current information that is being transferred. 
The electronic systems have been raised throughout all studies within this section of the 
thesis. A common frustration for staff, within the Northern Territory Department of Health, 
is the fact that the systems are unable to ‘talk to each other.’ Efficient electronic 
communication would enable more information sharing and make for safer continuity of 
patient care. 
Working with what we currently have, we are again approaching the information systems 
managers to place the MITF template on the same software on which the hospital 
discharge summaries are created and dispatched. This will be beneficial for two main 
reasons; to ensure that it is accessible for doctors to have this medicines information so 
that they can more effectively complete their hospital discharge summaries, and for it to be 
saved and dispatched electronically. 
Issues with supply for our remote patients have been long-standing. Further arrangements 
are being pursued for the supply of more appropriate quantities of medicines to ensure 
that there are no breaks in therapy.  
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In terms of what is included in the MITF template, the pharmacist team appears to be 
meeting the end user’s needs; however, a few areas have been highlighted for 
consideration to add and perhaps remove. For example, there was strong consensus that 
a clear plan for the documentation of short term medicines, date of admission and 
diagnosis be added. However, including dose administration aid information and 
community pharmacy information may be taking up precious space on this concise 
document. 
The final study in this section is to demonstrate sustainability. Many interventions 
demonstrate their impact after implementation, but, as described in the introduction to this 
section, it is rare that interventions are reviewed to address their sustainability. This final 
study in this chapter repeats the methods from Paper 3 to determine if the accuracy and 
timeliness of the MITF have been upheld throughout the study period. 
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5.4 Providing Timely, Accurate and Sustainable Discharge Medicines Information: 
What is Required? 
5.4.1 Background 
Hospitals are becoming busier. The pressure to discharge patients from hospital is at an 
all-time high. The increase in patient turn-over, represented as shorter hospital stays, and 
the increase in separations5F††, means that the staff within the hospital setting have less 
time to plan and prepare discharges as the pressure to move patients out of beds 
becomes increasingly demanding.307  
In Australia in 2013–14, there were more than 9.7 million separations from hospitals. 
Between 2009–10 and 2013–14, the number of separations increased by 3.3% on average 
each year. This was greater than the average increase in population over this period 
(1.6%). Between 2009–10 and 2013–14, average lengths of stay for public acute and 
private hospitals fell slightly. For overnight separations, the average length of stay in all 
hospitals combined fell from 5.9 days to 5.5 days, an average annual decrease of 1.7%.307  
The pressure to discharge patients from hospital is increasing. The discharge process has 
undergone scrutiny around the world to encourage a ‘whole system approach.’ The 
recognition that discharge planning should begin the day of admission, or prior to 
admission for planned hospitalisations, and continuum of care realised, is the ideal 
outcome that is raised often, but rarely seen.251 
The primary mode of communication between the hospital and community healthcare 
providers is the hospital discharge summary.299,308 The hospital discharge summary (EDS) 
is the international standard of discharge communication and is defined as a “collection of 
information about events during care by a provider or organisation.”280This places huge 
importance on the one document, and the information in it, and relies on the successful 
transmission to the next point of care. Often the responsibility for producing discharge 
summaries are delegated to junior doctors.285 Both junior doctors and medical students 
have reported receiving inadequate training on how to write discharge summaries, and 
recognise that a higher priority is often given to more immediately-pressing clinical 
tasks.284 
Communication failures at the transition between hospital and community can contribute to 
adverse events and poor patient outcomes.207,309 A study in 2006 was the first to 
                                                          
†† Separations are patient discharges, recorded each time a patient leaves the hospital following treatment. 
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investigate the incidence of adverse events reported by Australian GP’s.310 They found 
that 15% of all reported events were related to hospital care, largely due to communication 
failures at the time of discharge. Similarly, a North American study found that one in five 
patients, during the transition of care period, suffered an adverse event. Poor 
communication was the most common cause (59%) of any adverse event at the time of 
discharge.304 At discharge (and admission), a substantial proportion of adverse events are 
related to medication discrepancies.234,304 
Often medicine-related problems are due to miscommunication regarding the 
continuation/discontinuation of medications on a patient’s admission to, or discharge from, 
hospital. 101,230,291,311 More than 50% of medication errors occur at transitions of care, and 
up to one third of these errors have the potential to cause harm.233,312 Omitting one or 
more medicines from a patient’s discharge summary exposes patients to 2.31 times the 
usual risk of re-admission to hospital.313 One in three older people who has recently been 
in hospital, returns to hospital due to medicine-related problems.314 Approximately 3% of 
all hospital admissions within Australia occur due to medication-related problems.190 A 
systematic review of studies from around the world found that a median of 3.7% of all 
hospital admissions were preventable medication-related admissions.315 
Literature regarding transition of care (referral, admission and discharge) demonstrated 
that there is ample evidence, and now large numbers of studies (particularly on discharge), 
that have investigated various aspects of these processes.251 Despite the high number of 
studies, the proportion of high quality evidence-based interventions, that display the 
potential for repetition, remains low. Also, although the literature of successful 
interventions has been published, few have demonstrated sustainability over time.251 
Along the medication management cycle, pharmacists must provide input. There is strong 
evidence supporting the positive impacts pharmacists can have at the point of admission, 
in particular when medication histories and reconciliations are completed.231 There is also 
supportive evidence regarding pharmacists input post discharge, or management of 
medicines in the community setting, especially in the area of Home Medication Reviews 
(HMR’s).6F‡‡ 279  
                                                          
‡‡ A Home Medicines Review (HMR) is a comprehensive clinical review of a patient’s medicines in their 
home by an accredited pharmacist on referral from the patient’s general practitioner (GP). The patient may 
choose to be referred to their usual community pharmacy or an accredited pharmacist who meets the 
patient’s needs. The service involves cooperation between the GP, pharmacist, other health professionals 
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Many interventions to improve the continuum of care have been evaluated and trialled 
utilising the skills of a pharmacists12,251. Interventions such as pharmacist reconciliation at 
discharge, counselling and follow up phone calls have shown success. There is however, 
little evidence of pharmacists taking responsibility and accountability for the handing over 
of medicines information between healthcare professionals.251 
In 2009 a study supporting a medicines information transfer fax (MITF) was conducted 
within the largest tertiary teaching hospital in the Northern Territory (NT), Australia.248 The 
importance of providing this service for high risk patients, and standardising this process, 
was quickly realised and implemented in all remaining hospitals across the NT. Results of 
the improved accuracy and timeliness of medicines information in comparison to the 
traditional hospital discharge summaries (EDS) have previously been published.248,316 Our 
previous work has also demonstrated that clinical pharmacists working within the acute 
healthcare setting can assist in providing essential information and correctly prioritise high 
risk patients who would benefit most from this service.248 
The NT Health Services discharge summary policy states: ‘A discharge summary must be 
provided or disseminated within 48 hours of discharge.’289 This is consistent with best 
practice recommendations internationally.251 The results from our previous study 
highlighted the need for pharmacists to be involved in this critical step in patient care and 
that collaboration and multidisciplinary discharge summaries should be encouraged and 
supported by hospital executives.248 
The study hospital has had extensive changes since 2009.  
The major changes between Study period 1 (2009) and Study period 2 (2014) include: 
1. Increase in NT population:  Although the population serviced by the study hospital 
increased substantially, the demographics of the region in which it is located, along 
with the types of presentations to the hospital, remained consistent. The NT has a 
young population with a high birth rate, more males than females, and the largest 
proportion of Indigenous people in any Australian state or Territory.317  
                                                                                                                                                                                                 
and their patient (and, where appropriate, their career).  A HMR service improves the patient’s and health 
professionals’ knowledge and understanding about medicines, facilitates cooperative working relationships 
between members of the healthcare team in the interests of patient health and wellbeing and provides 
medication information to the patient and other healthcare providers involved in the patient’s care. 
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2. Increase in workload of the NT hospitals: The number of separations from the NT 
public hospitals in 2009-10 was 99 694. This increased to 123 847 in 2013-14. Average 
change of 5.6% was the highest of any Australian state or Territory.307   
3. Increase in number of clinical pharmacists employed: Multiple successful business 
cases were submitted by the hospitals’ pharmacy department and funding granted from 
the NT Department of Health to increase the number of pharmacists employed at the 
study hospital, from 9 (2009) to 17 Full-Time Equivalent in 2014. 
4. Implementation of an Electronic Medication Management System (EMMS) across 
the hospital (part implemented in 2009): An EMMS enables prescribing, supply and 
administration of medicines to be completed electronically. EMMS covers the entire 
hospital medication cycle including prescribing by doctors, review and dispensing of 
medication orders by pharmacists, and administration of medicines by nurses.288 One 
key benefit, that is documented to support the clinical uptake of an EMMS, is the ability 
of systems to auto-populate the medicines from the electronic discharge prescription to 
the electronic discharge summary. The study hospital’s EMMS has the ability to 
perform this function. To complete this function, when the current medications are 
prescribed at discharge, this discharge list is imported from the eMMS to populate the 
discharge medicines section of the electronic discharge summary.286,318 
This study examines the sustainability of the Medicines Information Transfer Fax (MITF); a 
quality improvement activity driven by clinical pharmacists. 
5.4.2 Aims 
The objectives of this study were to examine the following: 
1. If the MITF has been successfully implemented and sustained as a routine practice 
for hospital pharmacists at a tertiary teaching hospital in Australia  
2. If the quality of the MITF has been maintained by reviewing the accuracy and 
timeliness of the medicines information provided by pharmacists compared with 
EDS 
3. If medicines, ‘auto populated’ into medical discharge summaries via an EMMS, 
improved the EDS accuracy and timeliness. 
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5.4.3 Methods 
Design: This study was a retrospective audit of a randomised convenience sample of 99 
patients who had a MITF completed by a pharmacist in April-September 2014. 
Setting: This audit was conducted by four senior clinical pharmacists within an Australian 
Tertiary Teaching Hospital. 
Hospital demographics: At the time the study was conducted there were 363 beds, with 
the capacity for up to 400 patients, serviced by 17 clinical pharmacists. There was an 
average of 260 discharge prescriptions per week dispensed by the hospital pharmacy. 
Inclusion/exclusion criteria: A template that has undergone multiple revisions due to 
feedback received, provided the standard for the MITF. If the pharmacist did not use this 
template their work was excluded. To prevent individual bias, if a reviewer was allocated 
their own work, they switched with another reviewer to prevent self-assessment. If a 
patient selected was discharged from the Mental Health wards, they were excluded, as the 
discharge summary template and the prescriptions used were not consistent with the 
remaining hospital wards. 
Standardisation of auditors: Exemplary patient information, together with the audit tool, 
was sent to each of the four auditors. The exemplary patient information included the 
MITF, EDS, Discharge Prescription and a list of medicines on admission. Each auditor 
completed the audit tool independently. The primary researcher reviewed the answers, all 
four auditors met to discuss discrepancies, and all four auditors agreed on a consistent 
way to interpret the information. 
Accuracy: Medication errors and omissions were identified in the audits and were 
categorised into error types and omissions.   
Changes and reason for changes: Changes were assessed by using a subgroup of 
patients who had a best possible medication history completed by a clinical pharmacist to 
determine if changes were documented and reasons for changes provided. The 
information regarding changes provided in the MITF was compared to the explanations 
provided in the EDS. Both templates provided a prompt for clinicians to complete a table 
indicating changes to medicines and justifications.  
In this study we did not regard acknowledging the change, such as “Ramipril 5 mg mane 
ceased” as sufficient information. To qualify for including a reason for the change the 
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auditors needed details such as “Ramipril 5 mg mane ceased due to hypotensive 
episodes.” 
Timeliness: The date of sending the MITF was recorded on the faxed document and filed 
in the pharmacy department. The time to delivery of the EDS was calculated using the 
study hospital’s admission and discharge software. The timeliness of both the MITF and 
the EDS were assessed against the Hospital Discharge Policy which states that the 
information should be delivered to the patient’s community-based practitioners within 48 
hours of discharge. 
Impact of an EMMS: The 2014 discharge summaries were also compared to the 2009 
discharge summaries to assess the influence of the ‘auto-populated’ medication list 
function influenced their timeliness and quality. 
Sustainability:  These results were then compared back to the original 2009 MITF data to 
compare both the sustainability and quality of the MITF.  
Comparison of patients:   The patient demographics that were examined in 2009 and 
2014 using a Chi-square test to determine the comparability between groups. 
5.4.4 Results 
Of the 99 patient MITF’s selected for this study, 16 were excluded: Eight discharge 
prescriptions could not be located, six did not use the correct MITF template and two were 
discharged from the hospital’s Mental Health facility. This left 83 patients included in the 
study. There was no significant change in age, gender and number of medicines on 
discharge between 2009 and 2014. There was a significant change in the number of 
conditions for Aboriginal and Torres Strait Islander patients (median number of conditions 
7 compared to 6 respectively) and also a significant change for both Indigenous and Non-
Indigenous in the number of changes which occurred to medicines, increasing in 2014. 
(See Table 5.4). 
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Table 5.4: Patient characteristics  
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Figure 5.9: Results overview 
Accuracy: Of the 83 MITF’s in this study, 81(98%) included the Electronic Discharge 
Prescription (EDP) as an attachment. This detailed complete and accurate medicines 
information.  Of the two MITF’s that did not attach the EDP, one matched the EDP by 
including all required information as a table and the second matched all names of 
medicines, however, it did not include dosage information or frequency, making it 
incomplete. The information contained only in the MITF was evaluated against the EDP. 
Sixty-four (77%) included all accurate information, of which some only contained 
information on changes while others detailed all medicines on discharge. Of the 19 (23%) 
that did not have correct information; 7 (8%) had one or more omission of a required 
medicine (range 1-7), 11 (16%) had at least one discrepancy (range 1-3) and 2 (2%) had 
both an omission and an error. The most common discrepancies for pharmacists 
documenting medicines on the MITF were omitting information from a prescription, such 
as frequency, and wrong dose form.  
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An EDS was completed for 75 (90%) study patients within the audit timeframe.   The 
accuracy of the information provided in the EDS was directly compared against the EDP. 
Fifty-eight (77%) were deemed accurate and had used the auto-populated discharge 
prescription integrated into their summary. Of the 17 (23%) who had incomplete 
information, 7 (41%) did not utilise the auto-population function of EMMS, this was made 
up of 3 (17%) not having any medicines information as no data was transferred into the 
EDS, with 4 (24%) having transcription errors. For the ten patients who utilised the auto-
populated function, nine (12%) had amendments to their discharge prescription, that were 
not reflected in the EDS; these changes were either handwritten or not transferred using 
the EMMS. One (1%) had an incomplete list of medicines, missing three of the patient’s 
regular medicines. This audit cannot determine if there were late amendments at the time 
of discharge for this one patient.  
Of the 17 EDSs that did not match the discharge prescription, 8 (47%) had omissions of 
required medicine (range 1-15), twelve (70%) of EDSs had errors in one or more of the 
patients’ discharge medicines (range 1-2), with the most common errors being inclusion of 
a medicine that had been ceased, and wrong dose. Three (18%) patients had both an 
omission and an error in their EDS. 
Changes and reasons for changes: Seventy-nine (95%) patients had a best possible 
medication history and reconciliation conducted at the point of admission. Seventy-eight 
(99%) had changes to their medicines during admission (range 2 to 16). Seventy-four 
(95%) MITF’s included information on changes to a patient’s medicine during admission. 
Eighteen (24%) had all changes documented, 52 (70%) had included some, but not all, 
changes documented (partial information) and 4 (5%) MITFs did not include any 
information regarding these changes.  The MITF was also evaluated to see if a reason 
was provided for the change to a medicine. Of the 74 patients who had changes 
documented within the MITF, 13 (18%) had an explanation against each change, 37 (50%) 
had included some reasons for changes, and 24 (32%) provided no explanation for 
changes. 
Of the 79 patients who had a best possible medication history and reconciliation, 74 (97%) 
had a completed EDS. Seventy-three (92%) of patients had changes to their medicine 
during the admission (range 2-16). Forty-two (58%) EDSs included information on 
changes to the patient’s medicine, 35 (48%) utilised the table provided, and manually 
entered this information, with the remainder free-texting the details within the EDS. Eight 
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(11%) included all changes within the EDS, 29 (40%) had changes documented but only 
partial information and 36 (49%) did not include any information regarding changes to 
medicines. Eight (11%) provided reasons for changes to all medicines.  
Timeliness: Seven (8%) MITF’s were sent to the primary care provider prior to the 
patient’s discharge date and therefore were excluded from the timeliness analysis, leaving 
76 for evaluation. Seventy-one (93%) MITFs met the Hospital’s policy of patient 
information being sent within 48 hours of discharge. The remaining 5 were sent between 
3-6 days of discharge. The median timeliness for the MITF was the same day as 
discharge. 
Of the 83 patients, 5 (6%) EDSs were sent prior to the patient being discharged and 
therefore were excluded from the timeliness analysis, leaving 78 for evaluation.  Forty-
seven (60%) met the hospital policy and were sent within 48 hours. Of the remaining 31 
EDSs that were outside the 48 hours window, 8 were not completed and 23 were greater 
than 48 hours, with a range of 3 days to 55 days (median of 8 days). The median of all 
completed EDSs was 24 hours after discharge. 
Impact of the Electric Medication Management System (EMMS): The implementation 
of EMMS, with its capacity to ‘auto-populate’ discharge medicines from the electronic 
prescription to the EDS has greatly improved the accuracy and timeliness of the medicines 
information provided at the transition of care to primary healthcare practitioner. Prior to the 
implementation of the EMMS, prescribers were required to transcribe medicines 
information from a handwritten discharge prescription to the EDS. With medicines being 
transferred from the electronic discharge prescription directly to the EDS via EMMS in 
2014 the accuracy significantly improved the doctors’ accuracy between the two audits 
with 11% (8/74) accurate in 2009 compared to 77% (58/75) accurate in 2014 (chi-
square=14.3, p-value=0.00015). Timeliness of the EDS also significantly improved from 
45.9% (28/61) in 2009, compared to 60% (47/78) in 2014, meeting the Hospital Policy of 
being dispatched within 48 hours of discharge (chi-square=17.1, p-value=0.00036). 
Sustainability: The accuracy of the MITF demonstrated a significant improvement in 
between the two audits with 93% (71/76) accurate in 2009 compared to 98% (81/83) 
accurate in 2014 (chi-square=18.5, p-value=0.00017). In 2014 the accuracy of the MITF 
was rated as 77% with a sample size of 83. Eight-one (98%) of the MITF’s attached a copy 
of the electronic discharge prescription that would provide clarification.  Timeliness of the 
MITF showed a significant change decreasing from 100% (80/80) in 2009 compared to 
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93% (71/76) in 2014 meeting the Hospital Policy of being dispatched within 48 hours of 
discharge (chi-square=18.5, p-value=0.000017). 
5.4.5 Discussion 
Multiple revisions to the MITF have occurred between the study periods. The results 
demonstrate that it has continued to provide a high quality service, despite staff turnover or 
new employees, the MITF has been embedded into routine practice at this hospital. 
Having started with a team of 9, the team has now grown to 17 pharmacists who provide a 
clinical pharmacy service to specific patient care areas. While evaluating the MITF’s during 
this study, it was evident that the MITF was utilised across the team, specifically 11 
pharmacists were identified in the audit to have completed one or more MITFs. 
The use of the MITF remained consistent between the two study periods, although there 
was slight variation between the patient demographics in 2009 and 2014. The patients 
selected by the clinical pharmacists were deemed high risk, in both time periods, for 
medicine misadventure.319,320 
The accuracy of the MITF has improved, while the timeliness decreased from 100% in 
2009 to 93% in 2014. Of the five MITF’s which were outside the 48 hours, all were sent 
within 7 days’ post-discharge. 
It was noted during the assessment of this audit that the MITF is now used much more as 
a “cover sheet” with the electronic discharge prescription attached rather than manually re-
typing the information on the one page. The MITF details patient information such as date 
of birth, date discharged, discharging team, dose administration aids, the amount of 
medicine supplied, changes to medicines and the reasons for these changes.  To this 
extent, both the MITF and the EDS have the electronic prescription either ‘auto-populated’ 
or attached. There were, however, still discrepancies, both between the discharge 
prescription and the handover information, and between both the MITF and the EDS. The 
main reason for discrepancies was late amendments to the discharge prescription. This is 
the reason that both MITF’s and EDS’s, which were sent prior to the day of discharge, 
were excluded from some analyses as they would not reflect any late changes. With the 
auto-populated function within EMMS the prescription needs to be amended and re-printed 
to ensure that the information is updated and re-populated in the EDS and is correct. This 
may need to be re-emphasised with medical officers in training. Regardless, it was clear 
that the auto-populated medicines information in the EDS was not checked or changed by 
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medical staff. There is multiple formatting, and there are amendments to the readability of 
the medicines information transferred from the EDP to the EDS, that have been identified 
in this audit.   
The majority of the pharmacists (98%) in the audit sample attached the electronic 
discharge prescription to the MITF, which ensured greater accuracy as it was the last 
version which had been used for supply and reconciled by the pharmacist.  
Importantly, throughout the revisions of the MITF template, the most pressing issue was to 
include room for explanation of changes. In the original study, the template included what 
changes had occurred but there was no section to provide information as to the reasons 
why. Feedback from community-based practitioners deemed this to be 
essential.281,282,291,311 In the 2014 audit sample the changes to medicines were often listed 
but only 24% included reasons for each of the changes, 70% included reasons for some of 
the changes, and the remainder did not include any information regarding changes, 
suggesting that this is an area for future improvements. Within the MITF, the pharmacists 
used the area assigned for explanation of changes to annotate if a medicine was new or 
ceased, as they would in a reconciliation process. We did not consider this an explanation. 
A recent study 318 evaluated if Electronic Discharge Summaries contain more complete 
medication information compared with a paper-based discharge summary. This study 
demonstrated that there was a significant improvement in prescribers including an 
explanation when a medicine was added to a patient’s regime (14.3% on paper vs 37.2% 
electronic p<0.001); however, it did not significantly improve explanations for other 
changes such as discontinuation, dose or frequency change. This indicates similar results 
to our study, and more importantly, the low percentage of explanations which are provided 
and which need our focus. This study did consider terms such as ‘ceased’ as an 
explanation for changes. We consider that using this method does not provide all the 
information that a GP would need to assess the clinical application around changes to 
medicine. For example, a discharge summary stating that aspirin was ceased, does not 
provide information or reason. We would expect our information to include explanations 
such as, “aspirin was ceased due to a gastric bleed”, to have this explained.  
Better documentation of reasons why changes are made to medicines throughout the in-
patient stay, in the form of a medication action plan, has been shown to improve the 
inclusion of this information by both pharmacists and doctors at the point of discharge251. 
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The performance of doctors appropriately completing EDS greatly improved after the 
introduction of an EMMS, particularly with regard to accuracy and timeliness. This 
improvement can be partly attributed to the “auto-population” function within the EMMS of 
the discharge medicines that reduced the need for transcription of this information and 
saved time for the prescribers. Other reasons for improvement could be the increased 
accessibility to computers after the implementation of EMMS, or more supportive training. 
The ability to integrate the two documents, or to copy the MITF into the EDS, is the long-
term ideal outcome. However, five years on, this software capacity is yet to be realised: 
This is not uncommon for government services, and it emphasises the slow uptake of 
initiatives within healthcare services. The program and design have now been scoped, and 
is expected to be implemented within the next twelve months.  
The knowledge of the MITF service is sought after among hospital staff. One prescriber 
within their EDS, who was included in this audit, acknowledged that their list of medicines 
contained mistakes and directed the GP to go to the MITF for the most accurate 
information. 
A formalised end-user survey is currently seeking feedback from both GP’s and 
community pharmacists to ensure that the full potential of the MITF is being realised, and 
that it is meeting their needs for medicines information. 
As less than ideal medicine management and communication between healthcare settings 
continues to put patients at risk of medication related misadventure, this simple innovation 
has empowered clinical pharmacists to take responsibility for ensuring that essential 
medicines information is transferred to the primary care providers at the point of discharge.  
5.4.6 Conclusion 
The sustainability and continued high quality of the Medicines Information Transfer Fax 
has been demonstrated in this second clinical audit, five years post implementation. The 
value of this tool has been recognised and its use is now embedded in the clinical 
pharmacist team’s practice. Integration and availability of the MITF, for use by the doctors 
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5.5 Conclusion of Chapter 5: Summary and translation to Practice  
The MITF is a concise, informative, timely, accurate and trusted handover tool for 
medicines information. Not only has it become the responsibility of a pharmacist to provide 
this critical information, but it is also a reliable source of information for community-based 
healthcare professionals. The MITF is providing them with this information to ensure 
continuum of care for our patients. This series of studies has, however, identified key 
areas within our healthcare system that need further investigation and refinement. 
The hospital discharge summaries, still the main handover tool used nationally and 
international, is essential and contains much information on investigations and procedures 
that are far outside the scope of the MITF. The MITF sits alongside the hospital discharge 
summary. The medical profession has historically taken the load of providing the hospital 
discharge summary. As the care provided within the hospital is multidisciplinary, the 
discharge summary should be compiled with information from specialists within each 
discipline. As the MITF has been shown to be more accurate and timely in terms of 
medicines information, embedding the MITF into the hospital discharge summaries as a 
shared care document would be ideal. 
A common theme throughout all six studies is the electronic systems have yet to provide a 
workable solution to the issue of handover. As mentioned within the studies, the EPhR and 
the director of pharmacy continue to approach the managers of the hospital software to 
have the MITF uploaded as a document and sent electronically in the same manner as the 
discharge summaries. Although this has been on the table for seven years, which is not 
uncommon for government departments, it is finally coming to fruition and the first hospital 
in the NT, Gove District Hospital, will be trialling the electronic version within the next six 
months. 
The next stage in the evaluation of the MITF is to determine the impact of the MITF on 
patient outcomes. Does it help prevent readmissions? Does it prevent ‘medicine related’ 
admissions? Does it help the primary healthcare providers make informed decisions on 
medicine management for their patients’ post discharge? All of these factors can also be 
tailored to evaluate the financial impact that it would have on our healthcare system. 
Another interesting piece of research would be to evaluate how the community 
pharmacists action recommendations within the MITF and how receptive patients and 
GP’s/RMP’s are to their advice. It is common that patients present to their community 
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pharmacist prior to their doctor after discharge, therefore the changes that have happened 
within a hospital admission must be communicated to the community pharmacists.305  
The remote patients, who are a high proportion of the Northern Territory community, have 
additional challenges when relaying medication changes. Due to medicines often being 
packed and sent from the urban centres to the remote clinics, the changes need to be 
made and sent to the clinics, often before the patient returns home. The risk of old 
medicines (such as blister packs) being used by clinic staff when a patient presents for 
their medicines is high. Also, the wastage from medicines being sent on ‘cycles’ by the 
contracted pharmacies, often unaware that a remote patient has been admitted into 
hospital, can lead to a huge amount of medicine having to be discarded.  
Clinical handover continues to be an ‘at risk’ process of our healthcare system. Medicines 
in particular are often where communications fall down. The MITF initiative has 
demonstrated that it is a sustainable, comprehensive and practical tool to overcome many 
of these issues. The next stage will be engaging with other jurisdictions to trial the MITF 
within their hospitals in the hope that the MITF tool will go beyond the Northern Territory. 
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Chapter 6 Risk Management  
6.1 A Background on Risk Management  
Medicines use is accepted by our patients due to the evidence of benefits. Within 
healthcare, medicines provide a role for preventative therapy, symptom relief, slowing 
progression of disease or to cure. The use of medicines, however, is not without risk. The 
overarching Quality Use of Medicines (QUM) Principles1 are designed as a guide to 
ensure that patients receive the best possible chance of benefiting from decisions 
regarding their medicines. As a partnership between the healthcare professionals and 
patients, it becomes a seesaw - weighing the benefits and risks of treatment options. 
There are no correct answers, as answers are fluid and may change depending on 
patients’ characteristics and outcomes. Most importantly, patients must be well-informed to 
understand the risks of treatment with medicines as well as the risks of no treatment. The 
QUM principles help provide a framework for this analysis.1,84  
Adverse Drug Events (ADE’s) are broken down into two branches, Adverse Drug 
Reactions (ADR’s) and Medication Errors. Difficulties lie in terminology across healthcare 
sectors and this area is no exception. ADR’s may result from Medication Errors, however 
many do not. “Medication errors are more common than adverse drug events, but result in 
harm less than 1% of the time. About 25% of adverse drug events are due to medication 
errors.”321 See figure 6.1. It should be noted that the vast majority of Medication Errors are 
not associated with an ADR (i.e. do not cause harm). Similarly, most ADE’s are not 
associated with a medication error and therefore may not be preventable. 
 
Figure 6.1: Relationship between adverse drug events (ADEs), potential ADEs, and medication 
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There are four main causes of medication errors; 
• Knowledge based (Lack of knowledge)  
• Rules based (Bad rule, misapplying a good rule)  
• Action based (Slip-ups e.g. selecting wrong drug) 
• Memory based (Lapses e.g. forgetting patient allergies)323,324 
The current research suggests that the significance of medication errors results in about 
20% causing a degree of harm to our patients and 3% causing significant harm, including 
death.219 Physical harm is not the only factor to consider, with other impacts including 
psychological harm to both the professional and patient, loss of trust in an organisation or 
individual, and potentially a medico-legal proceeding.325 
Adverse Drug Event’s, including those resulting from Medication Errors; result in a large 
burden on our healthcare system, both financially and in an increase in capacity 
pressures. The prevalence of Medication Errors are of particular concern because the 
majority of these errors are preventable.190,326,327  
Unfortunately, within healthcare systems, documentation of a benefit and risk analysis is 
often lacking, as clinicians perform these important calculations instinctively and move 
efficiently to the next decision. For clear evidence-based, risk-assessments, multiple tools 
have been designed to support clinicians in calculating the risk, but also to provide 
evidence of the risk calculation being completed and documented.101 Examples include: 
Venous Thromboembolism Prophylaxis194, Falls assessment328, and Metabolic Monitoring 
Tools.329 
When comparing healthcare to other professions, it appears that healthcare 
documentation of risk assessment is subpar, and if an incident does occur it is reported 
retrospectively. When using another industry, such as mining, as an example, their work 
cannot proceed until perceived risk is documented and preventative actions initiated, such 
as the ‘take five’ principles.330 There are multiple variations of risk assessment tools under 
which the mining profession work, but the evaluation remains the same. It ensures that 
workers view the task at hand and, if it is not safe, it must be made safe. Within the 
healthcare profession risk reporting happens retrospectively which allows review in the 
form of documenting near-misses or actual incidents.182,331 
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Risk reporting within the healthcare system is voluntary in Australia.182,190 This is 
consistent and reflected as the most common method of risk management 
internationally.332-337 Risk reporting and incident reporting go hand in hand. To report a 
‘near-miss’ is a risk which is defined as “an event, situation, or error that took place but 
was captured before reaching the patient. For example, penicillin was ordered for a patient 
allergic to the drug; however, the pharmacist was alerted to the allergy during computer 
order entry, the prescriber was called, and the penicillin was not dispensed or 
administered to the patient. Or the wrong drug was dispensed by pharmacy, and a nurse 
caught the error before it was administered to the patient.”338  
Why should we, as researchers and clinicians, worry about risks and incidents? Because, 
as healthcare professionals and given the modern interpretation of the Hippocratic Oath, 
our guiding principle, is to ‘first do no harm.’339 It is essential that patient safety must be the 
first aim in every setting, in order to build safer systems, we must learn from errors and to 
reduce the financial burdens associated.340 Unfortunately, there will always be risks with 
medicine use, but there are successful ways to reduce the known risks and therefore 
prevent commonly occurring incidents.195,326,327,334 Reporting near-misses and incidents 
allows for an understanding of the potential harm that may occur. Often staff find it hard to 
move away from ‘human error’ but that is rarely the cause; it is usually NOT an individual 
but the SYSTEM that needs to be reviewed.212,341-343 By acknowledging the errors or near-
misses we can work towards safer systems. 
“Systems solutions, such as standardisation, or making things as routine as possible, are 
recognised as the best way to overcome slips and lapses, which are the most common 
cause of medication errors in acute care.”326 
This section of the thesis is dedicated to a system-wide approach to reduce risk and 
prevent incidents in relation to the use of medications.  
The studies presented below are an ‘investigation’ into systems that are known to reduce 
risk through their implementation and provide models that explain how this is translated 
into practice. These studies demonstrate the work of the EPhR in the process of 
implementing best practice interventions with evidence that enables a reduction in 
medicine incidents. 
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There are three studies in this section that investigates different system solutions for 
managing risk. 
The first study presented in 6.2 focuses on an Electronic Medication Management System 
(EMMS). The Royal Darwin Hospital was the first hospital within Australia to pioneer an 
EMMS. An Electronic Medication Management System (EMMS) enables the prescribing, 
supply and administration of medicines to be completed electronically. EMMS covers the 
entire hospital’s medication cycle including prescribing by doctors, review and dispensing 
of medication orders by pharmacists, and administration of medicines by nurses.288 
This situation prompted the EPhR to review the risk and incident reports that were 
provided by clinicians to provide an insight into the types and severity of medicine-related 
adverse events with, and without, an EMMS.  
The second study presented in 6.3 evaluates the accuracy of risk reporting by clinicians. 
As described, voluntary risk reporting is the current practice within health care systems 
both nationally and internationally.332,344,345 As system evaluation relies on risk reporting it 
is important to evaluate the incident severity that is assigned by the clinician as this 
dictates the level of review by the health care system.  
The third study presented in 6.4 looks at high risk medication and how they are managed 
within the hospital setting. This study utilises a rapid implementation method which is 
unique to the other studies. The external driver of accreditation enabled the EPhR to 
implement a quality improvement activity which originally had much resistance from staff. 
The paper associated with this study (Paper 7) shows an evaluation process of the quality 
improvement intervention against policy, as well as an evaluation of the implementation 
method utilised by the EPhR. 
All studies have a background and detailed description of methods and evaluation 
techniques. As medication safety and risk management plays a large role in developing 
best practice medication management it is essential that current practice and interventions 
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6.2 Multidisciplinary Medicine Incident Reports and Risk Allocation With and 
Without an Electronic Medication Management System. 
Ethics: Full ethics approval granted by the Human Research Ethics Committee of the 
Northern Territory Department of Health and Menzies School of Health Research. 
Approval number: HREC-13-19. (See Appendix 17) 
6.2.1 Introduction 
Medicine-related errors are one of the most common causes of adverse events in a 
patient’s hospital stay.190 Medicine incidents are second only to falls and within Australian 
healthcare incident monitoring systems, approximately a quarter of all reported incidents 
relate to medicines.288,325,346  
Within Australia, the use of a robust hospital-wide system of reporting, investigating and 
managing change in response to medicine incidents, is a core criterion used when 
hospitals are audited against the Standards of Safety and Quality in Healthcare.193 
Central to risk management is the reporting, monitoring and management of incidents. 
Incident reporting is the mainstay of quality improvement activities and risk reduction. It 
enables hospital and health service staff to commence an investigation to identify factors 
that may have caused or contributed to the incident.212  
Many medicine errors can be prevented by introducing safe systems and safe medicine 
practices. Improving medicine error reporting rates is a primary component of 
understanding the causes of medicine errors and making system wide changes to reduce 
risk to our patients.193,332  
An Electronic Medication Management System (EMMS) enables prescribing, supply and 
administration of medicines to be completed electronically. EMMS covers the entire 
hospital medication cycle including prescribing by doctors, review and dispensing of 
medication orders by pharmacists, and administration of medicines by nurses.288 
Comprehensive literature reviews 347-349 of recent evidence related to Electronic 
Medication Management Systems (EMMS) concluded that “the evidence-base regarding 
the effectiveness of e-prescribing systems to reduce prescribing errors, and the severity of 
those errors, reveals that the amount of evidence is very modest and the quality and 
generalisability of results is limited.” 347 Pg. 620. Most studies reviewed only prescriber 
errors, and did not examine errors occurring from activities of all disciplines. Analysis of 
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serious errors always reveals multiple system failures and the involvement of many 
individuals.332 Therefore, it is important to look at the medicine errors occurring across 
disciplines and within the health service as a whole.   
Our study is the first, to our knowledge, to examine reporting of errors by all professionals 
in the medication management cycle (medical, nurses and pharmacists) with and without 
EMMS. We also examined the accuracy of risk allocated by reporters in terms of patient 
harm. 
Risk reporting by staff at the study hospital is supported by an incident monitoring policy 
which requires all staff to report both actual incidents and near misses.350 This reflects 
common practice both nationally and internationally.343,344  
Despite the limitations of non-mandated staff reporting, it is still recommended and 
encouraged internationally as the preferred method of capturing information on medicine 
incidents.332,343-345,351 Little research has been done to reflect on the accuracy of voluntary 
reporting in identifying clinical risk. Use of Incident Severity Rating (ISR) scores is common 
in Australian public hospitals. In particular, most hospitals rely on ISR as a means to 
reduce medicine-related incidents in patient care.190,193,346,350 A recent paper from the USA 
indicated “inconsistency in the way nurses scored the scenarios, suggesting that the event 
reporting system may not accurately portray the severity of harm in patient safety 
events.”345 (Page 218) 
The EMMS was withdrawn from the study hospital in Dec 2010. The three main concerns 
which led to the hospital-wide decision to revert to paper-based prescribing included the 
following: lack of governance, software limitations, and hardware accessibility and 
usability. In Period 2 (Feb 2011-July 2011), hospital staff on all participating wards 
returned to using the pre-2006 paper-based prescribing system. 
After addressing the concerns of the hospital the following steps were taken: forming a 
clinical governance group (which including all key stake holders) to manage the 
implementation and to provide ongoing support; upgrading the software and disaster 
response backup; and purchasing of new hardware, such as laptops and more user-
friendly trolleys. The EMMS re-installation began in December 2011. The roll-out of the 
EMMS to the last ward was completed in September 2012. In Period 3 (Feb 2013 – July 
2013), all participating wards had returned to using the EMMS. 
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This study was a natural experiment, using routinely collected data entered into the risk 
management software system, by hospital staff. This data was used to compare medicine 
incidents (MI) associated with prescribing, dispensing and medicines administration, to 
discover who reported incidents and who was involved in the incident (accountability), and 
as well, to judge the severity of incidents. 
6.2.2 Objectives 
The need for monitoring clinical outcomes, and risk allocation provided with reported 
incidents, is a key area which needs to be explored. This study’s objectives are to explore 
the following:  
(1) If the utilisation of EMMS is associated with the number of medicine incidents reported 
by doctors, pharmacists, and nurses;  
(2) If having medication management and risk reporting available on the same computer 
increases the number of incidents reported, and  
(3) If the level of clinical risk associated with a medicine incident report changes over time. 
6.2.3 Method 
An historic longitudinal study design was used to assess changes in medicine-related 
incident reporting associated with the introduction, removal and re-introduction of an 
EMMS in an Australian Tertiary Teaching Hospital. Routinely collected data from the 
hospital’s incident reporting software system was examined across a four-year timeframe. 
This timeframe covered the introduction of an EMMS within the study hospital (2010), its 
removal and reversion to the original paper-based system (NIMC) for one year (2011), and 
the re-introduction of the EMMS (2012-2013). Data was collected from 1st February to 
30th July, for each of the years 2010 (T1), 2011(T2) and 2013(T3). 
Ethics approval was granted (4/12/2013) by the Human Research Ethics Committee 
(HREC) of the Northern Territory Department of Health and Menzies School of Health 
Research. Ethics reference number is HOMER-13-19. Patient records/information was 
anonymised and de-identified prior to analysis.  
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Inclusion criteria 
For each of the time periods the incident report data was examined for all medicine-related 
incidents: 
• T1 (Feb 2010-July 2010) all participating wards had the EMMS fully implemented 
and staff had used it for at least 6 months prior to initial data collection. The EMMS 
was withdrawn from the study hospital in Dec 2010. 
• T2 (Feb 2011-July 2011) hospital staff on all participating wards returned to using 
paper-based prescribing system: National Inpatient Medication Chart.  
• T3 (Feb 2013 – July 2013) all participating wards returned to using the EMMS.  
Data was extracted from the incident database using the reporting function of the software. 
Data was first sorted by the three data collection time periods and then filtered by medicine 
incidents. 
Exclusion criteria 
TIME PERIODS EXCLUDED: Incidents reported between 1st of August and 31st of 
January for each of the study periods were excluded. All incidents reported in 2012 were 
excluded as both paper and EMMS were operational. For each of the time periods, we 
collected data on all medication-related events using the hospital risk management 
software system. In periods using EMMS, participating wards had the EMMS fully 
implemented and staff used it for at least 6 months.  
AREAS EXCLUDED: Four areas of the hospital did not participate in the EMMS and were 
excluded from data collection. Exclusions were: the Emergency Department (ED), 
because of software limitations related to admissions and discharges in ED, and hardware 
issues with limited room to move laptops to patients; the Mental Health unit (MH) as it was 
not under the hospital network, and its governance group elected not to participate with 
electronic prescribing; the Intensive Care Unit (ICU) where continuous complex infusions 
had not been worked into the software, therefore this limited its functionality in ICU; and 
Theatres, as charts were often ‘pre-written’ and adjusted by the theatre nurse on directions 
from a doctor, and there was no way to reflect this practice in the software.  
INCIDENTS EXCLUDED: Incidents that were not related to medicine or the management 
of medicine. 
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DUPLICATES EXCLUDED: Incidents which were given multiple classifications (such as 
medicine administration and wrong time) appeared in the data multiple times. The unique 
incident code was used to identify the duplicates in the data. If an incident appeared more 
than once it was counted as a single incident and classified by the primary researcher into 
the appropriate incident classification. Incidents that had been reported by different staff 
recording the same event were counted as a single incident. These incidents were 
confirmed by the patient’s unique hospital number, location, time and date of the incident. 
If re-classification needed to occur, both incidents were used to assess the appropriate 
incident classification which was assigned by the primary researcher. 
Once exclusions were applied, the data was analysed by sorting incidents into firstly time 
period (T1-T3), then into reporter’s profession, incident severity rating, incident type and 
area of accountability under which the incident occurred.  
Chi-square, or Fisher’s exact test when necessary, due to low numbers, were both used in 
statistical analyses. Reporters were classified as doctor (including consultant to medical 
student), nurse/midwife or pharmacist/pharmacy technician; the area of accountability of 
each incident was reported as medical, nursing or pharmacy; and the incident severity 
rating was reviewed. 
The Incident Severity Rating (ISR) was graded from 1 (catastrophic) to 5 (insignificant) and 
was rated by the incident reporter.352 This rating guides the level of investigation 
undertaken.350 During the primary researcher’s initial examination of incident reports, it 
became clear that there was no standardisation of the selection of classification of ISR 
levels. Consequently, all 448 incidents were re-examined and reclassified in their incident 
ratings using the ISR system by the primary researcher (pharmacist). A representative 
20% sample of incidents with all ratings was blinded then reviewed by a multidisciplinary 
team (medical officer and nurse), who independently provided their ratings. A kappa 
analysis was completed to measure the degree of agreement between committee 
members and to validate the primary researcher’s accuracy when assigning ISR’s. We 
used Fleiss's equally arbitrary guidelines which characterises Kappa scores over 0.75 as 
excellent, 0.40 to 0.75 as fair to good, and below 0.40 as poor.353 If an incident did not 
include sufficient information to correctly classify it or give it an appropriate severity rating, 
the primary researcher examined case notes and associated information such as 
laboratory reports and medication charts. 
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We hypothesised that there would be no difference between the three time periods in an 
analysis of the reporting of medicine incidents, reporter’s profession, and the severity 
rating of reported medicine-related incidents. 
6.2.4 Results and Discussion 
Table 6.1 reviews the medication management systems in use as well as key patient and 
staff numbers during the study period. 
Table 6.1: Northern Territory Hospitals and Patient Demographics over time 
 T1  T2 Transition 
period 
T3 
Year 2010 2011 2012 2013 
Medication management system EMMS NIMC NIMC/EMMS EMMS 
Total bed numbers on average (study 
hospital only) 
401 401 401 401 
Total beds included in study; 
applying exclusion criteria [19 
Emergency Department (ED), 31 
Mental health, 8 Intensive Care Unit 
(ICU)] 
343 343 343 343 
Percentage of separations in the NT – 
Indigenous and Torres Strait 
Islanders@ 
70% 70% 70% 70% 
Emergency department presentations 
(NT) on average per month^ 
11 419  11 734 11 765 11 793 
Total separations (all NT hospitals)+^ 59 735 64 597 64 588 64 593 
Staff numbers (FTE) –NTH 5361 5624.5 5872 6065  
Ratio of NT separations to NTH staff 0.09 0.09 0.09 0.09 
^Due to remoteness, the dispersed population and absence of alternative healthcare providers, NT public hospitals fill 
numerous non-acute care service gaps in the community. A number of the measures in the table are therefore not 
directly comparable with other jurisdictions. 
+Separation refers to the completion of an episode of admitted patient care where the period of hospitalisation ranges 
from admission to discharge, transfer or death. It may also refer to a portion of a hospital stay, resulting in the change of 
type of care for example, from acute to rehabilitation care. 
@The profile of separations by Indigenous status across Northern Territory hospitals shows that, with the exception of 
Royal Darwin Hospital, all had 70% or more Aboriginal separations. The Royal Darwin Hospital profile suggests between 
50% to 60% of separations are for Indigenous and Torres Strait Islanders and remained consistent across the study 
period. 
# Comparison of prevalence between populations adjustment for the variation in age distributions of these populations 
(estimated). 
* The Aboriginal and Torres Strait Islander population of the Northern Territory is projected to have the lowest growth rate 
of Australia between 1.4% and 1.6% per year over the projection period. 
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Objective 1: The utilisation of EMMS is associated with the number of medicine incidents 
reported by doctors, pharmacists, and nurses.  
Measurement of medicine incidents (MIs) across the three time periods demonstrated that 
there was a significant difference between the proportion (testing equal proportions) of MIs 
per time period (p<0.001). (See table 6.2).  
Table 6.2: Medicine incidents reported in study periods 






P values or 
Fisher exact p-
value 
Total Incidents reported for 
patient related indicators 
(medication, falls, pressure 
ulcers, transfusion, and 
obstetrics) 
1 050 1 188 1 998 p<0.001 
Total Medicine incident 
reports 
673 858 911 
Medicine incidents with study 








There was a significant association between reporters’ profession and time period 
(Fisher’s exact p-value=0.001): Nurses were the highest incident reporters in each time 
period. Over all, nurses were involved in reporting 83% of incidents, pharmacists 14% and 
doctors 3%. Pharmacists changed their reporting with a large increase in medicine 
incidents reported in T2. (See table 6.3). 
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There was a significant association between area of responsibility of incidents and time 
period (p-value=0.001), with nursing responsibilities associated with more incidents. There 
was a doubling of medicine incidents allocated to the medical profession within T2. (See 
table 6.4).  
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Objective 2: Having medication management and risk reporting available on the 
same computer increased the number of incidents reported. 
The numbers of computers, and staff accessibility to computers, changed between T1 and 
T3. The implementation of EMMS, particularly in the second rollout (T3), the Northern 
Territory Department of Health increased the number of computers available to staff. The 
rate of medicine incidents reported in the time periods with EMMS was significantly less, 
showing that the increase in number of computers did not change the rate of medicine 
incident reports due to greater opportunity and convenience for staff to report. (See Table 
6.3 and Table 6.4). 
Objective 3: The level of clinical risk associated with a medicine incident reported 
changes over time 
The accuracy of determining the level of clinical risk was allocated by the primary 
researcher (pharmacist). A random sample of 90 incidents (20%) was selected to validate 
the incident severity rating (ISR) accuracy by the primary researcher. six reports were 
excluded as they were duplicates of the same incident entered by different reporters or, 
after review, recognition of it being classified as a medicine incident when it was not. 
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A nurse and a doctor independently provided an ISR to the remaining 84 reports. A Kappa 
score indicated Po=0.78 agreement between all three reviewers (the pharmacists, nurse 
and doctor). This allowed the primary reviewer to extrapolate all re-classified ISR with the 
confidence that the panel would have provided matched results. (See figure 6.2).  
 
Figure 6.2: Proportion of ISR by time period 
This chart demonstrates the distribution of proportion of severity ratings. From the re-
classified analysis there was no difference in severity scores across the three time periods 
(serious (ISR 1-2): 7.41%, 12.18% and 11.21% respectively) p =0.44. 
This study reviewed incident reports and risk allocation provided by all professionals within 
the medication management cycle with and without an EMMS. This study provides data 
which supports the benefits of EMMS in reducing the number of medicine incident reports 
by clinicians compared with a paper-based medication management system. 
The EMMS was withdrawn in T1 after serious concerns were raised by staff, and 
supported by hospital executives. The same EMMS was re-introduced in T3, after 
addressing the concerns of the hospital by the following steps: forming a clinical 
governance group (which included all key stake holders), to manage the implementation, 
and provide ongoing support; upgrading the software and disaster response backup; and 
the purchasing of new hardware, such as laptops and more user-friendly trolleys. The 
EMMS was re-installed after a two-year implementation program, with re-activation 
















Mild (ISR 4,5) Moderate (ISR 3) Severe (ISR 1,2)
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A weakness of natural experiments, such as this study, is the lack of control over the 
external and internal environmental factors that change over time. These changing factors 
could influence the number of incident reports. The location of this study helped account 
for such factors, and although not eliminating these, it may account for some bias.  The 
study hospital, an Australian tertiary teaching hospital, has 401 beds and was at capacity 
throughout the study period. The population that the hospital services have a high 
proportion of Indigenous patients (approximately 30% of the population), high birth rates, 
and a younger population than other Australian States and Territories. This remained 
consistent throughout the study period.  
Internal factors, such as bed numbers and patient acuity, shows stability across the study 
period (Table 6.1). The hospital provides a broad range of services in all speciality areas to 
the urban population as well as serving as a referral centre to the Top End of the Northern 
Territory (NT), Western Australia and South-East Asia.134 The number of presentations to 
the emergency department, and the separations from the hospitals, showed an increase 
over the four-year time period. The staff for the Northern Territory Department of Health 
also increased in number and the ratio of staff to hospital separations remains consistent. 
This suggests that staff had the same opportunities to report incidents across the time 
periods. Hospital bed numbers did not fluctuate and the hospital was at capacity with no 
changes to the types of presentations to the hospital, such as an external disaster, which 
could change the demographic. 
The time periods used in this study were selected to try to minimise the seasonal impacts 
on staffing and changes that occur at the study hospital from September to November 
when the ‘build up’ occurs. The trying climate often sees a turnover of staff during these 
later months and into the wet season. This leads to an increase in staffing pressures 
including staff shortages, training of new staff, and the need for locums. The Northern 
Territory has the largest population turnover of all Australian states. The transient 
population needs to be considered when trying to investigate the medical care which is 
able to be provided due to changing personnel, resources and skills. The months from 
February to September are the most stable period in the Royal Darwin Hospital for a 
number of reasons. In January new interns arrive, and this can lead to an increase in 
medication errors as they are learning to prescribe. January is also associated with a high 
intake of medical practitioners, nurses, pharmacists and allied health professionals, who 
have relocated to Darwin after Christmas. Beginning work at a new hospital requires a 
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training period for doctors, nursing staff and pharmacists to become accustomed to the 
hospital’s normal conduct and procedures.   
Two variables which did change were the numbers of computers and staff accessibility. 
With the implementation of EMMS, particularly in the second rollout (T3) the NT 
Department of Health increased the number of computers available to staff. As the risk 
reporting system was electronic, the accessibility to the risk reporting system would have 
been increased and the convenience of both the medication management system and the 
risk reporting system being electronic could have influenced incident reporting. This was 
one of our study questions. The rate of medicine incidents reported in the time periods with 
EMMS was significantly less, showing that the increase in number of computers did not 
change the rate of medicine incident reports due to greater opportunity and convenience 
for staff to report. 
Looking at reporter’s professions, nurses reported >80% of medicine incidents within the 
study period. Of note, nurses reported more frequently in the periods of EMMS (T1and 
T3), whereas pharmacists reported a significantly greater proportion whilst on the paper 
system (T2). The higher number of reports from nursing staff could be related to a culture 
of reporting within the nursing profession and/or also an indication of staff ratios (i.e. more 
nursing staff than medical and pharmacists). The large increase in reporting from 
pharmacists in T2 may be due to the frustrations of clerical work that is required from 
pharmacists on a paper-based system. For example, incident reports from pharmacists in 
this time period included illegible hand writing, prescriptions not being signed but still 
administered, and incomplete prescriptions such as slow release not being indicated.  
The limitations of non-mandated event reporting systems have been well documented. 
Incident reports are subject to selection bias due to their nature.343,344 Compared with 
medical record review, and direct observation, event reports capture only a fraction of 
errors and may not reliably identify serious events. There was little control over numbers of 
reported incidents, because reporting risk is non-mandated within the Australian 
healthcare system. This may have impacted on the power of this study to detect changes 
over time.  
However, non-mandated reporting reflects a real health system environment and is 
deemed as best practice both nationally and internationally.193,332 Previous studies have 
focused on prescription errors or administration errors independently to demonstrate the 
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benefits of an EMMS and do not provide an all-inclusive approach to the hospital 
setting.345,347 
The spectrum of reported events is limited, because most physicians do not utilise event 
reporting systems.343,351 Our study reflected the evidence base that the medical profession 
was the lowest to report, accounting for 3% of the medicine incidents reported in the study 
period.  
The lack of standardisation and classification of ISR levels in the database meant that 
severity scores needed to be re-classified by the lead researcher and verified by a panel 
this is consistent with other studies. 66,347,351,354 
Research has demonstrated351 that risk classification and risk identification is done at the 
highest standard when clinical records are reviewed. The majority of Australian hospitals, 
including the study hospital, now have medication management committees or risk review 
groups which govern medicine incident reporting.  
The severity of incident reports (ISR) has been grouped into three categories, ISR 1-2 
being severe, ISR 3 moderate and ISR 4-5 minor. A previous study has divided the risk 
reports into two groups, ISR 1-3 severe with 4-5 being moderate to minor.351 Our data 
shows that, if we divided our ratings for the same two groups, a change in severity over 
time as for the previous study would not be demonstrated.  
Medicine incident reporting is fundamental to address the overall aim of reducing medicine 
errors. However, reporting medicine incidents is wasted unless there is a well-designed, 
supported, clinical body responsible for analysis and response to these reports. To 
improve safety, incident reporting should be managed by a multidisciplinary team that can 
objectively determine the system-based causes of errors, and promote change that is 
supported by both internal governance and accrediting bodies.332 
What is the answer to our three study questions?  
The first question is: How does implementation and utilisation of EMMS influence the 
number of medicine incidents reported by doctors, pharmacists, and nurses? Our study 
indicates that incident reporting increased within a hospital setting when using paper-
based medication management systems compared to the periods when EMMS were in 
use. 
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The second question is: Does having medication management and risk reporting available 
on the same computer increase the number of incidents reported? This was not supported 
by our study results. Our results indicated that the number of medicine incidents reported 
decreased during the periods where clinicians were utilising EMMS. 
The third question is: Does the level of clinical risk associated with a medicine incident 
report change over time? The answer is that severity of incidents when utilising the 
independently reviewed data remained unchanged across both systems. 
6.2.5 Conclusion 
Medicine Incidents, and their reporting, is important in order to review the outcomes of 
incident reports, their use for changing practice, insight into gaps in medication 
management, and assuring patient safety. The use of EMMS changed the number of 
medicine incidents reported; however, there was no change in the severity of incidents 
reported in this study. A safe culture encourages risk reporting and the introduction of 
EMMS has changed this practice, and highlighted the need for education of staff as well as 
close clinical governance of analysing reports to identify system flaws and promote 
positive change. 
Acknowledgements 
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6.2.6 Translation to Practice 
The initial implementation of EMMS was commenced in 2004 as a staged roll out across 
wards. This was chosen so that training of staff and the system being built, tested and 
updated during the implementation would enable a smooth roll-out. This implementation 
was met with strong resistance from senior clinicians in the hospital. Due to pressure from 
staff, infrastructure deficits, such as network issues, software and hardware limitations, 
hospital executives, responding to a final petition from the Medical Advisory Committee, 
decided to withdraw EMMS and revert to a paper-based system in 2010.  
However, evidence was emerging for the benefits of EMMS, including its potential for 
decision-based support, the legibility of prescriptions, and a reduction in transcription 
errors, to name a few.347,351,355,356 The NT government had also made a significant 
investment, both in EMMS as well as the resources that sit alongside EMMS: however, the 
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actual monetary number has never been released. The reversion of the EMMS was 
always to be seen as a temporary measure until the ‘show stopping’ items were rectified.  
During the next implementation of EMMS, it was clear that the divide between the 
Software Company and clinical staff must be bridged for this project to be successful. 
Funding was granted to provide clinical leaders to drive this implementation by supporting 
their peers, and by translating issues between both the technical team and the hospital 
staff. The EPhR was employed as the Pharmacist clinical champion for this project. The 
clinical team consisted of a medical consultant, a senior registered nurse and senior 
clinical pharmacist (EPhR). Within this role the EPhR noticed the lack of local and national 
evidence, considering that the RDH was a primary hospital implementing an EMMS, and 
for staff it was a difficult decision to trust that an electronic system was safer. To improve 
resistance from staff, unconvinced that an EMMS could be a safer alternative to paper 
charts, it was important to gather evidence to demonstrate this safety. 
  
  
Alice Victoria Gilbert | 2016    P a g e  | 197 
 
6.3 Risk Reporting 
6.3.1 Background 
During the review of medicine incidents in section 6.2, and the available literature, it was 
clear that incident reports and their ratings were inconsistent. Incident reports and near 
misses determine how hospitals review systems and initiate change. Incident reports are 
given a severity rating by the reporter. It was clear from review that they varied greatly. 
The risk reported does not always reflect the assigned severity rating, which in turn will 
affect the allocation of review and prevention strategies implemented by hospital 
executives. As discussed above, incident reporting is the current system implemented 
within the healthcare area that helps to promote a culture of safety and the prevention of 
adverse events. As risk reporting is the mainstay of risk management for healthcare, the 
EPhR thought it vital to review the risk reporting ratings by clinicians, see Paper 6.  
6.3.2 Discussion and Translation to Practice 
Risk reporting within healthcare has improved with the development of education and 
system supports for hospitals to encourage clinicians to make risk reporting a part of the 
culture; to be seen as a duty of health professionals.  
The reporting of medication incidents should include all errors and mishaps involving 
medicines, breakdowns in systems, adverse drug events and near misses. Reporting 
medication incidents is not intended to identify or punish those involved in the incident, but 
to provide the opportunity for information to be collated about circumstances leading to 
these incidents which can then be used to inform risk minimisation strategies.  
Research has demonstrated that risk classification and risk identification is done at the 
highest standard when clinical records are reviewed. As numbers of reports increase, 
which of course should be encouraged, this becomes less practical and often leads to 
organisations making the decision to perform root cause analysis and risk reviews of 
incidents reported of ISR 1 and 2, hence the importance of accuracy in the rating.  
Clinical outcomes and follow up studies need to be performed to correlate the risk 
allocated and clinical outcomes of our patients. Education for clinicians who are entering 
incidents and policies dictating the need for panel reviews will become an important and 
necessary requirement for all healthcare organisations. 
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6.4 Evaluation of a Rapid Implementation Quality Improvement Program for 
Medicine Security 
The final study in this thesis is to improve medication safety and security. Medications 
within Australia are scheduled and should be stored and monitored in relation to their 
scheduling. This is a risk reduction strategy by the Australian Government to ensure high 
risk medicine is not readily available for misuse or abuse.357 One of the highest risk areas 
identified by the EPhR was the storage and accountability for high risk medicine within the 
Mental Health setting. This study is one example of a quality improvement activity which 
has improved medication safety and reduced risk to our patients. The final study in this 
thesis is also an example of medication management and moving a service in line with 
best practice. Working as the sole clinical pharmacist in the Mental Health service one of 
the first observed risk was the management of their high risk medicines, in particular, the 
benzodiazepines. This study utilises change management principles and reflects an 
example of a rapid implementation quality improvement approach by the Embedded 
Researcher.  
6.4.1 Background 
Certain Schedule 4 (prescription only) medicines are subject to further restriction of supply, 
distribution and possession, to reduce abuse, misuse & physical/psychological 
dependence. In Australia, these medicines are restricted schedule 4’s (S4R’s). Mental 
Health (MH) is recognised as a high risk for medication misadventure. The management of 
S4R's within MH at the study hospital was poor and rapid change was required to prevent 
harm. The management of S4R's did not comply with policy or best practice.239,240 The 
EPhR decided to conduct this change within a 24 hour period. Due to the risks involved, 
such as diversion of medication, as well as the confusion to staff by providing a staged roll 
out, the EPhR decided to implement and evaluate a rapid change management program to 
transition S4R medicines to move MH in line with best practice and policy. See Paper 7. 
6.4.2 Discussion and Translation to Practice 
The demonstration of compliance with policy and decrease in supply could indicate an 
improvement in patient care. Benzodiazepines are commonly prescribed and administered 
in the MH setting for sleep, anxiety and agitation.228,237 These results could indicate that 
non-pharmaceutical interventions, which are first line therapy for the above indications, are 
increasing in practice.228,237  
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The other benefit of this intervention is that it prevents the opportunity for diversion and 
misuse of these restricted medications. The decrease in supply of S4R’s was not related to 
change in patient numbers; patient numbers on the MH wards did not fluctuate during the 
study period.  
This study, however, does not look at changes in complexity and individual variability of 
the study patient population. It is expected that this would not account for the observed 
change. 
The low number of respondents to the survey (12) does not necessarily mean disinterest 
but could indicate satisfaction of busy health professionals.  This rapid implementation for 
best practice management of S4R's has demonstrated high uptake of policy and a 
decrease in supply, see Paper 7. 
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6.5 Conclusion of Chapter 6: Summary and Future Prospective 
Risk management is integral in providing Quality Use of Medicines for our patients. 
Reporting and monitoring incidents related to medicines is currently our best insight into 
where system improvements can be targeted and safety and quality improvement plans 
implemented.  
The value of having an Embedded Pharmacist Researcher in identifying risk, implementing 
practical and sustainable solutions, and evaluating their impact, is a true advantage to any 
organisation looking to move their medication management to best practice. Being 
embedded into the workplace, allows the researcher to have an understanding of culture, 
lines of communication and limitations which will all impact on the success or failure of any 
change management project.  
The management of Incident and Risk Reporting has moved in a positive direction. This 
can be attributed, in a lot of ways, to the implementation of the National Safety and Quality 
Healthcare standards for Accreditation. 
Reporting risk is aligned with multiple core criteria for healthcare agencies. Incident 
reporting and evaluating trends and system failures is the mainstay of identifying and 
minimising the chance of medication errors. 
Not long after the development of the Northern Territory Mental Health Safety and Quality 
Working Group, there was the formation of the TEHS Medication Safety Committee, of 
which the EPhR was the Mental Health representative. The Mental Health Safety and 
Quality Group reported back to the TEHS committee.  
Driven by Accreditation, the TEHS committee developed a Risk Register which included 
multiple areas of medication management that needed to be addressed. Along with this, 
was the process of presenting the medicine incidents reported each month, identifying 
trends, and forming smaller working groups to perform Root Cause Analysis and to 
provide recommendations back to the committee. Often a frustration by clinicians is the 
perceived lack of follow-up and feedback after an incident has been reported.343,344 This 
method enabled detailed feedback as well as evidence of recommendations being 
actioned. 
Another interesting piece of research would be to complete a follow-up study of patient 
outcomes after an incident report to see if it matches the incident severity rating 
designated by the reporter. Additionally, providing a training package for incident reporting 
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and standardisation across the acute healthcare system may lead to increasing incident 
reporting, which will help lead to safer systems. 
The next stage of Risk Management is to implement a sustainable working group to 
manage and review medicine incidents that occur and are reported in the community 
setting. Due to working within Mental Health, and acknowledging the unfortunate truth, that 
Mental Health patients are consistently in and out of hospital, the EPhR had the 
opportunity to uncover medicine incidents that have occurred whilst they have been 
managed in the community. This is a large gap in the evidence regarding medicine 
incident reporting within the literature. It is mainly captured by auditing retrospectively, 
rather than as ‘real time’ risk analysis. Risk reporting that would help to decrease medicine 
misadventures within our community healthcare setting is an evidence-practice gap and a 
future opportunity to be explored. 
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Chapter 7 Limitations in this Thesis 
This thesis has some shortcomings which reflect those which are reported in the literature 
and have been described in 1.8. In particular, the majority of this research has been 
conducted within the Northern Territory, and the application or replication within other 
organisations may be challenging. Aboriginal and Torres Strait Islander people are hugely 
diverse and they are not all represented in this thesis; therefore, it is difﬁcult to extrapolate 
ﬁndings to all Aboriginal and Torres Strait Islander people. There is also a lack of 
published literature regarding medication management in remote populations, as well as 
Indigenous perspectives regarding medication management systems which prevents 
comparison data or background information. 
As with most studies conducted with the Embedded Researcher method, there are 
limitations around generalisability of the initiatives presented. Furthermore the quality 
improvement strategies presented have all been conducted in a single health setting 
among relatively small clinician and patient numbers. It must be noted however that a key 
characteristic of being an Embedded Researcher is to know your organisation and culture, 
and therefore an Embedded Researcher can adapt and adopt the methodology to replicate 
the same work, with some tailoring to suit their individual work environments. 
A successful Embedded Researcher relies on their ability to be a part of the healthcare 
team, and this may not always be possible if the clinicians around you are unwilling to 
participate. The research presented within this thesis was conducted in the NT and the 
EPhR was welcomed to practice by this technique, collaborating with clinicians. This 
privilege may be a reflection of the NT culture and it may not be seen in all healthcare 
settings.  
Another shortcoming of this thesis, as with the Embedded Researcher approach itself, is 
the potential to incorporate bias. This can be particularly challenging when interpreting 
qualitative results from a study of which you have designed, developed and implemented. 
Ensuring that the results are a true thematic interpretation, and often having another 
researcher review the results independently can help reassure the credibility of the 
research. 
One follow-up study has been included in Chapter 5 and repeat audits have been 
presented in Chapter 4, however the ability to evaluate all interventions long term was 
beyond the scope of this thesis. 
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Potentially the biggest limitation of this thesis has been ensuring the balance of clinical 
work with research. I believe that clinical work and research are one and the same, of 
which I hope I have demonstrated throughout this thesis. In saying that, prioritising writing 
up the results and presenting the research findings broader than your local organisation 
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Chapter 8 Summary and Conclusions 
Outcomes for all interventions under taken within this thesis were successful. Within the 
thesis there were over twenty studies, all of which used the Embedded Pharmacist 
Researcher (EPhR) technique which practices reflexivity and allows interventions to be 
modified throughout the process of implementation and in evaluation, to ensure quality 
outcomes.  
Prior to the employment of the EPhR, there were high risk medication practices occurring 
within the Mental Health setting. The initial observation period completed by the EPhR 
identified significant evidence-practice gaps in the care of patients with mental illness. 
Evaluation of the medication management systems identified potentially dangerous 
practices that could result in patient harm. For example, stock piling of medication on the 
inpatient wards. The intervention outcomes and the practice change initiatives that have 
been sustained, as well as the large array of practice change initiatives translated into 
practice have been detailed within each project. Throughout each project the EPhR 
applied the Clinical Value Compass to target a multifaceted assessment of clinical 
outcomes, functionality of the service, patient satisfaction, and costs due to direct medical 
or indirect social expenditure.358 The quality improvement activities, that included a 
medication safety action plan as well as the accompanying audit schedule allowed each 
intervention to be monitored and continually improved. 
Key changes resulting from the EPhR’s work in the Mental Health setting ensured the 
service passed Australian Accreditation Standards by the identification of areas that 
needed improvement. A key initiative was the establishment of a Mental Health medication 
safety and quality working group, chaired by the EPhR. This enabled the correct level of 
governance required to support changes and allowed for stakeholder engagement. As a 
result of this initiative, medicines management in both the inpatient and community 
settings were changed to meet best practice standards and by doing so, improved the 
safety and accessibility to the required medicines, and reduced expenditure on medicines 
by the Mental Health setting with an ongoing annual savings of greater than $35 000.  
The design and implementation of a Community Mental Health Medication Chart provided 
a safe and legal document to prescribe and administer medicines within the community 
setting, as well as a tool to improve continuity of care. The likelihood for this chart to be 
adopted and used as a National Community Mental Health Medication Chart endorses the 
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necessity for development of this tool and acknowledges its applicability for use in multiple 
healthcare settings.  
Funding and implementation of an independent, non-biased patient resource for Mental 
Health medication information filled an important gap by providing patients with up-to-date 
and reliable medicines information.  
Evaluation of the impact of pharmaceutical company representatives influence on 
prescribing practices also encouraged the opportunity for the EPhR to provide more 
education sessions to the prescribers and nursing staff within the Mental Health service, 
which in turn allowed for greater adherence to evidence-based practices. 
A rapid implementation project to change the management of high risk medicines during 
the process of accreditation ensured the service successfully met the required national 
standards.  
Finally, all projects were used to build and develop a pharmacy team for the Mental Health 
service. By demonstrating the positive outcomes resulting from the EPhR’s research, a 
pharmacist for the Central Australian Mental Health Service, a ward based clinical 
pharmacist for the Top End Mental Health Service, and two pharmacy technicians have 
subsequently been employed. This is of particular significance as the government had 
placed a freeze, due to a cap on financial expenditure, on any new positions during this 
time period. The implementation of this team has enabled the contribution of a pharmacist 
to have an impact across the entire Mental Health service and has ensured that the 
Quality Use of Medicine principles are applied across both sectors of the healthcare 
setting. 
Medication errors are high when patients are transferred between healthcare settings. The 
introduction of a Medicines Information Transfer Fax (MITF) improved the quality of 
medicines information provided to healthcare professionals at the next point of care. This 
initiative, conducted over a seven-year period, has demonstrated sustainability. This tool is 
now a part of everyday practice for the hospital pharmacists of the Northern Territory. The 
end user survey demonstrates the need and support for this tool to continue. The next 
stage is trialling an electronic version of the tool which will be commenced in 2017. 
Finally to address the area of risk management, the Embedded Pharmacist Researcher 
has been able to provide further evidence to support the use of an Electronic Medication 
Management System in the hospital setting. While focusing on incident reporting by clinical 
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staff the EPhR’s research has uncovered multiple areas to target for education and 
evaluation of clinical risk.  
Chapter 9 Future Directions 
This thesis aims to help endorse pharmacists, as healthcare professionals and leaders 
within healthcare organisations in the field of medication management. 
All research was conducted using the Embedded Researcher Approach, and targeted 
areas, which were identified during clinical work as a translation gap between literature 
and practice. 
The studies presented throughout this thesis examine all aspects of the medication 
management cycle. See figure 8.1. 
 
Figure 8.1: Medication Management Cycle from Guiding Principles To Achieve Continuity in 
Medication Management101  
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Much of the research included within this thesis has been based in the Mental Health care 
setting. There are still many challenges within the provision of medication management for 
patients with mental illness and still much to explore in terms of improving patient care in 
this setting, as well as those in other countries.  
The exploration of the mental illness within the Australian Indigenous population, as well 
as the medication management within this population, requires priority for future research 
to help improve health outcomes. The Quality Use of Medicine principles, which are 
achieved with support of a pharmacist, needs to be examined, refined and implemented 
within the remote healthcare settings. Ongoing funding as well as professional 
socialisation needs to occur to train and mentor pharmacists to work remotely. Embedded 
Research is a best fit for conducting Quality Use of Medicines activities within remote 
settings as it provides the opportunity to build trusting, two-way relationships with 
Indigenous patients. As stated in the QUM principles this ensures that all stakeholders, 
which include; policy writers, funders, doctors, nurses, pharmacists, allied healthcare, 
patients and the community, are involved in decision making to enable safe and effective 
use of medicines. Due to the relatively isolated environment within remote healthcare, 
sustainable systems must be implemented, and peer support provided, for the successful 
integration of pharmacists into this field.  
A further advantage of the EPhR’s position was that it spanned both inpatient and 
community care for patients with mental illness. More pharmacist positions working across 
both sectors of healthcare should be explored as there are many potential advantages in 
providing clinical pharmacist services across the continuum. 
This thesis presents assessments of aspects of prescribing practices, medication 
management, electronic medication management, medication safety and quality, 
medicines information and patient outcomes. This indicates the abundance of research 
opportunities available for EPhR’s within a practice-based setting. Providing these studies 
demonstrates how an EPhR can develop research questions from clinical practice, 
conduct appropriate evaluations using scientific methodology, and put forward a 
translation of the results to practice development. 
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Additional research that the author suggests which could be conducted beyond this thesis 
includes; 
• Exploring the role of mental illness in health-related behaviours within the 
Indigenous Population 
• Exploring the opportunity to close the gap between Indigenous Mental Health and 
non-Indigenous Mental Health 
• Improving the integration of Traditional Healers into western healthcare settings, 
such as hospitals, and acknowledging Traditional Healers as health professionals 
• Improving the training provided to other healthcare professionals to understand and 
acknowledge the role of traditional healers for Indigenous patients 
• Development of culturally specific diagnostic and treatment tools for Mental Illness 
for Indigenous patients 
• Development of culturally specific medicines information, with a focus on health 
literacy 
• The inclusion of pictures of medicine on Consumer Medicines Information to 
determine if it improves patient’s understanding and compliance 
• Integration of pharmacists into the remote healthcare settings 
• Translation and evaluation of the Quality Use of Medicines principles to remote 
healthcare settings 
• Improve transition of care for our patients moving from hospitals to remote locations 
• Evaluation of medication stability and efficacy in remote storage conditions 
• Examination of medication choice due to environmental conditions, e.g. when 
prescribing mood stabilisers, is Valproate (hygroscopic medicine) appropriate in a 
tropical environment versus lithium, where there is a potential for dehydration and 
subsequent toxicity, in a dry desert environment  
• The monitoring and evaluation of general medicines within the mental health setting 
(e.g. warfarin monitoring or insulin) to prevent deterioration of co-morbidities while 
treating mental illness 
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• Consumer support groups for Indigenous patients and carers with Mental Health, an 
evaluation of what is available and if it is effective 
• Impact of pharmaceutical companies on hospital prescribing practices 
• Impact of pharmaceutical companies on hospital formularies 
Further research which could follow-on to ensure the continual development and 
modification of the MITF; 
• Evaluation of pharmacists providing the MITF via a secure electronic email 
• Tailor the MITF to make it appropriate for patients to also receive a copy (Review 
the language included) 
• Assessment of the uptake of the recommendations made by pharmacists within the 
MITF 
• Community pharmacist/GP’s to provide a MITF on admission to hospital pharmacist 
to help provide accurate medication histories and reconciliation 
• Examine if having the MITF available for prescribers at preparing a hospital 
discharge summary improves their accuracy 
• Incorporate the MITF into pharmacist key performance indicators to continually 
evaluate their use and standard 
• Development and implementation of a multidisciplinary discharge summary, with 
the medicines information prepared by a pharmacist 
• Determine if the MITF or a multidisciplinary discharge summary prevents hospital 
readmissions 
Additional research to identify and address remaining areas of risk that could be 
undertaken by an Embedded Researcher includes; 
• Provide a risk assessment tool for common hospital procedures and tasks 
• Evaluation of new risks on patient outcomes that have been introduced due to 
Electronic Medication Management Systems 
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• Improving incident reporting by automatically populating risk forms from electronic 
prescribing (e.g. missed doses) 
• Improving the medication history, reconciliation and medication action plans within 
Electronic Medication Management Systems 
• Assessment of pharmacist roles associated with Electronic Medication 
Management Systems 
• Providing ongoing reviews of the incident reporting risk severity rating and patient 
outcomes 
• Improving the training and outcome learnings for staff from risk reporting 
• Targeting cluster areas of risk from risk reporting software with system based 
changes 
• Development of self-managed risk reporting for patients, e.g. what risks do they 
identify in healthcare or medication management  
There are significant opportunities for pharmacists to practice using the Embedded 
Researcher technique. The examples used throughout this thesis show beneficial impacts 
on all areas of the clinical health compass. The benefits of defining research questions, 
implementation and evaluation, whilst being a part of the clinical team, are plentiful. Not 
only are limitations apparent, prior to beginning an implementation project, but so too are 
the potential drivers of change which can be used to the researcher’s advantage. The 
understanding of how systems have developed, of culture and of communication methods, 
cannot be underestimated for their capacity to impact on the success of interventions. 
Being part of the team to determine sustainability, and to offer flexibility to best fit a 
service, will encourage engagement from stakeholders as well as provide a group of allies 
who can be called on for future projects. From an Embedded Researcher’s point of view 
there is nothing more satisfying than remembering the challenges of implementing change 
and to witness the benefits of positive outcomes to all involved in patient care. To realise 
that a change has been incorporated into practice, enables the challenges of change 
management to be met with optimism and encouragement. 
The barrier mentioned most often by pharmacists as preventing the incorporation of 
research into their practice, is a lack of time or prioritising their immediate, core daily 
  
Alice Victoria Gilbert | 2016    P a g e  | 211 
 
clinical activities. Chapter 4, should encourage those who are uncertain that, by prioritising 
research, there can be more opportunities to provide core clinical duties and that research 
should not be seen as a luxury for those with time, but rather a necessity for those who are 
time poor. Pharmacists must grasp opportunities to demonstrate ways to apply their 
clinical knowledge and their expertise in medicines. Integration into clinical teams, 
embedding research into practice, and recognising gaps between evidence and practice, 
are all exciting and rewarding areas in which pharmacists can work. 
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Paper 1: Medication Safety Issues From Within Hospital Distribution of Medicines 
Gilbert AV and Gilbert AL. Poster presentation provided at the 29th International 
Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 25-28, 
2013, Montreal, Canada.  
Medicine Safety Issues from within Hospital Distribution of Medicines. Abstract published: 
Pharmacoepidemiology and Drug Safety Journal: Volume 22, Issue Supplement 
S1, pages 467-8, September 2013. 
 
ABSTRACT 
Background: Medicine safety is a priority for governments.198 In Australian hospitals the 
distribution to, and storage of, selected regularly required medicines speciﬁc to each ward 
(imprest), is a common practice. Nurses administer these medicines based on information 
in the patients medicines chart. It is a high risk area for medication 
misadventure.207,208,210,211 
Objectives were to;  
1. determine the safety of the imprest system in two acute psychiatric wards (32 beds)  
in a 415 bed Australian tertiary hospital and 
2. implement necessary changes to the imprest system. 
Methods: A Drug Utilisation Review (DUR) was conducted on the imprest systems in the 
two wards.  
Seven key requirements of Society of Hospital Pharmacists of Australia’s (SHPA) 
Distribution of Medications Guidelines197 were used as the gold standard.  
These requirements stipulate that a healthcare facility should: 
1. Provide medicines in a timely manner to patients as they are needed; 
2. Carry the lowest possible medication error rate system (i.e. be the safest system) 
for the resources available; 
  
Alice Victoria Gilbert | 2016    P a g e  | 214 
 
3. Minimise the cost of medicines stored throughout the facility; 
4. Minimise wastage; 
5. Minimise opportunities for medicines diversion; 
6. Provide data on medicines utilisation, preferably to the level of the individual patient; 
and 
7. Identify unusual medicines usage patterns. 
Results were discussed with ward staff and the mental health team.  
Appropriate changes to the current system were implemented. 
 
Picture 1: Imprest prior to DUR 
Results 
1. Provide access to medicines in a timely manner to patients as they are needed: 
DUR - 141 imprest unique medicines were approved for use in these wards; the review 
found 240 unique medicines available for use.  
Non-imprest stock was being added ‘ad-hoc’ into the imprest cupboard. Medicines were 
procured through incorrect pathways and remained on the ward for use due to poor stock 
management. (See picture 1 & 2) Commonly requested had not been available or added 
and medications which were no longer first line had not been removed.  
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Picture 2: Imprest prior to DUR 
Implementation: Usage and stock levels have now been reviewed and updated to reflect 
Northern Territory Health Services (NTMHS) needs and first line therapies.(Picture 3) 
 
Picture 3: Imprest Post DUR 
2. Lowest possible medication error rate system; High potential for medication error 
due to using a disorganised and non-uniform imprest system used for administration of a 
medication to a patient. The imprest had no logical order, such as dose form (i.e. injections 
then tablets), alphabetical or using generic names of medications (picture 4 & 5). This 
increased the chance of medication errors by nursing staff selecting incorrect medications, 
was time consuming for new staff trying to locate a particular medication and prevented 
consistent training of new staff around medication storage and procurement. 
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High risk medication practices were also identified; e.g. incorrect stocking of imprest and 
using patient’s own medications of which the integrity could not be verified. (See picture 4 
& 5) 
  
Picture 4 and 5: High Risk Practices 
Implementation: Both wards required immediate action due to the high risk associated 
with medication storage and dispensing. Best practice, individual patient- based 
medication systems have demonstrated decreased administration errors compared with 
imprest systems (5% error rate vs. 17% error rate). Although it is more labour intensive, it 
is an important patient safety initiative. Using individual patient storage is also useful for 
patients transferring between wards. (Picture 6) 
 
Picture 6: Patient Specific Medicines 
3-5. Minimising cost, wastage and diversion: Large cost to the service due to 
medications not being returned when appropriate: 
• 171 different medications (4713 units) were suitable for return –which were re-
credited to the service $A6 060.87.  
• Wastage due to medications not being returned before expiry dates: (46 different 
medications (855 units) were expired – total cost $A1 347.70. All of these expired 
medications would have been suitable for return and re-use.  
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• Patients own medicines not returned at discharge - 110 different patients’ own 
medications (1555 units) where still on the ward for patients who had been 
discharged – total potential cost to patient and service $A2 649. 06. (Picture 7) 
•  
• Picture 7: Unreturned patients’ own medicine 
• Implementation: A process for “returns” has now been implemented, requiring that 
it is done on a weekly basis  
• Total cost of medicines suitable for return, expired stock and patients own 
medicines; $A10 058. 
• 6 & 7. Provide data on medicines utilisation, preferably to the level of the 
individual patient; and identify unusual medicines usage patterns:  Current 
practice meant that supply and integrity of medications could not be verified, 
including the use of patients’ own medications, and the stockpiling prevented any 
individual patient or prescribing habits to be identified. 
Implementation:  
• Recommended that this DUR is performed bi-annually. 
• The amount of each medication stored has been adjusted to the minimum quantity 
required.  
• The reviewed list and recommended additions and deletions were circulated 
electronically to NTMHS prescribers and nursing managers for comment. 
Conclusion 
Regular ward specific DURs of hospitals’ imprest systems, and pharmacist input, is 
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Paper 2: Clinical Pharmacists help prescribers and patients make informed 
decisions 
Gilbert AV. Clinical pharmacists help prescribers and patients make informed decisions. 
BMJ. 2015; 350: h20960 doi: 10.1136/bmj.h2960 
 
Response to original article: McCartney, M. Margaret McCartney: Forever indebted to 
pharma—doctors must take control of our own education. BMJ, 2015. 350: p. h1965. 
Thank you, Dr McCartney, for acknowledging that the sweet temptations gifted with 
education by the pharmaceutical companies are never ‘free’.  I work in a tertiary teaching 
hospital, in psychiatry. The pathology of disease and mechanism of actions of many 
medicines in psychiatry are still unknown. This can further inflate the wonders of new 
medicines. An example I would like to share is the recent addition of Aripiprazole Long-
Acting Injection (ALAI) (Abilify Maintana®) to our Pharmaceutical Benefits Scheme (PBS) 
in Australia.  A pharmaceutical company representative (rep) was given an opportunity to 
educate the prescribers on this medicine at the weekly medical meeting at my hospital. 
The rep was kind enough to provide lunch. Her opening statement of ‘I’m not here to sell 
anything, I am just here to present the facts’ led into a presentation of specifically chosen 
pieces of data, whilst omitting to complete the picture, which would help prescribers be 
guided by evidence to understand ALAI place in therapy.  Her key points (as the drug rep) 
were: 
• That aripiprazole has been available for years as the oral form and is ‘unique’  
• Side-effects which antipsychotics commonly cause but ALAI did not, such ALAI 
being weight neutral (suggesting no weight gain) and ‘no-effect’ on QTc 
intervals which can precipitate cardiac events   
• And suggestion that failure to respond to ALAI is likely to be due to a sub-
therapeutic oral coverage during initiation   
The director of psychiatry allowed me to have 5 minutes at the end of the presentation to 
clarify the evidence-based for ALAI place in therapy and local implications. I tried to ensure 
the ‘take home’ messages for the prescribers in my area, were not negative but a 
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balanced informed view of ALAI, mindful of the drug rep being present to listen to my 
advice. My key points (as a clinical pharmacist):  
• Currently no head-to-head trials to compare ALAI to other antipsychotic long 
acting injection. Hence, suggestions regarding the use of one long-acting 
injection over another cannot be readily made263  
• Although aripiprazole has a different side-effect profile, it is not immune to side 
effects and is still considered a second generation antipsychotic. The main 
reported side-effects from the clinical trials have been akathesia/restlessness 
and insomnia.264 These are important to note particularly in unwell patients, 
prescribers often expect sedation to occur with the initiation of an antipsychotic. 
With the use of aripiprazole this will not be the case and may lead to a 
prescribing cascade to facilitate sleep. Changes to QTc can occur and has with 
the oral form as a Treatment Emergent Adverse Event and is listed within the 
product information (PI)267, metabolic monitoring (which includes weight 
changes and cardiac) needs to be a priority for all patients treated with 
antipsychotics to ensure we are not causing harm 
• Aripiprazole is only listed on the PBS for schizophrenia. As antipsychotics can 
be indicated for other psychiatric conditions, such as bipolar disorders, if it is not 
approved for those indications on the PBS it will have a large financial impact to 
our patients increasing cost of treatment from $6.90 per month (if they are a 
concession card holder) to $399.95 plus dispensing fees.93  
• Within Australia the PI recommends that treatment with oral aripiprazole, or 
other oral antipsychotics, should be continued for 14 consecutive days to 
maintain therapeutic antipsychotic levels during initiation.267 Other countries, 
where ALAI is licenced, have specified aripiprazole oral to be used which 
clinically ensures patients are showing a response, but also prevents the use of 
multiple antipsychotics, especially if the oral is also being used for its sedating 
properties. The main studies showing non-inferiority data are for patients 
stabilised first on oral aripiprazole, meaning they have responded to the 
therapeutic agent prior to trialling the Long-acting form.269 
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ALAI is currently not on our hospital formulary, this means that it has not yet gone through 
our local drugs and therapeutics committee which is again a chance for independent 
review and also addressing the cost: benefit for our patients. It also means that ALAI is not 
currently stocked at the hospital and therefore a delay may be expected in treatment until it 
is sourced, this leads to increasing costs of prolonged admissions.  The pharmaceutical 
rep added her input throughout my summary as a ‘right of reply’ such as ‘there is a head to 
head trial against another antipsychotic’ and that ‘another hospital in Australia is also 
awaiting formulary approval but they have been keeping a “stash of stock” so there is no 
delay when it is required.’ Again, blurring the lines for prescribers and when questioned 
about the head to head trial, we discovered it has not yet been published, leading to 
questions of the quality, the results and if the research had been peer reviewed. 
Disregarding the drugs and therapeutics committee’s process encourages prescribers to 
work around our hospital policies and prohibits the quality use of medicines principles. The 
constant denial by prescribers of being influenced by pharmaceutical reps and their ability 
to ‘see-through’ the biased information has been held under a magnifying glass in my 
organisation.  Exactly one week after the representative’s presentation the psychiatric 
ward which currently has 25 admitted patients, had 10 patients prescribed oral 
aripiprazole. Seven of these have transitioned to the long-acting injection form. Of the 
remaining 15 patients 7 were admitted for mood disorders (such as suicidal ideation) and 
therefore aripiprazole is not indicated.  I am not anti-aripiprazole by any means and it is 
good to have another option for our patients, however I do have a duty of care as a 
pharmacist to help promote quality use of medicines and evidence-based practices. The 
change needs to occur from doctors, such as Dr McCartney, promoting the importance of 
independent information. Above all the change needs to be by the policy makers. The 
government needs to support education such as the National Prescribing Service, and 
allow time for clinical pharmacists to do what they do best, help prescribers and patients 
make informed decisions about medicines.  
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Paper 3: Providing Community-Based Health Practitioners with Timely and Accurate 
Discharge Medicines Information. 
Gilbert AV, Patel B, Morrow M, Williams DB, Roberts MS, Gilbert AL. Providing 
Community-Based Health Practitioners with Timely and Accurate Discharge Medicines 




Accurate and timely information on medication management along the continuum of care 
is essential to achieving best outcomes for patients and for avoiding harm.234,250,292,359 
Approximately 3% of hospital admissions occur due to medication-related problems.207 
Often these problems are due to miscommunication regarding the 
continuation/discontinuation of medications on hospital discharge.207 The interface 
between hospital and the community care is a high risk area for medication 
misadventure.207,291,311 
The Australian Pharmaceutical Advisory Council (APAC), a Federal Government 
appointed, multidisciplinary council, has attempted to address these issues by preparing 
Guiding Principles for Achieving the Continuum of Medication Management.101 The 
Guiding Principles state that “Health service managers and healthcare professionals are 
jointly and individually accountable for making sure that activities to support the continuity 
of medication management are implemented.” (101, page 17). The Guiding Principles also 
reinforce the responsibility of health professionals to work in partnership with patients in all 
aspects of medication management.101 Similarly, the Society of Hospital Pharmacists of 
Australia’s (SHPA) Standards of Practice for the provision of medication reconciliation 
require that “when a patient is transferred to another episode of care the transferring 
health professional should supply comprehensive, complete and accurate information to 
the healthcare provider responsible for continuing the consumer’s medication 
management.” (230, page 2). Continuity of care between hospitals and the community 
sector is a key element in Australia’s Healthcare Reforms360, and the Federal Government 
has provided extra funding for hospitals conditional on implementation of the Guiding 
Principles. 
  
Alice Victoria Gilbert | 2016    P a g e  | 222 
 
The need for high quality clinical handover is exaggerated in the Northern Territory (NT) of 
Australia. It covers a large geographic area and it has a relatively small, transient, widely 
distributed and remote population (n = 225 900): 30% of the NT population is Aboriginal 
and Torres Strait Islanders (ATSI)7F§§. The life expectancy for male ATSI is 61.5 years, 17 
years less than non-Indigenous males, and for female ATSI 69.2 years, 13 years less than 
non-Indigenous females. The median age at death of ATSI males is 50 years.361 Many 
issues, including low health literacy, differing cultural beliefs about health and illness, 
access to health services and availability of health professionals limit people’s ability to 
access and navigate their way through the complex health system.108 The majority of 
health services are accessed through health centres based in remote communities. The 
case mix at the study hospital differs from other large Australian hospitals; patients are 
younger and presentations for trauma and severe sepsis are higher. The Emergency 
Department sees approximately 60 000 patients per year, ATSI account for 30% of 
attendance and 50% of admissions. It should be noted that in this study, patients at high 
risk of medication misadventure were selected. Nearly half of those selected were ATSI 
and their average age was 58 years; 15 years younger than the rest of the study cohort 
(See Table 1). 
  
                                                          
§§ Torres Strait Islanders are the Indigenous people of the Torres Strait Islands, which are a part of Australia. 
They are culturally and genetically linked to Melanesian and Papua New Guinea peoples, and are regarded 
as being distinct from other Aboriginal peoples from the rest of Australia. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 223 
 
Table 1: Patient Characteristics 
 Aboriginal and 
Torres strait 
islanders (n = 37) 
Non-Aboriginal and 
Torres strait islanders 
(n = 43) 
All patients (n = 80) 
Mean age (years), (Range) 58 (33–78) 73 (29–97) 66.1 (29–97) 
Gender (Female), n (%) 16 (43%) 19 (44%) 17.6 (43.5%) 
Mean number of Medical Conditions 
(range) 
7.4 (3-18) 7.3 (2-12) 7.3 (2-18) 
Mean number of medication on discharge  
(range) 
8.6 (3-16) 9.4 (3–23) 9.1 (3–23) 
Mean number of changes on Discharge 
(range) 
3 (0–8) 4 (1-13) 3.5 (0–13) 
 
The current discharge procedure at the study hospital requires an intern or registered 
medical officer to complete an electronic Hospital Discharge Summary (HDS). The HDS 
contains a section documenting changes to medications and provides a list of discharge 
and continuing medicines. The hospital provides the HDS to the patient’s general medical 
practitioner (GP), aged-care facilities, remote area clinics, or the patient once the HDS has 
been completed. 
Evidence indicates that a patient in an urban area will visit their pharmacy within 10 days 
and their doctor 30 days after discharge.305 While most GPs are provided with a discharge 
summary, community pharmacists are rarely provided with this information and patients 
are not encouraged to notify their community-based practitioners of recent hospitalisations 
and changes to their medicines.305 In this study, the MITF was delivered to medical 
practitioners, community pharmacists and remote area clinic staff. 
Clinical pharmacists from the study hospital had reported frequent contacts from 
community-based practitioners seeking clarification of the medicines information provided 
in the HDS. They also identified that the length of time for the provision of the HDS to the 
patient’s community-based practitioners was outside of hospital guidelines of 48 hours. In 
response to this information, pharmacists at the study hospital developed a Medicines 
Information Transfer Fax (MITF). 
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Aim 
This study compares the number and clinical significance of medication errors and 
omissions in, and the timeliness of delivery of, discharge medicines information provided 
to community-based health professionals in the existing Hospital Discharge Summary 
(HDS) and the Medicines Information Transfer Fax (MITF). 
Method 
The study was conducted using a convenience sample of 80 MITF’s prepared for patients 
at high risk of medication misadventure during a four month period June 2009 – October 
2009. At the time the study was conducted there were 9 clinical pharmacists employed in 
the hospital and 1000 discharges/week. The clinical pharmacists selected patients for 
whom they developed a MITF based on their assessment of those most at risk of 
medication misadventure post discharge. On average 30 MITFs were completed each 
week. The project team did not have had access to all MITF’s and DPs completed within 
the study period because of filing systems adopted by individual pharmacists; for example, 
some filed their MITF’s on a monthly basis, and the hospital, for example storing DP off-
site as part of their record archiving process. The sample of 80 represented 20% of 
available MIFTs and was considered sufficient to identify significant differences, if they 
existed, between the current HDS and the MITF. 
High risk patients were defined as; those taking multiple medications, those who had 
medication changes during admission, those suspected of poor adherence, those taking 
high risk or complex medications and those with multiple medical conditions. They had a 
medication history and reconciliation conducted for the admission and at the point of 
discharge as part of standard care. The reconciled Discharge Prescription (DP) was used 
to complete a MITF which also included a complete list of discharge medications and 
provided information on any medication-related changes that occurred during the 
admission. MITFs were faxed to the patient’s GP or Remote Medical Officer and 
community pharmacist at the time of the patients discharge. The date of sending the MITF 
was recorded on the faxed document and filed in the pharmacy department. The aim was 
to have the MITF delivered to the patient’s community-based practitioners within 48 hours 
of discharge. The time to delivery of the HDS was calculated using the study hospital’s 
admission and discharge software. 
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Two members of the project team audited the MITF against the gold standard, the DP. The 
DP was considered gold standard as it had been reconciled by a clinical pharmacist as 
part of the routine hospital medicines reconciliation process. Medicines information 
contained in the HDS was compared with that in the validated MITF. Medication errors in 
the HDS were categorised into five classes; wrong dose, wrong medication, wrong 
strength, wrong dose frequency or wrong dose form. Omissions were also documented 
(Figure 1: Audit flow chart). 
Medication errors and omissions identified in the audits were reviewed for their clinical 
significance by a panel of three senior clinical pharmacists. Panel members were blinded 
to the patient’s name and the name of the pharmacist who had prepared the MITF. Clinical 
significance was determined from information on the patient’s health status and the 
accuracy and quality of information provided at discharge. Prior to the review advice was 
sought by the panel from the hospital’s liaison GP to gain insight into how a community-
based prescriber would interpret the medication information. For example, if medications 
were omitted from the HDS, the advice given to the panel was that a medical practitioner 
would interpret this as there being no change to current medication and would continue the 
patient’s pre-hospitalisation medicines, unless deemed clinically inappropriate. Each panel 
member rated the clinical significance of each error or omission independently using the 
“consequence or impact scale” of the SHPA assessment of intervention tool.176 The five 
point Likert scale ranged from 1 (insignificant), 2 (minor), 3 (moderate), 4 (major) to 5 
(catastrophic). The overall agreement between the three assessors was measured using 
the Kappa statistic.362 
Results 
Of the 80 patients whose MITFs were selected for this study, three patients’ did not have a 
DPs available for comparison. Of the 77 MITFs with DPs available: 6 (8%) MITFs had 
errors; four errors were rated by the clinical panel as “insignificant to minor” and two errors 
were viewed as “minor to moderate”. 
A completed HDS was available for 61 (79%) of the 80 patients within the audit time 
frame; these were compared with the validated MITFs. Seven of the 61 (11%) HDS’s were 
consistent with the MITF; 149 medication omissions and 100 errors were identified in the 
remaining 54 HDS’s. An omission occurred when a medication appeared on the discharge 
prescription but was not documented in the HDS. Errors were categorised into five 
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classes; wrong dose (29, 29%), wrong medication (23, 23%), wrong strength (20, 20%), 
wrong dose frequency (19, 19%) or wrong dose form (9, 9%). The clinical panel members 
independently rated the clinical significance for the 70 patients who had errors or 
omissions in their HDS’s or had no HDS completed. Based on advice from the hospital’s 
liaison GP, patients with no HDS completed were reviewed for their clinical risk associated 
with no information being provided at handover. 
Figure 1: Audit flow chart 
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Of the 70 reviews; for 17 (24%) patient’s the clinical significance was “insignificant to 
minor”; 23 (33%) “minor to moderate”; 24 (34%) “moderate to major” and 6 (9%) were 
“major to catastrophic” (See Table 2). 






84 year old non-Indigenous male discharged after treatment for community 
acquired pneumonia.    Past medical history includes; fractured neck of 
femur, urinary incontinence, chronic cardiac failure, atrial fibrillation, and 
gastro oesophageal reflux disease. Changes to medication during admission 
included commencing digoxin, and ceasing Bisoprolol, spironolactone, and 
ramipril. 
Pharmacist had incorrect dosing for omeprazole on MITF. Omeprazole 40 mg 
nocte on discharge prescription and   20 mg BD in the MITF all other 




75 year old Indigenous male discharged after being admitted for shortness 
of breath due to worsening chronic cardiac failure. Past medical history 
includes; chronic obstructive airways disease (current smoker), atrial 
fibrillation, chronic cardiac failure, myocardial infarction and hypertension. 
During admission frusemide was increased from 40 mg mane to 60 mg mane. 
All medications were omitted in the HDS, therefore from advice from the 
hospital’s liaison GP assumed all medications and doses were continued. 
Primary healthcare professional would not be aware of increase in frusemide 




55 year old non-Indigenous male discharged post an episode of chest pain on 
the back ground of high risk cardiac disease. Past medical history includes; 
ST segment elevation myocardial infarction, severe arterial stenosis 
(ischaemic heart disease), asthma, and transient ischaemic attack. Patient 
was discharged after an increase in nicorandil from 5 mg BD to 10 mg BD 
and an increase in Isosorbide mononitrate from 60 mg mane to 90 mg. 
This patient did not have HDS completed. Therefore is a moderate risk that 
this patient will be re-admitted due to reverting back to original dosing and 
increasing angina attacks. Also risk of confusion of medications to patient. 
Major to 
catastrophic 
37 year old Indigenous female discharged with osteomyelitis. Past medical 
history of end stage renal  disease (on dialysis), chronic intermittent vomiting 
since starting dialysis which has been fully investigated, type 2 diabetes, 
hypertension, dyslipidaemia, and a previous right toe amputation with residual 
osteomyelitis. 
During admission diabetic control was reviewed and changed by increasing 
insulin dose from 10 units nocte to 14 units nocte and metformin XR 500 mg 
mane was ceased.  
Osteomyelitis treatment was changed by ceasing Trimethoprim/ 
Sulphamethoxazole 160/800 mg BD and folic acid 5 mg and commencing on 
Doxycycline 100 mg mane and ciprofloxacin 500 mg nocte for lifelong 
treatment. 
Metformin XR 500 mg was included in HDS (it had been ceased during 
admission) with new dose of insulin correct, therefore putting patient at risk of 
hypoglycaemia. 
Doxycycline and ciprofloxacin had been omitted from HDS therefore primary 
healthcare provider would not be aware of change to antibiotic regime. High 
risk of further amputations and losing foot due to osteomyelitis infection. 
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Analysis of the individual panel member’s ratings of clinical significance indicated a 
satisfactory level of interrater agreement (Kappa for overall agreement = 0.7). 
The HDS was dispatched to 28 (35%) patient’s healthcare providers within the study 
hospital’s guideline of 48 hours; 38 (47%) were sent within seven days and 55 (69%) were 
sent within 30 days: 25 (31%) HDS’s had not been dispatched after 30 days post 
discharge. All MITFs were dispatched within 48 hours post-discharge. 
Discussion 
Despite national guidelines, extensive research, the availability of funding for more 
pharmacists to implement the APAC guiding principles for the continuum of care and 
professional practice standards related to clinical handover, medication management 
along the continuum of care is still problematic. This audit of the current discharge process 
has found significant issues in terms of the accuracy, quality and timeliness of delivery of 
the HDS to community-based practitioners responsible for the next episode of care. 
Studies from Europe, North America and New Zealand have produced similar 
results.234,250,292,359 
Our analysis of the clinical significance of medication errors or omissions in the HDS, 
based on information on the patient’s health status, and the accuracy and quality of 
information provided at discharge revealed significant risks to patient’s well-being. An 
alarming 43% of medication errors or omissions discovered in our review on 80 HDS were 
rated as moderate to catastrophic. 
While our findings are also consistent with previous Australian studies207,246,311, the context 
in which these errors and omissions occur adds extra cause for concern. Nearly 50% of 
patients in this audit were Aboriginal or Torres Strait Islanders (ATSI) and clinical handover 
was often to remote area health services. The lack of a discharge summary, or errors and 
omissions in the discharge medicines information provided, may be even more significant 
because of poorer health status, low health literacy and the low access to medical 
practitioners and community pharmacy services.108,363,364 Many adult ATSI patients have 
multiple chronic health problems at a much younger age than non-Indigenous people. 
Over 35% will have diabetes, often coupled with other chronic conditions such as mental 
health problems, arthritis and cardiovascular disease.361,365 Medicines management is 
consequently complex, with multiple medications in use. 
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The study hospital’s current policy for discharging patients with only 7 days of medications, 
with an option of an increased supply for patients returning to a remote community, may 
exacerbate many of the problems identified in this audit. This may have significant health 
consequences, when people with multiple chronic health problems visit their community 
pharmacist, health clinic or medical practitioner, if accurate information on medication 
changes associated with the hospitalisation are not available within this timeframe. 
Findings of this study indicate that only 47% of HDSs were delivered within 7 days from 
discharge. 
Due to work load and time restraints the clinical pharmacists only focused on high risk 
patients. The ability of the clinical pharmacists’ to deliver an accurate and high quality 
medication discharge process, with timely delivery of the medicines discharge information 
to those health practitioners involved in the next episode of care was demonstrated in this 
project. 
The time is right for a new model for the hospital discharge process. Guidance for hospital 
and community pharmacists to support patient discharge from hospital has recently been 
published by the United Kingdom National Prescribing Centre.366 The guidance aims to 
foster relationships between community pharmacists and hospital staff. In Australia, new 
funding is expected to be available for hospital pharmacists, GP’s and community 
pharmacists to deliver a comprehensive medicines discharge process, including a Hospital 
Initiated Home Medicines Review.319 Developing the relationships between community 
pharmacists, hospital pharmacists, medical practitioners, health clinic staff and engaging 
patients, will be critical success factors. 
Limitations were identified while conducting this study. Pharmacists prioritised patients 
with complex medication-related issues for a MITF. These patients have many, and often 
“last minute” changes to their medications near discharge, making it difficult for those 
completing the HDS to accurately complete the discharge medication record. Further, 
medical practitioners in the hospital were not asked about how they make decisions about 
information to be included in their HDS. They may, for example, concentrate more on 
accurate recording of diagnoses, expecting pharmacists and nurses to ensure accurate 
recording of medication changes. Whilst the hospital’s liaison GP was asked for assistance 
when the clinical panel was rating the significance of omitted medicines, not having 
prescribers represented on the panel was a limitation that should be rectified in 
subsequent audits. The usefulness of information contained in the MITF has not been 
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formally tested by requesting feedback from the community based practitioners. There is 
the likelihood of confusion if a community-based practitioner received conflicting 
information from the hospital, as may be the case when the HDS and the MIFT have 
different medication management information. This may increase time demands on the 
community-based practitioners as they will need to contact the hospital to clarify 
discrepancies. Finally, the small sample size was determined by the capacity of the 
research team to undertake this study while maintaining a full-time case load and other 
professional responsibilities. The magnitude of the issues uncovered, even with this small 
sample size, has meant however meaningful conclusions can be drawn. 
Notwithstanding these limitations, this simple innovation has identified significant issues 
with the existing HDS and has demonstrated that the MITF delivered accurate, timely and 
complete handover of medication management information from the hospital service 
providers to community-based practitioners. The study was led by clinical pharmacists 
working full-time in the hospital. Its success is an important example of the usefulness of 
embedded practitioner research methods.58 Being embedded in the setting means that the 
researchers knew from conversations about the limitations of the HDS, the frustrations 
caused to community–based practitioners and the risk to patients when they had no 
discharge information or when the information provided was not correct. The researchers 
also knew about the hospitals culture and what was possible in terms of engagement of 
other health workers in the study, work force capacity and pathways to implement change 
based on the study results. 
The promise of an information technology (IT) solution to the problem of timely and 
accurate clinical handover has not yet been realised. In the NT alone there are at least five 
different IT patient administration systems (for example primary care information systems, 
remote area information systems, GP prescribing software and pharmacy dispensing 
software) that need to be negotiated in what is a highly transient population group. The 
MITF provides an ideal interim measure for consideration as electronic support for 
discharge processes are implemented. 
The results reported in this paper relate only to the introduction period of the MITF in 2009. 
Based on the data generated in the study, the MITFs are now required to be completed by 
all pharmacists as part of their daily duties. The MITF template has also been adopted by 
four of the five hospitals in the NT (the remaining hospital does not have a pharmacist). 
Training in the completion of the MITF is now also fully integrated into the orientation 
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process for new pharmacists to the NT hospital Network. The MITF template is currently 
being mapped by the programmers of the electronic based hospital discharge software to 
provide the capability for prescribers to examine and utilise the information available in the 
MIFT at the time of creating their HDS. 
Conclusion 
This study demonstrated increased accuracy, quality and timeliness of medication 
information relayed from the hospital to community-based practitioners through the use of 
the MITF. The MIFT provides an excellent platform for further strengthening and 
standardising the medicines discharge processes in hospitals. Based on the results of this 
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Paper 4: An audit of medicines information quality in electronically generated 
discharge summaries – evidence to meet the Australian national safety and quality 
health service standards 
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Gilbert AL. An audit of medicines information quality in electronically generated discharge 
summaries – evidence to meet the Australian national safety and quality health service 
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Background 
Problems with the continuum of medicines management are a long standing issue.101 
Transfer of patients between healthcare providers, health service organisations, and within 
health organisations, provides opportunity for medication errors if the communication of a 
patient’s medicines information is incomplete or inaccurate. More than 50% of medication 
errors occur at transitions of care, and up to one third of these errors have the potential to 
cause harm.312 Omitting one or more medicines from a patient’s discharge summary 
exposes patients to 2.31 times the usual risk of re-admission to hospital.313 One in three 
older people return to hospitals due to medicine related problems.314  
Quality Use of Medicines (QUM) forms an essential part of Australia’s National Medicine 
Policy.84 The now defunct Pharmaceutical Health and Rational Use of Medicines (PHARM) 
Committee established a manual of performance indicators to monitor the implementation 
of, and effect on, Australia’s National Strategy for QUM. 89 In 2014 the Australian 
Commission of Safety and Quality in Healthcare (The Commission) funded the revision of 
these indicators to include additional indicators on continuity of medicines management. 
These indicators became more specific for the hospital setting and are a key resource for 
hospitals to monitor compliance with processes of care related to medicines management 
that has been shown to improve health outcomes.216 Audits are valuable instruments as 
part of Drug Use Evaluation (DUE)/Drug Utilisation Research (DUR) activities. Utilising 
audits against QUM indicators help hospitals guide quality improvement activities and can 
assist by monitoring performance, evaluating quality improvement activities and the 
sustainability of interventions.216  
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Australia moved towards a National Accreditation program in 2011 with the Australian 
Health Minister endorsing the National Safety and Quality Health Service (NSQHS) 
standards to improve the safety and quality of healthcare delivered throughout the country.  
These ten standards were developed by the National Committee of Safety and Quality in 
Healthcare, focusing on key health priority areas with engagement by consumers 
(Appendix 15). These standards were designed to prevent harm to patients and improve 
the quality, as well as standardisation, of healthcare within Australia182. Accreditation of 
hospitals and day procedure services against these standards began in January 2013. 
Each standard includes key criteria and actions. There are 256 actions in the NSQHS 
Standards and these are assessed during accreditation. Core actions are critical to the 
safety and quality of care and must be met. There are 209 core actions for hospitals, the 
remaining actions are aspirational, and cover areas where health services should focus 
their future efforts and resources to improve patient safety and quality. Activity in these 
areas is required, but the actions do not need to be fully met to achieve accreditation.182 In 
order for a service to be accredited, an external accreditor examines the health service. 
Evidence is normally generated through observation of everyday activities. 
Medication safety is identified as one of The Commissions priorities and has formed a 
NSQHS Standard, Standard 4. Specific criteria in Standard 4: Medication Safety, require 
regularly monitoring of the organisation’s performance in communicating accurate and 
current medicines information using indicators and quality improvement measures. 
Standard 4 requires action to be taken to address any issues identified, in particular 
discharge summaries, which also cover the process of clinical handover. Audit tools have 
been developed to test QUM indicators to assist hospitals to undertake self-assessments 
against the standards.367 Although the QUM indicators do not address all actions within the 
Medication Safety Standard, they focus on those areas where there are known gaps 
between evidence and practice. The Commission has recommended that hospitals use the 
Quality Use Medicine’s indicator 5.3 “Percentage of discharge summaries that include 
medication therapy changes and explanations for changes”. This entails a simple 
quantitative audit of the number of discharge summaries that include medication therapy 
changes, and explanations for changes, against the number of discharge summaries in the 
sample.193,216,367  
The study hospital has spent significant resources in developing and implementing an 
Electronic Medicines Management System (EMMS), in an attempt to meet best practice 
guidelines288 and uses a standardised electronically generated discharge summary tool 
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which is auto-populated from the discharge prescription generated in the EMMS, a 
function previously demonstrated to reduce transcription errors.286,288,318 Despite these 
measures, the quality of discharge summaries were highlighted by the hospital network’s 
Medication Safety Committee as a high risk area. The study hospital had not formally 
reviewed the standard of medicines information within the Electronic Discharge Summary 
(EDS) using the auto-populated feature since its implementation. The primary driving 
factor for the hospital to complete this audit was to provide evidence against two NSQHS 
standards; Standard 4 “medication safety” and Standard 6 “clinical handover.” 182,193 Due 
to the implementation of EMMS, it also provided an opportunity to assess the auto-
populated feature of the EDS against a previous audit within the study hospital.248 
Accreditation should be grasped as an opportunity to review current systems and 
implement quality improvement activities. An EDS was available in the hospital prior to the 
implementation of EMMS, however a process of transferring the medicines information into 
the EDS had been implemented as part of an Electronic Medication Management System, 
therefore this audit also provided an opportunity to assess the effectiveness of this 
process. 
The objective of this audit was to identify the current status of the EDS’s against Standard 
4 and Standard 6 to develop a quality improvement action plan to assist the hospital in 
meeting 17 NSQHS core actions.216 The audit was conducted by three senior clinical 
pharmacists. The audit was designed to test the effectiveness of processes which are 
intended to ensure that patients’, and their community-based healthcare providers, receive 
adequate information for safe and effective medicines management after discharge. In 
addition to the collection of simple quantitative data, this audit tool also included an 
assessment of the quality and timeliness of medicines information provided within the 
EDS.  
The audit tool had seven quality outcome measures which were deemed essential for 
recognising effective communication across the continuum of medication management.  
Aim 
To evaluate the accuracy and timeliness of EDS provided to patients and their primary 
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Method 
Design: This study was a retrospective audit of a random sample of hospital patients. 
Setting: This audit was conducted by three senior clinical pharmacists within a 400 bed 
Australian Tertiary Teaching Hospital. On average, 260 discharge prescriptions per week 
were dispensed by the hospital’s pharmacy. Clinical services are provided by 17 clinical 
pharmacists.  Hospital beds were at capacity (400 occupied beds) throughout the audit 
period.134  
Patient selection was done by the hospital audit team utilising the same random sample as 
selected for use in the audit of National Quality Use of Medicines (QUM) Indicator 3.1: 
“Percentage of patients whose current medications are documented and reconciled at 
admission completed in March 2014”.216 The patients selected for the audit of the QUM 
indicator 3.1 were then used in this audit of indicator “5.3: Percentage of discharge 
summaries that include medication therapy changes and explanations for changes.”216 The 
audit was a forerunner to the study hospital’s National Accreditation Examination and for 
routine safety and quality evaluation.  
Sample selection: A sample size was generated using the “Sample Size for a Proportion or 
Descriptive Study” on line calculator.368 
Outcome measures 
The audit collected data against seven individual outcome measures. The aim for all 
outcome measures was a best practice standard of 100%. 
1. Percentage of hospital discharge summaries (EDS) completed.  
Exclusions: 
• Inpatient admissions for ongoing routine day procedures such as chemotherapy or 
haemodialysis and day surgery endoscopy procedures.  
• The well newborn  
• Outpatient presentations for ongoing routine procedures e.g. wound dressings, and 
plastering.  
2. Percentage of hospital discharge summaries which were completed electronically. To 
be completed on the hospital electronic Clinical Work Station (CWS) software.  
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3. A nominated primary healthcare provider recorded on the CWS system to ensure 
discharge medicines information is provided to the patient’s next point of care. Patients 
need to nominate their primary healthcare provider at admission to hospital or during 
their stay for this information to be stored and used to deliver the EDS to their chosen 
provider. 
4. Timeliness: Discharge summaries are to be dispatched to the nominated community-
based healthcare providers within 48 hours of discharge to meet hospital policy and 
best practice. 
5. Accuracy of discharge summaries: Patients with a best possible medication history 
(BPMH) completed by a clinical pharmacist were used to determine the accuracy of the 
list of medicines within the EDS. A BPMH is defined as using 1) a systematic process 
of interviewing the patient/family; and 2) a review of at least one other reliable source of 
information to obtain and verify all of a patient's medication use (prescribed and non-
prescribed). The BPMH was obtained and documented in the hospitals Electronic 
Medication Management System (EMMS) by a clinical pharmacist referencing two or 
more sources. Complete documentation includes medicine name, dosage, route and 
frequency. This enabled a review of medication errors and omissions within the EDS. 
6. Documentation of medication changes and the reasons for change. Changes to 
medicines which are determined to be intentional, and provision of information for the 
reasons of these changes are essential to achieve continuum of care. Discharge 
summary templates must include a table to list the medication changes and the reason 
for these changes. This will also give scope to identify areas for medication 
management improvement within the hospital electronic discharge summary template. 
7. Short term therapy, including the duration of therapy and or a plan for cessation. Short-
term therapy was determined by the clinical pharmacist to be medicines such as; 
antibiotics, steroid courses, pain management courses and electrolytes.  
Data tool: The tool used for this audit was an adaption of the New South Wales (NSW) 
indicator “5.3 Percentage of discharge summaries that include medication therapy 
changes and explanations for changes”.216,369 The additions to the NSW tool included; 
assessing the timeliness of completion of discharge summaries, the accuracy of the 
information and their delivery to primary healthcare providers.216 134,216,368,369 
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Standardisation of auditors: An exemplary patient’s discharge summary, with the audit 
tool, was sent to each of the three auditors. The patient’s information included the EDS, 
Discharge Prescription and a list of medicines on admission. Each auditor completed the 
audit tool independently. The primary researcher reviewed the answers and all auditors 
met and agreed on a consistent interpretation of the information.  
Ethics: This research was exempt from ethics approval as it is deemed a low risk quality 
assurance audit as assessed against the national statement on ethical conduct in human 
research and ethical review and research involving only low or negligible risk by the 
Hospital Executive. 296 
Results 
Study numbers: Of the 400 patients in the study hospital; 31 mental health patients were 
excluded, leaving a study number of 369 patients. The study hospital’s medication 
management governance committee agreed with an 85% confidence level and therefore a 
sample size of 86 was deemed a suitable sample size for this audit. 
Of the 86 initially selected patients, nine were excluded due to remaining as inpatients by 
audit completion, and one patient was excluded due to classification as a “boarder”8F***, 
resulting in a final audit of 76 patients. (Figure 1)  
Results against outcome measures 
Discharge summary completed 
Hospital outcome: 75% (57 of 76 patients) had a discharge summary completed. 
EDSs 
Hospital outcome: 100% (57) of completed discharge summaries were electronic. 
Nominated primary healthcare provider to ensure information is provided to their next point 
of care 
Hospital outcome: 58% (33 of the 57 completed dis- charge summaries) had a GP 
nominated. 
                                                          
*** A hospital boarder is defined as a person who is receiving food and/or accommodation but for whom the hospital does not accept 
responsibility for treatment and/or care. A boarder thus defined is not admitted to the hospital. However, a hospital may register a 
boarder. 
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Figure 1: Audit flow chart 
Timeliness of discharge summaries 
Hospital outcome: 22 out of the completed 57 (38%, 28% of 76 study patients) were 
completed on the same day of discharge and 32 of the 54 completed EDS (59%, 42% of 
the 76 study patients) were dispatched  within 48 h of discharge, indicating compliance 
with hospital policy. Three discharge summaries were dispatched prior to date of 
discharge (1-3 days early), and were therefore excluded. Nineteen of the completed 57 
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dis- charge summaries (33%) were completed outside of 48 h of discharge. Median time to 
dispatch was 1 day (range 0-53 days). 
Accuracy of discharge summaries 
Of the 57 patients who had a discharge summary completed, 29 (51%) had a documented 
BPMH completed at the point of admission which could be used to assess the accuracy of 
medicines information at the point of discharge. 
Of the 29 patients who had both a BPMH and an EDS, two died during their hospital stay 
and therefore did not have medicines recorded in their EDS. One further patient had been 
transferred to another hospital and therefore did not have a formalised list of discharge 
medicines. These three patients were excluded from accuracy analysis. 
Eighteen (69%) of the 26 patients had all the medicines information that were required to 
continue with post-discharge in their EDS and were deemed accurate by the auditing 
clinical pharmacists. Eight (31%) of the 
26 patients had omissions within their EDS (ranging from one to 20 medicines per patient). 
Documentation of medication changes 
The small subgroup who had a BPMH on admission and a discharge summary completed 
(n = 26) were used to analyse the documentation of changes to medicine during the 
inpatient stay and the reasons for these changes. 
All 26 patients had at least one change to their medicines during admission (100%, range 
1-19). The median number of changes between medicines on admission (BPMH) and 
discharge prescription was eight. 
The hospital has a standard template for completing EDS. Within this template there is a 
table to specify changes to medicine, and the reasons for changes (Figure 2). Of the 
completed 26 EDS assessed for accuracy, 19 (73%) had a table prompting documentation 
of medication changes. This indicates that seven EDS had the table actively removed by 
the physician completing the EDS. None of the 26 EDS (0%) had the reason for change 
documented in the speciﬁed table provided in the template (see Figure 2). 
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Short-term therapy 
Thirty-two patients of the 57 (56%) with completed EDS were discharged with short-term 
therapies. Twenty-three of the 32 (71%) patients on short-term therapies had the intended 
duration included in the discharge summary with the majority of durations omitted being for 
courses of antibiotics. 
Discussion 
To assist consumers in moving safely and effectively among multiple healthcare providers 
and settings, QUM must be realised across the healthcare continuum. Achieving continuity 
in medication management depends on commitment, cooperation and coordination among 
all partners in QUM.101 
Frequently, the discharge summary is the only communication provided to the primary 
healthcare providers about their patients and the events that occurred while their patients 
were in hospital.286 
Discharge summaries which were not completed on the day of discharge, indicate that the 
patient was not given a copy of this information. Therefore, the hospital procedure relies 
on a nominated primary healthcare provider to which the discharge summary is forwarded. 
In our sample, 50% of the patient’s GPs would not have received a discharge summary. Of 
the 32 patients who had a completed discharge summary but were not provided with this 
information on the day of discharge, 19 had a nominated GP (59%). This indicates that 38 
(50%) of the study patients’ GPs did not receive a hospital dis- charge summary (19 did 
not have a discharge summary completed at time of audit and 19 did not have an allocated 
primary healthcare professional). 
Our ﬁndings are consistent with other studies which indicate that 78% of GPs were not 
directly informed that their patient had been admitted to hospital, and 73% of GPs did not 
directly receive any discharge summary information.281,370 
When analysing the results, the presence of a high proportion of patient records which had 
‘no nominated GP’ entered into the hospital admission and discharge software posed a 
major barrier to transferring information when the patient was discharged. Once entered, 
usually at admission, this information automatically populates onto the discharge 
summary, thus allowing communication to occur to the appropriate GP. 
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Accurate and timely information on medication management along the continuum of care 
is essential to achieving best outcomes for patients and for avoiding harm.190 
Approximately 3% of hospital admissions occur due to medication-related problems. Often 
these problems are due to miscommunication regarding the continuation/discontinuation of 
medications on hospital discharge.190,281 Our audit indicated that 59% of EDS met hospital 
policy of being completed and delivered within 48 h of discharge. A literature review of 
communication and information transfer between hospital- based and primary care 
physicians, identiﬁed that the template availability of a discharge summary at the ﬁrst post- 
discharge visit to the patient’s primary care physician was low (12% to 20%), remaining 
poor at 4 weeks (51% to 77%).281,371 The interface between hospital and community care 
is a high-risk area for medication misadventure.101,312,370 
 
Figure 2 Table prompting documentation for changes to medications within the 
electronic discharge summary (EDS)  
There is evidence of discontinuity between episodes of care, as well as evidence that this 
leads to signiﬁcant harm.281,313,371 Omission of medicines from the discharge summary list 
sent to primary healthcare professionals was associated with an increased risk (by a factor 
of 2.3) of hospital readmission or adverse medicine event.313,371 Although a small sample 
size, our study also demonstrates that omission of a medication was common at 31%. 
Despite the hospital meeting best practice standards  in the design of the EDS tool, this 
audit demonstrates that the EDS is far from error free and the tool is not being utilised to 
its full potential. In particular, the dedicated area on the tool to document the reason for 
changes to medicines is not completed by the doctors using the EDS. 
The importance of publishing experiences and sharing results from a national accreditation 
program can assist healthcare organisations improve their standards and continue to drive 
higher the baseline of quality within healthcare. 
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Limitations of the audit 
A sample size calculation was undertaken based on 85% conﬁdence level but more than 
10% of the selected patients were excluded at the outset mainly because they were still 
admitted. Further, for many of the outcome measures the numbers able to be analysed fell 
even further due to lack of required information. Hence, while the intention of establishing 
a sample size for a population of 400 is sound, the required numbers of patients to achieve 
the planned conﬁdence level were not able to be examined. 
Data available to examine the accuracy of medicines information provided was limited, due 
to the low numbers of reconciled medication lists on admission. The sample for outcome 
measure 6 could have been selected from patients who had a medication history taken by 
a clinical pharmacist, to provide a greater pool of patients. However, this method was not 
used, leaving the sample with a potentially higher risk of discrepancies because no 
reconciliation process was undertaken. 
The discharge summary should, for each medicine, also document details, such as 
medication name, dose and frequency, indications for use, intended duration or review 
period. Similarly there should be sufﬁcient additional information to ensure clear and 
unambiguous communication about the intended medicines management plan to primary 
care clinicians and the patient or carer.284,286 Although equally important, these additional 
details are not included in the audit tool recommended by the Australian Commission on 
Safety and Quality in Healthcare for this indicator.369 Further, this audit does not provide 
the date when a discharge summary was commenced to help with future development for 
discharge planning. Speciﬁc information on which medical ofﬁcer completed each EDS 
was not analysed, thus limiting the opportunity to provide individualised feedback, which 
has been shown to drive practice change.79 
Information on whether the patient was given a hard copy of the EDS or the accuracy and 
timeliness of any other disciplines’ discharge information was not collected.248 
Recommendations and action plan 
Based on audit results, an action plan was structured with a view to present it to the 
Medication Safety Committee, to help improve clinical handovers. Although it is 
acknowledged that training is a relatively weak intervention, it has been documented within 
the literature as lacking for junior doctors within the hospital environment in regards to 
completing an EDS.284 
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Recommendations within the action plan include the following; 
Examine the reasons why these EDS were not completed (25%). Examine methods to 
solve the identiﬁed barriers such as commissioning local champions, allocated responsible 
medical ofﬁcer time, and implementing workshops particularly at the commencement of 
employment to improve compliance with the percentage of discharge summaries 
completed. There should also be a copy provided to the patient. 
The hospital’s Medication Safety Committee must decide who has responsibility for 
collection of primary health practitioners’ details when a patient is admitted and at 
discharge. Entering this information into the electronic systems has to be addressed from 
a governance level to standardise practice across our healthcare network. The authors 
recommended that this is a clerical role and should be delegated to the ward clerk. 
To help improve both accuracy and timeliness we believe it is best to engage medical 
consultants to discuss with their team of doctors the importance of accurate and timely 
discharge summaries. Monitoring of each team’s performance should be reported at the 
Medication Safety Committee meetings to enable individual feedback and consultant 
accountability. This will encourage medical consultants to mentor and provide adequate 
time for junior staff to complete EDSs. 
In regards to the template, training to complete the medication changes table must occur 
and we suggest adding a section into the EDS template speciﬁcally for short-term therapy, 
including reason for treatment, expected duration and cessation plans. 
Conclusions 
The lack of information on the primary care provider recorded in the patient’s clinical 
system and discharge summaries limited the timely transfer of essential information on 
post-discharge medicine management to the patient’s primary care provider. Work has 
commenced on an educational program to improve data entry of the patient’s primary care 
provider when they are admitted. 
A multidisciplinary working group has been established to focus on discharge planning and 
EDS, while also addressing a multidisciplinary approach to identify areas of accountability 
to drive improvements. One approach has been the development of a Medicines 
Information Transfer Fax (MITF) which is completed by a clinical pharmacist at the time of 
discharge.248 The plan will be to give a copy to the patient and a copy will be sent 
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electronically to the nominated primary care provider and available electronically for 
medical doctors completing EDSs. This collaborative approach aims to provide critical 
medicines-related information in a timely manner to primary care providers and allows 
medical ofﬁcers and clinical pharmacists the ability to work more closely together to 
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Paper 5: Hospital Discharge Medicines Information: From Trial to Policy 
Gilbert AV, Roberts MS, Williams DB and Gilbert AL. Poster presentation provided at the 
International Conference on Pharmacoepidemiology and Therapeutic Risk Management, 
August 22–26, 2015, Boston, Massachusetts, USA. Hospital Discharge Medicines 
Information: From Trial to Policy. Abstract published: Pharmacoepidemiology and Drug 
Safety Journal: Volume 24, Issue Supplement S1, pages 70-71, September 2015. 
 
Background 
Medications are the most common form of health therapy in our society. However, 
medicines are also one of the most common causes of harm.190 Approximately 3% of 
hospital admissions within Australia occur due to medication-related problems.190 
This project assesses the effectiveness of processes intended to ensure that patients and 
their community-based healthcare providers receive adequate information for safe and 
effective medicines management after discharge. 
Communicating medicines information is a guiding principle in the Australian 
Pharmaceutical Advisory Council (APAC) to achieve continuity in medication 
management101. To assist patients in moving safely and effectively among multiple 
healthcare providers and settings, quality use of medicines (QUM) must be realised across 
the healthcare continuum. Achieving continuity in medication management depends on 
commitment, cooperation and coordination among all partners in QUM.101,216,369 
Frequently, the discharge summary is the only communication provided to the General 
Practitioner (GP) about their patients and the events that occurred whilst their patients 
were in hospital.193 Results from previous studies indicated that 78% of general 
practitioners were not directly informed that their patient had been admitted to hospital and 
73% of general practitioners did not directly receive discharge summary 
information.193,281,372 
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The Top End Health Services (TEHS) Discharge Summary Policy states: ‘A discharge 
summary must be provided or disseminated within 48 hours of discharge.’289  This is 
consistent with best practice recommendations within Australia. 
Accurate and timely information on medication management along the continuum of care 
is essential to achieving best outcomes for patients and for avoiding harm.101,289,311,369,373 
Often these problems are due to miscommunication regarding the 
continuation/discontinuation of medications on hospital discharge.248,311,370,374 The 
interface between hospital and the community care is a high risk area for medication 
misadventure.182,190,248,311,369,370,374 
There is evidence of discontinuity between episodes of care as well as evidence that this 
leads to significant harm, such as the omission of medicine from the discharge summary 
list sent to community healthcare professionals. This has been associated with an 
increased risk (by a factor of 2.3) of hospital readmission or adverse medicine event.101 
Our previous research demonstrated that clinical pharmacists working within the acute 
healthcare setting can assist in providing this essential information.248 
The accuracy and timeliness of this information was superior to that of the medical 
discharge summary prepared and dispatched by hospital physicians. For discharge 
medicines information; (92%) of the MITFs matched that of the gold standard – the 
discharge prescription (DP). In comparison, examination of the Hospital Discharge 
Summary (HDS) revealed that no HDS was prepared for 16 (21%) patients. Of the 
remaining 61 patients; 33 (54%), had required medications omitted and 38 (62%) had 
medication errors in their HDS. 28 (35%) patients had their HDS dispatched to their 
community-based practitioners within 48 hours post discharge compared to 80 (100%) of 
MITFs.248 
This study is the next stage in the development of a multidisciplinary medicines discharge 
policy. 
Aim 
To examine patient prioritisation by pharmacists when providing MITF to inform policy 
development and direct clinical services. 
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Methods 
Design: This study was a retrospective audit of a randomised sample of 99 patients who 
had a MITF completed by a pharmacist in April-September 2014. (See figure 1) 
Setting: This audit was conducted by four senior clinical pharmacists within an Australian 
Tertiary Teaching Hospital. 
Inclusion/exclusion criteria: Patients were excluded from the study if a medical 
discharge summary was not finalised at the time of the analysis. A template that has 
undergone multiple revisions and feedback provides the standard for the MITF. If the 
pharmacist did not use this template their work was excluded. To prevent individual bias, if 
a reviewer was randomly allocated their own work, they switched respective numbers with 
another reviewer to prevent having included self-assessment.  
Interventions: A combination tool utilising the ‘safety and quality risk stratification tool’278, 
and the ‘society of hospital pharmacist of Australia patient risk stratification instrument’176, 
was used to assess selection criteria by clinical pharmacists when providing a MITF for 
their patients. (See table 1). 
Table 1: Tool for identifying patients at HIGH RISK of medication misadventure post 
discharge 
Elderly (Age greater than 65 non-Indigenous Australians or age greater than 55 for 
Indigenous Australians).176,278 
Is currently prescribed 5 or more medications AND/OR 12 or more doses of medicine per 
day.176,278  
Has multiple co-morbidities (i.e. more than one chronic disease)278 
Symptoms suggestive of a medicine-related admission278 
Having difficulty managing medicines because of literacy, language difficulties, dexterity 
problems, impaired sight, dementia, compliance issues or other cognitive difficulties176,278 
Is receiving therapy with high-risk drugs (such as anticoagulants and immuno-
suppressants) or a medicine with a narrow therapeutic index176,278 
Renal or hepatic impairment176,278 
Multiple changes made to their regular medicines during hospital admission176,278 
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Main outcome measures: To compare the clinical presentation of each patient randomly 
selected against the criteria that would identify them as high risk for medication 
misadventure. Do the high risk factors qualify for prioritisation of a MITF prepared by a 
clinical pharmacist to assist in clinical handover at the dangerous transition between acute 
and community based healthcare? 
Results 
All patients met at least one of the high risk criteria as defined in the high risk medication 
misadventure tool. 
The most common high risk factors identified for the study group to have a MITF prepared 
by a pharmacist were the following: being prescribed 5 or more medications, multiple co-
morbidities, and changes to the patient’s regular medicine during their hospital admission 
(72, 77, 78 patients respectively). (See figure 2). 
 
Figure 1: Patient selection for study (exclusion and inclusion) 
99 patients  
Randomly selected who had a MITF completed between 
April-Sept 2014 
Excluded 20 patients: 
11 no medical discharge summary completed 
5 discharge prescriptions could not be located to assess 
accuracy 
4 Information was not provided on correct MITF template 
79 patients  
remained in study and were assessed for high risk criteria 
using material in Table 1. 
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Figure 3: Proportion of patients meeting multiple high risk criteria 
Figure 3 demonstrates that the majority of the pharmacists selected patients who met at 
least 2 high-risk criteria. Of the random sample no patients met only one high risk criteria. 
The highest proportion of patients had between 4 to 6 high-risk criteria of 88% (16, 31 and 
23 patients respectively). 
The utilisation of the MITF is embedded in all 5 public hospitals within the Northern 
Territory of Australia. It ensures that quality and timely medicines information is handed 
over to the community healthcare providers who will be responsible for the patient’s next 
episode of care. It is however, still a voluntary activity. Pharmacists within Australia usually 
work to Key Performance Indicators or Activity Based Funding. This study has 
Number of 
patients who met 
2 high risk criteria 
2% 
Number of 
patients who met 
3 high risk criteria 
5% 
Number of 
patients who met 
4 high risk criteria 
20% 
Number of 
patients who met 
5 high risk criteria 
39% 
Number of 
patients who met 
6 high risk criteria 
29% 
Number of 
patients who met 
7 high risk criteria 
5% 
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demonstrated that pharmacists are allocating patients appropriately by selecting those 
who are at the greatest risk of medication misadventure post-discharge.  
Clinical handover is key to safe transition for our patients and is a responsibility for all 
healthcare providers.  The results from this study will help inform policy by which clinical 
pharmacists can be assessed. It has led to mandating MITF as a crucial activity of 
pharmacists when handing over a patient’s medicines information at the point of 
discharge. 
Conclusions 
Two to three percent of all hospital admissions in Australia are medication-related.190 MITF 
is now embedded within the Northern Territory public hospitals. Policy development will 
commence, based on these results, to ensure that MITF is a mandated activity undertaken 
by clinical pharmacists. 
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Paper 6: Can Reporters of a Medicines Incident Accurately Reflect the Clinical Risk? 
Gilbert AV, Roberts M S, Williams D B and Gilbert A L. Poster presentation provided at 
the International Conference on Pharmacoepidemiology and Therapeutic Risk 
Management, August 22–26, 2015, Boston, Massachusetts, USA. Can Reporters of a 
Medicines Incident Accurately Reflect the Clinical Risk? Abstract published: 
Pharmacoepidemiology and Drug Safety Journal: Volume 24, Issue Supplement S1, 
pages 170-171, September 2015. 
 
Background 
Use of Incident Severity Rating (ISR) scores is common in Australian public hospitals. In 
particular, most hospitals rely on ISR as a means to reduce medication-related incidents in 
patient care.190,207,346  
Medicines are one of the most common causes of harm in healthcare.190 Medication 
incidents are the second highest reported category of incident, second only to falls, within 
healthcare incident monitoring systems.207 Approximately a quarter of all incidents 
reported relate to medicines.207,346  
The use of a robust hospital-wide system of reporting, investigating and managing change 
in response to medication incidents is a core criteria used when a hospitals are examined 
against the Standards of Safety and Quality in Healthcare within Australia.193 
A recent paper from the USA “indicated inconsistency in the way nurses scored the 
scenarios, suggesting that the event reporting system may not accurately portray the 
severity of harm in patient safety events.” Page 218375  
Many medication errors can be prevented by introducing safe systems and safe 
medication practices. Most detection studies have concentrated on improving reporting 
rates as the answer.332  
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Limitations of Event Reporting 
The limitations of voluntary event reporting systems have been well-documented. Event 
reports are subject to selection bias due to their voluntary nature. Compared with medical 
record review and direct observation, event reports capture only a fraction of events and 
may not reliably identify serious events. The spectrum of reported events is limited, in part 
due to the fact that physicians generally do not utilise voluntary event reporting systems.344 
Table 1: Top 5 self- perceived barriers to incident reporting by doctors343 
Top 5 self- perceived barriers to incident reporting for doctors 
1 No feedback on incident follow-up (57.7%) 
2 Form too long; lack of time (54.2%) 
3 Incident seemed “trivial” (51.2%) 
4 Ward was busy, forgot to report (47.3%) 
5 Not sure who is responsible for making the report (37.9%) 
 
Despite the bias and limitation of voluntary reporting, it is still the recommended and 
encouraged international method of capturing medication incidents.332,344,375 Little research 
has been done to reflect on the accuracy of voluntary reporting in identifying clinical risk. 
Determining the correct clinical risk both for incidents and near misses is essential to 
correctly prioritise root cause analysis reviews and system reviews in order to continually 
improve the quality of healthcare and patient safety. 
Aim 
To examine and compare ISRs from a sample of hospital-wide reports from individual 
hospital staff, and ISRs of the same reports when examined by a group of clinicians 
consisting of Medical Practitioner, Nurse and Pharmacist. 
Methods 
Design and setting: 
This study was a retrospective randomised audit assessing severity ratings of medication-
related incident reporting within an Australian tertiary teaching hospital across a three-year 
time period (2010-2013). A 20% sample of routinely collected data from the hospital’s 
RiskMan®352 software system was examined.  
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Severity rating was independently reviewed by a multidisciplinary clinical panel using a 5 
point Likert scale to assign an ISR352. The review panel consisted of a doctor, a senior 
clinical pharmacist and a registered nurse. 
A Kappa score was used to determine the inter-rater agreement. We used Fleiss's equally 
arbitrary guidelines which characterises Kappa scores over 0.75 as excellent, 0.40 to 0.75 
as fair to good, and below 0.40 as poor-353. The initial reporter ISR was compared to that of 
the review panel. A Kappa score using the same agreement scale was then used to 
determine the accuracy of the initial rating.  
Results 
The bed numbers were at capacity or overflow throughout the three-year study period with 
patient numbers consistent at 401. A total of 458 medication incidents were reported. A 
random sample of 90 (20%) was selected for analysis; 6 reports were excluded as they 
were duplicates of the same incident entered by different reporters, or after review, 
recognition of it being classified as a medicine incident when it was not.  
A multidisciplinary review panel was formed and independently reviewed the remaining 84 
incidents. The panel, consisting of a medical practitioner, a nurse and a clinical 
pharmacist, demonstrated a Po 0.78 agreement between raters; this is deemed as 
excellent.353 The original reporter’s ISR was then included and the Kappa score 
recalculated. When including the original reporter’s ISR the Kappa agreement dropped to 
Po 0.56 (fair to good).353 
The review panel gave identical rating independently for 57 incidents (68%) with the initial 
reporter entering the same ISR as the review panel for 21 of the 57 incidents (37%), see 
chart 1. Ten (12%) incidents were given an ISR 1 or 2 by the review panel, with 1 of the 10 
incidents identified as an ISR 1 by the original reporter. Four incidents were classified as 
ISR 2’s by the original reporter. The multidisciplinary panel each raised the severity of 1 of 
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Table 2: Data demonstrating differences in ISR between the original reporters and the three clinicians 
NURSE DOCTOR PHARMACIST REPORTER 
3 3 3 3 
3 3 3 4 
2 2 2 5 
3 3 3 4 
4 3 3 4 
3 3 3 3 
5 5 5 5 
4 4 4 3 
2 3 3 5 
3 3 3 3 
5 4 4 5 
3 3 3 4 
3 3 3 3 
4 4 4 3 
3 4 3 3 
5 4 5 2 
3 3 3 3 
2 2 2 4 
1 1 1 2 
4 3 3 5 
4 3 3 4 
4 4 4 3 
4 3 3 4 
4 3 3 3 
2 2 2 3 
4 3 3 3 
4 4 4 5 
3 4 4 5 
3 3 3 3 
5 4 5 4 
3 3 3 4 
4 3 3 3 
3 3 3 5 
1 1 1 3 
4 3 3 5 
3 3 3 4 
3 3 3 4 
3 3 3 3 
3 3 3 3 
3 3 3 4 
4 4 4 5 
3 3 3 3 
4 4 4 4 
3 3 3 3 
3 3 3 3 
4 4 4 4 
1 1 1 1 
3 3 3 5 
5 4 4 4 
4 4 4 4 
3 3 3 2 
3 4 3 5 
3 3 3 5 
4 3 3 5 
2 2 2 4 
3 3 3 3 
3 3 3 5 
3 3 3 3 
4 4 4 3 
3 3 3 4 
3 3 3 4 
3 3 3 4 
3 3 3 5 
1 1 1 3 
4 2 4 2 
3 3 3 4 
3 3 3 4 
4 4 4 3 
5 4 4 5 
3 3 3 5 
3 3 3 3 
4 4 4 5 
4 4 3 3 
4 3 4 4 
3 3 3 5 
3 3 3 3 
3 3 3 3 
3 3 4 4 
4 3 3 4 
4 4 4 5 
2 2 2 4 
3 3 4 5 
4 3 3 4 
1 1 1 5 
 
  









Reporter allocated ISR of 3 
Panel individual rating of ISR 1 (unanimous)  
Report details entered into RiskMan®: 
“Mismanagement of the blood sugars when patient was not eating post a long surgical 
procedure. The surgical procedure was debridement of infected diabetic foot ulcer due to 
uncontrolled blood glucose levels. Insulin infusion was ceased but glucose 5% left running. 
Blood Glucose Levels (BGLs) remained high and patient was not eating. Patient also had 
glucose running as compatible fluid background for the patient controlled analgesia (PCA) 
fentanyl. Ketones were noted as high. Endocrine registrar reviewed patient and was not 
happy with the management as he had clearly documented that insulin infusion could only 
be stopped an hour after patient has had food and glucose infusion to be ceased 
simultaneously dependant on BGL’s. There was no documentation as to when the insulin 
infusion was ceased and the reason why it was stopped.  Patient was later transferred to 
intensive care unit (ICU) for further management and he actually gave his own insulin 
before going to ICU as he was not happy with the way his sugars were managed by ward 
staff.” 
From this information the panel rated this incident as an ISR 1 (Catastrophic). From clinical 
knowledge this mismanagement and transfer to ICU indicated that it met the criteria for an 
ISR 1: “Serious, infrequent, clear cut events that occur independently of a patient’s 
condition and commonly reflect hospital system and process deficiencies. These events 
have resulted in, or have realistic potential to result in an unexpected death, permanent 
disabling injury or psychological harm.”352 
Patient outcome was investigated after this study as part of the hospital policy to follow up 
all ISR 1’s.  
This patient was returned to surgery for amputation of limb. 
  




Chart 1: Agreement and variability between panel members and agreement between 
reporters original ISR to panel members.  
Discussion 
Risk reporting within healthcare has improved with the development of education and 
system supports for hospitals to encourage clinicians to make risk reporting a part of the 
culture, thus to be seen as a duty of health professionals.  
The reporting of medication incidents should include all errors and mishaps involving 
medicines, breakdowns in systems, adverse drug events and near misses. Reporting 
medication incidents is not intended to identify or punish those involved in the incident, but 
to provide the opportunity for information to be collated about circumstances leading to 
these incidents which can then be used to inform risk minimisation strategies.  
Research has demonstrated that risk classification and risk identification is done at the 
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which of course should be encouraged, this becomes less practical, and often leads to 
organisations making the decision to perform root cause analysis and risk reviews of 
incidents reported of ISR 1 and 2.  
Hence the importance of accuracy in the rating.  
Clinical outcomes and follow-up studies need to be performed in order to correlate the risk 
allocated and clinical outcomes of our patients. Education for clinicians who are entering 
incidents, and policies dictating the need for panel reviews, will become an important and 
necessary requirement for all healthcare organisations. 
Conclusions 
This study indicates that there is potential for incidents that require a full review, being 
overlooked by organisations due to the initial ISR supplied by the reporter. A clinical panel 
has the ability to more correctly assign risk ratings, which could enable further review and, 
if necessary, quality improvement activities, to reduce the occurrence of similar medication 
incidents and target trends. 
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Paper 7: Evaluation of a rapid implementation quality improvement program for 
medicine security 
Gilbert A V, Roberts M S, Williams D B and Gilbert A L. Poster presentation provided at 
the International Conference on Pharmacoepidemiology and Therapeutic Risk 
Management, August 22–26, 2015, Boston, Massachusetts, USA.  Evaluation of a rapid 
implementation quality improvement program for medicine security. Abstract published: 
Pharmacoepidemiology and Drug Safety Journal: Volume 24, Issue Supplement S1, 




Certain Schedule 4 (prescription only) medicines are subject to further restriction of supply, 
distribution and possession, to reduce abuse, misuse & physical/psychological 
dependence. In Australia, these medicines are restricted schedule 4’s (S4R’s). Mental 
health (MH) is recognised as high risk for medication misadventure. The management of 
S4R's within MH at the study hospital was poor and rapid change was required to prevent 
harm. The management of S4R's did not comply with policy or best practice. 
Objectives 
Implement and evaluate a rapid change management program to transition S4R medicines 
in line with best practice and policy. 
Methods  
Baseline evaluation of S4R medicines was completed using pre and post supply data from 
dispensing software. A communication strategy was implemented in order to communicate 
this project internally; strategies included text message notification, education sessions 
and training handbooks. This change was implemented within 48 hours. Feedback was 
sort from nursing staff and an audit was conducted to review practice against policy. 
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Results  
None of S4R’s were being stored and managed in line with policy at baseline, 100% are 
now stored correctly. Supply reports for the 5 most common S4R’s all decreased post 
implementation; diazepam 5mg tablets decreased by 993(41%), temazepam 10mg tablets 
by 325(76%), paracetamol/codeine 500/30mg tablets by 120(40%), lorazepam 1mg tablets 
by 25(10%), midazolam 5mg/mL ampoules 35(58% reduction). 75% (9 out of 12) of 
nursing staff were satisfied with the information provided. 92% (11 out of 12) received 
information with highest proportion (73%) via email. 83% had been provided with the 
knowledge and skills required to manage this new system and 63% (7 out of 12) do not 
require additional information. 15 indicators were audited against 920 entries in the S4R 
register to assess policy compliance. 6 indicators showed 100% compliance; e.g. signed 
by second nurse, balance completed 3 shifts/day. The remaining showed good compliance 
e.g; Date noted (99%) and prescriber’s name (94%). 
Conclusions 
Rapid implementation for best practice management of S4R's has demonstrated high 
uptake of policy and a decrease in supply. 
BACKGROUND 
Mental health has been recognised as an area where there is high risk for medication 
misadventure.  
A range of Schedule 4 medicines, such as the benzodiazepines, are liable to high use and 
abuse, within mental health.357  
The traditional storage and record keeping requirements for these medicines are 
inadequate and do not provide the level of accountability required in the public health 
system. 
The Australian Commission of Safety and Quality of Health Care Standards and the 
Northern Territory Medication Management Framework drove the scope of the key quality 
indicators for this project.212,240 
As an Embedded Pharmacist Researcher (EPhR)376 working within the MH service, I was 
able to use the National Accreditation of Health Services, to facilitate a change which I had 
recognised as an essential safety and quality initiative for this service.  
I recognised that this project would attempt to change established practices which have 
been used for 18 years. 
Further, I recognised that the current management of S4R medicines within the study 
wards did not cover issues of storage, administration, documentation, destruction and 
monitoring, in line with best practice guidelines and regulations.212,239,240 
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OBJECTIVE 
Using an EPhR to prepare, implement and evaluate a rapid change management program 
involving the transition to, and use of, S4R medicines in line with policy, best practice 
guidelines and hospital accreditation requirements. 
METHODS 
Design: 
A ‘rapid change management program’ which is the transitioning of individuals, teams 
and organisations to a desired future state.192,212,376 The EPhR developed,  implemented 
and evaluated the program.  
Population: 
Three mental health wards in an Australian tertiary teaching hospital. During study period 
all wards were at capacity throughout the study. All patients admitted and treated during 
the study period, and the practice of all nursing and medical staff rostered during this 
timeframe were evaluated.  
Pre-audit 
Supply records were compiled from dispensing software. A stock-take of S4R’s, and 
storage methods at the ward level, was undertaken to acquire baseline numbers.  
Interventions: 
Stage 1: Engaging key stakeholders and fostering the recognition for change 
In order to bring about change, managers should recognise, as a minimum:  
• the forces creating or driving the need for change: e.g. Legislation, Policy and best 
practice Guidelines. 
• the right time and environment for change: e.g. the immanent examination of the 
study hospital against the National Accreditation standards for Safety and Quality in 
Health Care for hospitals. 
• any resistance to change: This involved recognising staff concerns.3,192,212 
Consultation: Initial consultation by the EPhR with the general manager and director of 
nursing confirmed support and approval for MH to correspond with Top End Health 
Service policy.  
Recommendation and directive: Staff within an organisation often do not recognise the 
culture of that organisation. The EPhR was able to identify the culture, and support the 
required changes, within the organisation; e.g. to implement a rapid roll out approach, 
recognising an opportune time for change with National Accreditation looming. 
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The EPhR’s  project plan and timeframe was presented to general manager of MH and 
agreement achieved.  
The urgency of implementation was presented to senior nursing staff by the general 
manager. This ensured united support prior to presenting the intervention to front-line staff. 
The project plan and implementation strategy was presented to all MH staff by the EPhR. 
Stage 2: Communication action plan 
In order to communicate this quality improvement project internally:  
• Educational sessions were provided twice daily for three days prior to 
implementation to alert currently rostered nursing staff of the pending change. 
• Identification of nursing staff who attended sessions that would be rostered either 
on night shift or the weekend to help educate and communicate change to peers.  
• Key nurses were provided with a one on one chance for further questions and 
education provided by the EPhR. 
• A strategy for staff who were unable to be informed in person and may be later 
exposed to change: 
• Emails written by EPhR and distributed by the General Manager 
• Text message alerts distributed by the nursing resource co-ordinator to non-
rostered staff.  
• Text message email strategy was also utilised for staff who were not rostered 
during this program, but may be needed in an emergency.  
• High habit areas were identified and visual change prompts were used e.g. Signs to 
indicate change. 
• Written ‘How To Guides’ were distributed in key nursing areas which allowed staff to 
refer to guides during any stage of the new process for re-assurance and 
standardisation of practice. 
• Attendance and information provided to medical staff at weekly meeting (Figure 1) 
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Figure 1: Example of ‘How To Guides’ 
Stage 3: Recognition of potential for non-adherence to policy. 
Two primary concerns raised from staff: 
a) What to do in an emergency? Benzodiazepines are used during rapid tranquilisation 
and protect patients help prevent staff assaults, staff raised concern that locking S4R’s 
may delay action.  
The EPhR organised for senior nursing staff to visit the emergency department to view 
organisation, accessibility and management in high stress, volatile and time pressured 
situations. The EPhR encouraged senior staff to feedback this experience to peers. 
b) Will reduction of stock levels leave periods of time without required medicine being 
available on the wards? 
Stock requirements were calculated using dispensing software reviewing 6 months of 
usage and averaging it to a weekly requirement; stock was slightly over requirement due 
to raised nursing concerns.  
  
  
Alice Victoria Gilbert | 2016    P a g e  | 264 
 
Stage 4: Outcome measures 
 a) Post intervention audit  
Supply records of three months post intervention data was reviewed to assess quantities 
of S4R’s supplied from pharmacy. 15 key indicators were used to evaluate compliance 
with policy.  
 b) Satisfaction questionnaire 
An anonymous survey was distributed to all staff with an opportunity to comment on the 
rapid implementation initiative and to gauge the usefulness of different communication 
methods. 
RESULTS 
 Section 1: Supply of S4R’s 
The supply data of the five frequently used S4R’s were evaluated. All had decreased post 
intervention.  
Throughout the 6 month study period (pre and post) patient numbers remained consistent. 































3 months Post -
intervention
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Section 2: Compliance against policy 
Pre-intervention, all actions with S4R’s were non-compliant with policy. They are 
expressed as 0% on the graph below.  
A repeat audit at six months demonstrated continual compliance with policy. 
 
 
* The “breakage recorded correctly” column is empty because no breakages occurred over the study period. 
Section 3: Satisfaction questionnaire 
An anonymous survey, via Surveymonkey® was sent to all inpatient MH staff 
(approximately 80) to give the opportunity to provide feedback on both the implementation 


















Figure 3: Quality indicators  * 
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Figure 4: Satisfaction with skills information 
 
Figure 5: Source of information on the changes 
Do you feel that you were provided with the knowledge and 























How did you receive information that this 
change would occur? (Tick as many that 
apply) 
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Do you have any other feedback you would like to share regarding the transition or 
the management of restricted schedule 4's? 
“A long time coming. Great to see it here now.”  
“No” 
“Very impressed with rapid transition, three cheers team pharmacy!” 
“I think given the amount of time it was very well managed” 
DISCUSSION 
The demonstration of compliance with policy and decrease in supply could indicate an 
improvement in patient care. Benzodiazepines are commonly prescribed and administered 
in the MH setting for sleep, anxiety and agitation. These results could indicate that non-
pharmaceutical interventions, which are first line therapy for the above indications, are 
increasing in practice.  
The other benefit of this intervention is that it prevents the opportunity for diversion and 
misuse of these restricted medication.  
CONCLUSION 
The Rapid Change Management Program used for implementation of best practice 
management in this study of S4R's has demonstrated high uptake, and compliance, with 





















Alice Victoria Gilbert | 2016    P a g e  | 269 
 
1 Department of Health and Ageing. The National Strategy for Quality Use of Medicines. 
Commonwealth Government of Australia. Publication number 3024. Canberra; 2002. 
 
2 Winett RA, King AC, Altman DG. Health Psychology and Public Health. An Integrative Approach. 
Pergamon General Psychology Series, editor. New York: Pergamon Press; 1989. 
 
3 Green LW, Kreuter MW. Health Program Planning: An Educational and Ecological Approach. 
Boston: McGraw-Hill; 2005. 
 
4 Roughead EE, Gilbert AL. Education Session: Advanced Drug Utilisation Research. 31st International 
Society of Pharmacoepidemiology; 2015; Boston, USA. 
 
5 Green L, Kreuter M. The Precede–Proceed Model. Health promotion planning: an educational 
approach 3rd ed Mountain View (CA): Mayfield Publishing Company. 1999: 32-43. 
 
6 Hansen E, Walters J, Howes F. Whole Person Care, Patient-Centred Care and Clinical Practice 
Guidelines in General Practice. Health Sociology Review. 2016; 25(2): 157-70. 
 
7 Tsuyuki RT, Krass I. What Is Patient-Centred Care? /  Que Sont Les Soins Axés Sur Le Patient? 
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2013; 146(4): 177-80. 
 
8 Australian Commission on Safety and Quality in Health Care. Patient-Centred Care: Improving 
Quality and Safety by Focusing Care on Patients and Consumers. ACSQHC. Canberra; 2010. 
 
9 Rigby D. The Imperative–to Become Patient-Centred and Collaborative. Australian Pharmacist. 
2011; 30(10): 825-6. 
 
10 Donegan TE. Book Review: William N. Kelly and Elliott M. The Good Pharmacist: Characteristics, 
Virtues, and Habits. . American Journal of Pharmaceutical Education. 2011; 75(7): 146. 
 
11 McMillan SS, Kelly F, Sav A, King MA, Whitty JA, et al. Australian Community Pharmacy Services: A 
Survey of What People with Chronic Conditions and Their Carers Use Versus What They Consider 
Important. BMJ open. 2014; 4(12): e006587. 
 
12 Avalere Health LLC. Exploring Pharmacists’ Role in a Changing Healthcare Environment Washington 
DC, USA, 2014. 
 
13 Smith M, Nigro S. The Patient-Centred Medical Home. Science and Practice of Pharmacotherapy. 
2014; VI: 88-102. 
 
14 Phatak A, Prusi R, Ward B, Hansen L, Williams M, et al. Impact of Pharmacist Involvement in the 
Transitional Care of High-Risk Patients through Medication Reconciliation, Medication Education, 
and Post-Discharge Call-Backs (IPTCH Study).  Journal of Hospital Medicine 2016. p. 39-44. 
 
15 Freeman C, Cottrell W, Kyle G, Williams I, Nissen L. Does a Primary Care Practice Pharmacist 
Improve the Timeliness and Completion of Medication Management Reviews? International Journal 
of Pharmacy Practice. 2012; 20(6): 395-401. 
 
16 Brummel A, Lustig A, Westrich K, Evans MA, Plank G, et al. Best Practices: Improving Patient 
Outcomes and Costs in an ACO through Comprehensive Medication Therapy Management. J Manag 
Care Pharm. 20(12): 1152-8. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 270 
 
17 Dooley MJ, Allen KM, Doecke CJ, Galbraith KJ, Taylor GR, et al. A Prospective Multicentre Study of 
Pharmacist Initiated Changes to Drug Therapy and Patient Management in Acute Care Government 
Funded Hospitals. British journal of clinical pharmacology. 2004; 57(4): 513-21. 
 
18 Abukres S, Hoti K, Hughes JD. Patient Attitudes Towards a New Role for Pharmacists: Continued 
Dispensing. Patient Preference and Adherence. 2014; 8: 1143-51. 
 
19 Avorn J. Teaching Clinicians About Drugs - 50 Years Later, Whose Job Is It? New England Journal of 
Medicine. 2011; 364(13): 1185-7. 
 
20 Lalonde L. A Pioneer of Pharmaceutical Care: Dr. Linda Strand. Canadian Pharmacists Journal / 
Revue des Pharmaciens du Canada. 2008 2017/02/17; 141(5): 268-70. 
 
21 Luetsch K, Rowett D, Punchard H. The Sweet Spot for Pharmacy. Journal of pharmacy practice and 
research. 2016; 46(2): 107-11. 
 
22 Freeman C, Rigby D, Aloizos J, Williams I. The Practice Pharmacist: A Natural Fit in the General 
Practice Team. Australian Prescriber. 2016; 39(6): 211-14. 
 
23 Hale A, Coombes I, Stokes J, Aitken S, Clarke F, et al. Patient Satisfaction from Two Studies of 
Collaborative Doctor - Pharmacist Prescribing in Australia. Health Expectations. 2016; 19(1): 49-61. 
 
24 Eassey D, Smith L, Krass I, McLachlan A, Brien J. Consumer Perspectives of Medication-Related 
Problems Following Discharge from Hospital in Australia: A Quantitative Study. International 
Journal for Quality in Health Care. 2016; 28(3): 391-7. 
 
25 Maine LL, Knapp KK, Scheckelhoff DJ. Pharmacists and Technicians Can Enhance Patient Care Even 
More Once National Policies, Practices and Priorities Are Aligned. Health Affairs 2013; 32(11): 1956-
62. 
 
26 Meyer CE. Opportunities and Challenges Related to Pharmacy Technicians in Supporting Optimal 
Pharmacy Practice Models in Health Systems. Am J Health Syst Pharm 2011; 68(15): 1128-36. 
 
27 Herrera H, Brown D, Portlock J. A Case Study of the Recognition of the Foundation Degree 
Qualification for Pharmacy Technicians. J Vocational Education and Training. 2013; 65(1): 127-42. 
 
28 Bradley F, Schafheutle EI, Willis SC, Noyce PR. Changes to Supervision in Community Pharmacy: 
Pharmacist and Pharmacy Support Staff Views. Health and Social Care in the community 2013; 
21(6): 644-54. 
 
29 Sheridan J, Kelly F, Basheer M, Jan R, Lee A. Can I Help You? A Qualitative Study of the Pharmacist 
and Pharmacy Assistant Views on the Role of Pharmacy Assistants in New Zealand. IJPP. 2011; 19: 
288-38. 
 
30 National Association of Pharmacy Regulating Authorities. Professional  Competencies for Canadian 





31 Northern Territory Government of Australia. Department of Health - Royal Darwin Hospital. 2015 
[Date accessed: Sept 2015]; Available from: 
http://www.health.nt.gov.au/hospitals/royal_darwin_hospital/. 
  
Alice Victoria Gilbert | 2016    P a g e  | 271 
 
 
32 Evlidge S. Automated Hub-and-Spoke Dispensing: Technology Set to Transform the Business Model 
of Community Pharmacy. The Pharmaceutical Journal. 2016; 296: 7888. 
 
33 Australian Bureau of Statistics. Australian Demographic Statistics. Australian Bureau of Statistics. 
Report number: 3101.0 Canberra, Australia; June 2015. 
 
34 Yap KK. The Clinician-Scientist: Uniquely Poised to Integrate Science and Medicine. Aust Med Stud J. 
2012; 3: 10-1. 
 
35 Tuosto K. The" Grunt Truth" Of Embedded Journalism: The New Media/Military Relationship. 
Stanford Journal of international relations. 2008; 10(1): 20-31. 
 
36 McGinity R, Salokangas M. Introduction: 'Embedded Research' as an Approach into Academia for 
Emerging Researchers. Management in Education. 2014; 28(1): 3-5. 
 
37 Vindrola-Padros C, Pape T, Utley M, Fulop N. The Role of Embedded Research in Quality 
Improvement: A Narrative Review. BMJ quality & safety. 2016; 0: 1-11. 
 
38 Groundwater-Smith S, Mockler N. The Knowledge Building School: From the Outside in, from the 
inside Out. Change Transform Educ 2002; 5: 15-24. 
 
39 Reiter-Theil S. Does Empirical Research Make Bioethics More Relevant? “The Embedded 
Researcher” as a Methodological Approach. Med Health Care Philos 2004; 7: 17-29. 
 
40 Hentschel R, Lingner K, Krueger M, et al. Restriction  of Ongoing Intensive Care in Neonates: A 
Prospective Study. Pediatrics. 2006; 118: 563-9. 
 
41 Pyett P, Waples-Crowe P, van der Sterren A. Challenging Our Own Practices in Indigenous Health 
Promotion and Research. Health Promot J Austr 2008; 19: 179-83. 
 
42 Nutley S, Jung T, Walter I. The Many Forms of Research - Informed Practice: A Framework for 
Mapping Diversity. Cambridge Journal of Education. 2008; 38(1): 53-71. 
 
43 Pluto JV. Prisons, and Plaintiffs: Notes on Systematic Back-Translation from an Embedded 
Researcher. Soc Probl. 2008; 55: 1-22. 
 
44 Nutley S, Walter I, Davies H. Promoting Evidence-Based Practice: Models and Mechanisms from 
Cross-Sector Review. Soc Work Pract 2009; 19: 552-9. 
 
45 Wong S. Tales from the Frontline: The Experiences of Early Childhood Practitioners Working with an 
‘Embedded’ Research Team. Eval Program Plann 2009; 32: 99-108. 
 
46 Hackett EJ, Rhoten DR. Engaged, Embedded, Enjoined: Science and Technology Studies in the 
National Science Foundation. Sci Eng Ethics. 2011; 17: 823-38. 
 
47 Lewis SJ, Russell AJ. Being Embedded: A Way Forward for Ethnographic Research. Ethnography. 
2011; 12: 398-416. 
 
48 Rowley H. Going Beyond Procedure: Engaging with the Ethical Complexities of Being an Embedded 
Researcher. Manag Educ. 2014; 28: 19-24. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 272 
 
49 Marshall M, Pagel C, French C, Utley M, Allwood D, et al. Moving Improvement Research Closer to 
Practice: The Researcher-in-Residence Model. BMJ quality & safety. 2014; 23(10): 801-5. 
 
50 Marshall MN. Bridging the Ivory Towers and the Swampy Lowlands; Increasing the Impact of Health 
Services Research on Quality Improvement. Int J Qual Health Care 2014; 26: 1-5. 
 
51 Marshall M. Researchers-in-Residence: A Solution to the Challenge of Evidence-Informed 
Improvement. Prim Health. 2014; 15(337-8). 
 
52 Duggan J. Critical Friendship and Critical Orphanship: Embedded Research of an English Local 
Authority Initiative. Manag Educ. 2014; 28: 12-8. 
 
53 Klotzbucher S. “Embedded Research” in Collaborative Fieldwork. J Curr Chin Aff. 2014; 43(2): 65-85. 
 
54 Eyre L, George B, Marshall M. Protocol for a Process-Oriented Qualitative Evaluation of the 
Waltham Forest and East London Collaborative (WELC) Integrated Care Pioneer Programme Using 
the Researcher-in-Residence Model. BMJ Open. 2015; 5(e009567). 
 
55 Platt R, Ramsberg J. Challenges for Sharing Data from Embedded Research. New England Journal of 
Medicine. 2016; 374(19): 1897-. 
 
56 Salokangas M, McGinity  R. Embedded Researchers Go Global! In: The University of Manchester UK, 
editor. The European Conference on Educational Research, The Need for Educational Research to 
Champion Freedom, Education and Development for All; Cádiz, Spain 2012. 
 
57 MacDonald S, Sharpe H, Shikako-Thomas K, Larsen B, Mackay L. Perspective: Entering Uncharted 
Waters: Navigating the Transition from Trainee to Career for the Nonphysician Clinician Scientist. 
Academic Medicine. 2013; 88(1): 1-6. 
 
58 Westfall J, Mold J, Fagnan L. Practice-Based Research - "Blue Highways" On the NIH Roadmap. 
JAMA. 2007; 297(4): 403-6. 
 
59 Barniskis SC. Embedded, Participatory Research: Creating a Grounded Theory with Teenagers. 
Evidence Based Library and Information Practice. 2013; 8(1): 47-58. 
 
60 Green LA, Hickner J. A Short History of Primary Care Practice-Based Research Networks: From 
Concept to Essential Research Laboratories. The Journal of the American Board of Family Medicine. 
2006; 19(1): 1-10. 
 
61 Lander B, Hanley GE, Atkinson-Grosjean J. Clinician-Scientists in Canada: Barriers to Career Entry 
and Progress. PLoS One. 2010; 5(10): 1-8. 
 
62 Morris ZS, Wooding S, Grant J. The Answer Is 17 Years, What Is the Question: Understanding Time 
Lags in Translational Research. Journal of the Royal Society of Medicine. 2011; 104(12): 510-20. 
 
63 Greyson D, Surette S, Dennett L, Chatterley T. “You're Just One of the Group When You're 
Embedded”: Report from a Mixed-Method Investigation of the Research-Embedded Health Librarian 
Experience. Journal of the Medical Library Association: JMLA. 2013; 101(4): 287. 
 
64 Marshall M, Pagel C, French C, et al. Moving Improvement Research Closer to Practice: The 
Researcher-in-Residence Model. BMJ Qual Saf. 2014; 23: 801-5. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 273 
 
65 Miller PJ, Goodnow JJ. Cultural Practices: Toward an Integration of Culture and Development. New 
directions for child and adolescent development. 1995; March(67): 5-16. 
 
66 Eccles M, Grimshaw J, Walker A, Johnston M, Pitts N. Changing the Behavior of Healthcare 
Professionals: The Use of Theory in Promoting the Uptake of Research Findings. Journal of clinical 
epidemiology. 2005; 58(2): 107-12. 
 
67 Kuhne GW, Quigley BA. Understanding and Using Action Research in Practice Settings. New 
Directions for Adult and Continuing Education. 1997; 1997(73): 23-40. 
 
68 Barab S, Zuiker S, Warren S, Hickey D, Ingram-Goble A, et al. Situationally Embodied Curriculum: 
Relating Formalisms and Contexts. Science Education. 2007; 91(5): 750-82. 
 
69 Anderson T, Shattuck J. Design-Based Research:   A Decade of Progress in Education Research? 
Educational Researcher. 2012; 41(1): 16-25. 
 
70 Hoskins ML. Living Research: The Experience of Researching Self, Other, and Discourse. Journal of 
Constructivist Psychology. 2000; 13(1): 47-66. 
 
71 Reis A. Bringing My Creative Self to the Fore: Accounts of a Reflexive Research Endevour. Creative 
Approaches to Research. 2011; 4(1): 2-18. 
 
72 Li J. Ethical Challenges in Participant Observation: A Reflection on Ethnographic Fieldwork. The 
Qualitative Report. 2008; 13(1): 100-15. 
 
73 Miller PJ, Goodnow JJ. Cultural Practices: Toward an Integration of Culture and Development. New 
directions for child and adolescent development. 1995; 1995(67): 5-16. 
 
74 Tsoukas H. The Validity of Idiographic Research Explanations. Academy of Management Review. 
1989; 14(4): 551-61. 
 
75 Anderson L, Anderson D. The Change Leader's Roadmap: How to Navigate Your Organization's 
Transformation: John Wiley & Sons; 2010. 
 
76 Burke WW, Litwin GH. A Causal Model of Organizational Performance and Change. Journal of 
management. 1992; 18(3): 523-45. 
 
77 Berwick DM. Developing and Testing Changes in Delivery of Care. Annals of Internal Medicine. 
1998; 128(8): 651-6. 
 
78 BehaviourWorks Australia. Stage Theories and Behaviour Change: Think Piece.  Victoria; 2016 [cited 
2016 21 April]; Available from: http://www.behaviourworksaustralia.org/. 
 
79 National Institute for Health and Clinical Excellence. How to Change Practice: Understand, Identify 
and Overcome Barriers to Change. National Institute for Health and Clinical Excellence. London, UK; 
2007. 
 
80 Australian Commission on Safety and Quality in Health Care, NSW Therapeutic Advisory Group. 
National Quality Use of Medicines Indicators for Australian Hospitals ACSQHC. Sydney; 2014. 
 
81 Nelson EC, Mohr JJ, Batalden PB, Plume S. Improving Health Care, Part 1: The Clinical Value 
Compass. The Joint Commission journal on quality improvement. 1996; 22(4): 243-58. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 274 
 
82 Batalden PB, Davidoff F. What Is “Quality Improvement” and How Can It Transform Healthcare? 
Quality and Safety in Health Care. 2007; 16(1): 2-3. 
 
83 Ravitch SM, Riggan M. Reason & Rigor: How Conceptual Frameworks Guide Research: Sage 
Publications; 2016. 
 
84 Department of Health and Ageing. National Medicines Policy. Australian Government. Canberra, 
ACT Australia; 2000. 
 
85 Department of Health and Ageing. Health for All Australians. Report to the Australian Health 
Ministers' Advisory Council and the Australian Health Ministers' Conference. The Health Targets and 
Implementation (Health for all) Committee. Canberra; 1988. 
 
86 Consumers Health Forum of Australia. Consumers Health Forum of Australia. 2010 [cited 2016 20 
April]; Available from: https://www.chf.org.au/      
 
87 Day RO. Pharmaceutical Health and Rational Use of Medicines Committee. Journal of Pharmacy 
Practice and Research. 2003; 33(2): 87-9. 
 
88 Grimshaw JM, Eccles MP, Lavis JN, Hill SJ, Squires JE. Knowledge Translation of Research Findings. 
Implementation Science. 2012; 7(50). 
 
89 Department of Health and Ageing. Manual of Indicators to Measure the Quality Use of Medicines 
Component of Australias National Medicines Policy. Commonwealth Government of Australia. 
Canberra, ACT; 2003. 
 
90 Australian Government Department of Health. Consumer Medicine Information (CMI). 2003 [cited 
2016 21 April]; Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-consumers-cmi.htm. 
 
91 Mant A. Quality Use of Medicines: Ten Years Down the Track. Australian Prescriber. 2001; 24(5): 
106-7. 
 
92 World Health Organization. How to Develop and Implement a National Drug Policy: World Health 
Organization; 2001. 
 
93 Australian Government Department of Health. Pharmaceutical Benefits Scheme. 2015 [cited 2014 
24 Sept]; Available from: http://www.pbs.gov.au/pbs/home  
 
94 Mabbott V, Storey P. Australian Statistics on Medicines 2014 2015 [cited 2016 14 Dec]; Available 
from: http://www.pbs.gov.au/statistics/asm/2014/australian-statistics-on-medicines-2014.pdf. 
 
95 PBS Information Management Section of the Pharmaceutical Policy Branch. Expenditure and 
Prescriptions Twelve Months to 20 June 2014. Department of Health and Ageing. Canberra; 2014. 
 
96 Australian Government Department of Health and Ageing. Therapeutic Goods Administration. 2014 
[cited 2016 21 April]; Available from: http://www.tga.gov.au. 
 
97 Industry Commission. The Pharmaceutical Industry. Australian Government Publishing Service,  
Melbourne, 1996. Report No: 51. 
 
98 Productivity Commission. Evaluation of the Pharmaceutical Industry Investment Program. SSRN 
Working Paper Series. 2008. 
  
Alice Victoria Gilbert | 2016    P a g e  | 275 
 
 
99 Department of Industry Tourism and Resources. Management of the Pharmaceutical Partnerships 
Program. Australian National Audit Office 46. ACT, Australia; 2007. 
 
100 Department of Health. Memorandum of Understanding with Medicines Australia. Commonwealth 
Government of Australia. Canberra, Australia; 2010. 
 
101 Australian Pharmaceutical Advisory Council. Guiding Principles to Achieve Continuity in Medication 
Management. Canberra, Australia: Australian Pharmaceutical Advisory Council,; 2005. 
 
102 NPS Medwise. National Prescribing Service (NPS).  NSW, Australia; 2016 [cited 2016 21 April]; 
Available from: http://www.nps.org.au/. 
 
103 Department of Health and Ageing. Guiding Principles for Medication Management in the 
Community. Australian Pharmaceutical Advisory Council. ACT, Australia; 2006. 
 
104 Glover JD, Tennant SK. Remote Areas Statistical Geography in Australia: Notes on the 
Accessibility/Remoteness Index for Australia (ARIA + Version): Public Health Information 
Development Unit, the University of Adelaide; 2003. 
 
105 Australian Institute of Health and Welfare. The Health and Welfare of Australia’s Aboriginal and 
Torres Strait Islander People, an Overview AIHW, editor. Canberra, Australia: Australian Institute of 
Health and Welfare; 2011. 
 
106 Australian Institute of Health and Welfare & Melbourne: Australian Institute of Family Studies. 
Improving the Accessibility of Health Services in Urban and Regional Settings for Indigenous People. 
Ware VA. Canberra, Australia; 2013. 
 
107 Department of Health. Annual Report: 2014-2015. Northern Territory Government. Casuarina, NT; 
2015. 
 
108 Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low Health Literacy and Health 
Outcomes: An Updated Systematic Review. Annals of internal medicine. 2011; 155(2): 97-107. 
 
109 Vaughan F. Pharmacists Where There Is No Pharmacy 9th National Rural Health Conference; 2007; 
Albury, NSW. 
 
110 Humphreys J, Wakerman J. Primary Health Care in Rural and Remote Australia: Achieving Equity of 
Access and Outcomes through National Reform. Paper commissioned by the National Health and 
Hospitals Reform Commission. 2008. 
 
111 Lowrie R, Morrison G, Lees R, Grant CH, Johnson C, et al. Research Is ‘a Step into the Unknown’: An 
Exploration of Pharmacists’ Perceptions of Factors Impacting on Research Participation in the NHS. 
BMJ open. 2015; 5(12): e009180. 
 
112 Boettcher-Dale S, Taylor JA. Do as I Do: The Importance of the Clinical Instructor as Role Model. The 
Journal of extra-corporeal technology. 1994; 26(3): 140-2. 
 
113 Bandura A, McClelland DC. Social Learning Theory. New York: General Learning Press. 1977. 
 




Alice Victoria Gilbert | 2016    P a g e  | 276 
 
115 Olesen VL, Whittaker EW. The Silent Dialogue: A Study in the Social Psychology of Professional 
Socialization: Jossey-Bass; 1968. 
 
116 Scott D, Brown A, Lunt I. Professional Doctorates: Integrating Academic and Professional 
Knowledge: Integrating Academic and Professional Knowledge: McGraw-Hill Education (UK); 2004. 
 
117 Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory. New York: 
Prentice-Hall, Inc; 1986. 
 
118 Prochaska JO, DiClemente CC. Toward a Comprehensive Model of Change. Treating Addictive 
Behaviors. USA: Springer; 1986. 
 
119 Ajzen I. From Intentions to Actions: A Theory of Planned Behavior. In: Kuhl J, Beckmann J, editors. 
Action Control: From Cognition to Behavior. Berlin, Heidelberg: Springer Berlin Heidelberg; 1985. p. 
11-39. 
 
120 Winett RA. A Framework for Health Promotion and Disease Prevention Programs. American 
Psychologist. 1995; 50(5): 341. 
 
121 Fishbein M, Ajzen I. Belief, Attitude, Intention, and Behavior: An Introduction to Theory and 
Research: Addison-Wesley 1975. 
 
122 Rosenstock IM, Strecher VJ, Becker MH. Social Learning Theory and the Health Belief Model. Health 
Education & Behavior. 1988; 15(2): 175-83. 
 
123 Lefebvre RC, Flora JA. Social Marketing and Public Health Intervention. Health Education & 
Behavior. 1988; 15(3): 299-315. 
 
124 Prochaska JO. Decision Making in the Transtheoretical Model of Behavior Change. Medical decision 
making. 2008; 28(6): 845-9. 
 
125 Langley GJ, Moen R, Nolan KM, Nolan TW, Norman CL, et al. The Improvement Guide: A Practical 
Approach to Enhancing Organizational Performance: John Wiley & Sons; 2009. 
 
126 Berwick DM, Nolan TW. Physicians as Leaders in Improving Health Care: A New Series in Annals of 
Internal Medicine. Annals of Internal Medicine. 1998; 128(4): 289-92. 
 
127 Victorian Government Department of Human Services. A Guide to Using Data for Health Care 
Quality Improvement. Victorian Quality Council. Melbourne, Australia; 2008. 
 
128 Solomon RJ. The Physician Manager's Handbook: Essential Business Skills for Succeeding in Health 
Care. 2 ed. Massachusetts: Jones and Bartlett; 2008. 
 
129 Khanna N, Nesbitt L, Roghmann M-C, Tacket C. Translation of Clinical Research into Practice: 
Defining the Clinician Scientist. Fam Med. 2009; 41(6): 440-3. 
 




131 Mental Health Council of Australia. Mental Health, Housing and Homelessness in Australia. MHCA 
Housing and Homelessness Working Group, 2009. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 277 
 
132 National Survey of Mental Health and Wellbeing: Summary of Results. Australian Bureau of 
Statistics. 4326. Canberra; 2007. 
 
133 Centre of Perinatal Excellence. COPE.  Flemington, Victoria; 2014 [cited 2016 02 Mar]; Available 
from: www.cope.org.au. 
 
134 Northern Territory Government of Australia. Department of Health - Royal Darwin Hospital, 2015 
[Sept 2015]; Available from: http://www.health.nt.gov.au/hospitals/royal_darwin_hospital/. 
 
135 Houston S. National Aboriginal Health Strategy Working Party. Aboriginal and Islander Health 
Worker Journal. 1989; 13(4): 7. 
 
136 Jorm AF, Bourchier SJ, Cvetkovski S, Stewart G. Mental Health of Indigenous Australians: A Review 
of Findings from Community Surveys. Med J Aust. 2012; 196(2): 118-21. 
 
137 Australian Government. Aboriginal and Torres Strait Islander Suicide: Origins, Trends and Incidence. 




138 Australian Bureau of Statistics. Cause of Death, Australia. Australian Bureau of Statistics. Canberra, 
Australia; 2014. 
 
139 Australian Indigenous HealthInfoNet. Summary of Australian Aboriginal and Torres Strait Islander 
Health, 2015. 2016 [cited 2016 11 July]; Available from: 
http://www.healthinfonet.ecu.edu.au/health-facts/summary. 
 
140 Department of Health. 2017 Cultural Awareness Training Program. Department of Health Training 
and Development 2017. 
 
141 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 
USA: American Psychiatric; 2013. 
 
142 Westerman T. Spinz National Symposium 2009 Culture and Suicide Prevention in Aotearoa: 
Aboriginal Mental Health and Suicide Prevention. In: Mental Health Foundation of New Zealand, 
editor.2009. 
 
143 Westerman T. Indigenous Psychological Services. 2014 [cited 2016 3 March]; Available from: 
https://www.indigenouspsychservices.com.au/. 
 
144 Gooda M, Dudgeon P, Dulumunmun Harrison M, et al. The Elders’ Report into Preventing 
Indigenous Self-Harm & Youth Suicide. National Mental Health Commission: Produced by People 
Culture Environment in partnership with Our Generation Media, , 2015. 
 
145 Short M. Choosing Lore and Life: The Campaign against Aboriginal Youth Suicide. Sydney Morning 
Herald. 2014. 
 
146 Horton DR. AIATSIS Map of Indigenous Australia. 1996 [cited 2016 12 July]; Available from: 
http://aiatsis.gov.au/explore/articles/aiatsis-map-indigenous-australia. 
 
147 Korff J. Aboriginal Culture - People - Mourning an Aboriginal Death. 2017 [cited 18 Feb 2017]; 
Available from: www.CreativeSpirits.info. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 278 
 
148 National Aboriginal Community Controlled Health Organisation. NACCHO - Aboriginal Health in 
Aboriginal Hands.  Canberra, Australia: NCN Communication Network; 2014 [cited 2016 10 March]; 
Available from: http://www.naccho.org.au/. 
 
149 Nagel TM, Thompson C. The Central Role of Aboriginal Families in Motivational Counselling: Family 
Support and Family "Humbug". Australian Indigenous Health Bulletin. 2010; 10(1). 
 
150 Day B. The Freedom to Sleep: A History from the Long Grass in Darwin, Northern Territory. Parity. 
2006; 19(10): 14. 
 
151 Larkin C, Murray R. Assisting Aboriginal Patients with Medication Management. Australian 
Prescriber. 2005; 28: 123-5. 
 
152 Mithen V, Vass A, Bulkanhawuy J, Saffi E, Mapleson J. Supporting Aboriginal Mental Health 
Workers; Research into Perspective System Change Gove: ARDS Aboriginal Corporation and NT 
Primary Health Network, , 2015. 
 
153 Pridmore S. Download of Psychiatry (DoP). Discipline of Psychiatry, editor. Tasmania: University of 
Tasmania; 2015. 
 
154 Flinders University through the Centre for Remote Health. CARPA: Standard Treatment Manual. 
Alice Springs: Centre for Remote Health; 2014. 
 
155 National Academies of Sciences Engineering and Medicine. The Health Effects of Cannabis and 
Cannabinoids: The Current State of Evidence and Recommendations for Research.  Washington DC, 
2017. 
 
156 Maher P. A Review of ‘Traditional’ aboriginal Health Beliefs. Australian Journal of Rural Health. 
1999; 7(4): 229-36. 
 
157 Nagel T, Thompson C. AIMHI Yarning About Mental Health - Make Change Grow Strong Story. In: 
Menzies School of Health Research, editor. Darwin, NT2007. 
 
158 Ngaanyatjarra Pitjantjatjara Yankunytjatjara Women's Council Aboriginal Corporation. Traditional 
Healers of Central Australia: Ngankari. Broome WA: Magabala Books; 2013. 
 
159 Arnott A, Guenther J, Davis V, Foster D, Cummings E. Evaluation of the Akeyulerre Healing Centre.  
Darwin: Charles Darwin University, 2010. 
 
160 Panzironi F. Hand-in-Hand. Report on Aboriginal Traditional Medicine. Anangu Ngangkari Tjutaku 
Aboriginal Corportation,  South Australia, 2013. 
 
161 Kenyon G. Is There a Place for Indigenous Healers in Australia's Health System? The Atlantic. 2016. 
 
162 Hastwell A. Aboriginal Healers Working to Keep Traditional Medicine Alive.  ABC Radio National. 
Australia 2014. 
 
163 Australian Health Ministers’ Advisory Council. Aboriginal and Torres Strait Islander Health 
Performance Framework 2014 Report. AHMAC. Canberra; 2015. 
 
164 World Health Organization. Adherence to Long-Term Therapies Evidence for Action. World Health 
Organisation. Switzerland; 2003. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 279 
 
165 Kumble S. Improving Medication Adherence Amongst Aboriginal and Torres Strait Islander Peoples. 
Discover the opportunities in general practice. 2013: 79. 
 
166 Murray R. Prescribing Issues for Aboriginal People. Australian Prescriber. 2003; 26: 55-7. 
 
167 Ring IT, Firman D. Reducing Indigenous Mortality in Australia: Lessons from Other Countries. 
Medical Journal of Australia. 1998; 169: 528-33. 
 
168 Commonwealth Grants Commission. Report on Indigenous Funding 2001. Commonwealth 
Government of Australia. Canberra; 2001. 
 
169 Swain L, Barclay L. They've Given Me That Many Tablets, I'm Bushed. I Don't Know Where I'm Going. 
Australian Journal of Rural Health. 2013; 21(4): 216-9. 
 
170 Stoneman J, Taylor SJ. Improving Access to Medicines in Urban, Regional and Rural Aboriginal 
Communities: Is Expansion of Section 100 the Answer? Rural Remote Health. 2007; 7(2): 738. 
 
171 Australian Institute of Health and Welfare. Australia's Health 2016. AIHW. AUS 199. Canberra; 
2016. 
 
172 Tett G. The Silo Effect: The Peril of Expertise and the Promise of Breaking Down Barriers: Simon and 
Schuster; 2015. 
 
173 The Legislative Assembly of the Northern Territory. Health Services Act, Act No 18  Northern 
Territory Government. (2014).  
 
174 Department of Health and Ageing. National Mental Health Report 2013: Tracking Progress of 
Mental Health Reform in Australia 1993 - 2011. Commonwealth Government of Australia. 10161. 
Canberra; 2011. 
 
175 Department of Health. Submission to the Senate Select Committee on Mental Health. Northern 
Territory Government. Northern Territory; 2005. 
 
176 Dooley M, Bogovic A, Carroll M, Cuell S, Galbraith K, et al. SHPA Standards of Practice for Clinical 
Pharmacy. Journal of Pharmacy Practice and Research [P]. 2005; 35(2): 122-46. 
 
177 AHRQ Patient Safety Network. Plan-Do-Study-Act. 2013 [cited 2016 25 Oct]; Available from: 
http://psnet.ahrq.gov/popup_glossary.aspx?name=plandostudyact  
 
178 Commonwealth Government of Australia. Development of the National Safety and Quality Health 
Service Standards. Australian Commission on Safety and Quality in Health Care. Sydney, Australia; 
2011. 
 
179 Grimshaw JM, Eccles MP. Is Evidence-Based Implementation of Evidence-Based Care Possible? 
Medical Journal of Australia. 2004; 180(6): S50. 
 
180 Grol R. Beliefs and Evidence in Changing Clinical Practice. BMJ. 1997; 315: 418-21. 
 
181 Commonwealth Government of Australia. National Safety and Quality Health Service Standards 
Australian Commission on Safety and Quality in Health Care. Sydney, NSW; 2012. 
 
182 ACSQHS. NSQHS Standards in 2013: Transforming the Safety and Quality of Health Care Australian 
Commission on Safety and Quality in Health Care. Sydney, NSW; 2014. 
  
Alice Victoria Gilbert | 2016    P a g e  | 280 
 
 
183 Øvretveit J. What Are the Best Strategies for Ensuring Quality in Hospitals? World Health 
Organization, editor: Citeseer; 2003. 
 
184 Scrivens E. Accreditation and the Regulation of Quality in Health Services. Regulating 
entrepreneurial behaviour in European health care systems. 2002: 91. 
 
185 Shaw C. Quality and Accreditation in Health Care Services: A Global Review. World Health 
Organization, editor: Evidence and Information for Policy & Department of Health Service Provision 
& World Health Organization; 2003. 
 
186 Hort K, Djasri H, Utarini A. Regulating the Quality of Health Care: Lessons from Hospital 
Accreditation in Australia and Indonesia. The Nossal Institute for Global Health, Working Paper 
Series. 2013; 28. 
 
187 O'Leary DS. Accreditation's Role in Reducing Medical Errors. British Medical Journal. 2000; 
320(7237): 727. 
 
188 Shaw CD. Toolkit for Accreditation Programs. Melbourne: International Society for Quality in Health 
Care (ISQua). 2004. 
 
189 Fletcher M. The Quality of Australian Health Care: Current Issues and Future Directions: Department 
of Health and Aged Care; 2000. 
 
190 Roughead EE, Semple SJ, Rosenfeld E. Literature Review: Medication Safety in Australia.  Sydney: 
Australian Commission on Safety and Quality in Health Care, 2013. 
 
191 Woodward CA, Egger D, Lipson D, Adams O, Buchan J, et al. Issues in Health Services Delivery: 
Improving Provider Skills: Strategies for Assisting Health Workers to Modity and Improve Skills, 
Developing Quality Health Care, a Process of Change. World Health Organization, editor: World 
Health Organization; 2000. 
 
192 Todnem R. Organisational Change Management: A Critical Review. Journal of Change 
Management. 2005; 5(4): 369-80. 
 
193 ACSQHC. Safety and Quality Improvement Guide Standard 4: Medication Safety. Australian 
Commission on Safety and Quality in Health Care. Sydney, Australia; 2012. 
 
194 NSW Therapeutic Assessment Group Inc. Medication Safety Self-Assessment® for Antithrombotic 
Therapy in Australian Hospitals. Clinical Excellence Commission. Sydney, Australia; 2007. 
 
195 Clinical Excellence Commission. Medication Safety Self-Assessment for Australian Hospitals. Clinical 
Excellence Commission. Sydney; 2007. 
 
196 Bazire S. Choice and Medication.  United Kingdom: Mistura Enterprise Ltd; 2016; Available from: 
http://choiceandmedication.org/northernterritory/. 
 
197 O'Leary K, Burke R, Kirsa S. Shpa Standards of Practice for the Distribution of Medicines in Australian 
Hospitals. Journal of Pharmacy Practice and Research. 2006; 36(2): 143-9. 
 
198 Roughead EE, Semple SJ. Second National Report on Patient Safety: Improving Medication Safety. 
Australian Council for Safety and Quality in Health Care. Canberra; 2002. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 281 
 
199 Westbrook J, Woods A, Rob M, Dunsmuir W, Day R. Association of Interruptions with an Increased 
Risk and Severity of Medication Administration Errors. Archives of Internal Medicine. 2010; 170(8). 
 
200 Thornton PD, Koller LJ. An Assessment of Medication Errors in a Seven-Day Issue Individualised 
Patient Drug Distribution System. Australian Journal of Hospital Pharmacy. 1994; 24(5): 387-91. 
 
201 Howkins E, Ewens A. How Students Experience Professional Socialisation. International Journal of 
Nursing Studies. 1999; 36(1): 41-9. 
 
202 Dooley M, Allen K, Dowling H, Y. A. Improved Medication Use and Reduction in Adverse Events in 
Hospitalised Patients: Impact of Clinical Pharmacists in Acute Care Australian Public Hospitals 
[Abstract]. Proceedings of the 1st Asia Pacific Forum on Quality Improvement in Health Care; 2001; 
Sydney, Australia. 
 
203 Davies H, Powell A, Rushmer R. Healthcare Professionals' Views on Clinician Engagement in Quality 
Improvement: A Literature Review.  Health Foundation 2007. 
 
204 The Department of Education and Training. HLT31412 - Certificate Iii in Hospital-Health Services 
Pharmacy Support. Australian Government. Canberra, Australia; 2013. 
 
205 General Pharmaceutical Council. Standards for the Initial Education and Training of Pharmacy 




206 SANE Australia. Antipsychotic Medication: Factsheet & Guide.  Victoria, Australia; 2016 [cited 2016 
11 July]; Available from: http://www.sane.org/mental-health-and-illness/facts-and-
guides/antipsychotic-medication. 
 
207 Roughead EE, Semple SJ. Medication Safety in Acute Care in Australia: Where Are We Now? Part 1: 
A Review of the Extent and Causes of Medication Problems 2002-2008. Australia and New Zealand 
Health Policy,. 2009; 6(1): 18. 
 
208 Allan E, Barker K. Fundamentals of Medication Error Research. American Journal of Health-System 
Pharmacy. 1990; 47(3): 555-71. 
 
209 Thornton PD, Koller LJ. An Assessment of Medication Errors in a Seven-Day Issue Individualised 
Patient Drug Distribution System. Australian Journal of Hospital Pharmacy. 1994; 24(5): 387-91. 
 
210 Rippe M, Hurley S. A Survey of Medication Errors in a Community Hospital. Aust J Hosp Pharm. 
1988; 18: 201-04. 
 
211 Stewart R, Naismith N, Biro J, Marinos Y, Woonton B. Establishing the Need for Ward Pharmacy: A 
Survey of Drug Administration and Medication Errors in a Public Teaching Hospital. Aust J Hosp 
Pharm. 1991; 21: 378-83. 
 
212 ACHS. Risk Management and Quality Improvement Handbook. The Australian Council on Healthcare 
Standards (ACHS). Sydney, Australia; 2013  
 
213 Therapeutic Goods Administration. Poisons Standard March 2016. Commonwealth Government of 
Australia. ACT, Australia; 2016. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 282 
 
214 Australian Commission on Safety and Quality in Health Care. Recommendations for Terminology, 
Abbreviations and Symbols Used in the Prescribing and Administration of Medicines. In: Working 
Group of the NSW TAG Safer Medicines Group. www.safetyandqualitygov.au 2008. 
 
215 Australian Commission on Safety and Quality in Health Care. National Inpatient Medication Chart 
Audit Tool. Commonwealth Government of Australia. http://www.safetyandquality.gov.au/wp-
content/uploads/2009/01/National-Inpatient-Medication-Chart-Audit-Form.pdf; 2010. 
 
216 ACSQHC. National Quality Use of Medicines Indicators for Australian Hospitals. . Australian 
Commission on Safety and Quality in Health Care, NSW Therapeutic Advisory Group. Sydney, NSW; 
2014. 
 
217 Kurr K. Mental Health Quality Use of Medicines Indicators Project. NSW Therapeutic Advisory Group 
& The Australian Commission on Safety and Quality in Health Care,  Sydney, NSW, 2013. 
 
218 ACSQHC. National Inpatient Medication Chart User Guide. Australian Commission on Safety and 
Quality in Health Care. Sydney, Australia; 2016. 
 
219 National Prescribing Service. Medication Safety Training, Online Courses. 2015 [cited 2016 4 April]; 
Available from: http://learn.nps.org.au/mod/page/view.php?id=4277. 
 
220 Shaw H, Mackie CA, Sharkie I. Evaluation of Effect of Pharmacy Discharge Planning on Medication 
Problems Experienced by Discharged Acute Admission Mental Health Patients. Int J Pharm Pract,. 
2000; 8: 144-53. 
 
221 Finley PR, Crismon ML, Rush AJ. Evaluating the Impact of Pharmacists in Mental Health: A 
Systematic Review. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,. 2003; 
23(12): 1634-44. 
 
222 Wolf C, Pauly A, Mayr A, Gromer T, Lenz B, et al. Pharmacist-Led Medication Reviews to Identify and 
Collaboratively Resolve Drug-Related Problems in Psychiatry - a Controlled, Clinical Trial. PLoS ONE,. 
2015; 10(11). 
 
223 Chan EW, Taylor SE, Marriott J, Barger B. An Intervention to Encourage Ambulance Paramedics to 
Bring Patients' Own Medications to the Ed: Impact on Medications Brought in and Prescribing 
Errors. Emergency Medicine Australasia. 2010; 22(2): 151-8. 
 
224 Australian Institute of Health and Welfare. Mental Health Services—in Brief 2015. AIHW. Cat. no. 
HSE 169. Canberra, Australia; 2015. 
 
225 Sorensen H. Northern Territory’s First Youth Mental Health Inpatient Program Launched in Darwin. 
 NT News. 2016. 
 
226 Tompson A, Peterson G, Jackson S, Hughes J, Raymond K. Utilizing Community Pharmacy 
Dispensing Records to Disclose Errors in Hospital Admission Drug Charts. International Journal of 
Clinical Pharmacology and Therapeutics. 2012; 50: 639-46. 
 
227 Marotti SB, Kerridge RK, Grimer MD. A Randomised Controlled Trial of Pharmacist Medication 
Histories and Supplementary Prescribing on Medication Errors in Postoperative Medications. 
Anaesthesia and intensive care,. 2011; 39(6): 1064-70. 
 
228 Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry: John Wiley & Sons; 
2015. 
  
Alice Victoria Gilbert | 2016    P a g e  | 283 
 
 
229 Roughead E, Procter N, Westaway K, Sluggett JK, Alderman CP. Medication Safety in Mental Health 
Report for the Australian Commission on Safety and Quality in Health Care.  Canberra: Quality Use 
of Medicines and Pharmacy Research Centre, 2016. 
 
230 Burridge N. SHPA Standards of Practice for the Provision of Medication Reconciliation. Journal of 
Pharmacy Practice and Research. 2007; 37(3): 231-3. 
 
231 Mueller SK, Sponsler K, Kripalani S, Schnipper JL. Hospital-Based Medication Reconciliation 
Practices: A Systematic Review. Archives of Internal Medicine. 2012; 172(14): 1057-69. 
 
232 Australian Commission on Safety and Quality in Health Care. Match up Medicines. 2010 [cited 2016 
10 Nov]; Available from: www.safetyandquality.gov.au/our-work/medication-safety/medication-
reconciliation/match-up-medicines/. 
 
233 Sullivan C, Gleason KM, Rooney D, Groszek JM, Barnard C. Medication Reconciliation in the Acute 
Care Setting: Opportunity and Challenge for Nursing. Journal of nursing care quality. 2005; 20(2): 
95-8. 
 
234 Vira T, Colquhoun M, Etchells E. Reconcilable Differences: Correcting Medication Errors at Hospital 
Admission and Discharge. Quality & safety in health care. 2006; 15(2): 122-6. 
 
235 Gleason K, McDaniel M, Feinglass J, Baker D, Lindquist L, et al. Results of the Medications at 
Transitions and Clinical Handoffs (Match) Study: An Analysis of Medication Reconciliation Errors and 
Risk Factors at Hospital Admission. J Gen Intern Med. 2010; 25(5): 441-7. 
 
236 ACSQHC. National Medication Management Plan User Guide. Australian Commission on Safety and 
Quality in Health Care. Sydney; 2009. 
 
237 Bazire S. Psychotropic Drug Directory 2016: The Professionals' Pocket Handbook and Aide Memoire. 
Mile Cross Lane, Norwich, Norfolk: Lloyd-Reinhold Publications Limited; 2016. 
 
238 Roughead E, Gadzhanova S. Reducing Adverse Medication Events in Mental Health National Survey 
Report: A Survey of Acute Inpatient Mental Health Units.  Adelaide: Quality Use of Medicines and 
Pharmacy Research Centre, 2016. 
 
239 Department of Health. Medicines, Poisons and Therapeutic Goods Act. Northern Territory 
Government. REPM052. Darwin; 2016. 
 
240 Department of Health. Northern Territory Medicines Management Framework. Northern Territory 
Government. Darwin; 2014. 
 
241 Coombes ID, Reid C, McDougall D, Stowasser D, Duiguid M, et al. Pilot of a National Inpatient 
Medication Chart in Australia: Improving Prescribing Safety and Enabling Prescribing Training. 
British Journal of Clinical Pharmacology,. 2011; 72(2): 338-49. 
 
242 Coombes ID, Stowasser DA, Reid C, Mitchell CA. Impact of a Standard Medication Chart on 
Prescribing Errors: A before-and-after Audit. Quality and Safety in Health Care. 2009; 18(6): 478-85. 
 
243 Breeding J, Welch S, Whittam S, Buscher H, Burrows F, et al. Medication Error Minimization Scheme 
(MEMS) in an Adult Tertiary Intensive Care Unit (ICU). Australian Critical Care. 2013; 26(2): 58-75. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 284 
 
244 Patel B. Moving to a Paperless Medication Management Process.  SHPA Medicines Management 
Conference Brisbane, Australia: SHPA;  2005. 
 
245 Australian Commission on Safety and Quality in Health Care. NIMC (Long-Stay). 2009 [cited 2016 11 
July]; Available from: http://www.safetyandquality.gov.au/publications/national-inpatient-
medication-chart-long-stay-version-for-acute-care/. 
 
246 Elliott RA, Tran T, Taylor SE, Harvey PA, Belfrage MK, et al. Gaps in Continuity of Medication 
Management During the Transition from Hospital to Residential Care: An Observational Study 
(Medgap Study). Australasian journal on ageing. 2012; 31(4): 247-54. 
 
247 Elliott RA, Tran T, Taylor SE, Harvey PA, Belfrage MK, et al. Impact of a Pharmacist-Prepared Interim 
Residential Care Medication Administration Chart on Gaps in Continuity of Medication 
Management after Discharge from Hospital to Residential Care: A Prospective Pre-and Post-
Intervention Study (Medgap Study). BMJ open. 2012; 2(3): e000918. 
 
248 Gilbert AV, Patel BK, Morrow M, Williams DB, Roberts MS, et al. Providing Community-Based Health 
Practitioners with Timely and Accurate Discharge Medicines Information. BMC health services 
research. 2012; 12(1): 453. 
 
249 Gilbert AV, Patel BK, Roberts MS, Williams DB, Crofton JH, et al. An Audit of Medicines Information 
Quality in Electronically Generated Discharge Summaries - Evidence to Meet the Australian National 
Safety and Quality Health Service Standards. J Pharm Pract Res. 2016. 
 
250 Wong JD, Bajear JM, Wong GG, Alibhai SM, Huh J-H, et al. Medication Reconciliation at Hospital 
Discharge: Evaluating Discrepancies. Annals of Pharmacotherapy. 2008; 42(10): 1373-9. 
 
251 Cummings E, Showell, C, Roehrer, E, Churchill, B, Turner, B., Yee, K.C, Wong, M.C, Turner, P. 
Discharge, Referral and Admission: A Structured Evidence-Based Literature Review.  On behalf of 
the Australian Commission on Safety and Quality in Health Care, and the NSW Department of 
Health). University of Tasmania, Australia, 2010. 
 
252 Wong M, Yee K, Turner P. Clinical Handover Literature Review, eHealth Services Research Group. 
University of Tasmania Australia: Australian Commission on Safety and Quality in Health Care. 
2008. 
 
253 Ramasamy S, Baysari M, Lehnbom E, Westbrook J. Evidence Briefings on Interventions to Improve 
Medication Safety Double-Checking Medication Administration. Australian Commission on Safety 
and Quality in Healthcare. 2013; 1(3). 
 
254 Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, et al. Schizophrenia, Neuroleptic 
Medication and Mortality. The British Journal of Psychiatry. 2006; 188(2): 122-7. 
 
255 Waddington JL, Youssef HA, Kinsella A. Mortality in Schizophrenia. Antipsychotic Polypharmacy and 
Absence of Adjunctive Anticholinergics over the Course of a 10-Year Prospective Study. The British 
Journal of Psychiatry. 1998; 173(4): 325-9. 
 
256 Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low Health Literacy and Health 
Outcomes: An Updated Systematic Review. Annals of internal medicine. 2011; 155(2): 97-107. 
 
257 Andrulis DP, Brach C. Integrating Literacy, Culture, and Language to Improve Health Care Quality for 
Diverse Populations Am J Health Behav. 2007; 31(Suppl 1): S122-S33. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 285 
 
258 Patel B. Communicating across Cultures: Proceedings of a Workshop to Assess Health Literacy and 
Cross-Cultural Communication Skills. Journal of Pharmacy Practice and Research. 2015; 45: 1-8. 
 
259 Fenton WS, Blyler CR, Heinssen RK. Determinants of Medication Compliance in Schizophrenia: 
Empirical and Clinical Findings. Schizophrenia bulletin. 1997; 23(4): 637-51. 
 
260 Nicolson D, Knapp P, Raynor DK, Spoor P. Written Information About Individual Medicines for 
Consumers.  Cochrane Database Syst Rev 2009. 
 
261 Jin M, Naumann T, Regier L, Bugden S, Allen M, et al. A Brief Overview of Academic Detailing in 
Canada: Another Role for Pharmacists. Canadian Pharmacists Journal: CPJ,. 2012; 145(3): 142-6.e2. 
 
262 National Prescribing Service. Aripiprazole for Schizophrenia. NPS RADAR. 2004; March: 1-5. 
 
263 National Prescribing Service. Aripiprazole Modified Release (Abilify Maintena) for the Treatment of 
Schizophrenia NPS RADAR. 2015; April. 
 
264 Bilal Motiwala F, Stasia Siscoe K, El-Mallakh RS. Review of Depot Aripiprazole for Schizophrenia. 
Patient Preference & Adherence. 2013; 7. 
 
265 Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, et al. Predictors and Clinical Consequences of 
Non-Adherence with Antipsychotic Medication in the Outpatient Treatment of Schizophrenia. 
Psychiatry research. 2010; 176(2): 109-13. 
 
266 National Institute for Health Care and Excellence. Evidence Summary: New Medicine: Schizophrenia: 
Aripiprazole Prolonged Release. London, UK: NHS; 2014. 
 
267 Lundbeck Australia Pty Ltd. Product Information for Auspar Abilify Maintena Aripiprazole In: 
Lundbeck Australia Pty Ltd, editor. Lundbeck Australia Pty Ltd. North Ryde NSW, 2014. 
 
268 Gopalakrishna G, Aggarwal A, Lauriello J. Long-Acting Injectable Aripiprazole: How Might It Fit in 
Our Tool Box? Clinical schizophrenia & related psychoses. 2013; 7(2): 87-92. 
 
269 Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, et al. Aripiprazole Once-Monthly 
for Treatment of Schizophrenia: Double-Blind, Randomised, Non-Inferiority Study. The British 
Journal of Psychiatry. 2014: bjp. bp. 113.134213. 
 
270 Royal Australian New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the 
Treatment of Schizophrenia Related Disorders. Royal Australian and New Zealand College of 
Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders. 
Australian and New Zealand Journal of Psychiatry. 2005; 39(1-2): 1-30. 
 
271 Keks N. Are Atypical Antipsychotics Advantageous? The Case For. Australian Prescriber. 2004; 27(6): 
146. 
 
272 Therapeutics Good Administration. Auspar: Aripiprazole Monohydrate. Commonwealth 
Government of Australia. PM-2013-01100-1-1. NSW; 2016. 
 




Alice Victoria Gilbert | 2016    P a g e  | 286 
 
274 Australian Commission on Safety and Quality in Health Care. High Risk Medicines.  Canberra; 2016 
[cited 2016 31st of Oct]; Available from: https://www.safetyandquality.gov.au/our-
work/medication-safety/medication-alerts/. 
 
275 Pfizer Australia Pty Ltd. Clopine Central. 2016 [cited 2015 27 Nov]; Available from: 
https://www.clopine.com.au/ClopineCentral/index.jsp. 
 
276 Society of Hospital Pharmacists of Australia. SHPA ClinCAT: Clinical Competency Assessment Tool for 
Australian Pharmacists. Collingwood, Australia: Society of Hospital Pharmacists Australia; 2010. 
 
277 Mekonnen A, McLachlan A, Brien J. Pharmacy-Led Medication Reconciliation Programmes at 
Hospital Transitions: A Systematic Review and Meta-Analysis.  Journal of Clinical Pharmacy and 
Therapeutics2016. p. 128-44. 
 
278 Angley M. Implementing and Evaluating a Parallel Post-Discharge Home Medicines Review (HMR) 
Model: Pharmacy Guild of Australia; 2011. 
 
279 Guérin A, Lebel D, Bussières J-F. Evidence for the Role and Impact of Pharmacists: Description of a 
Website. Canadian Pharmacists Journal : CPJ. 2015; 148(2): 68-70. 
 
280 Australian Commission on Safety and Quality of Health Care. Electronic Discharge Summary 
Systems Literature Scan Sydney, Australia, 2010. 
 
281 Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, et al. Deficits in Communication and 
Information Transfer between Hospital-Based and Primary Care Physicians: Implications for Patient 
Safety and Continuity of Care. JAMA. 2007; 297(8): 831-41. 
 
282 Hopcroft D, Calveley J. What Primary Care Wants from Hospital Electronic Discharge Summaries. 
NZFP, 2008. 
 
283 van Walraven C, Rokosh E. What Is Necessary for High-Quality Discharge Summaries? American 
Journal of Medical Quality. 1999; 14(4): 160-9. 
 
284 Yemm R, Bhattacharya D, Wright D, Poland F. What Constitutes a High Quality Discharge Summary? 
A Comparison between the Views of Secondary and Primary Care Doctors. International Journal of 
Medical Education. 2014 07/0506/01/accepted; 5: 125-31. 
 
285 Callen J, McIntosh J, Li J. Accuracy of Medication Documentation in Hospital Discharge Summaries: 
A Retrospective Analysis of Medication Transcription Errors in Manual and Electronic Discharge 
Summaries. International Journal of Medical Informatics. 2010; 79(1): 58-64. 
 
286 ACSQHC. Safety and Quality Evaluation of Electronic Discharge Summary Systems Final Report. 
Australian Commission on Safety and Quality in Health Care. Sydney, NSW; 2011. 
 
287 Reid DB, Parsons SR, Gill SD, Hughes AJ. Discharge Communication from Inpatient Care: An Audit of 
Written Medical Discharge Summary Procedure against the New National Health Service Standard 
for Clinical Handover. Australian Health Review. 2015; 39(2): 197-201. 
 
288 ACSQHC. Electronic Medication Management Systems — a Guide to Safe Implementation. 
Australian Commission on Safety and Quality in Health Care. Sydney, Australia; 2012. 
 
289 Quirke C. Hospital Network: Discharge Summary Policy.  Northern Territory Government, 2012. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 287 
 
290 Mant A, Rotem W, Kehoe L. Continuity of Care in Therapeutics from Hospital to Community. Stage 
Two: Reducing the Risk of Miscommunication About Medications. Final Report to Commonwealth 
Department of Health and Aged Care.  Canberra, 2001. 
 
291 Perren A, Previsdomini M, Cerutti B, Soldini D, Donghi D, et al. Omitted and Unjustified Medications 
in the Discharge Summary. Quality and Safety in Health Care. 2009; 18(3): 205-8. 
 
292 Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse Drug Events Occurring Following 
Hospital Discharge. Journal of General Internal Medicine. 2005; 20(4): 317-23. 
 
293 Hellström LM, Bondesson Å, Höglund P, Midlöv P, Holmdahl L, et al. Impact of the Lund Integrated 
Medicines Management (LIMM) Model on Medication Appropriateness and Drug-Related Hospital 
Revisits. European Journal of Clinical Pharmacology. 2011; 67(7): 741-52. 
 
294 Krueger RA, Casey MA. Focus Groups: A Practical Guide for Applied Research: Sage publications; 
2014. 
 
295 Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing 
Grounded Theory: Sage publications; 2014. 
 
296 National Health and Medical Research Council. National Statement on Ethical Conduct in Human 
Research and Ethical Review and Research Involving Only Low or Negligible Risk Northern Territory 
Government of Australia. Canberra, ACT; 2007. 
 
297 (NEHTA) NE-HTA. Discharge Summary. New South Wales, Australia: NEHTA; 2014. 
 
298 Smith CM. Documentation Requirements for the Acute Care Inpatient Record (AHIMA Practice 
Brief). Journal of AHIMA. 2001; 72(3): 56A-G. 
 
299 Department of Health. Discharge from Hospital: Pathway, Process and Practice. A Manual of 
Discharge Practice for Health and Social Care Commissioners, Managers and Practitioners. Health & 
Social Care Joint Unit and Change Agents Team. London, UK; 2003. 
 
300 Courtney J. Skype on Office 365, Outlook. Com and Lync.  Experience Skype to the Max: Springer; 
2015. p. 205-15. 
 
301 Stewart DW, Shamdasani PN. Focus Groups: Theory and Practice: Sage Publications; 2014. 
 
302 Gilbert AV, Morrow M, Patel B. Continuum of Care - a Simple Fax Helps. Across The Divide: 
Medicines Management 2009: The 35th SHPA National Conference; 2009; Perth, Australia. 
 
303 Gilbert AV, Roberts MS, Williams DB, Gilbert AL. Hospital Discharge Medicines Information: From 
Trial to Policy. Pharmacoepidemiology and Drug Safety. 2015; 24(Abstracts): 1-587. 
 
304 Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The Incidence and Severity of Adverse 
Events Affecting Patients after Discharge from the Hospital. Annals of Internal Medicine. 2003; 
138(3): 161. 
 
305 Roughead E, Kalisch L, Ramsay E, Ryan P, Gilbert A. Continuity of Care: When Do Patients Visit 




Alice Victoria Gilbert | 2016    P a g e  | 288 
 
306 Australian Government. Nt Primary Health Weekly: Primary Health Network, Northern Territory.  
Darwin; 2016 [cited 2016 23 Oct]; Available from: http://www.ntphn.org.au/news/nt-primary-
health-weekly. 
 
307 Australian Institute of Health and Welfare. Admitted Patient Care 2013–14: Australian Hospital 
Statistics. Australian Institute on Health and Welfare. Canberra, Australia; 2015. 
 
308 Alper E, O’Malley TA, Greenwald J, Aronson MD, Park L. Hospital Discharge and Readmission. 2014 
[cited 2015 1st of Feb]; Available from: 
http://www.uptodate.com/contents/topic.do?topicKey=PC/2790. 
 
309 Muecke S, Kalucy L, McIntyre E. Continuity and Safety in Care Transitions: Communication at the 
Hospital/Community Care Interface. RESEARCH ROUNDup. 2010; 11. 
 
310 Makeham MA, Kidd MR, Mira M. Lessons from the Taps Study: Communication Failures between 
Hospitals and General Practices. Australian Family Physician. 2008; 37(9): 735-6. 
 
311 Mant A, Kehoe L, Cockayne NL, Kaye KI, Rotem WC. A Quality Use of Medicines Program for 
Continuity of Care in Therapeutics from Hospital to Community. The Medical journal of Australia. 
2002; 177(1): 32. 
 
312 Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, et al. Unintended Medication 
Discrepancies at the Time of Hospital Admission. Archives of internal medicine. 2005; 165(4): 424-9. 
 
313 Stowasser DA, Stowasser M, Collins DM. A Randomised Controlled Trial of Medication Liaison 
Services-Patient Outcomes. Journal of Pharmacy Practice and Research. 2002; 32(2): 133-40. 
 
314 Kalisch LM, Caughey GE, Roughead EE, Gilbert AL. The Prescribing Cascade. Aust Prescr. 2011; 
34(6): 162-6. 
 
315 Howard R, Avery A, Slavenburg S, Royal S, Pipe G, et al. Which Drugs Cause Preventable Admissions 
to Hospital? A Systematic Review. British journal of clinical pharmacology. 2007; 63(2): 136-47. 
 
316 Gilbert AV RM, Williams D, Gilbert AL. Hospital Discharge Medicines Information: From Trial to 
Policy. Pharmacoepidemiology and Drug Safety. 2015; 24(Abstracts): 1-587. 
 
317 Australian Bureau of Statistics. 2011 Census - Northern Territory Specific Statistics. 2011 [updated 




318 Lehnbom EC, Raban MZ, Walter SR, Richardson K, Westbrook JI. Do Electronic Discharge Summaries 
Contain More Complete Medication Information? A Retrospective Analysis of Paper Versus 
Electronic Discharge Summaries. Health Information Management Journal. 2014; 43(3): 4. 
 
319 Angley M, Ponniah AP, Spurling LK, Sheridan L, Colley D, et al. Feasibility and Timeliness of 
Alternatives to Post-Discharge Home Medicines Reviews for High-Risk Patients. Journal of Pharmacy 
Practice and Research. 2011; 41(1): 27-32. 
 
320 Braet A, Weltens C, Sermeus W, Vleugels A. Risk Factors for Unplanned Hospital Re-Admissions: A 
Secondary Data Analysis of Hospital Discharge Summaries. Journal of Evaluation in Clinical Practice. 
2015; 21(4): 560-6. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 289 
 
321 Nebeker JR, Barach P, Samore MH. Clarifying Adverse Drug Events: A Clinician's Guide to 
Terminology, Documentation, and Reporting. Annals of internal medicine. 2004; 140(10): 795-801. 
 
322 Morimoto T, Gandhi T, Seger A, Hsieh T, Bates D. Adverse Drug Events and Medication Errors: 
Detection and Classification Methods. Quality and safety in health care. 2004; 13(4): 306-14. 
 
323 Aronson J. Medication Errors: What They Are, How They Happen, and How to Avoid Them. QJM. 
2009; 102(8): 513-21. 
 
324 Fryer-Edwards K. Teaching Module: Talking About Harmful Medical Errors with Patients Seattle, 
WA; 2016 [cited 2016 18 Jan 2016]; Available from: 
https://depts.washington.edu/toolbox/errors.html. 
 
325 Semple S. Literature Review: Medication Safety in Acute Care in Australia. Adelaide: Australian 
Commission on Safety and Quality in Healthcare. 2008. 
 
326 Roughead E, Bedford G. Medication Safety: Will Adverse Drug Events Be Reduced. Windows into 
safety and quality in health care. 2008; 2008. 
 
327 Roughead EE, Lexchin J. Adverse Drug Events: Counting Is Not Enough, Action Is Needed. The 
Medical Journal of Australia. 2006; 184(7): 315. 
 
328 Oliver D, Daly F, Martin FC, McMurdo ME. Risk Factors and Risk Assessment Tools for Falls in 
Hospital in-Patients: A Systematic Review. Age and ageing. 2004; 33(2): 122-30. 
 





330 Pertrain. Risk Assessment Tools: Industry Specific Stationery, Forms, Permits and Posters.  
Queensland, Australia; 2014 [cited 2016 5th of March]; Available from: 
http://www.pertrain.com.au/risk-assessment-tools/. 
 
331 Barach P, Small SD. Reporting and Preventing Medical Mishaps: Lessons from Non-Medical near 
Miss Reporting Systems. British Medical Journal. 2000; 320(7237): 759. 
 
332 Cohen MR. Why Error Reporting Systems Should Be Voluntary: They Provide Better Information for 
Reducing Errors. BMJ: British Medical Journal. 2000; 320(7237): 728. 
 
333 Wolf ZR, Hughes RG. Patient Safety and Quality: An Evidence-Based Handbook for Nurses: Error 
Reporting and Disclosure. Amsterdam: Elsevier Science B.V; 2008. 
 
334 Cohen M. Discussion Paper on Adverse Event and Error Reporting in Healthcare. Huntingdon Valley: 
Institute for Safe Medication Practices. 2000. 
 
335 Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human: Building a Safer Health System: National 
Academies Press; 2000. 
 
336 Cousins D. Safety in Doses: Improving the Use of Medicines in the NHS. London: National Patient 
Safety Agency. 2007. 
 
  
Alice Victoria Gilbert | 2016    P a g e  | 290 
 
337 Milch CE, Salem DN, Pauker SG, Lundquist TG, Kumar S, et al. Voluntary Electronic Reporting of 
Medical Errors and Adverse Events. Journal of General Internal Medicine. 2006; 21(2): 165-70. 
 
338 ISMP Survey Helps Define near Miss and Close Call. Institute for Safe Medication Practices. 2009; 
2009(September 24): 1. 
 
339 Sokol DK. “First Do No Harm” Revisited. BMJ. 2013 2013-10-25 14:33:45; 347. 
 
340 Montesi G, Lechi A. Prevention of Medication Errors: Detection and Audit. British journal of clinical 
pharmacology. 2009; 67(6): 651-5. 
 
341 Coombes ID, Stowasser DA, Coombes JA, Mitchell C. Why Do Interns Make Prescribing Errors? A 
Qualitative Study. Medical Journal of Australia. 2008; 188(2): 89. 
 
342 Nichols P, Copeland T-S, Craib IA, Hopkins P, Bruce DG. Learning from Error: Identifying 
Contributory Causes of Medication Errors in an Australian Hospital. Medical Journal of Australia. 
2008; 188(5): 276. 
 
343 Evans SM, Berry J, Smith B, Esterman A, Selim P, et al. Attitudes and Barriers to Incident Reporting: 
A Collaborative Hospital Study. Quality and Safety in Health Care. 2006; 15(1): 39-43. 
 
344 PSNet A. Patient Safety Primer: Voluntary Patient Safety Event Reporting (Incident Reporting). 2014 
[updated Aug 2014;  2015]; Available from: 
http://psnet.ahrq.gov/printviewPrimer.aspx?primerID=13. 
 
345 Abbasi T, Adornetto-Garcia D, Johnston PA, Segovia JH, Summers B. Accuracy of Harm Scores 
Entered into an Event Reporting System. Journal of Nursing Administration. 2015; 45(4): 218-25. 
 
346 Vincent C, Taylor-Adams S, Chapman EJ, Hewett D, Prior S, et al. How to Investigate and Analyse 
Clinical Incidents: Clinical Risk Unit and Association of Litigation and Risk Management Protocol. 
BMJ: British Medical Journal. 2000; 320(7237): 777. 
 
347 Reckmann MH, Westbrook JI, Koh Y, Lo C, Day RO. Does Computerized Provider Order Entry Reduce 
Prescribing Errors for Hospital Inpatients? A Systematic Review. Journal of the American Medical 
Informatics Association. 2009; 16(5): 613-23. 
 
348 Chaudhry B, Wang J, Wu S, Maglione M, Mojica W, et al. Systematic Review: Impact of Health 
Information Technology on Quality, Efficiency, and Costs of Medical Care. Annals of internal 
medicine. 2006; 144(10): 742-52. 
 
349 Qureshi NA, Al-Dossari DS, Al-Zaagi IA, Al-Bedah AM, Abudalli ANS, et al. Electronic Health Records, 
Electronic Prescribing and Medication Errors: A Systematic Review of Literature, 2000-2014. British 
Journal of Medicine and Medical Research. 2015; 5(5): 672-704. 
 
350 Department of Health. Health Incident Management Policy. Northern Territory Government. 2014. 
 
351 Westbrook JI, Li L, Lehnbom EC, Baysari MT, Braithwaite J, et al. What Are Incident Reports Telling 
Us? A Comparative Study at Two Australian Hospitals of Medication Errors Identified at Audit, 
Detected by Staff and Reported to an Incident System. International Journal for Quality in Health 
Care. 2015; 27(1): 1-9. 
 
352 RiskMan. Riskman; Practical Innovative Risk Management.  Level 2, 11 Meaden St, Southbank, VIC 
3006; 2015 [cited 2015 Sept]; Available from: http://www.riskman.net.au/. 
  
Alice Victoria Gilbert | 2016    P a g e  | 291 
 
 
353 Fleiss JL. The Measurement of Interrater Agreement. Statistical methods for rates and proportions. 
1981; 2: 212-36. 
 
354 Kaur S, Roberts JA, Roberts MS. Evaluation of Medication-Related Problems in Medication Reviews: 
A Comparative Perspective. Annals of Pharmacotherapy. 2012; 46(7-8): 972-82. 
 
355 Westbrook JI, Reckmann M, Li L, Runciman WB, Burke R, et al. Effects of Two Commercial Electronic 
Prescribing Systems on Prescribing Error Rates in Hospital in-Patients: A before and after Study. 
PLoS Med. 2012 Jan; 9(1): e1001164. 
 
356 Day RO, Roffe DJ, Richardson KL, Baysari MT, Brennan NJ, et al. Implementing Electronic Medication 
Management at an Australian Teaching Hospital. The Medical Journal of Australia. 2011; 195(9): 
498. 
 
357 Department of Health. Therapeutic Goods Administration: Scheduling of Medicines & Poisons. 
Commonwealth Government of Australia. Canberra, Australia; 2015. 
 
358 Woodward M, Beer J, Mackay S, Gray L. The Clinical Value Compass: Achieving Benchmarking and 
Quality Improvement in Aged Care. Australasian journal on ageing. 2000; 19(1): 11-3. 
 
359 Bergkvist A, Midlöv P, Höglund P, Larsson L, Bondesson Å, et al. Improved Quality in the Hospital 
Discharge Summary Reduces Medication Errors—LIMM: Landskrona Integrated Medicines 
Management. European journal of clinical pharmacology. 2009; 65(10): 1037-46. 
 
360 Bennett C. National Health and Hospitals Reform Commission: A Healthier Future for All 
Australians. Final Report of the National Health and Hospitals Reform Commission, Canberra. 2009. 
 
361 Australian Indigenous HealthInfoNet. Summary of Australian Indigenous Health. 2012 [cited 2015 
12 Dec]; Available from: http://www.healthinfonet.ecu.edu.au/health-facts/summary. 
 
362 Randolf J. On Line Kappa Calculator. 2012 [cited 2012 13 March ]; Available from: 
http://justusrandolph.net/kappa. 
 
363 Stamp K, Duckett S, Fisher DA. Hospital Use for Potentially Preventable Conditions in Aboriginal and 
Torres Strait Islander and Other Australian Populations. Australian and New Zealand journal of 
public health. 1998; 22(6): 673-8. 
 
364 Madden A. HMRs with Indigenous Communities - Challenges and Rewards [Online]. Australian 
Pharmacist. 2011; 30(11): 911-2, 4-5. 
 
365 Patel B. Chronic Disease Management for Aboriginal and Torres Strait Islander Australians. 
Australian Journal of Pharmacy. 2007; 88: 23–4. 
 
366 National Institute for Health and Care Excellence. Guidance for Hospital and Community 
Pharmacists to Support Patient Discharge from Hospital.  UK; 2012 [cited 21 Nov 2015]; Available 
from: http://www.npc.nhs.uk/rapidreview/?p=4916. 
 
367 Queensland Governement. Audit Tools for National Safety and Quality Health Service Standards.  




Alice Victoria Gilbert | 2016    P a g e  | 292 
 
368 Dean AG, Sullivan KM, Soe MM. Openepi: Open Source Epidemiologic Statistics for Public Health. 
2015 [29 Oct 2015]; Available from: www.OpenEpi.com. 
 
369 NSW Therapeutic Advisory Group. Indicators for Quality Use of Medicines in Australian Hospitals. 
2007. 
 
370 Mant A, Rotem WC, Kehoe L, Kaye KI. Compliance with Guidelines for Continuity of Care in 
Therapeutics from Hospital to Community. The Medical Journal of Australia. 2001; 174(6): 277-80. 
 
371 Stowasser DA, Stowasser M, Collins D. A Randomised Controlled Trial of Medication Liaison 
Services-Acceptance and Use by Health Professionals. Journal of Pharmacy Practice and Research. 
2002; 32(3): 221-6. 
 
372 ACSQHC. Safety and Quality Improvement Guide Standard 6: Clinical Handover (October 2012). 
Australian Commission on Safety and Quality in Health Care. Sydney; 2012. 
 
373 NSW Therapeutic Advisory Group Inc. Ensuring Explanations for Changes to Medication Therapy in 
the Discharge Summary – a Quality Improvement Project. Feedback Presentation. 2007. 
 
374 Mant A, Kaye K, Kehoe L, Brien J. Continuity of Care in Therapeutics from Hospital Community. 
Evaluation of the implementation and effectiveness of the 1998 APAC national guidelines to 
achieve the continuum of quality use of medicines between hospital and community: Report 
prepared for the Commonwealth Department of Health and Ageing. 2002. 
 
375 Abbasi T, Adornetto-Garcia D, Johnston PA, Segovia JH, Summers B. Accuracy of Harm Scores 
Entered into an Event Reporting System. Journal of Nursing Administration. 2015; 45(4): 218-25. 
 
376 Creswell JW, Piano VL. Designing and Conducting Mixed Methods Research. Sage Publications, Ltd.; 
2011. 
 
377 Georgatos G. The Extensiveness of Aboriginal & Torres Strait Islander Suicides – 1 in 20. The Stringer 
Independent News. 2015. 
 
378 Bonson D. Indigenous Suicide – White Comfort Politics and Survivorship. The Stringer Independent 
News. 2016. 
 
379 Skelton R. Girls at Greater Risk of Suicide since Intervention. Sydney Morning Herald. 2012. 
 
380 Scrymgour M. NT Suicide Report Findings Backed. THE KOORI MAIL. 2012; Sect. 1-96. 
 
381 Parke E. Families Urged to Look after Each Other as Kimberley Region Records Seven Suicides in 
Seven Weeks. ABC News. 2014. 
 
382 McMullen J. Can NT's First Indigenous Chief Minister Turn Back the Tide? Sydney Morning Herald. 
2013. 
 
383 Middleton S. Suicide: The Tragic Facts. Koori Mail. 2013;Sect. 1-98. 
 
384 Brown P. Aboriginal Suicide. The Stringer. 2014. 
 
385 Georgatos G. Catastrophic Suicide Crisis Will Escalate “Unless”…. The Stringer. 2015. 
 
386 Georgatos G. Understanding Australia’s Suicide Crises. The Stringer. 2015. 
  
Alice Victoria Gilbert | 2016    P a g e  | 293 
 
 
























Alice Victoria Gilbert | 2016    P a g e  | 295 
 
Appendix 1: Aboriginal and Torres Strait Islander Mental Illness Statistics130 
“Western Australia leads the Aboriginal suicide rates, with 35.8 per 100,000 
Aboriginal populations. The Northern Territory has a similar suicide rate – 
35.2 suicides per 100,000 people. These rates are three times the suicide 
rate of Aboriginal people in NSW, and twice the Queensland rate.”377 
“95% of Aboriginal people in Australia are affected by suicide”378 
“On the Tiwi Islands, north of Darwin in the Northern Territory, steel spikes 
on power poles were removed to try to stop young people from hanging or 
electrocuting themselves.379 From 2000 to 2005 the Islands were known as 
the “suicide capital” of the world.” 
“Young Aboriginal men are the highest risk group, with young Aboriginal 
women catching up.380 In the Northern Territory, Aboriginal youth suicide is 
10 times higher than for non-Aboriginal youth. ”144 
“The likelihood of an Aboriginal person committing suicide is 6 times more 
likely than a non-aboriginal person. The Kimberly Region, Western Australia, 
and The Northern Territory, has one of the highest suicide rates in the 
world.”381 
“30 young people in every 100,000 commit suicide in the Northern Territory. 
Same figure for New South Wales: 1 in 100,000” each year 379 
“80% of suicides of youth aged 10 to 24 in 2011, the victim was Aboriginal. 
Same figure for 1991: 10%”.382 
“The proportion of suicide rate for Aboriginal males is 40% higher than that 
for non-Aboriginal males”383 
 “The Aboriginal youth suicide rate is higher than every country in the world, 
except for Greenland”384 
“For Aboriginal children aged 14 years and less, suicide is the second 
leading cause of death – and they are 8 times more likely to die by suicide 
than their non-Aboriginal peers. For young Aboriginal people aged 15 to 35 
years, suicide is the leading cause of death – 30% of deaths in this vast age 
group are reported as suicides – therefore nearly one in three deaths in this 
20-year age group are suicides.”385 
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“For every suicide there are many more attempted suicides (some estimate 
up to 40386), and hundreds of incidences of self-harm. The hospitalisation 
rate for intentional self-harm for non-Aboriginal Australians in 2014 stood at 
142 per 100,000 people but for Aboriginal Australians the rate was 379 per 
100,000, an increase from about 260 per 100,000 in 2004. Aboriginal women 
endured hospitalisation rates of 440 per 100,000 as opposed to 320 per 
100,000 for their men.”377 
“A 10-year-old has taken her own life. She was one of my people, your 
people. Our people. She was a young Australian girl. My heart is heavy as I 
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Appendix 2: Australian Institute of Aboriginal and Torres Strait Islander Studies: Map of Indigenous Australia146 
 
The map was produced by David 
Horton in an attempt to represent 
all the language, tribal or nation 
groups of the Aboriginal people 
of Australia. Aboriginal groups 
were included on the map based 
on the published resources 
available between 1988 and 
1994 which determine the 
cultural, language and trade 
boundaries and relationships 
between groups.146  
 
  
Alice Victoria Gilbert | 2016    P a g e  | 298 
 





Alice Victoria Gilbert | 2016    P a g e  | 299 
 





Alice Victoria Gilbert | 2016    P a g e  | 300 
 
Appendix 5: Key Mental Health Reforms and Policy Context in the Northern Territory (Reproduced from 175)  
 
 
July 1993 - June 1998 First National Mental Health Plan Medicare Agreements 
July 1998 - June 2003 Second National Mental Health Plan Australian Health Care Agreements 
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Appendix 6: National Safety and Quality Health Service Standards181 
 
1. Governance for Safety and Quality in Health Service Organisations which 
describes the quality framework required for health service organisations to 
implement safe systems. 
 
2. Partnering with Consumers which describes the systems and strategies to 
create a consumer-centred health system by including consumers in the 
development and design of quality healthcare. 
 
3. Preventing and Controlling Healthcare Associated Infections which 
describes the systems and strategies to prevent infection of patients within the 
healthcare system and to manage infections effectively when they occur to 
minimise the consequences. 
 
4. Medication Safety which describes the systems and strategies to ensure 
clinicians safely prescribe, dispense and administer appropriate medicines to 
informed patients. 
 
5. Patient Identification and Procedure Matching which describes the systems 
and strategies to identify patients and correctly match their identity with the 
correct treatment. 
 
6. Clinical Handover which describes the systems and strategies for effective 
clinical communication whenever accountability and responsibility for a patient’s 
care is transferred. 
 
7. Blood and Blood Products which describes the systems and strategies for 
the safe, effective and appropriate management of blood and blood products so 
the patients receiving blood are safe. 
 
8. Preventing and Managing Pressure Injuries which describes the systems 
and strategies to prevent patients developing pressure injuries and best practice 
management when pressure injuries occur. 
 
9. Recognising and Responding to Clinical Deterioration in Acute 
Healthcare which describes the systems and processes to be implemented by 
health service organisations to respond effectively to patients when their clinical 
condition deteriorates.  
 
10. Preventing Falls and Harm from Falls which describes the systems and 
strategies to reduce the incidence of patient falls in health service organisations 
and best practice management when falls do occur.  
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Appendix 7: TEMHS Medication Safety and Quality Working Group: Terms of 
Reference 
 
MEDICATION SAFETY AND QUALITY WORKING GROUP (TEMHS) 
Terms of Reference 
 Version: 3 
 Review Interval: Annually 
 Date for Review: 1 April 2015 
 Controller: Alice Gilbert 
 Approved: 1 April 2014 
Endorsed by Director Mental Health Services: ………………………………….. 
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1. VISION 
The TEMHS medication safety and quality working group will promote Quality Use of 
Medicines in line with Australia’s National Medicines Policy. This multidisciplinary group 
will work to enhance medication safety and quality by improving safe medication use 
practices throughout the acute setting and the wider community. 
 
2. AIM 
The TEMHS medication safety and quality working group aims to ensure safe, 
appropriate and cost-effective use of medicines and to minimise patient harm due to 
medication errors. The working group has been established to co-ordinate communication 
and activities throughout the service to positively contribute to the health and safety of the 
TEMHS patients and staff.   
 
3. ROLE & FUNCTION 
• Co-ordinate, promote, evaluate and oversee initiatives and structures to improve 
medication safety across TEMHS. 
• Promote rational, high quality, cost-effective use of medicines throughout the 
service. 
• Identify policy directives, priorities and strategic directions for service development 
and delivery, relevant to medication safety and medication safety-related research.  
• Provide TEMHS directives related to medication safety, and coordinate the 
implementation and evaluation of these as appropriate.  
• Facilitate communication regarding medication safety between relevant 
stakeholders involved, including hospital and community healthcare professionals, 
patients and policy-makers.  
• Promote a culture of shared learning and ongoing practice improvement regarding 
medication safety. 
• To facilitate ongoing practice improvement and knowledge of medication safety and 
efficacy issues through education and research.  
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• Support the Northern Territory drug and therapeutics committee including 
development of appropriate formulary applications.  
• Develop or adopt national or hospital-developed guidelines aimed at 
standardisation of practices which are medication-related. 
• Provide input into education programs in relation to access, quality, and safety of 
medicines across all sites.  
• Develop, disseminate and support strategies or working groups to assist TEHMS in 
achieving the safe and efficacious use of medicines. 
4. REPORTING 
The medication safety working group reports to the TEMHS Corporate leadership and 
clinical governance and to the Top End Hospital Service medication safety and quality 
committee. 
Minutes of meetings will be distributed electronically to Committee members no later than 
fourteen days following each meeting. Previous meeting minutes are to be confirmed and 
accepted by two members at the following meeting. Confirmed minutes will be forwarded 
electronically to the TEMHS staff for information. 
Reports of activities are presented at appropriate meetings (such as Friday doctors’ 
meeting for prescribing activities, team meetings or grand rounds for service-wide 
activities) or via written information and shared electronically. 
Implementation and evaluation of medication quality improvement activities will be 
documented in to RiskManQ. 
 
5. STRUCTURE AND MEMBERSHIP 
 5.1 Membership 
Members of the group will be initially appointed by the chairperson, in consultation with the 
director of psychiatry and nursing director of TEMHS. The representatives will be TEMHS 
wide. 
The committee will be multidisciplinary representing healthcare professionals involved in 
the medication management cycle including consumers, medical, pharmacy, nursing and 
executive.  
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Each member will nominate a proxy reflecting the profile of the member who will attend in 
the member’s absence. The committee will recommend a nominee(s) for any vacant 
position/s that may arise.  
The term of appointment has no fixed time limit.  
Senior Clinical Pharmacist RDH (Chair) 
Quality Unit Representative (Secretary) 
Pharmacy Technician– Position  
Community Mental Health Pharmacist representative – discharge and outpatient 
medication supply 
General Manager of TEMHS 
Director of Psychiatry 
Nursing Director, Mental Health 
Medical Representative – Inpatient Unit  
Medical Representative –Tamarind 
Nursing Representative – Inpatient Unit  
Nursing Representative –Tamarind 
Forensic mental health team representative 
CATT Team representative 
Remote team representative 
Consumer Representative 
Carer Representative 
5.2 Declarations of conflict of interests (CoI) 
At the start of each meeting the Chair will require a completed CoI declaration from all 
members. The CoI relates to conflicts that arise for the set agenda for that meeting.  
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5.3 Officeholders  
• Election of officers  
To be reviewed at the commencement of each calendar year. 
 
5.4 Meetings 
Meetings are generally held every month at a place and time determined by the 
Chairperson. The Chairperson can also convene additional meetings, and cancel or defer 
meetings according to the Committee’s business requirements.  
A quorum is five in total including the chair, however, both a nursing and a medical 
representative must be present. 
The decision-making will be done by a majority of members present only when a quorum 
is available. An out-of-session decision can be made through a response that is supported 
by a majority to circulated proposal (the same quorum rules apply).  
The agenda will be circulated, a week before the next meeting, by the secretary and/or 
chair, and any member can submit items to be added to the agenda. 
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Appendix 8: TEMHS Medication Safety and Quality Action Plan and Audit Schedule 
Abbreviations:  
TEHS Top End Health Service 
TEMHS Top End Mental Health Service 
GM General Manager 
TM Team managers 
IFD Infectious diseases medical team 
eMMa Electronic medication management application 
NTDTC Northern Territory Drugs and Therapeutics Committee 
VTE Venous Thromboembolism 
NIMC National Inpatient Medication Chart 





ISSUE ACTION Responsibility Measures to check progress 









































NTMHS representative on 
the NTDTC. done 
Formation of TEHS 
medication safety committee 
and TEMHS representative. 
done  
TEMHS medication safety 
and quality working group 
(multidisciplinary) done 
Director of Psychiatry 
NTMHS pharmacist 
Chaired by NTMHS 
(represented by a 
member of each 
team within TEMHS) 
TOR’s, attendance records, 
agenda’s, minutes, actions, 
information distributed. 
 
Attendance records recorded.  
Proxy for director of psychiatry and 
formal feedback process to 
disseminate and feedback to and 










ISSUE ACTION Responsibility Measures to check progress 













Development of appropriate 
policies and guidelines, and 
identification of gaps where 
policies would enhance 
practice family tree 
complete/ additional 
actions required 
Educational activities, for all 
clinical safe, targeting their 
discipline needs done 
Audit schedule related to 
various essential 
components done 







See audit schedule 
See policy/ protocol family tree 
Awaiting policies and protocols to 
develop: 
• Medication management 
framework done 
• Medication administration policy 
done 
• Prescribing policy not done 
• Dispensing policy not done 
• Provision of medication for non-
hospitalised patients review 
• Missed depots review 
• Leave medications review 
• High risk meds for mental health 
review 
• Medication administration 
(remote/ community) not done 
• Using the fridge monitors (all) 
not done (KG to do) 
• Managing medicines in 
disasters (e.g. power failures, 

















ISSUE ACTION Responsibility Measures to check progress 






eMMa Implementation of eMMa 
across TEMHS  
eMMa working 
group/TEMHS 
governance/ DoH  
Delayed, due to software alterations. 
Progression to move Aim to be 
implemented on TEMHS inpatient 
units by March 2015  
Formation of TEMHS working group. 
Project officer to manager 
implementation. done 
Training of all staff 
Workflow of leave and outpatients 
using electronic environment 










Develop and Implement an 
antimicrobial stewardship 
program in conjunction with 
IFD/micro/Infection 
Control/RDH pharmacy. To 
follow NTDTC guidelines for 
restricted antibiotics and 
VTE prophylaxis  
Director of Pharmacy 
& NTDTC 
Identification of patients requiring 
monitoring within our service. 
Referral to clinical pharmacist for 
medication review. 
Report to antimicrobial stewardship 
pharmacist to be included in audit 
 
 
Review VTE prophylaxis guidelines 





NT wide formulary 
for medications 
Director of Psychiatry to sit 
as an active member on the 
NTDTC. Regular review of 
the NT formulary and related 
guidelines, and amend as 
where required 
Need to liaise with RDH 
Pharmacy and TEMHS 
clinical pharmacist 
TEMHS Medication 
Safety Group and 
NTDTC 
Audit compliance with the formulary 
established by Clinical Pharmacist 
and supported by collaborative work 
with RDH Pharmacy 
Group submission to NTDTC for 
additions and removal of MH 
medication 
 
New form for submissions to NTDTC 
formulary application  



































Create procedures and 
consistencies in all teams of 
working with multiple 
systems  
DoH and TEMHS 
governance 
Audit of community and NIMC ‘Cheat sheets’ for staff on where is 
the best place to find information 
(e.g. remote patients) 
 
Standardise documentation to have 

















ISSUE ACTION Responsibility Measures to check progress 















monthly report  
Monthly report from RiskMan 
discussed at TEHS medication safety 
committee. Trends identified 
Action plan for trends identified in 
TEMHS and standing item on 







taken on admission 
and documented in 
medical record 
As with RDH – a formal 
reconciliation process will 
need to be implemented. A 
source of truth between all 
systems will also need to be 
established 
 
Medical officers and 
clinical pharmacist  
 Baseline audit to be done in January 
to see current service standard 
during admission notes 
Audits to be done every six months 
by clinical pharmacist. Aim: Complex 
patients to be referred to clinical 
pharmacist for medication history and 
reconciliation All patients to have a 
medication history completed within 
24 hours of admission 
Training for staff to complete the 
most accurate history when clinical 
pharmacist not available 
 
Cheat sheet on where to confirm 

























ISSUE ACTION Responsibility Measures to check progress 








Provision of clinical 
pharmacy services 
Continue to prioritise clinical 
pharmacy services to clinical 
areas at highest risk of 
medication misadventure 
Clinical Pharmacist/ 
GM/ Director of 
pharmacy RDH 
Clinical pharmacist to be referred to 
HDU psychiatric patients for review. 
Clinical pharmacist to develop and 
document clinical KPI’s. Aim: 100% 
HDU psychiatric patients. 
Note: Currently, a priority is to 
establish documentation 
infrastructure for medication safety. 
Work load is high and clinical KPIs 
are currently impossible to achieve.  
Identify Drug Use Evaluation studies 
that can demonstrate cost savings to 
provide additional pharmacy services 
 
Additional pharmacy services to be 
provided to TEMHS 
Business case proposals to be 

















Implement a medication 
management plan at 
TEMHS/TEHS 
Clinical Pharmacist / 
Quality Manager / 
TEHS medication 
safety meeting 
An incremental process will be 
undertaken to change practice.  
Appropriate process and medication 
plan for service identified 
Medication management plan 
implemented across service 
Uptake and compliance of action 
plan to be audited within all staff 
documentation audit 
Note: Future plans to have a high risk 
identification to notify clinical 
pharmacist to complete 
 
Awaiting software upgrade within 
eMMa 
MSSA March 2015 
  





ISSUE ACTION Responsibility Measures to check progress 






























Documentation of known 
medication allergies and 
adverse drug reactions in the 
patient clinical record 
Quality Manager / 
Clinical Pharmacist/ 
All clinical staff’ 
responsibility to 
complete 
Audit strategies – to be included in 
documentation audit 
NIMC/eMMa/CCIS. Aim: 100% of 
patients with allergy status recorded 
(report can be generated from eMMa 
once system has been implemented) 
Aim: 100% of clients with drug 
intolerance have status recoded 
Implementation of TEHS policy on 
ADRs done 
 
RiskMan policy/protocol to be 
developed not done 
 








and Restricted S4’s 
Ensure that Medications are 




Manager and Clinical 
Pharmacist 
Monthly audit by pharmacy 
technician Results of DD register 
submitted to GM and team managers 
to distribute to staff  
Aim: 100% compliance with 
legislation and 0% discrepancies 
within register 
Move storage in line with TEHS 
policy 
Complete baseline audit using 
dispensary software data to see 
supply and utilisation  
NTDTC Jan 2015 
Ensure that all 
clinical areas have 
appropriate 
facilities for storing 
refrigerated items 
and that fridges are 
appropriately 
monitored 
Policy for monitoring and 
maintenance of medication 
fridges developed in 2011 
and reviewed in 2014 
Plan to replace all domestic 
fridge’s by 2015 




Daily temperature recording 
Audit of medication fridges 
Audit forms to be collected monthly 
and scanned into F drive by quality 
manager or team manager on ward 
Aim: 100% compliance with 
monitoring guidelines. Cost analysis 
sent to general manager if stock must 
be discarded 
ECT fridge to be replaced NTDTC Dec 2015 
Ensure that a 
system for 
identification and 
disposal of expired 
medication in 
pharmacy and ward 
Monthly expiry date checks 
for ward imprest 
Pharmacy technician 
or allocated RN 
Retain documentation for evidence 
Return to pharmacy department for 
correct destruction 
Disposal of medicines policy to be 
developed and implemented (see 
remote health manual) 
Family tree Aug 2015 
  





ISSUE ACTION Responsibility Measures to check progress 






areas is in place  
System for 
appropriate storage 
and management of 
patient’s own 
medication 
Develop guideline for 
management and storage of 
patient’s own medication 
Introduction of dedicated bag 
for storage of patient’s own 
meds 
Clinical Pharmacist/ 
director of pharmacy/ 
quality unit and GM 




Added check on nursing admission 
form done 
 
Consistent storage spots for POMs in 
all inpatient wards done 
 
Return of POM at point of discharge 
– develop discharge checklist for 
technician not done 





























on the ward 
Guidelines for storage 
developed and distributed 
June 2012 
Maintain and store non-
imprest medications in 





Monthly audit of missed doses due to 
meds unavailable pre & post 
(pharmacy tech) 
Random 3-month audit of correct 
medications in right patient’s 
containers. Aim: 0% missed doses 
and 100% correct medications  


























S Provision of medicines 
information and 
explanation of 
changes to primary 
care provider on 
discharge 
Discharge summaries 
populated in Jade Care and 
on CCIS by medical officers  
Once eMMa is implemented, 
pharmacists able to amend 
discharge prescriptions in 
eMMa  
Discharge medication will 
auto populate from eMMa 
into the discharge summary 
without need for transcription 
Pharmacist-generated 






Audit 12-monthly of discharge 
summaries from TEMHS 
Also to be audited within 
documentation audit 
Discharge summaries completed and 
forwarded within 24 hours, and 
accuracy of information contained 
Rolling audit of summaries completed 
weekly by administration staff 
Aim: All discharge summaries to be 
completed within 24 hours with 
accurate and complete medication 
See audit schedule MSSA Oct 2015 
  





ISSUE ACTION Responsibility Measures to check progress 






completed within 24 hours of 
discharge including changes 








Medication information is 
given verbally, and in written 
form whenever possible, and 
documented in hard copy of 
case notes when provided 
Pharmacy to implement 
patient copy of discharge 
medications supplied with all 
discharge medications post 
eMMa implementation 





Discharge summaries contain 
medication information notation that 
clients and carers have had 
education and information-related to 
these 
Aim: 100% of patients provided with 
information regarding their 
medications on discharge 
Choice and medication website 
subscription done 
 
Choice and medication patient 
brochure to go with every discharge 
done 
 
Medication profile from Merlin to go 
with every discharge from ward done 
 
Develop audit to review information 
at the point of discharge not done 
 
Develop audit for website feedback 
from consumers not done 
 
Contact website vendors to provide 
access statistics to feedback to 



























Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec AUDIT TOOL Responsibility 
Medication 
Storage 
Schedule 8: Compliance 
check of register  
Quarterly             S8 audit tool TEMHS inpatient 
nurse (working 





storage in clinical area and 
imprest room and 
cupboards locked 







Medication fridge audit  
(compliance with 
temperature recording - 
monthly) 
Report on condition and 


















Technician accuracy of 
medication buckets 
(inpatient) six monthly 
auditing will be performed 
by the supervising 
pharmacist and feedback 
and additional on the job 
training will be provided to 
ensure on-going accuracy 










Percentage of patients 
whose current medications 
are documented and 
reconciled at admission: 
review of medical records 
including medication 





group rep) & 
Pharmacist 
  










Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec AUDIT TOOL Responsibility 
charts and / or other 
purpose designed forms 
Medication 
History Guideline 
Percentage of patients 
with a documented best 
possible medication 
history 










Percentage of patients 
whose known adverse 
drug reactions are 
documented on the current 
medication chart: Review 
of medication charts and 
medical records. 












Percentage of medication 
orders that include error-
prone abbreviations 














Percentage of discharge 
summaries that include 
medication therapy 
changes and explanations 
for changes: Review of 
medical records including 
medication charts and 
discharge documentation. 
Differences between 
admission and discharge 
medications should be 
assumed to represent 
medication therapy 
changes. 
Annual             TEMHS 
discharge 
audit tool 
TEMHS med safety 
and quality working 
group 
  














Compliance Report - 
timeliness 
Weekly             Caresys 
report - Demi 
Administration staff 






documenting written info 






















Pharmacy involved in 
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Appendix 9: Business Case for Top End Mental Health Service Pharmacy 
Technician 
 
Service Development- Proposal - Describe Proposal: 
Enhancing pharmacy services to the Top End Mental Health Service (TEMHS) through the 
establishment of a Pharmacy Technician (T2) position, who will improve drug distribution 
services, improve patient safety by preventing medication related errors and provide a cost 
minimisation strategy. It will enable the senior clinical pharmacist and nursing staff to 
provide essential patient care services by reducing time which is currently taken up by 
essential technical duties.  Pharmacy technicians are well established in the acute care 
setting in the NT as an essential part of effective drug distribution services.  
Division/Department: 
Top End Mental Health Services 
Output Group: 
Top End Mental Health Services 
Person(s) Accountable for Proposal and Management there of: 
Specialist Mental Health Clinical Pharmacist and General Manager of Top End Mental 
Health Service 
Potential Benefits Justifying Proposal: (Describe) 
Improving medication safety is an urgent task. 1 in 5 things that go wrong in hospitals are 
associated with medication misadventure. Estimated costs to the Australian health system 
of adverse events resulting from medications has been estimated to be around $380M per 
year based on 2003 figures.198 A study in Australians hospitals showed a $23.00 saving for 
every $1 spent on clinical pharmacy services.17  
Medication Safety is a mandatory criterion in the new National Safety and Quality Health 
Service Standards.181  Pharmacy involvement in the distribution and storage of medicines 
to clinical areas is a key component of a hospitals ability to demonstrate compliance with 
this standard.  
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Recruitment of a suitably experienced pharmacy technician to work in the area of mental 
health is essential to ensure medications are used in a safe and efficacious manner and to 
ensure that harm associated with their use is minimised. Services provided by a clinical 
pharmacist and supported by an appropriately trained pharmacy technician have been 
shown to help reduce this risk. Integration of a pharmacy technician as an essential 
component of medication systems makes a significant contribution to reducing medication 
errors by having safe and appropriate storage of stock, supply of stock and evaluation of 
usage (cost minimisation). These technical duties are currently undertaken and monitored 
by the senior clinical pharmacist and nursing staff, reducing the amount of nursing time 
available for direct patient care.   
Roles for Technician 
The key roles for the proposed technician and the potential benefits to the service are: 
Organising and maintaining imprest. This includes ordering and delivery of stock, expiry 
date monitoring, returns, and stock rotation.  The technician will review and update the 
imprest list on a regular basis in accordance with the changing requirements of the unit.  
• An initial review of the inpatient unit’s imprest demonstrated multiple patient safety 
issues such as expired stock (therefore stock not available or expired being used) 
and patients own medicines being returned into imprest stock. 
• The imprest review showed a potential saving of over $10 000 to the unit by 
returning non-imprest medications to the hospital pharmacy and ensuring correct 
stock rotation. Imprest review should occur every six months and would be a 
responsibility of the technician.  
• $13 254 worth of medications have also recently been discarded due to lack of 
monitoring of ward fridges. This is a basic and key responsibility for a pharmacy 
technician.  
• The management of all aspects of ward imprest currently fall on the senior clinical 
pharmacist and nursing staff. A pharmacy technician is trained and efficient in stock 
supply and management and is more cost effective resource for this role. A 
technician providing this service enables both the senior clinical pharmacist and 
nursing staff to focus on essential patient care services. 
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Dispensing of discharge prescriptions and non imprest supplies and co-ordination of 
supply from external providers.  
• The pharmacy technician can prioritise discharges. This will reduce the time delay 
in providing medication at the point of discharge and therefore increasing patient 
flow.  
• Collection of healthcare card details and documentation is sub-optimal throughout 
TEMHS. This is a primary role of a pharmacy technician. An estimate from last 
month’s medication invoice for the outpatient clients indicated that approximately $2 
340 could be saved each month which would be predicted as a potential saving of 
$28 000 per annum.  
• The technician would also be responsible for liaising with the community 
pharmacies to ensure continuity of care and free up time for the specialist 
pharmacist to provide medicines information to patients and carers. 
Drugs of dependence review (in preparation for the planned amendments to Poisons and 
Dangerous Drugs Act) 
• This will be a large change for the service as currently schedule 4’s such as 
benzodiazepines are not being recorded or counted. This will be a significant 
increase in duties for both the senior clinical pharmacist and nursing staff. This 
monitoring and workflow could be co-ordinated and checked by the pharmacy 
technician.  
Preparation of pre-packs for out of hours’ use 
• “Leave medication” or after hours’ supply is currently a high risk area within the 
TEMH service (they are often labelled incorrectly and do not meet all of the 
legislative requirements.) A pharmacy technician would take the responsibility of 
stocking and maintaining pre-packs and adjusting according to the service’s needs. 
• Preventing the use of drug company sample packs is a key patient safety initiative 
which would be monitored by a pharmacy technician and prevented by the 
introduction of pre-packs. 
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Establishing a pharmacy technician service will provide a cost-effective means of 
addressing many of the current risks around medication safety within TEMHS, and reduce 
the burden of technical duties currently on nursing staff.  
Resource Requirements: (Specify) 
Include: 
The salary cost of a T2 Level Pharmacy Technician 
Annual salary        $ 57 861 
Building Space / Facilities 
Managed within existing facilities – no extra costs will be incurred 
Equipment 
Managed within existing facilities – no extra costs will be incurred 
Implications If Proposal Not Approved (Describe) 
If proper systems for ordering, storage and distribution of medicines within TEMHS are not 
implemented, medications will continue to be ordered in excessive amounts, stored 
inappropriately, and exceed their expiry date, which contributes to increased costs, a high 
risk of medication misadventure, and a reduction in patient flow. A pharmacy technician is 
the most appropriate and cost-effective employee trained to perform storage and supply 
duties. The lack of technical support throughout TEMHS places unnecessarily high 
demands on the time of the senior clinical pharmacist, and on nursing staff, that should be 
used on direct patient care activities. 
The commissioner for public employment has listed pharmacy technicians as front-line 
service in that they facilitate patient care in agreement with chief executives. The 
employment of pharmacy technicians is strongly supported by the Hospital Executive for 
the acute sector. 
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Appendix 10: Northern Territory List of Clinical Technician Duties 
DATE WARD  Technician 
   
DUTIES                                                                              TALLY                  TOTAL 
Check bed list for new admissions   
Discuss with pharmacist regarding which 
patients to review 
  
Check whether medication history is present in 
notes 
  
If no, complete non–clinical areas of MAP   
Ask patient if they have brought own meds and 
locate them 
  
Check bedside locker for previous patient’s 
medications 
  
Check relevant trolley compartment for 
previous patient’s medications 
  
Remove unwanted medicines found during 
trolley/locker check 
  
Identify patients for transfer by comparing list 
from previous day 
  
Contact the current patient’s GP, community 
pharmacy or nursing home and request 
medication list be faxed 
  




Review non-imprest list and check if previously 
supplied on Ascribe 
  
Order any imprest items on requisition, if 
required 
  
Arrange transfer of medication to & from other 
wards, if required 
  
Liaise with pharmacist for new medication 
required 
  
TOP UP DAYS 
Check supplies in medication drawers against 
med chart 
  




Prepare med prof’s and print any CMI’s   
Prepare dose instructions for complex 
medications e.g. prednisolone /warfarin 
  
Arrange discharge / warfarin stickers   
Transfer information from MAP to D/C fax: e.g. 
GP & community pharmacy details 
  
Dispense discharge prescriptions (DAA’s to be 
packed by dispensary staff) 
  
Other duties on ward Time spent on non-clinical work 
 Dispensary  
 Imprest  
 Pharmaceutical Reforms  
 Other  
Total   
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Appendix 11: Training and Accuracy Testing of Technician 
Part 1: Filling of Patient own medication bedside lockers for Inpatient Unit. 
Training of Technician accuracy  
A week must be set aside for the initial training of the technician. This will include practical 
sessions with a supervising pharmacist on the ward. 
The technician will continue to work under direct supervision for stocking of patients’ own 
medication bedside lockers until he or she has satisfied the requirements of the final 
assessment.  
Testing of Technician accuracy 
After the training period, a full week to be set aside for accuracy testing. This will expose 
the technician to a wide range of scenarios and a large number of items. This is also to 
make it as close to unsupervised work as possible.  
1. Discuss with your Manager when is the most appropriate time to complete the 
assessment. 
2. The suggested time frame in which you should complete the test is around 1-2 weeks: 
• ½  a week for practice with the assistance of the pharmacist and feedback with no 
testing 
• ½  a week for practice without pharmacist assistance with feedback and no testing  
• 1 week to complete 300 items chosen to be tested and checked for accuracy.  
3.  To start to acquire the medication charts from nurse’s station (after morning medication 
rounds and before lunch time round).  
4.  Remove the chart, and the corresponding patient medication basket, from the 
medication trolley (so as to stop confusion between patients) and check the following  
• All prescribed medication is to be in the basket (do not fill PRN’s in individual 
lockers as they are in the PRN draw) 
o Please add PRN’s that are not stocked in the PRN section of the medication 
trolley and are unique to a specific patient (e.g. salbutamol inhaler) 
• Medication is correct 
• Strength of medication is correct 
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• Form of medication is correct 
• All medication is in date and has a batch number visible 
• Enough doses for the patient are available in the basket until the next scheduled 
check 
• Any required non-imprest stock is ordered (see transcription procedure)  
• All medication in the basket is for the designated patient 
• Ceased or discontinued medications are removed 
5. To complete the assessment you are required to accurately store 500 items in 
medication lockers.   
6. To successfully achieve the assessment you should make no more than:  
1 'serious' and 2 'less serious' 
Or 0 ‘serious and 3 ‘less serious’ 
Serious errors are: 
• Incorrect medication in basket for selected patient 
• Incorrect drug ordered (see transcription accuracy)  
• Incorrect dose form of medication 
• Medication not available and not ordered for selected patient 
• Medication is expired or has no batch number available 
Less serious errors are: 
• Not enough doses of correct medication available 
• Too many doses available (overstocked) patient basket 
• Patient’s own, or discharge medication, is being used as inpatient stock (without 
approval) 
7. Throughout the first week, feedback will be given at the time of checking the individual 
lockers and any errors will be clarified and discussed upon error. This first week will be 
supervised work, and opportunity for the technician to ask questions to clarify processes 
which can be done at any time. 
In the second week the technician will fill lockers unsupervised and then be independently 
checked by the pharmacist. All feedback will be given after all checks have been 
completed and any errors have been discussed. 
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During the assessment week, no feedback will be given until all 300 items have been 
checked by the pharmacist and the testing finalised. The pharmacist will be checking after 
each re-stocking has been completed to ensure that errors are corrected and patients are 
not being put at risk. The feedback will be withheld until the end of the assessment period. 
If more than one serious error occurs early in the week, the assessment period can be 
suspended and additional training provided before re-starting the 300 item assessment.  
8. If you have not successfully achieved the standard set for the assessment, you should:  
• discuss the types of errors you have made  
• reflect on why you think they happened  
• decide if there is anything that can be done to improve your accuracy  
• then repeat the assessment.  
9. If you have successfully achieved the standard set for the assessment, well done on 
your achievement! 
10. After the accuracy testing has been completed, management and nursing staff will be 
notified that the technician will be responsible for the role of stocking patients’ own 
medication lockers on the inpatient unit. Please note that assessment of transcribing non-
imprest orders will need to be done and completed to finalise the complete responsibility of 
this role.  
11. Weekly checks, for four weeks post-assessment completion, will continue to ensure 
on-going accuracy. Six monthly auditing will be performed by the supervising pharmacist, 
and as well feedback and additional on-the-job training will be provided. 
12. The clinical pharmacist will be available, and contactable, at all times for any queries, 
clarifications or concerns to help support the technician with this duty. 
 
Pharmacist signature ………………………………………….. Date 03/06/13 
 
 
Technician signature ……………………………………………Date 03/06/13 
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Part 2:  Transcription accuracy for non-imprest items 
Training for technicians for transcribing non-imprest orders  
The clinical pharmacist will demonstrate how to transcribe non-imprest orders to the 
technician (including stat, regular and PRN.)  
The technician can practice transcribing, with the supervision of the pharmacist, to enable 
time to ask questions, identify any difficulties and to help expose the technician to a range 
of different orders, abbreviations and handwriting. 
Suggested amount of practice items to be transcribed by the technician is 250.  
The technician will continue to work under direct supervision until he or she has satisfied 
the requirements of the final assessment.  
Testing of Technician accuracy when transcribing non-imprest orders. 
A total number of 500 items should be correctly transcribed in 2 hours. 
1. Discuss with your Manager when and where is the most appropriate time to complete 
the assessment. 
2.  To begin make sure that there are enough photocopied medication charts with a variety 
of medication, quantities, doses, forms etc. and enough non-imprest sheets.  
3.  When ready, start the clock. All 500 items should be correctly transcribed within the 2 
hour time frame. 
4. To successfully achieve the assessment you should make no more than: 
1 serious' and 2 'less serious' 
Or 0 ‘serious and 3 ‘less serious’ 
Serious errors are: 
• Incorrect medication identified (incorrectly read) 
• Incorrect medication transcribed 
• Incorrect patient for ordered medication 
• Incorrect dose form of medication  
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Less serious errors are: 
• Not enough doses  
• Too many doses  
• Incomplete orders transcribed (not indicating frequency or route) 
5. If you have not successfully achieved the standard set for the assessment, you should:  
• discuss the types of errors you have made  
• reflect on why you think they happened  
• decide if there is anything that can be done to improve your accuracy  
• then repeat the assessment.  
 
6. If you have successfully achieved the standard set for the assessment, well done on 
your achievement! 
7. After completing the accuracy testing, the technician may now be responsible for 
ordering non-imprest medications. 
8. If a medication chart has been screened by the ward pharmacist, the technician may 
now order non-imprest items by transcribing what is required and sending the order to the 
dispensary. The technician is to photocopy, and fax medication charts, with non-imprest 
order to allow for double checking by pharmacist within the dispensary if a medication 
chart has not been screened. The original chart should be annotated as supplied by the 
technician and sent to pharmacy (via PCA) to be reconciled. 
9. The clinical pharmacist is to be available at all times to help clarify or support the 
technician with this role. 
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Appendix 15: Participant information sheet and an invitation to participate 
email and Survey Tool 
 
Participant Information Sheet  
THIS IS FOR YOU TO KEEP 
REVIEW  OF THE UPTAKE AND BENEFITS OF DISCHARGE 
MEDICINES INFORMATION PROVIDED BY PHARMACISTS:  AN 
END USER SURVEY.
 
INV ITATION   
You are being asked to volunteer in a research study titled, Review of the uptake 
and benefits of discharge medicines information provided by hospital pharmacists: 
An end user survey. 
 
The aim of this study is to ask primary healthcare providers to provide feedback on 
the discharge medicines information chart provided by hospital pharmacists. In 
particular we are hoping to gather information from General Medical Practitioner’s 
(GP’s), Remote Medical Practitioners (RMP’s) and Community Pharmacists (CPs) to 
determine if: 
• Is it useful?  
• Contains all the desired information?  
• Is utilised in a way that is intended?  
• Improves continuum of care by communication? 
 
Additionally, we would like to utilise this opportunity to plan for a multidisciplinary 
discharge summary in the future.  
 
This research is being conducted by the Northern Territory Department of Health.   
  
The research team is being led by Alice Gilbert, Senior Clinical Pharmacist. Other 
team members include Ms Bhavini Patel and Professor Michael Roberts.  
 
What is the aim of this study?  
  
The primary aim of this study is to explore and compare the priorities and values of 
healthcare practitioners working at either side of the primary and secondary care 
interface of medicines-related discharge information. The secondary objectives were 
to investigate perceptions of, and preferences for, the timeliness, level of accuracy, 
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What will I be asked to do?  
 
If you choose to complete the online survey you will be asked a small number of 
questions regarding medicines information provided to you after a patient is 
discharged from hospital. You will not be asked to identify yourself directly.   
You will only need to tick a box for most answers. It should take no more than 5-10 
minutes. If you would like a hard copy of the survey to complete, please let us know 
and we will post this out to you. Please complete the survey only once.  
 
Are there any possible benefits from joining this study?  
  
Whilst, you may find the questions interesting, you will not otherwise gain any 
personal benefit from participating in this study. More broadly, your contribution will 
help improve medicines information provided to primary healthcare providers after a 
patient has been discharged from hospital.  
  
Are there any risks from joining in this study?  
  
Apart from your time to complete the survey, we can foresee no risks for you. Your 
involvement in this study is voluntary and you may withdraw your participation at any 
time during the survey without your responses being recorded. Once you have 
completed the survey your responses will be recorded and will not be able to be 
withdrawn. Should you decide not to participate in this study your decision will not 
influence your relationship with the project and/or the researchers.  
Your survey responses will be anonymous and confidential.  The survey will not 
capture your email address and the link to the survey we have provided you is a 
generic link which does not contain any unique identifiers.  If you feel that by 
completing the questions about yourself and your current work you would be giving 
enough information to be directly identified, you may choose to leave the question on 
your Faculty unanswered to protect your identity.  All survey responses will be 
aggregated and your responses will not be used outside the needs of the current 
study.  Only aggregated data will be included in published reports on this study.   
Whilst overall, the risks from joining this study are deemed low, the survey questions 
may cause an emotional response. In the unlikely event this occurs please cease the 
survey and contact a support person. The research team are also happy to do this 
on your behalf. Options for further support including your local GP, Lifeline (Ph: 13 
11 14) and Beyond Blue (Ph: 1300 22 4636) should this be required.   
 
How will the results of the study be published?  
  
Results from this study will be made in to a report. You can ask for a copy of the 
report. The results may also be printed in an academic journal and presented at 
meetings.   
 
What if I have questions about this study?  
If you have any questions about this study you can contact the Chief Investigator, 
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This study has been approved by the Human Research Ethics Committee of the 
Northern Territory Department of Health and Menzies School of Health Research 
(HREC).  If you have concerns or complaints about the conduct of this study should 
contact the Executive Officer of the HREC on (08) 8946 8687 or email 
ethics@menzies.edu.au.  The Executive Officer is the person nominated to receive 
complaints from research participants. You will need to quote the HREC Ethics 
reference number: HREC-2015-2503.  
 
Now what?  
  
This Information Sheet is yours to keep. Proceeding with the online survey will 
indicate your consent to participate in the research.   
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Appendix 16: Would you prefer the Pharmacist Discharge Medication 
Management Summary to be sent at the same time as the doctor/medical 
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Appendix 17: Complete Survey Responses for Question 9 (Both GP’s, RMP’s 
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